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The emergence of zoonotic viruses is an inherent risk to our global civilisation as we encroach 
on new environments and increase our reliance on high‐intensity farming to feed a growing 
population. Aside from the current SARS‐CoV‐2 pandemic, zoonotic flaviviruses like dengue 
virus (DENV) and Zika virus (ZIKV) are significant human pathogens and are rapidly expanding 
their geographic range. Outbreaks caused by these viruses result in death and disease 
especially in young children and the developing foetus. Moreover, these viruses place a 
significant economic burden on the worlds most under‐developed nations. As a society we 
are now left grappling with the question of how we will manage future viral outbreaks and 
how we will protect ourselves when they occur. Type‐I Interferons (IFN) are expressed by the 
host in response to viral infection. The IFNs act to clear viral infection by inducing the 
expression of hundreds of interferon stimulated genes (ISGs) that have direct antiviral or 
immune regulatory functions. However, viruses have evolved mechanisms to counteract the 
IFN response allowing them to replicate, spread and cause disease. Furthermore, our 
understanding of the antiviral action of IFNs in specific anatomical niches is rudimentary. In 
this thesis we explore the virus dependent mechanisms that abrogate the type‐I IFN response 
and characterise the role of novel IFNε in preventing ZIKV infection of the female reproductive 
tract (FRT).  
Viral evasion of the innate immune system relies on interaction between viral and cellular 
proteins. These interactions are often not recapitulated by expression of individual viral 
genetic elements. While some of these evasion mechanisms are known for both viruses, the 
lack of whole genome mutational studies means that our knowledge of these interactions is 
incomplete. To overcome this limitation, this thesis aimed to apply a genome‐wide high‐
throughput mutagenesis approach coupled to Next Generation Sequencing (NGS) to screen 
for regions of the ZIKV and DENV genome that confer IFN evasion. Initial attempts to 
introduce genome‐wide mutations into ZIKV were hampered by reaction efficiency and 
recombination of the infectious clone. Within the field this is recognised as a commonly 
occurring issue and is often reliant on subtle nuances within the viral genome sequence. As a 
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result, a DENV mutant library was used to screen viruses based on their ability to complete 
the full virus lifecycle under low level IFN stimulation (IFNα, IC50 1 U/mL). This led to the 
generation of a functional map, highlighting regions of the DENV genome likely to be involved 
with IFN evasion including a specific region within NS5 as a known mediator of DENV evasion. 
Specific mutations highlighted as most likely to render DENV hypersensitive to IFN were 
systematically re‐introduced into the wildtype DENV genome. However, none of these 
mutations were able to confer IFN hypersensitivity likely because of accumulation of linked 
mutations in the library. Several important recommendations to improve future genome‐
wide high‐throughput mutagenesis screens have arisen from this thesis. These include 
reducing the rate of co‐infection, increasing selection pressure and utilising new long‐read 
sequencing technology to detect linked mutations. Collectively this would reduce the 
accumulation of unintended mutations in similar screens and provide the means to detect 
them when they occur.  
As mentioned above, the classical type‐I IFN response is reactionary, and this delay is 
exploited by viruses to gain a foothold and cause disease. In contrast, the newly discovered 
IFNε, is constitutively expressed predominantly in the FRT. The FRT is highly permissive to 
ZIKV infection via sexual transmission and in some cases infection of the developing foetus 
during pregnancy. Currently, IFNε is known to protect against Herpes Simplex Virus (HSV) in 
the FRT and Human Immunodeficiency Virus (HIV) in cell culture but its potential to protect 
against sexually acquired ZIKV is unknown. To address this a multifaceted approach using in 
vivo and in vitro modelling of ZIKV infection in the FRT was applied. The results of this thesis 
show that IFNε is unequivocally important to protect the FRT from viral infection. Using a 
mouse model of intravaginal ZIKV transmission we showed IFNε knockout mice were more 
susceptible to ZIKV infection compared to wildtype mice.  Our transcriptomic analysis 
revealed IFNε mediated the induction of a protective anti‐ZIKV gene profile involving multiple 
ISGs in FRT cells but with minimal induction of pro‐inflammatory genes. This discovery is 
significant to the field as inflammation disrupts FRT barrier integrity and may promote 
infection of deeper tissues. Although the antiviral activity of IFNε was susceptible to ZIKV NS5 
mediated evasion after infection was established, the prophylactic expression of IFNε was not 
inhibited by ZIKV meaning it can circumvent this evasion. The potential of IFNε as a 
prophylactic treatment was proven by intravaginal administration of exogenous IFNε that 
rescued antiviral protection in IFNε knockout mice challenged with ZIKV. Collectively this data 
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highlights the prophylactic potential of naturally expressed and exogenous IFNε in protecting 
the FRT from ZIKV sexual transmission. Importantly, this shifts our understanding of innate 
immunity in the FRT from its reliance on reactionary responses to pre‐emptive protection 
against viral infections.  
In conclusion, genome‐wide mutational studies are a valuable tool to provide insight into the 
molecular aspects of viral evasion. Despite not finding novel ZIKV or DENV evasion 
mechanisms by this method, the screening and NGS approach used here could be modified 
for future endeavours. Additionally, to protect environments with high exposure risk to viral 
pathogens the host has evolved niche specific immunity. One example of this is IFNε in the 
FRT. Here we have shown constitutively expressed IFNε prophylactically protects the FRT 
from ZIKV infection. This finding has shifted the paradigm of antiviral protection of the FRT, 
demonstrating constitutive protection rather than reactionary IFN responses can effectively 
protect against ZIKV sexual transmission. Collectively, this thesis has made significant 
headway in characterizing the molecular interactions between the host innate immune 
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1.1 Zika virus and dengue virus 
1.1.1 ZIKV and DENV epidemiology   
Flaviviruses that cause human disease exist on every inhabited continent and combined cause 
a significant health and economic burden [23]. The global distribution and geographic range 
of these viruses are largely determined by their corresponding arthropod vector [118]. In 
general, these are either tick‐borne viruses or they are transmitted by mosquitoes [23]. 
Specifically, this thesis will focus on Zika Virus (ZIKV) and Dengue Virus (DENV) that are 
primarily transmitted by mosquitoes of the Aedes species (aegypti and albopictus) and as a 
result have a broad geographic range as shown in Figure 1.1 [337]. Mosquitoes that transmit 
ZIKV and DENV are endemic in tropical and subtropical regions of the Americas, Africa, 
Europe, Asia and the South Pacific region including Australia [199].  
ZIKV is an emerging Flavivirus that has rapidly expanded its epidemiological niche due to a 
series of outbreaks occurring since the early 2000’s. ZIKV was first discovered in Uganda, 
Africa in 1947 and for the following 60 years its geographic range was confined to equatorial 
regions of Africa and Asia [240, 329]. In the years following its discovery ZIKV was not heavily 
studied because at the time it was thought to only cause mild symptoms in humans. In 2007 
ZIKV caused the first outbreak outside of Africa or Asia on Yap Island in the Pacific region. 
Introduction of ZIKV into a naive population resulted in approximately 73% of the Islands 7000 
inhabitants becoming infected, with the majority showing no clinical symptoms (see section 
1.1.3 for a list of symptoms) [86]. Following this initial outbreak, ZIKV spread to new regions 
causing a series of outbreaks incrementally increasing in size. First in French Polynesia during 
2013–2014 [39], then Latin America in 2015 [390] and finally disseminating into North 
America during 2016 [144]. The 2015‐2016 outbreak in the Americas was the event that 
brought ZIKV onto the world stage. Transmission was first detected in Brazil early 2015 [390] 
and by the years end between 440,000 and 1,300,000 suspected ZIKV cases were recorded in 
Brazil alone [38]. As the outbreak unfolded, scientists and clinicians began to realize that ZIKV 






smaller population sizes. These symptoms included neurological complications such as 
Guillain‐Barre Syndrome (GBS) in adults and microcephaly in new‐borns. Retrospective 
analyses have now confirmed that these symptoms were also a feature of prior outbreaks 
[40]. Because of its large scale and the developing knowledge of ZIKV pathology the World 
Health Organization (WHO) declared the 2015‐2016 outbreak a public health emergency of 
international concern [363]. In the wake of the 2015‐16 outbreak ZIKV has spread to more 
than 87 countries globally including a small number of transported cases to Europe. Most 
recently in October 2019 three vector‐borne autochthonous cases of ZIKV were detected in 
Hyeres, France indicating ZIKV is circulating in this region [112]. Several hypotheses have been 
proposed to explain the explosive scale of the Americas outbreak. Factors such as geo‐
climactic conditions, socio‐economic circumstances, increased travel into affected areas, 
introduction into a naïve population and viral adaptation all likely played a role [267]. The 
rapid spread of ZIKV across the globe serves as a warning against future outbreaks of 
emerging zoonotic virus infections.   
In contrast to the historically obscure ZIKV, the disease caused by DENV infection has been 
recorded in historical texts for centuries. The earliest record of symptoms compatible with 
DENV infection were published in a Chinese medical encyclopaedia in 992 AD [239]. However, 
the virus that is the causative agent of Dengue fever was not isolated until 1943 during an 
epidemic outbreak in Nagasaki, Japan [337]. DENV like ZIKV likely originated in Africa or Asia. 
However, by the 1800’s it had spread across the globe as a result of the increasing global 
shipping and trade [239]. DENV causes the greatest disease burden of all flaviviruses. Alone it 
is estimated to cause 390 million cases resulting in approximately 21,000 deaths annually. 
DENV is endemic in over 100 tropical and sub‐tropical countries in Southeast Asia, the Pacific 
and the Americas [126, 127]. Its wide‐spread distribution means that approximately 3.6 billion 
people are living in areas with a risk of DENV infection [23]. In Australia DENV is a nationally 
notifiable disease with seasonal cases reported each year. Between 2010‐2015 there was 
1,773 total cases and of these 632 resulted from autochthonous transmission with the 
remaining 1,141 cases being acquired overseas [8]. Alarmingly, DENV incidence has increased 
30‐fold in the last 50 years and has spread to new geographic regions [362]. Increasing 
incidence of DENV infection is caused by factors including population growth in endemic 
regions, global warming impacting mosquito population distribution, unplanned 
urbanization, inefficient mosquito control and increasing travel into DENV endemic regions 
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[119, 136]. In addition to the deaths caused by DENV, the scale of this disease has serious 
economic burden owing to the roughly 2 million cases of the severe disease requiring 
hospitalization annually [125].  
  
1.1.2 Transmission of ZIKV and DENV 
Human pathogenic flaviviruses are generally arthropod borne viruses (arboviruses) and are 
carried by two types of vectors, ticks and mosquitoes. Tick‐borne viruses circulate in regional 
Europe and Asia and are transmitted from rodents and small animals to humans [119]. As a 
result of this transmission cycle these viruses tend to have a limited geographic range and 
reduced epidemic potential [118]. Conversely mosquito borne flaviviruses such as DENV and 
ZIKV have an ability to rapidly expand their geographic range upon introduction into new 
populations due to the widespread and increasing dispersal of their vectors [199].  
 
1.1.2.1 Mosquito-borne transmission 
Both ZIKV and DENV are transmitted by mosquitoes of the Aedes species, mainly Ae. 
albopictus and Ae. aegypti. As a result of their shared vector transmission these viruses have 
a similar geographic distribution and mode of transmission. These viruses are circulated in 
two overlapping transmission cycles as depicted in Figure 1.2 [329]. The first transmission 
cycle is the sylvatic cycle, where these viruses circulate between non‐human primates and 
tree‐dwelling mosquitoes maintaining a zoonotic reservoir in forested areas. The second 
urban cycle occurs between humans and mosquitoes adapted to living in towns and cities and 
is the cause of epidemic outbreaks in human populations. Generally, the level of host viremia 
is the most important determinant for the duration of vector borne transmission [90]. Median 
viremia lasts 3.5 days for ZIKV and 5 days for primary DENV infections [246, 355]. Generally, 
ZIKV infections have lower levels of viremia compared to DENV [357]. For ZIKV, the level of 
viremia directly correlates to the rate of infection and transmission in mosquitoes [345]. This 
is more complicated in DENV infections where asymptomatic or pre‐symptomatic cases at 
any level of viremia are more infectious than symptomatic DENV as a result of exacerbated 
host immune responses interacting with the mosquito vector [90]. For ZIKV, the level of 
viremia has no correlation to the severity of clinical symptoms, facilitating a‐symptomatic 






vector borne transmission even for closely related flaviviruses and highlights the importance 
of detailed demographic studies to predict and manage future outbreaks.    
 
1.1.2.2 Alternative transmission modes  
In addition to vector‐borne transmission ZIKV is unique amongst flaviviruses because it can 
also be transmitted sexually and vertically from mother to foetus in utero as summarized in 
Figure 1.3 [329]. These a‐typical transmission routes are facilitated by ZIKVs tropism for a wide 
variety of cell types in the male and female reproductive tracts [223]. Both sexual and vertical 
transmission can occur without presentation of clinical symptoms [33, 258].  
 
1.1.2.2.1 Sexual transmission 
Cases of ZIKV sexual transmission occur mainly between male to female partners (92.5%), but 
cases of both female to male and male to male transmission have been reported [228]. Sexual 
transmission was responsible for several transported cases outside of ZIKV endemic areas and 
likely complicates existing control measures within endemic areas [124]. In addition to aiding 
spread of the virus, animal models show sexual transmission increases the risk of foetal 
infection during pregnancy [88]. Unlike vector transmission that is dependent on the duration 
of viremia and is relatively short‐lived, sexual transmission can occur months after the virus 
in cleared from the blood. In women, detection of ZIKV RNA persists in cervical mucous for 
up to 3 months post‐symptom onset [272], which is far longer than its persistence in blood or 
urine [271]. In men, viral RNA has been recovered at a median of 25 days post symptom onset 
but the longest recorded detection was a staggering 370 days [20]. More importantly, 
infectious virus can be recovered from semen up to 69 days post‐symptom onset [261]. This 
extended period of virus shedding in semen led the Centre for Disease Control’s (CDC) to 
recommend a preconception waiting period for male travellers of at least 3 months post‐
exposure to ZIKV [48].  
Sexual transmission relies on ZIKVs tropism for cells and tissues in both the male and female 
reproductive tract. In men, the long duration of sexual transmission correlates with viral 
persistence in the testes as an immune privileged site [334]. Studies in humans show ZIKV can 
infect spermatozoa [204]. Additionally, in non‐human primate models, ZIKV infects both 
sperm progenitor and macrophage cells inside the seminiferous tubules and can persist up to 
41 days post infection in semen [263]. Moreover, in vitro studies have demonstrated ZIKV 
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infection in prostate mesenchymal cells [331] and Sertoli cell culture persists for more than a 
month [177]. Currently there are fewer studies investigating ZIKV infection in the non‐
pregnant female reproductive tract. However, one study demonstrated that that ZIKV can be 
detected in both the vagina and uterus of vaginally inoculated non‐pregnant rhesus macaques 
[41]. Furthermore, this detection persisted in the uterus after clearance of ZIKV RNA in plasma 
suggesting ZIKV preferentially replicates in these tissues when challenged intravaginally 
compared to subcutaneous inoculation.  
The longevity of transmission risk, localised introduction into the female reproductive tract 
and the increased risk of infection during early pregnancy makes ZIKV sexual transmission an 
important consideration when preparing for future outbreaks and understanding ZIKV 
pathology. Interestingly one case of DENV sexual transmission has recently been reported by 
the European Centre for Disease Prevention and Control, perhaps suggesting this is an 
overlooked or evolving mode of DENV transmission [55]. 
 
1.1.2.2.2 Vertical transmission 
In addition to sexual transmission ZIKV also infects the placenta and the developing foetus in 
utero. Vertical transmission resulting in foetal infection underpins ZIKVs most severe 
pathologies in neonates [153].  
The placenta is an organ that transiently develops during pregnancy. It is derived from cells 
of foetal origin that embed into the maternal decidua, forming an interface between maternal 
and foetal circulation [201]. Its primary role is to facilitate the exchange of gases, nutrients, 
waste products, and hormones to support the growing foetus [227]. Additionally, the placenta 
functions as a physical and immunological barrier between maternal and foetal circulation 
[227]. The placenta contributes to the dynamic immunology of pregnancy, balancing roles in 
supporting the growth of a semi‐allogenic foetus while protecting against viral and bacterial 
infections [72].  
Like the male testes, ZIKV infection persists for longer in the placenta than it does in other 
tissues [25]. ZIKV persistence in the placenta likely exploits the unique immune environment 
of this tissue that balances between inflammatory processes during implantation and a 
tolerogenic response later in pregnancy to promote foetal growth [227]. In pregnant women 
infected during their first trimester, ZIKV RNA can be detected in the placenta up to 210 days 
(mean 81 days) after symptom onset with continued detection in the foetal brain and 
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placenta after clearance from maternal circulation [25]. In addition, studies show that 
placental infection is correlated with prolonged viremia in maternal circulation [338]. In some 
recorded cases ZIKV RNA persisted in blood until delivery [20]. Together this data implicates 
the placenta as a reservoir for both maternal and foetal ZIKV infections.  
The mechanisms used by ZIKV to cross this barrier and infect the foetus are currently the 
subject of considerable active research. It is now known ZIKV can infect a wide range of cells 
and tissues of the maternal‐foetal interface including maternally derived endometrial cells 
and decidua resident macrophages [92, 257, 359], as well as foetal derived cells of the 
placenta such as extra villous trophoblasts, Hofbauer cells, umbilical cord endothelial cells 
and the amniochorionic membranes [92, 340].  
Together, these tropisms of the male and female reproductive tracts aid ZIKVs sexual and 
vertical transmission while also hindering its clearance by the immune system due to 
persistence in immune privileged sites.  
 
1.1.3 Clinical presentation and pathogenesis of ZIKV and DENV infections 
Broadly, there are two major categories of clinical presentation for Flavivirus infections 
dependent on disease pathogenesis and tissue or cell tropism of the virus. The first is primarily 
a neurological disease, such as for ZIKV infection, and is caused by direct infection of neurons 
leading to neuronal death or damage as a result of inflammation [23]. The second is a systemic 
disease characterized by vascular leakage and may include haemorrhagic symptoms. These 
symptoms are characteristic of DENV infections and arise due to systemic inflammation 
impacting upon immune cell function and endothelial cell permeability [118]. However, these 
manifestations are not always mutually exclusive. DENV, although not considered a classical 
neurotropic Flavivirus, can cause neurological and ocular complications as a result of infection 
[323]. In addition to these specific clinical manifestations ZIKV and DENV also cause a range 
of non‐specific symptoms such as fever, rash, muscle pain and tiredness. These non‐specific 
symptoms vary in severity and are largely caused by the innate immune response to infection. 








1.1.3.1 ZIKV clinical manifestations 
ZIKV is now recognized as a neurotropic Flavivirus but historically these infections were 
considered relatively benign. This is because in healthy adults approximately 80% of cases are 
asymptomatic [329]. The remaining 20% of cases mostly result in a mild, self‐limiting febrile 
illness and includes symptoms such as fever, rash, arthralgia, and conjunctivitis [329, 388]. 
However, recent largescale outbreaks have highlighted previously undetected pathologies of 
ZIKV infection such as ocular symptoms, neurological disease, and adverse pregnancy 
outcomes. These include uveitis, meningoencephalitis, rare (24 per 100,000) cases of GBS in 
adults and Zika Virus Congenital Syndrome (ZVCS) [40, 294, 308]. ZVCS encompasses a 
spectrum of neurological or developmental symptoms that vary in severity and occur during 
pregnancy or are present in neonates born to infected mothers. These include spontaneous 
pregnancy loss, inter‐uterine growth restriction, ocular abnormalities and hearing 
impairment, developmental and neurological impairment and microcephaly [53]. Alarmingly, 
reported rates of microcephaly increased 20‐fold in affected regions during the 2015/16 
outbreak [54]. The incidence and severity of ZVCS increases when infection occurs during 
early pregnancy and it is estimated roughly one third of children born to ZIKV infected 
mothers display some degree of developmental delay or neurological impairment [251]. 
Alarmingly, ZVCS can arise even in the absence of clinical symptoms in the mother [258]. The 
correlation with neurological disease was confirmed retrospectively for the 2013 ‐2014 
French Polynesia outbreak [159, 223, 279, 329] and is now widely acknowledged to be 
causative due to patient studies, in vitro and in vivo modelling [37, 60, 80, 181].  
 
1.1.3.2 ZIKV pathogenesis 
The clinical manifestations and pathogenesis of ZIKV infection are a result of the tissue 
tropism of the virus. ZIKV can cause direct cytotoxic effects on target cells, but infection can 
also result in inflammation that drives ZIKV pathology. From work in patient studies and 
mouse models ZIKV infects a wide variety of cells and tissues.  
Ocular symptom pathogenesis: 
ZIKV infections are associated with varying degrees of ocular pathologies such as 
conjunctivitis and uveitis in adult patients [173], and or ocular abnormalities in new‐borns 
including focal pigment mottling and chorioretinal atrophy [69]. One study by Miner et al. 
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found in a mouse model using subcutaneous inoculation that ZIKV infected various tissues of 
the eye including the cornea, iris, optic nerve, and the ganglion and bipolar cells in the retina 
[222]. Infection of the eye in this model caused conjunctivitis and uveitis like the symptoms 
observed in humans. Correspondingly, in vitro modelling in induced pluripotent stem cell 
derived retinal pigment epithelial cells (cells lining the retinal‐blood barrier) demonstrated 
that these cells were highly permissive to ZIKV infection [324]. Furthermore, ZIKV infection 
triggered antiviral and inflammatory responses that correlated with impairment of 
membrane dynamics and retinal pigment epithelial cell homeostasis that could contribute to 
the ocular lesions observed in new‐borns.  
Neurological symptom pathogenesis: 
ZIKV is now known to be highly neurotropic. ZIKV can infect multiple cell types in the human 
brain, including neural progenitor cells [193], developed neurons, and glial cells within the 
cerebral cortex [25]. Infection of these cell types has been shown in an immune competent 
mouse model of intracranial injection to result in direct cytopathic effect on neuronal cells 
[153]. Additionally, in a similar model the contribution of ZIKV induced innate immune 
signalling was linked to encephalitis [138]. Furthermore, adaptive immune responses that 
generated anti‐ganglioside antibodies in response to ZIKV infection are linked to the 
development of GBS in patient studies [287].  
Adverse pregnancy outcomes: 
ZVCS is caused by infections of the placenta and developing foetus, disrupting the immune 
balance required to maintain healthy pregnancy as well as having direct cytopathic effects 
[226]. ZIKV has been shown in mouse models and organoid culture to have a striking affinity 
for the foetal brain and eye explaining neurologic and ocular manifestations. ZIKV infection in 
developing neurons causes cell death and neural inflammation [181, 353, 360]. Additionally, 
ZIKV directly infects the placenta resulting in activation of innate immune responses, 
abnormal placental development and intrauterine growth restriction that can result in 
spontaneous pregnancy loss or developmental impairment due to disrupted nutrient and gas 
exchange [382, 383].   
 
1.1.3.3 DENV clinical manifestations 
Like ZIKV, most (75%) of DENV cases are asymptomatic and patients that do present 
symptoms mainly have a self‐limiting febrile illness known as dengue fever (DF). DF or the 
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aptly named “break‐bone” fever, normally lasts between 7‐10 days and is characterised by 
severe muscle and joint pain, rash and headache [76]. A small proportion (<1%) of 
symptomatic infections progress to potentially lethal forms of severe disease [75]. This 
includes dengue haemorrhagic fever (DHF) or dengue shock syndrome (DSS). These severe 
forms of disease are characterized by the sudden onset of vascular leakage, 
thrombocytopenia, haemorrhagic manifestations and moderate liver damage [297].  
 
1.1.3.4 DENV pathogenesis 
DHF and DSS symptoms are caused by DENV’s tropism for, or pathological effect on cells of 
the immune system, the liver and endothelial cells lining blood vessels [208]. Several studies 
have used immunohistochemical analysis or in-situ hybridisation to detect DENV RNA or 
protein in tissues taken from patient autopsies. These show the presence of DENV in cells of 
the skin, liver, spleen, lymph node, kidney, lung, thymus and brain [24, 168, 219]. Generally, 
severe DENV infections lead to elevated levels of pro‐inflammatory and vasoactive cytokines 
released from infected cells that impact upon blood vessel permeability causing fluid loss 
either externally or into the tissue space that if left untreated leads to mortality [128, 291]. 
This wide array of DENV’s clinical manifestations and risk factors for severe dengue are 
dependent on the infecting serotype, pre‐exposure to heterotypic strains of DENV, age, 
gender, nutritional and immunological status of the infected host [130, 314, 330, 347]. The 
main risk factor for severe dengue across all demographic groups is pre‐exposure to a 
heterotypic strain of DENV. Recovery from infection provides life‐long immunity against DENV 
strains of the same serotype [367]. However, antibodies generated against one serotype 
provide incomplete protection against heterotypic serotypes as the antibody titers wane over 
time. This leads to antibody dependent enhancement (ADE) of infection. ADE occurs when 
the Fc portion of heterotypic non‐neutralizing antibodies facilitate DENV entry into target 
cells that express Fc receptors on their cell surface such as dendritic cells and macrophages 
[291]. DENV infection in these immune cell subtypes exacerbates inflammation and cytokine 
release and leads to increasingly severe symptoms [332]. Importantly, severe dengue is a 
leading cause of morbidity and mortality in young children in parts of Asia and Latin America 
[367]. Particularly young children and infants have an increased risk of DSS and DHF likely due 
to their increased microvascular fragility compared to adults. Additionally, young children also 
have a greater risk of exposure to DENV infections due to lifestyle factors [197].  
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1.1.4 Current control measures 
The main control measures for both ZIKV and DENV infections are vector control strategies 
and prevention of mosquito bites. For ZIKV these basic control measures include safe‐sex 
practices for a minimum of 3 months after potential exposure for men and 2 months for 
women [366].  There are no approved vaccines or antivirals for ZIKV, but several vaccine 
candidates are currently being investigated. As of late 2019, the WHO listed 15 vaccine 
candidates in phase I/II clinical trials [365]. These include DNA, RNA, recombinant protein, 
recombinant viral vector, and inactivated whole virus vaccines. As for DENV, there are also no 
approved antivirals but there is an approved vaccine (Dengvaxia®) developed by Sanofi 
Pasteur. However, this vaccine is not recommended for children under 9 years of age and has 
been plagued by controversy because it can increase the risk of severe DENV developing in 
people who are seronegative when receiving vaccination [364].  
The development of specific, effective, and safe treatments and vaccines for the prevention 
of both ZIKV and DENV requires understanding of their fundamental biology, pathogenesis, 
and interactions with host immune responses. 
 
1.1.5 Molecular virology of ZIKV and DENV 
1.1.5.1 ZIKV and DENV phylogeny and genetic diversity 
Flavivirus are a genus of primarily arthropod borne, enveloped, positive‐sense single stranded 
RNA (+ssRNA) viruses that include several major human pathogens including DENV and ZIKV, 
and other such as Yellow Fever Virus (YFV), Japanese Encephalitis virus (JEV), and West Nile 
Virus (WNV). Amongst flaviviruses DENV and ZIKV are closely related, sharing on average 55% 
amino acid identity [45]. 
ZIKV is classified as a single serotype but has two genetically distinct lineages; African and 
Asian, pertaining to their region of first isolation. Interestingly, all significant outbreaks have 
been attributed to the Asian lineage [329]. For this reason, considerable attention has been 
given to strain specific nucleotide substitutions occurring in both regulatory or protein coding 
regions and their potential contribution to altered pathogenicity and enhanced 
transmissibility of the Asian strains [267, 380]. Incidentally, a recent study found that an 
envelope protein V473M substitution mutation that occurred within the Asian strain prior to 
its introduction into the Americas conferred enhanced neurovirulence, maternal‐to‐fetal 
transmission, and increased viremia to facilitate mosquito borne transmission [315]. 
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Moreover, a single nucleotide polymorphism resulting in an Alanine to Valine switch within 
the NS1 dimerization domain of recent outbreak strains of ZIKV has been shown to enhance 
infectivity in mosquito vectors, likely contributing to enhanced transmissibility [195]. 
Additionally, there are strain specific differences in innate immune evasion between African, 
early Asian and the most recent South American clades. For example, a recent South American 
ZIKV strain demonstrated weaker and delayed interferon responses compared to the MR766 
strain that was originally isolated in Africa in 1947 and this likely contributes to strain specific 
differences in pathogenesis [93]. These findings support a possible evolutionary shift 
enhancing the severity of recent outbreaks and raise concern over future adaptation of the 
virus when introduced to naive populations.  
In contrast to ZIKV, DENV has 4 distinct serotypes with a 5th emerging (DENV1‐5), these have 
approximately 30% difference in their overall amino acid sequences [150, 191]. Importantly, 
neutralizing antibodies generated against one serotype offer little to no protection against 
heterotypic strains of DENV. This complicates vaccine design and contributes to ADE and 
DENV pathogenesis. Between the different serotypes there are clinically relevant differences 
in the outcome of both primary and secondary infections. One study found that the DENV3 
serotype from Southeast Asia (SEA) caused the greatest incidence of severe dengue during 
primary infections. In contrast, DENV2 caused the greatest incidence of severe infection upon 
secondary exposure to a heterotypic subtype in strains isolated from both SEA and non‐SEA 
regions [330].  
The elements that contribute to DENV and ZIKV pathogenesis and immune evasion are still 
poorly understood. To improve therapeutics and vaccines that can combat these viruses will 
require continued study into their genetics and specific functions of their encoded proteins.   
 
1.1.5.2 ZIKV and DENV genome and proteins  
Typical to flaviviruses, both DENV and ZIKV have an approximately 11 kb linear single‐
stranded positive‐sense RNA genome. The genome contains a single open reading frame 
(ORF) encoding the viral polyprotein. The central ORF is flanked by 5’ and 3’ untranslated 
regions (UTRs) and the 5’ end of the genome is capped. Both the 5’ and 3’ UTR contain 
conserved secondary structures that are involved in long range RNA:RNA interactions that 
promote viral RNA replication [247]. The overall structure and arrangement of the Flavivirus 
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genome is shown in Figure 1.5 (from source [29]) and its individual elements are described 
below in more detail.  
 
1.1.5.2.1 Genome structure 
5’UTR 
The Flavivirus 5’ UTR is an approximately 100 nucleotide (nt) sequence directly upstream of 
the capsid protein. It contains a 5’ type‐I cap that resembles host mRNA. This cap is important 
for recruitment of host translational machinery, preventing genome degradation by host 
exonucleases and evading innate immune recognition [247]. The 5’ UTR also contains two 
conserved stem‐loop structures, stem‐loop A and B (SLA, SLB). SLA is approximately a 70 nt 
length and is required for viral replication by recruiting the NS5 RNA dependent RNA 
polymerase (RdRp) protein [196]. The SLB is approximately 16 nt in length and contains a 
conserved AUG sequence that is complementary to the cyclization sequence in the 3’ UTR. 
Complementary binding of these 5’ and 3’ UTR regions promotes genome cyclisation and NS5 
recruitment [31].  
 
Open reading frame encoding the viral polyprotein  
The Flavivirus ORF encodes a polyprotein that is roughly 3400 amino acids in length. From 5’ 
to 3’ it encodes the structural Capsid (C), pre‐Membrane (prM), Envelope (E) protein, and 
non‐structural (NS) proteins NS1, NS2A, NS2B, NS3, NS4A‐2k‐NS4B and NS5. The polyprotein 
is synthesized by host translational machinery as a multi‐pass transmembrane protein 
inserted into the endoplasmic reticulum (ER) membrane [248]. This polyprotein is then co‐
translationally cleaved by host or by the viral proteases into its individual proteins (see Figure 
1.5) [234].  
 
3’ UTR 
The 3’ UTR is positioned immediately after the viral ORF and for ZIKV and DENV is roughly 450 
nt in length. The 3’ UTR of DENV contains two stem‐loop structures (SL1 and SL2), two 
dumbbell structures (DB1 and DB2), a small hairpin (sHP) and an evolutionarily conserved 3’ 
stem loop (3’SL) common to all flaviviruses [247]. The ZIKV 3’ UTR is similar to DENV except it 
has a single functional DB1 structure and a pseudo‐DB structure in place of DB2 [114]. These 






immune evasion through the generation of short sub‐genomic Flavivirus RNAs (sfRNAs) [82, 
247]. The generation and function of these sfRNAs is discussed further in section 1.3 of the 
Introduction. The evolutionarily conserved 3’SL is essential for complementary long range 
RNA:RNA with the 5’ UTR resulting in genome cyclisation. This 3’SL structure also contains the 
NS5 binding recognition sequences required to initiate RNA replication [31]. 
 
1.1.5.2.2 Virion structure  
Together the structural proteins are involved with the formation of new infectious virus 
particles (virions) shown in Figure 1.6 [260]. The mature Flavivirus virion is approximately 50 
nm in diameter consisting of an outer envelope and an internal nucleocapsid encasing a single 
copy of the +ssRNA genome. The viral envelope is a lipid bilayer derived from host cell 
membranes formed upon budding into the ER lumen. Embedded in the lipid bilayer is 180 
copies of each the E and M proteins [265]. The E protein dimerizes to form 90 homodimers 
that lie flat against the lipid surface forming a smooth outer coat. The M protein is positioned 
underneath this smooth coat and is embedded into the lipid bilayer. For both ZIKV and DENV 
these dimers are arranged in a characteristic herringbone structure in the mature virion [328]. 
The envelope surrounds the viral nucleoprotein. The nucleoprotein comprises multiple copies 
of the C protein associated with the viral RNA in a relatively unordered structure [256]. 
 
1.1.5.2.3 Viral proteins 
The viral genome encodes for a single, multi‐pass trans‐membrane polyprotein that is 
expressed embedded into the ER membrane. This polyprotein is cleaved by the viral protease 
(NS3) on the cytoplasmic side, and by host peptidases (ER resident signal peptidases or Golgi 
resident Furin protease) on the luminal side of the ER membrane or during virion maturation 
[234]. Following polyprotein cleavage, the individual viral proteins are released. These 
proteins either remain associated with the ER membrane, are released into the cytosol or into 
the ER lumen depending on their topology in the polyprotein transmembrane domain 
architecture (see Figure 1.5) [29, 234]. In general, the structural proteins have roles in 
generation of new infectious virus particles and the non‐structural proteins are involved with 





1.1.5.2.3.1 Structural proteins  
Capsid 
The immature C protein is formed by 114 amino acids that are cleaved by the NS3 viral 
protease into a final 100 amino acid mature form [256]. Structurally two copies of the C 
protein form dimers that organize symmetrically, with each monomer containing four α‐
helices and an unstructured N terminal region [256]. Helix 4 contains multiple arginine 
residues that are positively changed at physiological pH and are predicted to facilitate RNA 
binding [256]. Once cleaved from the viral polyprotein multiple copies of the mature C protein 
interact on the cytoplasmic side of the ER membrane with a single copy of the RNA genome 
thereby forming the unstructured nucleocapsid [234]. 
 
Envelope 
The E protein is the major surface glycoprotein and is 504 amino acids in length. In the mature 
virion 180 copies of the E protein dimerize to form a smooth outer coat [265]. In its dimeric 
form each E protein monomer is made up of three distinct domains (EDI, II and III) 
interconnected by flexible linkers and contains a helical anchor domain that is imbedded into 
the lipid bilayer [234]. The N‐terminal EDI plays a structural role at the centre of the dimer 
complex. EDII is a dimerization domain and contains the fusion peptide loop. EDIII is an 
immunoglobulin‐like domain and is thought to contain receptor binding sites [234]. Typically, 
the Flavivirus E protein contains one or more N‐glycosylation sites that are thought to play 
roles in receptor specificity. For DENV, the mature E protein is glycosylated at positions N67 
and N153 [97]. Interestingly, there are lineage specific differences in ZIKV E protein 
glycosylation leading to differences in strain virulence. Historical strains of ZIKV such as the 
African MR766 or the Malaysian P6‐740 lack the conserved N‐X‐T/S glycosylation motif at 
position N154 that is present in contemporary epidemic strains [97]. Mutation of the N154 
glycosylation site in contemporary stains causes attenuation of ZIKV virulence in mouse 
models [97].  
 
Membrane  
The mature M protein is anchored into the lipid bilayer and lies underneath the external E 
protein coat of the mature virion. Its domain structure consists of the soluble M‐loop at the 
N‐terminus, a single α‐helical stem region and a double α‐helical transmembrane region 
19 
 
[328]. The M protein is first synthesized in a pre‐protein form (prM). During virion egress the 
low pH environment of the trans‐Golgi network leads to a conformational change in prM, 
exposing a Furin cleavage site (Figure 1.5, yellow arrow) [234]. Furin then cleaves prM to the 
mature M protein. Cleavage of prM to M leads to virion maturation by causing disassociation 
of the immature 60 prM‐E trimers and formation of the 90 E homodimers present in the 
mature virion [234].  
 
1.1.5.2.3.2 Non-structural proteins  
The 7 non‐structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) play multiple roles 
in the virus lifecycle during viral replication, virion packaging and immune modulation. 
Historically, more is known about the specific functions of DENV NS proteins than ZIKV as this 
field of research is still under development. However, due to their close evolutionary 
relationship it is likely the essential functions of NS proteins are conserved between DENV 
and ZIKV. The specific immune modulatory functions of both DENV and ZIKV NS proteins are 
discussed in depth in section 1.3. 
 
NS1  
NS1 is a 45 kDa protein that is released into the ER lumen upon polyprotein processing and 
plays different roles in the virus lifecycle depending on whether it is cell associated or secreted 
[265]. In solution NS1 is present as stable oligomers (dimers or hexamers) [6]. Cell associated 
NS1 is important for viral replication, and secreted NS1 plays other roles in DENV 
pathogenesis [148]. Cell associated NS1 interacts with multiple host factors assisting in virus 
replication, translation of the viral polyprotein and virion production. Specifically, NS1 
interacts with and recruits multiple ribosomal proteins to the replication complex [280]. In 
DENV infection secreted NS1 activates the pattern recognition receptor TLR4 expressed on 
peripheral blood mononuclear cells, leading to upregulation of proinflammatory cytokines 
that contribute to DENV pathogenesis and symptoms severity [225].  
 
NS2A 
NS2A is 22 kDa multi‐pass transmembrane protein associated with the viral replication 
complex [265]. DENV NS2A has been shown to be essential for RNA replication, virus assembly 





NS2B is a 130 amino acid protein that acts as a co‐factor for the NS3 protease. It associates 
with NS3 by wrapping around the protease domain, forming part of the active site [265]. 
Structurally the N‐terminal domain of NS2B forms a β‐strand that interacts with the NS3 β‐
barrel, stabilizing NS3 conformation [396]. In DENV and WNV the C‐terminal portion of the 
protein makes up part of the active site and likely contributes to fine sequence specificity of 
the protease [396]. The flanking transmembrane regions are predicted to embed NS2B in the 
ER membrane [265]. 
 
NS3 
NS3 is the second largest protein encoded in the Flavivirus genome. It is a 618 amino acid 
protein that performs multiple enzymatic functions in the Flavivirus lifecycle [265]. The N‐
terminal protease domain in conjunction with its associated cofactor (NS2B) is responsible for 
cleaving multiple sites of the viral polyprotein (see Figure 1.5 white arrows). The C‐terminal 
domain is made up of three distinct sub domains and possesses RNA helicase, nucleotide 
triphosphatase and ribonucleotide triphosphatase activities [339]. The NS3 helicase is 
responsible for unwinding the dsRNA replication intermediate, releasing functional +ssRNA 




NS4A is a 16 kDa integral membrane protein [265]. DENV NS4A induces membrane 
remodelling to assist with replication complex formation. This activity is dependent on the 
proteolytic cleavage of the 2K fragment separating NS4A and NS4B [220] and likely involves 
other protein‐protein or protein‐lipid interactions [234]. 
 
NS4B 
Like NS4A, NS4B is a 27 kDa integral membrane protein embedded in the ER membrane [265]. 
NS4B is known to localize to the site of viral replication and interact with several host and viral 





NS5 is a 104 kDa, 900 residue protein and is the most highly conserved Flavivirus protein 
[265]. It is arranged into two distinct domains, the N‐terminal Methyltransferase (MTase) 
domain and the C‐terminal RNA dependent RNA polymerase (RdRp) domain. The MTase is 
structured in an α/β/α sandwich formation that generates the conserved 4 amino acid 
catalytic site at the centre of the domain. The RdRp domain is formed in a right‐hand structure 
made up of three subdomains the finger, palm, and thumb. This domain is shaped to generate 
three channels that individually bind the template RNA, allow the entry of new NTPs and allow 
the exit of the newly synthesized RNA [391]. NS5 performs essential functions in replicating 
the RNA genome and  5’ genome capping through its methyl transferase domain [289].  
 
1.1.5.3 Lifecycle 
As closely related flaviviruses, ZIKV and DENV share many similarities in their lifecycle within 
host cells. In overview, the Flavivirus lifecycle is carried out in several stages as shown in 
Figure 1.7. The lifecycle begins when a virion binds to its receptor expressed on the surface 
of a permissive host cell. Next, the virus‐receptor complex is internalized by receptor‐
mediated endocytosis. Acidification of the endosome leads to fusion of the viral and 
endosomal membranes, particle disassembly and the release of the +ssRNA genome into the 
cytosol. Once the viral genome enters the cytosol an initial round of translation is carried out 
by host translational machinery, generating new structural and non‐structural viral proteins. 
Next, the viral non‐structural proteins form the replication complex (RC) by modifying host 
ER membranes and then act to generate new viral RNA genomes through an ‐ssRNA 
intermediate. Genomes are then packaged into new immature virion structures comprised of 
the structural proteins and a single copy of +ssRNA. Immature virions are transported through 
the ER and trans‐Golgi network to the plasma membrane, simultaneously undergoing 
maturation processing mediated by Furin cleavage of prM to M. Finally, new mature virions 
are released by exocytosis to initiate a new cycle of infection [234].  
 
ZIKV and DENV entry 
The ability for both DENV and ZIKV to infect wide varieties of cell types largely depends on 
the host expression of each virus’s entry receptor. The specific entry receptor for ZIKV and 






combination or in different cellular contexts for virus entry [3, 264]. Some of these molecules 
likely act as attachment factors rather than as entry receptors that directly facilitate virion 
uptake by the cell.  
For flaviviruses the most common attachment factors are a family of receptor molecules 
called negatively charged glycosaminoglycans (GAGs), such as heparan sulphate [3]. These 
molecules are predicted to bind via electrostatic interactions with positively charged regions 
of the surface of the E protein [264]. Another family of cell surface receptor implicated in ZIKV 
and DENV attachment and entry are the C‐type lectin receptors (CLRs). CLRs are a family of 
pattern recognition receptors (PRRs) that bind to carbohydrate pathogen associate molecular 
patterns (PAMPs) and are normally expressed on myeloid cells such as DC’s and macrophages 
[264]. Normally they function to initiate innate immune responses and cause the uptake of 
PAMPs into endosomes for the purpose of antigen presentation. Flaviviruses exploit this 
interaction through binding through N‐linked glycans on the E protein, facilitating attachment 
and potentially virion entry into endosomes [264]. The most implicated CLRs for Flavivirus 
entry is DC‐SIGN (Dendritic cell‐specific intercellular adhesion molecule‐3‐grabbing non‐
integrin). Expression of DC‐SIGN in HEK293T cells was shown to enhance ZIKV infection [129]. 
Blocking of this interaction by anti‐DC‐SIGN antibodies has also been shown to decrease DENV 
infection in dendritic cells [344]. In addition to CLRs, two families of related transmembrane 
phosphatidylserine receptors the TIM (TIM1, TIM3 and TIM4) and TAM’s (Tyro3, AXL and 
MER) have been implicated in both ZIKV and DENV attachment and entry. These bind either 
directly (TIM) or indirectly (TAM) to lipids such as phosphatidylserine (PS) embedded in the 
viral membrane [3]. Indirect binding of TAM receptors is mediated through extracellular 
bridging molecules such as Gas6 or protein‐S [215]. Meertens et al. demonstrated ectopic 
expression of TIM and TAM receptors in 293T cells, and their natural expression levels in cell 
types demonstrably correlates with DENV infection [215]. Another publication by Hamel et al. 
demonstrated similar results with ZIKV using overexpression the TAM receptor AXL [129]. 
Interestingly, the role of AXL mediating ZIKV attachment and entry seems to be cell type 
specific, suggesting that multiple receptors are responsible for ZIKV attachment and entry. 
Wells et al. demonstrated the genetic ablation of the AXL receptor had no effect on ZIKV 
infection of neural progenitor cells and Hastings et al. demonstrated the TAM receptors were 
non‐essential for ZIKV infection in mice [137].  
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After virion attachment and entry receptor engagement the virion enters the host cell via 
clathrin‐mediated endocytosis [3]. This is a process where the virion‐entry receptor complex 
is trafficked to clathrin‐coated pits on the host cell membrane. This initiates membrane 
invagination, constriction and pinching off the membrane vesicle forming clathrin‐coated 
vesicles containing the virion [233]. Once inside the cell the clathrin‐coated vesicle is 
processed to form an early endosome, these then fuse with lysosomes to form late‐
endosomes [233]. The low pH environment of the late‐endosome drives conformational 
changes in the virus E protein exposing the fusion peptide, leading to membrane fusion, 
uncoating and release of the +ssRNA genome into the cytoplasm [234].  
ZIKV and DENV genome translation and replication 
After the viral +ssRNA genome gains access to the cytosol viral replication is initiated by direct 
translation by host translational machinery to form a polyprotein that is inserted into the ER 
membrane [234]. This polyprotein is then proteolytically cleaved to form three structural (C, 
prM and E) and seven non‐structural (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) proteins 
[289]. Together multiple NS proteins interact with host factors to induce changes in the 
structure of the ER membranes generating the viral RC [289]. The RC acts to concentrate viral 
and host proteins that are essential for viral genome replication and also functions to hide 
the replicating viral RNA from cytosolic PRR recognition detection [184, 289]. Ultrastructural 
analysis shows that ZIKV and DENV induce similar RC structures. They are both formed from 
the invagination of the rough ER membrane into the ER lumen generating a series of 
convoluted membranes and vesicle packets that contain the viral RNA and replication 
machinery [58]. Following formation of the replication complex, the +ssRNA genome is copied 
through a ‐ssRNA intermediate by the RdRp function of NS5 in coordination with other 
essential host and viral factors. The progeny genomes (+ssRNA) then exit vesicle packets 
through the vesicle pore and interact with capsid protein that forms the nucleocapsid 
encasing a single copy of the +ssRNA genome [289].  
ZIKV and DENV virion maturation and egress  
To generate new infectious virions the nucleoprotein complex buds into the ER‐derived 
membranes [238]. These membranes are embedded with viral prM–E heterodimers that coat 
the newly enveloped immature virion upon budding into the ER [234]. After entering the ER 
lumen, the immature Flavivirus particle is shuttled through the secretory pathway. During this 
process, the virion undergoes a maturation process mediated by the acid‐induced 
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rearrangement of the E protein and subsequent cleavage of the prM protein to M by host 
furin protease in the late Golgi compartment [387]. After maturation new virions are released 
from the host cell by fusion of secretory vesicles to the host membrane [238]. 
 
1.2 The innate immune response to viral infection overview  
The innate immune response is the first line of defence against viral pathogens and has been 
reviewed extensively in [214]. This arm of the immune system generates a rapid, non‐specific 
response aiming to control infection. The innate immune response also plays a crucial role in 
establishing adaptive immune responses, leading to pathogen specific and long‐lasting 
immunological memory [214]. In general, the innate immune response is initiated by 
recognition of “non‐self” molecules by the host. These evolutionarily conserved “non‐self” 
molecules are called pathogen associated molecular patterns (PAMPS) and include a range of 
pathogen associated molecules such as lipids, polysaccharides, nucleic acids, and protein. 
PAMPs bind to host germline encoded pattern recognition receptor (PRRs) on the cell surface, 
within endosomes or in the cytoplasm. The location of PRR engagement by PAMPs depends 
on the lifecycle of the pathogen and helps to broadly direct the innate immune response. For 
intracellular pathogens such as viruses PAMPs accumulate inside cellular compartments such 
as the cytosol or endosomes. PRR binding to PAMPs causes cellular signalling pathways to be 
activated, leading to the upregulation of multiple innate immune effector molecules and 
cytokines. These act directly or indirectly control infection, promote inflammation, and 
manage the immune response appropriately. The most important class of cytokine involved 
in the innate response against viral pathogens are the interferons (IFN). These cytokines are 
responsible for orchestrating an antiviral state within infected cells, in neighbouring cells and 
in directing immune cell activation or trafficking to control viral infection.  
 
1.2.1 Recognition of flaviviruses by innate immune pattern recognition receptors 
Typically, ZIKV and DENV are recognized by PRRs that bind to RNA PAMPs generated as a by‐
product of vRNA replication. The main class of PRR that recognize Flavivirus RNA PAMPs are 
members of the the DExD/H box RNA helicase family of RIG‐I‐like receptors (RLRs) located in 
the cytoplasm [122]. Flavivirus RNA detection can also occur in the endosomal compartment 
by the membrane associated Toll‐like receptors‐3 or 7 (TLR) [214]. Most recently it has been 
found that both DENV and ZIKV infection results in mitochondrial DNA (mitoDNA) release that 
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is sensed by Cyclic GMP‐AMP synthase (cGAS) and signals through the ER associated 
intermediate Stimulator of Interferon Genes (STING) [5, 214, 395]. Each of these pathways 
culminates in the phosphorylation and subsequent activation of the signalling intermediaries 
TANK‐binding kinase 1 (TBK1) and IκB kinase‐ε (IKKε). Following their activation, TBK1 and 
IKKε phosphorylate IFN‐regulatory factor‐3 or 7 (IRF) [214]. Additionally, IKKε phosphorylates 
the inhibitory subunit of nuclear factor‐κB (NF‐κB), leading to inhibitor degradation and 
subsequent activation of NF‐κB [162]. Activated IRFs and NF‐κB translocate to the nucleus 
where they act as transcription factors to promote expression of the IFNs and a small subset 
of antiviral or proinflammatory genes [182]. Figure 1.8 summarizes these pathways that are 
discussed in more depth below. 
RIG‐I like receptors 
The main drivers of the innate immune response against flaviviruses are the ubiquitously 
expressed RLRs, retinoic acid‐induced gene I (RIG‐I) and melanoma differentiation‐associated 
gene 5 (MDA5). RIG‐I recognizes short 5’‐triphosphorylated ssRNA and short dsRNAs whereas 
MDA5 is implicated in recognition of longer dsRNA products [161, 175, 303]. In structure 
these PRRs contain two N‐terminal caspase recruitment and activation domains (CARDs) 
followed by an RNA helicase domain [175]. PAMP binding causes a conformational change in 
the receptor that exposes the CARD interaction domains and facilitates interactions with 
translocation mediators such as TRIM25 and members of the 14‐3‐3 family of proteins [162]. 
The RLR translocase complex is then shuttled to the mitochondrial associated membranes 
where the exposed CARD domains interact with the complementary CARD domain of 
signalling intermediate mitochondrial antiviral signalling protein (MAVS) [162]. This 
interaction triggers MAVS activation leading to subsequent activation of cytosolic kinases 
TBK1 and IKKε [214]. Interestingly, CRISPR/Cas9‐mediated knockout of RIG‐I but not MDA5 
led to significantly increased ZIKV replication in A549 cells compared to control, indicating 
that RIG‐I is the main sensor of ZIKV infection in these cells [302]. Furthermore, knockout of 
the RLR signalling intermediate MAVS was shown to enhance ZIKV infection in human 
placental trophoblast cell lines [200]. Similarly, siRNA mediated knockdown of RIG‐I and 
MDA5 in the Huh7 cell line rendered them highly susceptible to DENV infection [243]. 
Collectively these studies demonstrate the importance of the RLRs in detection of both ZIKV 






Toll like receptors 
In addition to cytosolic PRR activation, ZIKV and DENV RNA generated during the viral lifecycle 
can be recognized in the endosomal compartment by toll‐like receptor 3 or 7 (TLR3/7) [245, 
349]. TLR3 is more widely expressed and recognizes dsRNA whereas TLR7 is mainly expressed 
in specialised IFN producing cells (plasmacytoid DCs) and is activated by ssRNA [175]. 
Signalling downstream of activated TLR3 is initiated by binding of the cytoplasmic TIR domain 
of TLR3 to the complementary TIR domain containing adapter protein (TRIF). Next, TRIF 
interacts with TNF receptor associated factors (TRAF3/6) and with receptor interacting 
proteins (RIP1/3). Collectively these interacting partners activate TBK1 and IKKε. 
Comparatively TLR7 activates a MYD88 dependent pathway that culminates in TRAF6 
signalling and subsequent TBK1 and IKKε activation [175, 245]. Evidence that TLR3 plays a 
significant role in ZIKV recognition is given by siRNA mediated gene silencing in HFF1 cells 
(foreskin fibroblast) increasing their permissive to ZIKV infection [129]. Additionally, HEK 293 
cells heterologously expressing either TLR3 or TLR7 demonstrated elevated levels of 
downstream cytokine release following DENV infection [349]. 
cGAS‐STING 
Other than RNA mediated PRR activation of the innate immune response, DENV and ZIKV 
infection also causes the release of mitoDNA into the cytoplasm [5, 395]. The presence of 
mitoDNA in the cytoplasm is a hallmark of cellular damage and acts as a potent stimulator of 
apoptosis and innate immune responses [232]. Release of mitoDNA during DENV infection is 
likely caused by disruption of normal mitochondrial function. Specifically, the DENV M protein 
disrupts mitochondrial membrane potential [43]. Also, the DENV NS2B/3 protease cleaves 
important mitofusion proteins (MFN1 and MFN2) that are important for membrane fusion 
and mitochondrial homeostasis [386]. ZIKV is also known to impair mitochondrial function 
[183], but the molecular mechanisms that drive the release of mitoDNA during ZIKV infection 
remain unknown. Once released into the cytoplasm in response to viral infection, mitoDNA 
can bind directly to the cytosolic DNA sensor cGAS. DNA binding to cGAS causes a 
conformational change allowing it to catalyse the conversion of GTP and ATP to produce the 
second messenger cyclic GMP–AMP (cGAMP). Next, cGAMP binds to the STING located in the 
ER membrane. Upon cGAS binding, STING oligomerizes and translocates to the Golgi, where 
it activates TBK1 and IKKε [232]. Importantly knockout of cGAS in PMBCs renders these cells 
more susceptible to ZIKV infection and limits IFNβ production in infected cells [395]. 
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Moreover, various human cell lines lacking STING demonstrate enhanced DENV replication in 
vitro [4].  
Each of these pathways stimulates the transcription and translation of the IFNs by infected 
cells. In turn the IFNs are secreted from the cell to orchestrate and amplify a broader antiviral 
response both within infected cells and in neighbouring cells and tissues.  
 
1.2.2 The Interferons  
The IFNs are antiviral cytokines generally produced by the host in response to sensing of viral 
pathogens. They are grouped into type – I, II or III, based on sequence homology and their 
cognate receptors [182]. Type – I and III IFNs incite a cell intrinsic antiviral state and are widely 
produced in the body. Comparatively, type – II IFNγ is produced by specialized immune cells 
including innate natural killer (NK) cells and certain subsets of adaptive T‐cells [306]. IFNγ acts 
as a pro‐inflammatory and immunoregulatory cytokine and play a role in the adaptive 
response to viral infections [11]. The following section will focus on the shared and distinct 
roles of the type‐I and III IFNs as innate antiviral effectors.  
 
1.2.2.1 Type-I Interferons 
In humans, the type‐I IFNs are encoded by a cluster of related genes located on chromosome 
9 [147]. They include 14 subtypes of IFNα and a single gene encoding IFNβ, IFNε, IFNκ and 
IFNω. In mice type‐I IFNs are encoded on a related region on chromosome 4 and have the 
same subtypes except for their lack of IFNω, expressing IFNζ instead [133]. IFNα and IFNβ are 
the main IFNs produced downstream of PRR activation, and therefore are also the most 
heavily studied. In general, IFNα expression is dependent on the activation of IRFs (especially 
IRF7) whereas efficient IFNβ expression requires both IRF3/7 and NF‐κB activation. The 
nuances of IRF‐mediated type‐I IFN expression regulation have been extensively reviewed 
elsewhere [343]. The type‐I IFNs are classified by their ability to signal through the type‐I IFN 
receptor that is composed of two heterodimeric subunits (IFNAR1 and IFNAR2) and is almost 
ubiquitously expressed throughout the body [70].  
 
1.2.2.1.1 Signalling from the type-I IFN receptor 
Once produced and secreted from infected cells, type‐I IFNs bind to the extracellular domains 
of the cognate type‐I IFN receptor (IFNAR1/2). Receptor binding can occur on the same cell 
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or on neighbouring cells to initiating autocrine or paracrine signalling, respectively. 
Importantly most cell types respond to type‐I IFNs due to the almost ubiquitous expression 
of IFNAR1/2 [70, 155]. Ligand binding causes hetero‐dimerization of the receptor subunits 
bringing the intracellular domains of the receptor into close proximity [179]. Each of the 
IFNAR1 and IFNAR2 intracellular domains are pre‐associated with tyrosine kinases that are 
activated upon receptor dimerization by close proximity trans‐phosphorylation [147]. IFNAR1 
is associated with Tyrosine Kinase 2 (TYK2) and IFNAR2 is associated with Janus Kinase 1 (JAK1) 
respectively [81, 377]. Once activated JAK1 and TYK2 phosphorylate the intracellular domains 
of the IFNAR subunits, allowing docking of signal transducer and activator (STAT) proteins via 
their SH2 domains. The canonical STAT proteins downstream of IFNAR signalling are STAT1 
and STAT2. Once docked to the receptor, JAK1 and TYK2 phosphorylate STAT1 and STAT2 at 
tyrosine residues Y701 or Y690 respectively [214]. STAT1/2 phosphorylation results in the 
formation of STAT1/2 heterodimers, nuclear translocation, and subsequent complexing with 
IRF9 [155]. This hetero‐trimeric complex (ISGF3) then binds to IFN‐stimulated response 
elements (ISRE) in the proximal promoter regions of over 100 interferon stimulated genes 
(ISGs), up‐regulating their transcription and translation [304]. Figure 1.9 shows a summary of 
the type‐I IFN signalling pathway. ISGs encode various proteins that act directly or indirectly 
to inhibit viral replication and spread [214]. These proteins carry out a range of effector or 
regulatory functions that give rise to an appropriately managed antiviral state. Effector 
functions are varied and include inhibition of viral entry, inhibition of protein synthesis, 
alterations to cellular metabolism, degradation of viral proteins or genetic material and 
inhibition of viral egress [304]. Regulatory ISGs include PRRs and signalling intermediaries of 
these pathways as well as immune modulatory molecules and negative regulators responsible 
for returning the cell to homeostasis [278].  
 
1.2.2.1.2 Switching off the type-I IFN response  
Negative regulation of the IFN pathway is essential for returning the body to homeostasis 
after infection is cleared, preventing over‐activation of inflammatory pathways. Unchecked 
type‐I IFN responses can lead to a range of auto‐inflammatory conditions called 
“interferonopathies” including systemic lupus erythematosus, Sjogren's syndrome, 






women [59]. As a result, there are several negative feedback mechanisms that switch off type‐
I IFN responses.  
One mechanism of negative regulation is the immediate ligand‐stimulated downregulation of 
the type‐I IFN receptor at the cell surface [14]. Upon ligand binding, the ligand‐receptor 
complex is rapidly internalised by endocytosis [70]. Once internalized the IFNAR1 subunit is 
degraded in a lysosome dependent manner. This effect is mediated by a serine protein kinase 
called PKD2 [394]. PDK2 is activated in response to IFN signalling and mediates 
phosphorylation of IFNAR1 leading to its ubiquitination, internalisation by endocytosis and 
subsequent lysosomal degradation [394]. The IFNAR2 subunit is either recycled to the cell 
surface or degraded [70]. The fate of IFNAR2 after ligand binding appears to rely on the 
strength of the ternary structure formed between the ligand and the two receptor subunits. 
Weaker binding by IFNα results in recycling to the cell surface but stronger binding by IFNβ 
leads to receptor degradation along with IFNAR1 [207]. 
Another method of shutting off the IFN response is via the suppressor of cytokine signalling 
(SOCS) proteins. SOCS proteins (e.g., SOCS1) are also ISGs that are upregulated early in 
response to, and can negatively regulate both type‐I and type‐III IFN mediated JAK/STAT 
signalling [27, 333]. SOCS1 protein contains an N‐terminal kinase inhibitory region (KIR), a 
central SH2 phospho‐protein interaction domain, and a C‐terminal SOCS box involved with 
ubiquitination of proteins for targeted degradation [385]. SOCS1 directly interacts with 
activated TYK2 protein that is associated with the IFNAR1 subunit of the receptor. By 
associating with TYK2 SOCS1 prevents the phosphorylation and activation of STAT proteins 
through the coordinated action of the SH2 and KIR domains [269]. In addition to this action 
on STAT phosphorylation, SOCS1 also inhibits the Lys‐63 ubiquitination mediated stabilisation 
of TYK2 protein [269]. Prevention of this Lys‐63 ubiquitination event likely destabilises the 
TYK2‐IFNAR1 interaction resulting in reduced IFNAR1 surface expression. As an ISG, 
expression of SOCS proteins occurs rapidly after IFN signalling is initiated by ligand binding 
[385]. However, SOCS mediated negative regulation is short lived with most of these proteins 
having half‐lives of less than two hours [322]. 
Additionally, the IFN response can also be switched off by the actions of the negative 
regulator Ubiquitin Specific Peptidase 18 (USP18). Like the SOCS proteins USP18 is an ISG that 
is produced in response to type‐I and type‐III IFN signalling [99]. In addition to causing 
degradation of IFN pathway proteins such as ISG15 via ubiquitination, USP18 expression also 
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leads to long‐term receptor desensitisation [14]. Once accumulated in the cell USP18 protein 
interacts with STAT2. This STAT2 mediated interaction recruits USP18 to the receptor complex 
and facilitating its subsequent interaction with JAK1 [13]. Interaction with JAK1 at the IFNAR2 
receptor subunit results in destabilisation of the ligand‐receptor heterotrimeric complex 
preventing downstream signal transduction [369]. Unlike SOCS mediated desensitisation that 
is short lived, USP18 mediated desensitization lasts several days [95, 100]. Importantly, USP18 
mediated receptor desensitisation is not equally applicable for all IFNs. For example, IFNβ is 
not susceptible to USP18 mediated desensitisation as a result of its stronger binding affinities 
for individual receptor subunits, partially explaining its differing signalling properties 
compared to IFNα [369]. 
 
1.2.2.1.3 Differential type-I IFN signalling  
Many of the genes upregulated by type‐I IFNs are the same because of their shared receptor 
and downstream signalling pathway. However, type‐I IFNs exhibit both overlapping and 
distinct biological activities. A key example of differential biological activity is the ability of 
IFNβ to induce stronger pro‐apoptotic and antiproliferative activity compared to IFNα despite 
eliciting the same antiviral protection on multiple cell lines [207]. Importantly the unique 
biological activities displayed by type‐I IFN subtypes underpins their different clinical 
applications for treatment of viral infections [107], cancers [361] and multiple sclerosis [281]. 
Consequently, there is considerable interest in uncovering the molecular mechanisms that 
drive these differential properties. There is growing evidence implicating differences between 
IFN subtypes in their receptor binding kinetics to differential downstream effects. The general 
model for receptor engagement is that type‐I IFNs first dimerize with a high affinity 
interaction to the IFNAR2 subunit. Subsequently, a lower affinity interaction to IFNAR1 
recruits this subunit to the signalling complex and initiates signalling [39]. The binding of 
IFNAR1 is the rate limiting step for classical signalling to progress [196]. Interestingly, the 
affinity and dissociation constants for type‐I IFNs with each receptor subunit differs between 
IFN subtypes. Notably, the binding affinities of IFNβ are stronger than for IFNα for both 
receptor subunits. Specifically, IFNβ binds the IFNAR2 ectodomain with ~100 pM affinity 
compared to IFNα binding in the nanomolar range [179]. For the interaction with the IFNAR1 
ectodomain IFNβ exhibits ~260 nM binding affinity compared to IFNα binding in the 
micromolar range [71]. The tighter binding of IFNβ to the IFNAR1 subunit is demonstrated to 
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drive non‐canonical signalling independent of IFNAR2 activation. This IFNβ‐IFNAR1 signalling 
axis was shown to drive pathological toxicity in a mouse model of LPS‐induced septic shock 
[71]. Additionally, IFNβ’s higher affinity interaction to the IFNAR1 subunit also acts to prevent 
USP18 mediated receptor desensitization for IFNβ but not IFNα. This occurs as a result of the 
ability of IFNβ to efficiently recruit IFNAR1 causing greater stability of the ternary ligand‐
receptor complex that resists USP18 mediated receptor‐ligand complex destabilisation [369]. 
Greater complex stability mediated by IFNβ but not IFNα is shown to result in prolonged ISG 
upregulation, including genes with pro‐apoptotic function [100]. Understanding the 
molecular basis that drives the distinct properties the type‐I IFN subtypes is important to tailor 
their therapeutic uses.  
 
1.2.2.2 IFN-epsilon overview  
IFN‐epsilon (IFNε) is the most recently identified member of the type‐I IFN family. Both the 
mouse and human IFNε gene were first annotated in a 2004 paper by Hardy et al. [133], 
however it was not until 2013 that it was more fully characterised [105]. Like others in the 
family, IFNε signals through the type‐I IFN receptor (IFNAR1/2) to elicit its antiviral effect 
[105]. Unlike the classical type‐I IFNs (α or β) that are mainly produced in reaction to sensing 
viral pathogens, IFNε displays the unique characteristic of being constitutively expressed in 
tissues of the female reproductive tract (FRT) [133]. Instead of regulation by PRR recognition 
the expression of IFNε is controlled by cycling female sex hormones and thus the level of IFNε 
change over the menstrual cycle and during pregnancy [105, 250]. This places IFNε in a unique 
position to pre‐emptively control infection in the FRT. This aspect of IFNε’s biology is 
especially important considering the ability of viruses to evade IFN response and cause 
disease after infection is established. A significant portion of this thesis will examine the 
antiviral properties of IFNε in control of viral infection in the FRT. The following section will 
discuss the current literature surrounding the biology, regulation, and antiviral effect of IFNε.  
 
1.2.2.2.1 Discovery of IFNε 
Both the mouse and human genes for IFNε (IFNe1) were discovered in 2004 by 
characterisation of novel gene sequences surrounding the type‐I IFN locus [133]. The IFNe1 
gene was found to have a similar structure and sequence to other members of the type‐I IFN 
family. Specifically, human IFNε has 32% and 36% amino acid identity with human IFNα‐2A 
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and IFNβ, respectively. This compares to 33% identity between IFNα‐2A and IFNβ [133]. 
Interestingly, human IFNε has a high level of relatedness to the mouse gene with 58% 
sequence identity plus 15% amino acid similarity [133]. From this study, sequence alignments 
and modelling indicated that the expressed protein from the IFNe1 gene likely displayed 
conserved folding and domain structure to other type‐I IFNs, including the predicted binding 
site for the IFNAR1/2 receptor. Despite the similarities in their coding regions, analysis of the 
IFNe1 proximal promoter region revealed divergence from canonical transcription factor (TF) 
elements normally found in canonical type‐I IFN promoters. Importantly, the IFNe‐1 promoter 
lacks conventional type‐I IFN TF binding sites downstream of PRR or IFN signalling pathways 
such as IRFs, NF‐kB or ISGF3 [105]. Instead of these conventional binding sites, the promoter 
contains a progesterone response element (PGR) that is conserved between the mouse and 
human genes.  
 
1.2.2.2.2 Expression of IFNε  
IFNε displays unique regulation and expression patterns in vivo as a result of differences in 
the promoter of the IFNe1 gene compared to other type‐I IFNs. IFNε expression is tissue 
specific and most highly expressed in the FRT of both mice and humans [105]. Several others 
have reported detectable mRNA or protein expression of IFNε in the gut, brain, lung and in 
the male reproductive tissues of either humans, mice or rhesus macaques [73, 133, 145].  
Unlike other type‐I and type‐III IFNs which illicit a reactionary response to viral infection IFNε 
expression is constitutive and mainly controlled by the levels of female sex hormones 
estrogen and progesterone [105]. In humans this means that IFNε expression changes over 
the menstrual cycle, is reduced in post‐menopausal women and during early pregnancy [105, 
250]. Importantly, IFNε is the only IFN to be expressed constitutively in the non‐pregnant 
human FRT [253]. Consequently, this places IFNε in a unique position to activate IFN signalling 
prior to viral infection, potentially circumventing many viral evasion strategies (discussed in 
the following section 1.3) that rely on first establishing the transcription and translation of 
viral proteins. On the other hand, this means when expression of IFNε is low the female 
reproductive tract may be more susceptible to viral or bacterial infections.  
The hormonal regulation of IFNε differs slightly between mouse and humans as illustrated in 
Figure 1.10. In the mouse, IFNε expression is highest during estrous and lowest during diestrus 






pregnancy, murine IFNε expression is reduced in early pregnancy (d4.5) and increases 
gradually at later time points of gestation (d12.5, d18.5) [105]. On the other hand, the most 
recent work by Nollaig et al. on IFNε expression in humans indicates there are differences in 
regulation between upper and lower FRT [253]. In contrast to observations in mice, IFNε 
protein is highly expressed in the basal epithelium of the lower FRT (vagina and the ectocervix) 
and this stays constant throughout the menstrual cycle. However, in the endometrium (upper 
FRT) IFNε protein levels are significantly higher during the luteal phase compared to the 
follicular phase of the menstrual cycle [253]. Another study investigating IFNε expression in 
human pregnancy found that the concentrations of IFNε in vaginal secretions were lowest in 
early pregnancy and then increased throughout pregnancy similar to the expression pattern 
seen in mice [250]. 
In addition to in vivo expression patterns, studies in human cell lines have demonstrated 
regulation of IFNε in vitro. Consistent with its hormonal control, human IFNε promoter activity 
was shown to decrease following stimulation with progesterone in a hormone responsive 
endometrial cell line (ECC1) [253]. Additionally, treatment of HeLa cells with TNFα increased 
the expression of IFNε leading to an increase in downstream RIG‐I expression [210]. 
Furthermore, IFNε mRNA expression was increased in an ectocervical cell line (Ect1) by 
exposure to semen [316]. IFNε expression can also be post‐transcriptionally controlled by 
molecular transporter importin 9 that binds the 5’ UTR of IFNε message acting to limit 
translation [211]. Together the unique expression pattern and regulation of IFNε suggests it 
has an important role balancing antiviral protection and normal biological function of the FRT.  
 
1.2.2.2.3 Properties of recombinant human and mouse IFNε protein 
Like all the type‐I IFNs, both the human and mouse IFNε signal through the IFNAR1/2 receptor 
to initiate ISG expression and induce an antiviral state [105]. However, as the most recently 
discovered member of the type‐I IFN family there is less known about the basic biology of 
IFNε compared to IFNα or IFNβ. In general, functional studies investigating the properties of 
the human IFNε protein have been hindered by difficulties in expressing the recombinant 
human IFNε protein and lack of commercially available antibody reagents [134]. Currently 
two groups have reported the successful expression of recombinant human IFNε protein. The 
first group (our collaborators led by Paul Hertzog at the Hudson Institute of Medical Research) 
published in 2017 on the anti‐HIV properties of human IFNε in vitro using protein expressed 
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and refolded from bacteria [110]. The second group published in 2018 also expressed the 
protein in bacteria and used it to investigate binding properties to the type‐I IFN receptor 
[134].  
This latter study found that human IFNε displayed a‐typical receptor binding kinetics with 
regards to the individual IFNAR1/2 receptor subunits. IFNε bound with significantly lower 
affinity to the extracellular domain of IFNAR2 compared to the equivalent interaction with 
IFNα. On the other hand, IFNε was able to bind with greater affinity to the IFNAR1 subunit 
compared to IFNα. Figure 1.11 compares the binding affinities of human type‐I IFNα, IFNβ and 
IFNε with the individual receptor subunits. This data suggests IFNε has evolved to maintain a 
high affinity interaction with IFNAR1 compared to its reduced efficiency binding IFNAR2. This 
study also found that human IFNε is roughly 1000‐fold less potent in biological assays 
compared to IFNα2, likely because of the lower affinity for IFNAR2.  
The properties of recombinant murine IFNε protein have also been investigated [335]. 
Consistent with the study of the human protein, murine IFNε displayed the non‐canonical 
binding affinities for the individual receptor subunits. Murine IFNε bound with higher affinity 
to IFNAR1 than IFNAR2. Compared to IFNα, murine IFNε bound to IFNAR2 with 3000‐fold 
lower affinity and to IFNAR1 with a 4‐fold higher affinity compared IFNα. This was consistent 
with a roughly 100 – 1000‐fold reduced potency in biological assays for antiviral, anti‐
proliferative and anti‐bacterial activities. Intriguingly murine IFNε was found to exhibit cross‐
species reactivity on human cells, displaying 100‐fold greater activity than on mouse cells.  
Taken together these studies highlight the subtle differences in type‐I IFN biology. IFNε 
appears to be less potent compared to canonical type‐I IFNs in biological assays. Furthermore, 
the abnormal binding kinetics to the IFNAR1/2 receptor suggests the potential for IFNε having 
unique signalling properties compared to other type‐I IFNs. These unusual characteristics of 
IFNε biology appear to be conserved between the mouse and human proteins. The 
differences in biological activity and unique expression pattern of IFNε suggests it likely plays 
a role in FRT innate immunity that is not yet fully understood. 
 
1.2.2.2.4 IFNε antiviral activity  
There is growing evidence that IFNε protects against sexually transmitted viral and bacterial 
pathogens. In a mouse model, Fung et al. demonstrated that IFNε knockout (IFNε‐/‐) rendered 






wildtype counterparts [105]. Interestingly, a pilot study in humans observed IFNε protein 
levels in the cervical‐vaginal secretions of pregnant women were inversely correlated to HSV 
infection status [250]. It is unclear at this stage if low IFNε levels promote HSV infection during 
pregnancy or if HSV infection reduces expression of IFNε in the human FRT to promote viral 
replication.  
In addition to mouse models of infection, in vitro assays using reporter cell lines show that 
recombinant IFNε can protect against late‐stage HIV replication events as a result of the 
upregulation of host restriction factors that block HIV infection [110]. Interestingly, this 
correlates with findings in a cohort of high exposure risk HIV negative female sex workers [1]. 
In this study the group of HIV negative sex workers had greater levels of IFNε expression 
compared to a low risk (non sex worker) control group. Interestingly, the levels of IFNε in the 
FRT positively correlated with increased exposure to semen. This suggests IFNε may 
contribute to cervical‐vaginal immunity reducing susceptibility for HIV‐1 infections in high risk 
groups. Taken together, in vitro experiments, in vivo mouse models and patient data imply 
IFNε has role in the protecting the FRT from sexually transmissible pathogens. Continued 
exploration into the host‐virus interactions between IFNε with a diverse range of viral and 
bacterial pathogens that can infect the FRT are required for us to fully understand this aspect 
of mucosal innate immunity.  
 
1.2.2.3 Similarities and differences between type-I and type-III IFN signaling 
Other than the classical type‐I IFNs, the type‐III IFN family was discovered more recently by 
two independent groups in 2003 [174, 318]. They are related to the IL‐10 family cytokines and 
are genetically distinct from the type‐I IFNs [318]. In humans there are three functional 
subtypes IFNλ‐I, IFNλ‐II and IFNλ‐III as well as one pseudogene IFNλ‐IV. In mice only IFNλ‐II 
and IFNλ‐III are functionally expressed, and IFNλ‐I is a pseudogene [182]. Like other IL‐10 
related cytokines, the type‐III IFN receptor is a heterodimer made up of the shared IL‐10 
receptor chain β (IL‐10RB) and the cytokine specific receptor chain (IFNLR1) [318]. Type‐III 
IFNs initially bind to their receptor with a high‐affinity interaction to the specific IFNLR1 
subunit and then trimerize with the lower affinity IL‐10R subunit [32]. Although type‐I and 
type‐III IFNs are genetically distinct and act through different receptors they display many 
overlapping functions. This is because of similarities in the pathways downstream of receptor 
binding (see Figure 1.9). Like the type‐I IFN receptor, binding of type‐III IFNs to the IL‐10RB/ 
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IFNLR1 initiates typical JAK/STAT signalling leading to the formation of STAT1/2 heterodimers 
and subsequent ISG induction [255]. As a result, transcriptional profiling has revealed that the 
vast majority of genes induced by type‐III IFNs are the same as those induced by type‐I IFNs 
[36, 98, 397]. However, despite their similarities these IFN families play non‐redundant roles 
in controlling viral infection due to their differing special‐temporal expression and activities. 
 
1.2.2.3.1 Production of type-III IFN 
Like type‐I IFNs, type‐III IFNs are produced in response to sensing viral infection. This occurs 
via the same PRRs (RIG‐I, MDA5 and TLRs) as with type‐I IFN [255]. However, type‐I and III 
IFNs are not uniformly produced in response to viral infection. Interestingly, differentiated 
epithelial cells favour the production of type‐III IFNs. This occurs because of the alternate sub‐
cellular localizations of the RLR signal intermediate MAVS to either the mitochondrial or 
peroxisomal membrane [79]. Whereas mitochondrial MAVS favours type‐I IFN production, 
MAVS that localizes to peroxisomes promotes greater levels of type‐III IFN production [255]. 
Importantly, epithelial cell differentiation has been shown to lead to an increased abundance 
of peroxisomes that is associated with an increase in type‐III IFN responses in these cells [254].  
 
1.2.2.3.2 Type-III receptor localization 
The main driver of different biological function between type‐I and III IFNs is the limited 
localization of the type‐III IFN receptor. Although the shared IL‐10B subunit is expressed 
widely throughout the body, the expression of the IFNLR1 subunit is tightly regulated and 
limited to epithelial cells or neutrophils [182]. Comparatively both subunits of the IFNAR1/2 
receptor are expressed almost ubiquitously throughout the body. As a result, type‐III IFNs act 
primarily at mucosal surfaces such as the lung, gut, and reproductive tract whereas type‐I IFNs 
can have broad systemic effects [172, 182, 255].  
 
1.2.2.3.3 Switching off the type-III IFN response 
The other main difference of type‐III IFNs is the kinetics of gene induction following receptor 
binding. Type‐III IFNs display a slower onset and more sustained ISG induction compared to 
type‐I IFNs in cell lines [28, 98]. The mechanisms driving differential kinetics of gene induction 
are likely due to differences in negative regulation of these pathways. As discussed previously, 
type‐I IFNs are shut off by both short‐term SOCS and long‐term USP18 negative regulation. 
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Conversely, there is evidence suggesting that type‐III IFNs respond to SOCS but are resistant 
to USP18 mediated regulation leading to a sustained ISG induction profile [27]. This is 
demonstrated in cell culture by IFN induced USP18 expression shutting off IFNα but not IFNβ 
or IFNλ signalling [99]. Additionally, IFNλ mediated ISG induction was enhanced in SOCS1 but 
not USP18 knockout cell lines [27]. However, this evidence is contrasted by results in USP18 
knockout mice that were hypersensitive to both type‐I and type‐III IFN signalling, leading to 
improved outcomes in an epithelial breast cancer model [34]. Additionally, overexpression of 
both SOCS1 and USP18 in cell lines was able to inhibit type‐I and III IFN signalling equally [27]. 
This contrasting evidence seems to imply there are situation dependent differences in type‐
III IFN responsiveness to USP18 mediated desensitisation. These differences could result from 
differences in the concentration of USP18 (overexpressed versus endogenous) or type‐III IFN 
receptor expression in individual cell lines or model systems. 
 
1.2.2.3.4 Physiological outcomes of type-I and III IFN signalling  
As a result of the different spatial‐temporal gene induction profiles mediated by type‐I and III 
IFNs they have distinct role in controlling viral infection. There is evidence showing that type‐
III IFNs have a lower propensity to activate inflammatory pathways compared to type‐I IFNs 
[32, 66, 98]. This effect is proposed to reduce the impact of type‐III IFNs on barrier integrity 
of epithelial surfaces, making it more suitable for protecting mucosal surfaces from viral 
infection [32]. In a mouse model, treatment with both type‐I and III IFNs were found to protect 
the mice equally well from Influenza A Virus (IAV) infection. However, in the process type‐I 
IFNα induced greater levels of inflammatory cytokines, immune cell infiltration and epithelial 
cell death compared to type‐III IFN treatment [66]. Importantly, despite type‐I and III IFNs 
inducing identical responses in lung epithelial cells in this model, only type‐I IFN treatment 
activated tissue resident immune cells leading to the release of pro‐inflammatory cytokines. 
This example of different cell types responding to type‐I or III IFN shows how differing 
receptor expression is a key driver of the biological differences between these IFN families. 
However, the tendency of type‐III IFNs to incite lower levels of inflammation may be 
dependent on the biological context. For example, studies have shown that type‐III IFNs are 
elevated in serum of systemic lupus erythematosus (SLE) autoimmune disease patients [190]. 
Additionally, mouse models of SLE showed that deletion of the IFNLR1 gene protects mice 
from organ damage [113]. This effect was driven by IFNλ mediated production of pro‐
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inflammatory chemokines (CXCL9, CXCL10 and CXCL11) in keratinocytes. Another example of 
how cell‐type specific responses differentiate the function of type‐I and III IFNs in vivo is 
comparing their efficacy in clearance of local or systemic viral infections. In a separate mouse 
model of IAV infection, IFNλ was found to offer greater protection in the upper airways 
compared to type‐I IFNs. However, when IAV was inoculated directly into the lung, only mice 
deficient in IFNAR1 and not IFNLR1 were more susceptible to IAV infection compared to WT 
[172]. This indicates that once infection has bypassed mucosal epithelial surfaces, type‐I IFNs 
contribute more to clearing viral infection than type‐III IFNs. Another example of differential 
functions between type‐I and III IFNs is the longevity of the antiviral response induced at 
mucosal surfaces. This is exemplified in mouse models where intranasal treatment with IFNλ 
provided longer lasting protection against IAV infection in the upper respiratory tract 
compared to similarly administered IFNα treatment [172]. The longevity of antiviral 
protection of type‐III compared to type‐I IFNs is likely dependent on differing properties 
regarding their negative regulation. 
Together this information highlights the role of type‐III IFNs as antiviral protectors of mucosal 
epithelial surfaces. Additionally, this implies the importance of type‐I IFNs in protecting 
against infections that spread beyond the epithelial cell layers. 
 
1.2.3 Inhibition of ZIKV and DENV infection by Interferon  
Both type‐I and III IFNs are important in controlling Flavivirus infection through the production 
of ISGs. These genes play a wide variety of roles in the innate antiviral response and have 
been extensively reviewed elsewhere [305]. Some ISGs are important for sensing viral 
pathogens, such as RIG‐I or the IRF proteins while others are important in directing immune 
cell trafficking, such as the chemokine CXCL10 that recruits antiviral effector NK cells to the 
site of infection. Importantly, some ISGs can act directly to inhibit various stages of the virus 
lifecycle. Some of these direct acting ISGs have been determined for ZIKV and DENV and their 
mechanism of action will be described in the following sections. 
 
1.2.3.1 Interferon stimulated genes that inhibit ZIKV and DENV  
Two complementary studies have demonstrated that Interferon Stimulated Gene 15 (ISG15) 
protects against ZIKV infection [326, 327]. Mature ISG15 is a 15 kDa member of the 
ubiquitin family of proteins that plays various roles in the innate immune response that 
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have been extensively reviewed [266]. One of the main functions of ISG15 is the covalent 
modification of target proteins via ISG15 conjugation (ISGylation) disrupting target protein 
localization and protein‐protein interactions. Additionally, ISG15 has immune modulatory 
functions through non‐covalent protein interactions and by acting as an immune cell 
signalling molecule. One study found that ZIKV infected ISG15‐/‐ mice had increased severity 
of retinal lesions and impaired antiviral responses compared to wildtype mice and this led to 
lower expression of other ISGs like RIG‐I and IFI6 [325]. A follow‐up study by the same group 
extended these observations to show that ZIKV infection in human primary corneal 
epithelial cells (HCEC) induced expression of ISG15 RNA and protein, and that siRNA 
mediated knockdown of this expression lead to increased ZIKV infection in these cells [327]. 
Conversely, heterologous expression of ISG15 protein was able to ameliorate this effect. 
Furthermore, this group found that ISG15 expression was important for both reducing ZIKV 
entry into host cells, and for inhibiting viral replication once inside the cell. Similarly, ISG15 
inhibits DENV infection. DENV infection has been shown to upregulate expression of ISG15 
in RAW264.7 cells, and its silencing increased DENV replication in these cells [64]. 
Furthermore, infection with DENV increased the total amount of ISGylated proteins in the 
cell, suggesting a link between the ISG conjugation activity of ISG15 with the observed 
antiviral effect [64].  
Members of the Interferon‐Inducible Transmembrane (IFITM) protein family also protect 
against both ZIKV and DENV infection. As their name suggests these proteins are found 
inserted into cellular membranes, most commonly localising in late endosomes, and can 
interfere with fusion of viral and host membranes following viral entry [19]. Importantly, 
siRNA mediated knockdown of IFITM1 or 3 was shown to increase ZIKV infection in human 
cell lines [300]. This effect could be rescued with overexpressed protein but relied on the 
protein’s endosomal localisation. Consistent with their localisation to endosomal 
membranes, knockdown of IFITM1 or 3 was shown to impact very early steps in the viral 
replication cycle following entry [300]. Likewise ectopically expressed IFITM2 or IFITM3 have 
been shown to reduce DENV infection in human cell lines to similar levels to those observed 
when treating cells with 100 U/mL IFNα [157]. Like ZIKV, this inhibitory effect was observed 
to impact the DENV lifecycle at a step prior to the initial round of viral RNA translation.  
Another ISG shown to directly inhibit ZIKV and DENV infection is interferon alpha‐inducible 
protein 6 (IFI6). IFI6 is a 13 kDa protein that is known to be involved in cell survival and 
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counteracting virus‐mediated apoptosis [275]. Increased expression of IFI6 was shown to 
reduce ZIKV replication and prevented ZIKV mediated cell death in the Huh7 (liver origin) 
cell line [89]. In this study, IFI6 localised to the ER near ZIKV RCs suggesting that it may play a 
role in inhibiting viral replication or virion production. Furthermore, this antiviral effect of 
IFI6 was independent of ZIKV protein stability or polyprotein processing. Likewise, Huh7.5 
cells stably transduced with a lentivirus IFI6 expression vector demonstrated decreased 
DENV replication compared to an empty vector control [285]. This study also demonstrated 
that CRISPR‐mediated knockout of endogenous IFI6 expression increased DENV replication 
in infected cells.  
Furthermore, the virus inhibitory endoplasmic reticulum associated interferon inducible 
protein (Viperin) has been shown in multiple studies to reduce ZIKV and DENV replication 
[141, 259, 354]. Viperin is a 42 kDa protein and as the name suggests is normally associated 
with ER membranes. Importantly, Viperin has antiviral effects against a wide range of 
viruses in both RNA and DNA families [140, 142, 244]. The first study to investigate the 
importance of Viperin in ZIKV infection found that Viperin was induced in response to ZIKV 
infection and overexpressed Viperin restricted ZIKV replication in human cell lines [354]. 
Additionally, murine embronic fibroblasts (MEFs) derived from Viperin knockout mice were 
more permissive to ZIKV replication compared to wildtype MEFs. Furthermore, the anti‐ZIKV 
action of Viperin relied on the highly conserved C‐terminal end of the protein [142]. A 
second study confirmed Viperin’s antiviral effect, finding that Viperin interacted directly 
with the ZIKV NS3 protein resulting in its degradation and reduced viral replication [259]. 
Similarly, DENV inhibition by Viperin is also dependent on the C‐terminal region of the 
protein and its interaction with the DENV NS3 protein [141]. 
Aside from these ISGs that are known to inhibit both ZIKV and DENV infection, other direct 
acting ISGs have been independently validated for either virus. Future studies may prove 
these ISGs are effective against both viruses, or they may reveal virus‐specific activity. One 
of these ISGs is interferon‐inducible factor 16 (IFI16). This ISG has multiple roles in 
modulating expression of viral proteins and activating the STING pathway during infection 
[77]. Overexpressed IFI16 was shown to reduce infection of both the +ssRNA alphavirus 
chickungunya virus (CHIKV) and ZIKV in human skin fibroblasts [368]. No specific mechanism 
for this effect was investigated. To our knowledge, IFI16 has not been independently 
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validated for its antiviral activity against DENV infection. However, the role of IFI16 in 
promoting STING activation suggests that this is a strong possibility.  
Other ISGs known to inhibit DENV infection are the ArfGAP with dual pleckstrin homology 
(PH) domains 2 (ADAP2) protein and the tripartite motif 69 protein (TRIM69). ADAP2 is most 
highly expressed in the heart, and skeletal muscle and is known to regulate the ADP 
ribosylation factor (Arf) family of proteins via its GTPase activating protein (GAP) function 
[132]. Arf proteins are involved in regulating vesicular trafficking and cytoskeletal 
organization. Importantly, ectopically expressed ADAP2 has been demonstrated to restrict 
DENV infection by inhibiting GAP mediated trafficking of incoming DENV containing vesicles 
[320]. TRIM69 mediates protein ubiquitination through its E2 conjugation enzymatic 
activity. It localizes to the cytoplasm and inside the nucleus of cells [131]. TRIM69 has been 
shown to directly interact with DENV NS3, resulting in its polyubiquitination and subsequent 
degradation to inhibit DENV replication [358]. To our knowledge, the roles of both ADAP2 
and TRIM69 in protection against ZIKV infection have not been investigated. 
In the context of natural infection, multiple ISGs are expressed in concert and as a result 
target many of the stages of DENV and ZIKV replication simultaneously. The combined 
effects of ISGs to inhibit ZIKV and DENV infection has applied strong selective pressure on 
these viruses to evolve mechanisms to evade detection by the cell or prevent the 
production of ISGs through blocking the IFN signalling pathway. 
 
1.3 DENV and ZIKV mediated evasion of the IFN response 
The IFN response is a barrier that viruses must overcome to cause infection, replicate, and 
spread. Not surprisingly, because of this strong selective pressure viruses have evolved ways 
to counteract IFN responses allowing them to gain a foothold and cause infection. Flaviviruses 
such as ZIKV and DENV are no exception. They have evolved a complex web of interactions 
with the host innate immune response to undermine both the production and downstream 
signalling of the IFNs. Some of these evasion mechanisms are common amongst flaviviruses 
but many are species specific and are yet to be fully elucidated. Discovery of new immune 
evasion mechanisms underpins the rational design of immune modulatory treatments or live‐





1.3.1 Common strategies between flaviviruses  
As obligate intracellular pathogens, flaviviruses have evolved many ways to avoid detection 
by host intracellular PRRs. For example, the 7‐methylguanylate cap that is incorporated on 
the 5’ end of the +ssRNA Flavivirus genome by the NS5 MTase domain mimics the 
appearance of host mRNA [234]. 5’ capping assists host translational initiation factors to 
bind the viral RNA and prevents RNA degradation by exonucleases in the cytoplasm [295]. 
Importantly, 5’ capping also interferes with the recognition of vRNA as ‘non‐self’ by the 
MDA5 PRR, limiting the production of IFN by infected cells [399]. In addition to hiding from 
detection, capping also avoids the antiviral effects of the interferon induced protein with 
tetratricopeptide repeats (IFIT) protein family that can bind to and sequester vRNA of 
uncapped or cap mutant Flavivirus genomes [170].  
The second mechanism commonly used by flaviviruses to avoid detection is the induction of 
membrane rearrangements allowing for the formation of the RC as part of the virus lifecycle 
[224]. As mentioned previously, for flaviviruses these structures are formed from modified 
ER membranes by the coordinated action of multiple host and viral proteins. Replication 
organelles form as a series of membranes that surround the dsRNA replication 
intermediate, acting to physically segregate this potent viral PAMP from detection by 
cytoplasmic PRRs like RIG‐I [7, 310]. In addition, these replication organelles limit the 
antiviral activity of the ISG encoded MXA protein, likely by blocking MXA‐mediated 
recognition of the forming viral nucleocapsid [149]. Evidence in support of this theory is 
provided in one study comparing DENV to JEV replication where they observed a greater 
degree of dsRNA in the cytosol during JEV infection compared to DENV and this correlated 
to increased IFN production in JEV infected cells [351]. Ultrastructural analysis of the ZIKV 
RC shows it to be highly similar to that of DENV, suggesting their related function [58].  
Aside from genome capping and the formation of replication organelles, several flaviviruses 
evade IFN production by expression of subgenomic Flavivirus RNA (sfRNA) [51]. Flavivirus 
sfRNAs are formed from the incomplete degradation of the viral genome by cellular 5’ to 3’ 
exonucleases [212]. Specifically, conserved stem‐loop (SL) or dumbbell (DB) RNA structures 
within the 3’UTR stall exonuclease activity and result in the production of short RNA 
sequences [106]. Importantly sfRNAs generated during ZIKV infection antagonize the activity 
of both RIG‐I and MDA5 [82], although a full mechanism of action has not been elucidated 
for this interaction. Likewise, DENV sfRNA inhibits RIG‐I mediated IFN production. This effect 
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is governed by a sequence‐specific interaction between DENV sfRNA and the tripartite motif 
containing 25 protein (TRIM25) [202]. TRIM25 functions as an RNA binding protein and a 
ubiquitin ligase, responsible for the polyubiquitination of activated RIG‐I leading to 
sustained signal transduction [162]. 
 
1.3.2 ZIKV specific mechanisms to evade IFN responses  
In addition to strategies common to all flaviviruses, some evasion mechanisms have been 
characterised for ZIKV that may be unique for this virus. These mechanisms prevent ISG 
production by interfering with PRR‐mediated IFN production, or by directly targeting 
signalling intermediaries downstream of the IFNAR1/2 receptor.  
One mechanism that limits the production of IFN is mediated by ZIKV NS4A that inhibits RIG‐
I and MDA5 signalling and has been demonstrated independently by two groups [200, 249]. 
Collectively these studies found that ectopically expressed NS4A binds directly to the N‐
terminal CARD domain MAVS. This binding competitively inhibited MAVS interaction with 
activated RIG‐I or MDA5, leading to potent inhibition of downstream type‐I IFN production.  
ZIKV can also prevent the translocation of activated RIG‐I and MDA5 to the mitochondrial 
membranes by acting on members of the 14‐3‐3 protein family. These proteins (14‐3‐3ε and 
14‐3‐3η) act as mitochondrial targeting chaperones that are required for translocation of 
RIG‐I and MDA5 respectively, facilitating their interaction with MAVS [188, 192]. 
Importantly, overexpressed ZIKV NS3 protein in HEK 293T cells was able to competitively 
bind to both 14‐3‐3ε and 14‐3‐3η via a conserved binding motif (64‐RLDP‐67) [286]. This 
sequence was found to contain a central negatively charged Aspartic acid residue (D66) that 
acted as a phospho‐mimetic to compete with RIG‐I or MDA5 binding. Mutation of this 
binging motif within the full length ZIKV genome attenuated viral replication compared to 
wildtype virus in A549 cells [286].  
ZIKV can also inhibit the cGAS‐STING pathway via the actions of NS1. One study found that 
ectopically expressed ZIKV NS1 interacts directly with host de‐ubiquitinase USP8 to facilitate 
the deubiquitination of caspase‐1, increasing its stability [395]. In turn caspase‐1 
proteolytically cleaves cGAS, reducing the production of IFN in the cell. Additionally, the 
ZIKV protease NS2B/3 mediates STING cleavage. Using exogenous expression in HEK 293T 
cells it was shown that ZIKV NS2B/3 cleaved human but not mouse STING [78]. This study 
extended these observations to natural ZIKV infection in human fibroblasts by detection of 
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STING cleavage products during infection. The reduction of cGAMP mediated STING 
activation as a result of ZIKV infection inhibited the production of IFN by infected cells.   
Other NS proteins also contribute to limit IFN production downstream of MAVS, TLR and 
cGAS‐STING pathways by targeting the shared signalling intermediaries TBK1, IKKε or IRF3. 
Ectopically expressed NS1 and NS4B interact directly with TBK1, preventing TBK1 
oligomerization and phosphorylation mediated activation [374]. Interestingly, another study 
found that NS1 mediated TBK1 inhibition was specific to recent outbreak strains that had 
evolutionarily acquired a 188‐Val substitution mutation [375]. Additionally, overexpressed 
ZIKV NS5 in HEK 293 cells was demonstrated to directly interact with IKKε [198]. This direct 
interaction resulted in reduced IKKε protein levels and phosphorylation, thereby preventing 
the activation of IRF3. In another study, NS5 was also shown to inhibit IRF3 activation by 
direct binding to endogenous IRF3 in studies involving co‐immunoprecipitation of 
overexpressed NS5 protein [375]. 
Downstream of the IFN receptor, ZIKV also acts to suppress JAK‐STAT signal transduction. 
The best characterized of these mechanisms is the ZIKV NS5 mediated degradation of STAT2 
protein. ZIKV NS5 can bind to STAT2 and initiate its degradation in a proteasome dependent 
manner [121]. Interestingly, this occurs with human but not mouse STAT2 protein, partially 
explaining the difference in species adaptation of ZIKV and difficulties associated with 
infecting IFN competent mice [231]. A separate study found that overexpression of NS5 
leading to STAT2 degradation also resulted in reduced STAT1 phosphorylation in cells 
overexpressing NS5 [146]. One study also demonstrated that ZIKV NS2B/3 expression 
induced the degradation of JAK1 protein in a proteasome‐dependent manner leading to a 
reduction in IFN mediated ISG expression [374]. In addition to the roles of NS proteins in 
inhibition of IFNAR signalling, ZIKV binding to the attachment factor Axl on the cell surface 
also inhibits IFN signalling. In a study using microglial cell lines, ZIKV binding was shown to 
activate the C‐terminal kinase domain of Axl that in turn acted to negatively regulate the 
type‐I signalling pathway via induction of SOCS1 protein expression [216]. 
 
1.3.3 DENV specific mechanisms to evade the IFN response 
Some of the mechanisms that govern DENV‐mediated IFN evasion closely reflect those of 
ZIKV, demonstrating their close evolutionary relationship. These tend to be evasion 
strategies mediated by the more conserved viral proteins, such as the NS3 helicase/protease 
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and NS5 RdRp/MTase. However, there are also mechanisms that differ entirely in their 
action and are unique to DENV.   
One mechanism preventing the production of IFN by DENV is mediated by NS2B. 
Overexpressed DENV NS2B directly interacts with cGAS and causes its degradation by auto‐
phagolysosomes, reducing STING‐mediated IFN production [5].  
Additionally, DENV NS2B/3 proteolytically cleaves human but not mouse STING in a similar 
manner to ZIKV [4]. This species‐specific cleavage was dependent on the presence of an NS3 
cleavage site in human STING. Mutation of this cleavage site was able to restore DENV‐
mediated induction of IFNβ. DENV NS3 also contributes to evasion of IFN by non‐proteolytic 
actions. HEK 293T cells expressing DENV NS3 demonstrated impaired RIG‐I translocation to 
MAVS in response to Sendai Virus infection. Like ZIKV, this interaction was also dependent 
on inhibition of RIG‐I binding to 14‐3‐3ε via a conserved phospho‐mimetic binding motif at 
the same location within NS3 (64‐RxEP‐67) [44]. However, the charged residue mimicking 
the natural phosphorylation site was found to be a Glutamic acid (Glu66) rather than 
Aspartic acid residue as was found for the ZIKV NS3 protein.  Furthermore, DENV NS2A and 
NS4B from multiple DENV serotypes inhibit PRR mediated IFN production via targeting TBK1 
and IRF3. Ectopically expressed DENV NS2A and NS4B were shown to specifically inhibit 
TBK1 auto‐phosphorylation, and reduced total IRF3 protein levels [65]. Moreover, this same 
study found that NS4A from serotype‐1 was in addition uniquely able to contribute to TBK1 
inhibition [65]. This additional evasion mechanism may contribute to the enhanced 
virulence of DENV1. Overexpressed DENV NS2B/3 in HEK 293/TLR3 expressing cells also 
directly interacts with the N‐terminal Kinase domain of IKKε, inhibiting kinase activity and 
reducing IFN production [10].  
Downstream of IFN receptor activation DENV NS4B blocks STAT1 phosphorylation and 
nuclear translocation [236]. DENV NS2A and NS4A were also shown to inhibit ISRE promoter 
activity downstream of IFNβ signalling in HEK 293T cells [236]. For NS4B this effect was later 
found to depend on the N‐terminal signal peptide of the NS4B protein and was enhanced by 
natural cleavage between the NS4A‐2K‐NS4B fragment [235]. For NS2A and NS4A the 
mechanism driving their IFN evasion properties has not yet been elucidated. Finally, similar 
to ZIKV, DENV NS5 mediates STAT2 degradation in a proteasome dependent manner [16]. 
However, in contrast to ZIKV this requires natural viral processing of NS5 from the 
polyprotein and is dependent on the ubiquitin ligase UBR4 [230].  
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During natural infection multiple genetic elements and NS proteins work synergistically to 
counteract the IFN responses in cells. Most of these studies described here investigated virus 
mediated IFN evasion by ectopic expression of individual viral genetic elements. However, 
many of the essential functions performed flaviviral NS proteins or genetic elements are not 
recapitulated by their individual expression [167]. For this reason, it is important to perform 
mutational studies on fully infectious viral model systems to further our understanding of this 
complex aspect of DENV and ZIKV biology. This intricate web of molecular interactions 
between these viruses with the host innate immune system generates a balance between a 
state of virus induced immune evasion or an antiviral state. This balance largely determines 
the outcome between viral persistence or clearance by the immune system.  
 
1.4 Experimental model systems used in this thesis 
Studying the molecular interactions of flaviviruses with the type‐I IFN response requires 
understanding of both viral and host biology. The following section will detail background 
information relating to the main model systems and experimental methods used in this thesis. 
These include methods to study the impact of changes to viral genetics on IFN evasion, and 
in vivo infection models to assess host innate responses.  
 
1.4.1 Reverse genetics systems as tools for mutational profiling of viral genomes  
A key method used to study the function of viral proteins or genetic elements is the targeted 
introduction of mutations within the viral genome. To do this requires viral expression 
systems that are genetically stable, can be faithfully propagated, manipulated, and cloned. 
For RNA viruses that have an inherently unstable genome this is underpinned by the 
development of reverse genetics systems [30]. In essence a reverse genetics system is a DNA 
vector containing reverse transcribed complementary DNA (cDNA) generated from the viral 
RNA genome under the control of a suitable promoter [17]. In general, two types of 
promoters have been utilised in these systems their different uses are illustrated in Figure 
1.12. The first of these is a mammalian promoter, such as the Cytomegalovirus (CMV) 
promoter. These promoters utilize host cell transcriptional machinery and initiate the 
production of functional +ssRNA by direct transfection into mammalian cells [17]. The other 
type of promoter commonly used in reverse genetics systems are bacteriophage promoters, 






transfected into permissive cells to initiate de novo virus production in mammalian or insect 
cells [17].  
Since flaviviruses have a non‐segmented RNA genome that is a manageable size for cloning, 
reverse genetics systems have been extensively used in the field of Flavivirus molecular 
biology. The full‐length cDNA genome of a Flavivirus incorporated into a reverse genetics 
system is termed an infectious clone. Infectious clones can independently initiate replication 
and production of infectious virus in permissive cells from a stable genetic starting point. As 
a result, infectious clone technology has revolutionized the study of flaviviruses. They have 
allowed the for controlled mutation of Flavivirus genomes and study of their effect on their 
biology and pathogenesis. 
In addition to providing a stable genetic starting point for mutational studies, full‐length 
infectious clones also overcome complications with over‐expression of individually expressed 
viral proteins. Flaviviruses have a limited genetic capacity compared to eukaryotic organisms. 
However, the complexity of the Flavivirus lifecycle that requires replication, immune evasion 
and spread in both vertebrate and invertebrate hosts is remarkable compared to the size of 
their genomes. To achieve this complexity, flaviviruses rely on interactions involving multiple 
viral proteins and host factors to perform their complete lifecycle. As a result, many of the 
essential functions performed by Flavivirus proteins or genetic elements are not recapitulated 
by their individual expression [194]. Accordingly, there is a need to perform mutational 
profiling in infectious clones to see the full impact these mutations have on the virus lifecycle. 
Despite the obvious advantages when performing mutational studies on Flavivirus biology, 
the use of full‐length infectious clones often presents a unique set of challenges. These 
challenges largely result from propagation of infectious clones in bacterial cells. Harbouring 
full‐length Flavivirus genome sequence is often detrimental to bacterial cells, causing slow 
growth or genetic instability of the infectious clone as a result of bacterial recombination 
[292]. This is because Flavivirus genomes contain cryptic bacterial promoters that lead to 
expression of toxic viral gene products when introduced into bacterial cells [17, 185]. To 
overcome these challenges several strategies are employed to reduce bacterial toxicity and 
improve infectious clone stability. Most infectious clones use low‐copy vectors to reduce the 
amount of toxic expression products that accumulate in bacteria [292]. Additionally, toxic 
sequences can be identified and disrupted by chimeric introns [17, 350]. These introns are 
present in bacterial hosts but are spliced out when introduced into eukaryotic cells due to 
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their different RNA processing capability. Alternatively, the full‐length genome can be 
separated across multiple vectors, independently propagated, and then stitched back 
together by in vitro methods such as overlapping PCR or in vitro ligation [17, 74]. Despite 
these challenges, infectious clones are valuable tools for studying Flavivirus biology.  
 
1.4.2 Transposon mutagenesis as a method for high-throughput genome wide mutational 
profiling 
Mu transposon mutagenesis is a molecular tool used to efficiently construct insertional 
mutant libraries for functional analyses of protein coding and regulatory regions [348]. The 
process of generating these insertional mutant libraries is illustrated in Figure 1.13 and 
described here in brief. First, the target DNA, such as infectious clone cDNA, is subjected to a 
MuA transposase reaction. In this reaction purified MuA transposase enzyme catalyses the 
insertion of a transposon randomly into the target DNA at a frequency of approximately one 
insert per clone. This transposon consists of an encoded selection marker (Kanamycin 
resistance) flanked by two unique NotI restriction sites.  Incorporation of the transposon into 
the infectious cDNA clone, followed by their introduction into bacteria allows for selection of 
successfully mutagenized infectious clones on dual antibiotic plates (Ampicillin and 
Kanamycin). After selection, the bacteria are pooled, and the plasmid DNA extracted. Next, 
the pooled library is further processed by NotI restriction digestion to remove the bulk of the 
transposon body. Re‐ligation of the NotI sites results in the formation of a 15 bp insert made 
up of 10 bp from the transposon and 5 bp from the target site duplication. After re‐ligation, 
the mutant library is re‐introduced into bacteria using single antibiotic selection. Then the 
mutant clones are again pooled, and the plasmid DNA extracted to generate the final purified 
library. If the insertion occurs in a protein coding region, an extra 5 amino acids (sequence 
dependent on the reading frame) are inserted. Importantly, insertions are designed to 
prevent premature stop codons in all 6 reading frames. These 15 bp insertion mutations act 
to disrupt normal sequence of translated protein or untranslated RNA allowing for their 
functional profiling.   
Compared to targeted mutational studies that use conventional labour‐intensive molecular 
cloning methods, MuA transposon mutagenesis allows for the rapid generation of mutations 
across the entire viral genome [348]. Alternative high‐throughput techniques for functional 






mutagenesis [312, 371]. Each of these methods allows for high‐resolution mutational studies 
that resolve to the individual nucleotide level. However, until recently these deep mutational 
scanning (DMS) methods were limited to investigating smaller regions of viral genomes in part 
due to their reliance on new high‐throughput sequencing technologies [12]. In comparison to 
DMS, the 15 bp insertion‐scar generated by MuA transposon mutagenesis allows for easy 
detection of mutations using readily available sequencing methods, such as the Illumina 
NextSeq 500 platform [94]. However, as new sequencing technologies are developed DMS 
methods will likely become more widely applicable. Indeed, one recent study utilised a DMS 
method to perform a genome‐wide functional screen on the Influenza genome [84]. Aside 
from the benefit of performing genome‐wide mutational studies using readily available 
sequencing platforms, the MuA transposon method allows for simple pre‐selection of 
successfully mutagenized clones based on the presence of dual antibiotic resistance encoded 
within the transposon body. This therefore reduces the contribution of wildtype genomes to 
mutant library population genetics [348]. Comparatively, DMS methods require sequencing 
of clones to confirm their mutation status. One downside of the MuA transposon mutagenesis 
method is the potential for insertion bias introduced by the Mu transposase enzyme. Studies 
in bacterial genomes have shown that Mu transposases displays bias toward GC‐rich 
sequences leading to less uniform spacing of insertions in AT‐rich genomes [123]. However, 
one study on adeno‐associated virus vectors has demonstrated the level of MuA insertion 
bias to be relatively low in this context [277]. 
 
1.4.2.1 Applications of MuA transposon mutagenesis for high-throughput mutational 
studies of viral infectious clones 
The MuA transposon mutagenesis method has been successfully applied to several RNA virus 
reverse genetics systems. These include Polio Virus, Norovirus, Influenza Virus and to 
flaviviruses such as Hepatitis C Virus (HCV), DENV and ZIKV [94, 103, 104, 139, 283, 346]. This 
method has allowed for high‐throughput mutational screening of viral genomes. Importantly, 
these studies have provided insight into regions of the viral genome that are important for 
replication and infectious virus production, regions tolerant to small insertions or regions that 
are important in evading the IFN response.   
In general, these screens function by generating a library of mutant virus from the 
mutagenized infectious clone and then placing the mutant library under selective conditions 
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in cell culture or in vivo model systems. Mutant viruses that are less fit under selection are 
outcompeted, reducing their frequency within the population. This process of selection 
coupled to Next Generation Sequencing (NGS) identifies the genomic position of the 
remaining insertions and allows for a functional map of the virus genome to be constructed. 
The first use of this method to study Flavivirus biology was applied to HCV, published in 2014 
by Remenyi et al. [283]. In this screen, a full‐length infectious clone of HCV was mutagenized, 
RNA was in-vitro transcribed and the pooled RNA was transfected into Huh‐7.5 cells for 
genetic selection. This pooled RNA was used to represent the input library of mutants prior 
to selection (Pool 0). The total cell associated RNA was then recovered at 96 h post‐
transfection (Pool 1), and then again following passaging of the de novo generated infectious 
virus on Huh‐7.5 cells (Pool 2). The cell associated RNA was extracted and RT‐PCR was 
performed to amplify the full‐length HCV genome in overlapping fragments. A map was 
generated for each pool based on NGS sequencing data identifying the location and frequency 
of insertions at each position of the genome. This study found that the MuA transposon 
mutagenesis generated 7,978 unique insertion events that covered 88% of the HCV genome 
in Pool 0. Following selection, the percentage of total insertion positions was reduced to 55% 
in Pool 1 and 17% in Pool 2. This indicated effective selection was applied to the mutant virus 
population based on their ability to replicate RNA (Pool 1) or generate infectious virus (Pool 
2). The functional map of the HCV genome demonstrated distinct patterns of selection 
separating proteins based on early or late‐stage replicative function. This knowledge was 
applied to elucidate novel functions of viral proteins not associated with their traditional roles 
in the HCV lifecycle. Specifically, this knowledge was used to validate a novel function for 
NS4B in late‐stage virus replication by individually cloning the insertion mutations into the 
original HCV reverse genetics system.  
Another example of the use of MuA transposon mutagenesis to study Flavivirus biology was 
a study conducted in our laboratory by Eyre et al. published in 2017 [94]. Briefly, a full‐length 
DENV2 infectious clone was subjected to MuA transposon mutagenesis resulting in a library 
of ~250,000 mutant clones. This library represented 4700 unique insertion positions in the 
DENV2 genome. A similar selection process was applied to the mutant library as described 
above. First, full‐length in vitro transcribed RNA was generated (Pool 0) and transfected into 
Huh‐7.5 cells (Pool 1) to initiate de novo virus production. The infectious virus produced as a 
result was passaged on naive Huh‐7.5 cells (Pool 2). This enriched for mutants that were 
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replication competent (Pool 1) and able to generate infectious virus (Pool 2). After selection, 
the initial 4700 unique insertion events were reduced to 1122 and 1003 in Pools 1 and 2 
respectively indicating successful selection. Regions that were highly tolerant to insertion 
after the second passage were selected for the rational design of tagged viruses. This allowed 
for the generation of multiple reporter‐tags to be inserted into NS1 region for use in high‐
resolution and live cell imaging or protein‐protein interaction studies.  
Other than using this approach to study the role of viral proteins in replication or to generate 
tagged viruses, the MuA transposon mutagenesis method has been used to discover novel 
Flavivirus immune evasion mechanisms. In 2017 Qi et al. published their work on applying this 
method to discover novel anti‐IFN functions of HCV proteins. This screen used the same 
library generation method as their previous publication described above (Remenyi et al 2014). 
The resultant in vitro transcribed RNA was transfected into Huh‐7.5 cells to reconstitute 
mutant virus library. Next, the mutant virus library underwent two rounds of selection on 
Huh‐7.5 cells that had either been pre‐treated with IFNα at a concentration that reduced 
infection to 50% (IC50) or untreated control cells. After selection, the remaining mutant 
insertions were mapped to the genome and their relative frequency at each genome position 
was compared between the treatment groups. Analysis revealed insertions in regions 
previously known to encode IFN evasion and in regions not previously identified. This led to 
the identification of specific mutations in the HCV p7 protein that conferred hypersensitivity 
to IFNα. Furthermore, mutant p7 HCV hypersensitivity could be rescued with the introduction 
of over‐expressed wildtype p7 protein.  
Together these examples demonstrate the broad applications of the MuA mutagenesis 
method when applied to infectious clone technology for functional screening of viral 
genomes. Importantly, it also validates this method as a way of finding novel immune evasion 
mechanisms encoded by flaviviruses. For these reasons this approach was applied in Chapters 
3 and 4 of this thesis with the aim of investigating novel innate immune evasion mechanisms 
for both ZIKV and DENV.  
 
1.4.3 Mouse models of ZIKV sexual transmission 
Small animal models that recapitulate human disease are important for understanding the 
pathophysiology of viral infections. For viruses such as DENV that have strong host specificity 
and cause disease that is specific to host immune responses the difficulty in establishing small 
59 
 
animal models has been a significant challenge to development of new treatments and 
vaccines [56].  
Fortunately, there have been significant developments in the space of small animal models 
for ZIKV infection since the 2015‐16 outbreak. Initial attempts to infect immune competent 
“wildtype” (WT) mice (C57BL/6, BALB/c, or CD‐1 mice) with ZIKV by intravenous (IV) or 
subcutaneous (SC) routes showed no disease signs and little to no detectable viral RNA in 
blood or tissues [231]. Unsurprisingly, due to the importance of the IFN response to Flavivirus 
infection the first susceptible mouse models developed for ZIKV were IFN pathway knockout 
(KO) mice [231]. Lazear et al. found male mice that cannot respond to type‐I IFN (IFNAR1‐/‐), 
or mice that produce almost no IFNα/β (IRF3/IRF5/IRF7 triple KO) or mice that cannot respond 
to type‐I or type‐II IFN (AG129) were highly vulnerable to SC or IV inoculation of 102 focus 
forming units (FFU) of ZIKV [181]. These mice displayed neurological symptoms, detectable 
viremia, and tissue tropism like those observed in humans including infection in the brain, 
spinal cord and testes. Similar results were seen by Rossi et al. in the IFNαβ receptor null A129 
strain mice [290].  
After validating these models for SC and IV inoculation, they were adapted to investigate 
alternative transmission modes of ZIKV, including sexual transmission. Several mouse models 
have been used to investigate ZIKV sexual transmission in the FRT using vaginal inoculation 
methods (iVag).  
Unexpectedly these studies found that unlike for SC or IV inoculation, immune competent 
mice were susceptible to ZIKV via iVag inoculation [164, 342, 381]. Importantly all these iVag 
models involved treatment of mice with progesterone or the progesterone mimic 
Depomedroxyprogesterone acetate (DMPA) to synchronize the estrous cycle to the diestrus 
phase. In mice diestrus thins the epithelial cell layer of the lower reproductive tract, however 
this does not occur to the same extent humans [370]. This thinning of the epithelial barrier 
caused by DMPA treatment likely contributes to the increased susceptibility of mice to iVag 
inoculation several viruses including LCMV, HSV and ZIKV [105, 165, 341]. Furthermore, DMPA 
treatment has been shown by our collaborators to reduce expression of IFNε in the FRT of 
mice and this also may be a contributing factor to permissiveness of WT mice (Hertzog, 
unpublished data).  
One of the first studies by Yockey et al. compared iVag to intraperitoneal (IP) ZIKV inoculation 
methods. In this model WT C57BL/6 virgin female mice were inoculated iVag with 2.5 × 104 
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PFU or IP with 1.5 × 105 PFU of Cambodian ZIKV strain FSS13025. Mice that received IP 
inoculation had undetectable levels of ZIKV viral RNA (vRNA) in the spleen and vagina by 3 
dpi. Comparatively mice that were iVag inoculated had high levels of vRNA detected in both 
tissues that increased over time. Importantly this data demonstrates the FRT selectively 
supports ZIKV infection and that mice infected via this route are more susceptible than those 
inoculated systemically. Additionally, the susceptibility of WT mice was compared to IRF3/7‐
/‐ and IFNAR1‐/‐ mice via iVag infection. It was found that mice with minimal ability to produce 
IFNα/β  (IRF3/7‐/‐ ) or those that could not signal via the type‐I IFN receptor were more 
susceptible to ZIKV infection via the iVag route compared to WT mice. While WT mice had 
detectable vRNA in FRT tissues from day 1 to 4 post infection this was almost completely 
undetectable by 7 dpi. Whereas IFNAR1‐/‐ remained infected through 7 dpi and succumbed to 
iVag infection with high dose challenge (5.2 X 105 PFU) of ZIKV [381].   
Similar results were seen in C57BL/6N mice by Khan et al. following ZIKV iVag inoculation with 
2 X 104 FFU of Puerto Rican ZIKV strain PRVABC59. ZIKV vRNA was detected in the LFRT and it 
increased roughly one log at day 2 compared to day 1 after iVag inoculation, indicative of 
productive infection. Despite the presence of replicating virus there was minimal induction of 
type‐I or type‐III IFN and corresponding ISG mRNA in these mice. In this model mice began to 
control infection by day 3, indicating that a minimal IFN response was sufficient to control 
ZIKV infection in the LFRT of mice [165].  
Another study looking at ZIKV iVag infection of mice by Tang et al. compared susceptibility of 
mice in estrus‐like or diestrus‐like phases induced by injection of either pregnant mare serum 
gonadotropin (PMSG) or progesterone, respectively. In this study estrus‐like or diestrus‐like 
AG129 mice (type‐I and III IFN receptor KO) were inoculated iVag with 1 X 105 FFU of ZIKV 
(strain FSS13025). Mice infected in the estrus‐like phase were resistant to iVag infection. 
However, AG129 mice in diestrus‐like phase became productively infected with peak viremia 
at 5 dpi and succumbed to infection by 10 dpi. This study demonstrates the influence of the 
hormonal environment on ZIKV permissiveness of the FRT [341]. 
Continuing this line of enquiry Caine et al. also found the hormone environment of the FRT 
could alter susceptibility to ZIKV iVag challenge. Like results in AG129 mice they found that 
estradiol pre‐treatment protected IFNAR1‐/‐ mice challenged with iVag administered ZIKV at 
106 FFU (African strain Dakar 41525). On the other hand, these mice were highly permissive 
to infection when treated with progesterone as measured by the amount of vRNA detected 
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in the vagina at 6 dpi. In addition, this group also tested the impact of type‐III IFN receptor KO 
(IFNLR1‐/‐) on ZIKV permissiveness in the FRT of mice. In this model WT or IFNLR1‐/‐ mice were 
treated with 1 mg of anti‐IFNAR1 monoclonal antibody (mAb) to block type‐I IFN one day prior 
to iVag infection with 106 FFU ZIKV Dakar. IFNLR1‐/‐ mice had increased viral burden measured 
by detection of vRNA in the LFRT but no showed no difference in the UFRT compared to 
similarly treated WT controls. To further explore the role of type‐III IFNs in ZIKV infection of 
the FRT WT mice treated with progesterone and anti‐IFNAR1 mAb were given 25 μg of 
pegylated IFNλ2 intravaginally 8 h prior to iVag challenge with ZIKV. Interestingly, pre‐
treatment with recombinant IFNλ2 significantly protected the mice, minimizing infection in 
the LFRT and leading to less infection in the UFRT and peripheral tissues such as the brain 
[36]. 
Together these models of iVag ZIKV infection demonstrate the inherent permissiveness of the 
FRT to ZIKV. This is exemplified by ZIKVs ability to infect immune competent WT mice via this 
the iVag route when systemic inoculation methods are ineffectual. These models also 
demonstrate the importance of both type‐I and III IFN signalling in the FRT to protect against 
ZIKV infection. However, although these IFNs protect against infection in the FRT, there are 
additional IFN‐independent mechanisms that alter permissiveness to ZIKV. For example, 
changes mediated by estradiol treatment result in the absence of infection in mice regardless 
of type‐I or type‐III IFN signalling. The blockade of type‐I IFN signalling appears to have a 
greater impact compared to type‐III signalling, especially in the UFRT. Additionally, this data 
shows that treatment with recombinant type‐III IFN is effective at controlling ZIKV infection. 
In combination, these experimental models of ZIKV iVag infection established the basis for 
the in vivo model of iVag infection to investigate the importance of IFNε that is described in 











1.5 Experimental rationale, hypotheses and aims 
Type‐I IFNs are key innate immune effectors involved in host antiviral defence, acting to 
protect the host from viral infection via the expression of hundreds of ISGs that have direct 
antiviral or immune regulatory functions. However, ZIKV and DENV have evolved mechanisms 
to evade the IFN response allowing them to cause disease in humans. Our existing knowledge 
surrounding virus‐mediated IFN evasion is limited by the lack of mutational studies conducted 
in fully infectious systems and on a genome‐wide scale. Additionally, type‐I IFNs are either 
expressed by the host in response to viral infection, or IFNɛ is constitutively expressed in the 
FRT. The contribution of IFNɛ as a constitutively expressed IFN in the FRT to circumvent viral 
evasion of the IFN response, and in protecting against ZIKV sexual transmission is not yet 
known. Therefore, this thesis explores the virus dependent mechanisms that abrogate the 
type‐I IFN response and characterises the role of novel IFNε in preventing ZIKV infection of 
the FRT. As a result, the following hypotheses and aims are proposed.  
 
Hypothesis 1: 
The ZIKV and DENV genomes contain undiscovered regions encoding evasion of the type‐I IFN 
response.  
 
Aim 1: To identify and characterize novel genetic elements that confer resistance to type–I 
IFN using a genome‐wide insertional mutagenesis screen of a recent outbreak strain of ZIKV. 
 
Hypothesis 2: 
IFNε is an important type–I IFN that protects against ZIKV infection in the female reproductive 
tract.  
 
Aim 2: To investigate the antiviral properties of IFNε and determine whether it effectively 









Material and Methods 
 
2.1 General laboratory methods 
2.1.1 Bacterial transformation methods 
2.1.1.1 Chemically competent cells 
For standard plasmid transformations, Alpha‐Select DH5α Escherichia coli (E. coli) Silver 
efficiency (Bioline) were used as per the manufacturer’s instructions. Briefly, cells were 
thawed on ice and a 25 – 100 μL aliquot was placed into pre‐chilled microcentrifuge tubes. 
Then DNA was added to the cells (either 1 ng of purified plasmid or <5 μL ligation reaction per 
50 μL cells). The bacteria and DNA were gently mixed by flicking the tube and these were 
rested on ice for a further 30 min. Next, the cells were placed in a heat block set to 42⁰C for 
30 sec then were placed back on ice for a further 2 min. Following heat shock, 900 ‐ 975 μL of 
Super Optimal broth with Catabolite repression (SOC) medium was added to the cells and the 
culture was placed at 37 ⁰C for 1 h on a rotating spinner. Next, the suspensions were 
centrifuged at 2000 ×g for 2 min, the supernatant was removed, and the transformed cells 
were resuspended in approximately 100 μL of SOC medium. This suspension was plated onto 
Luria Bertani‐Agar (LB‐Agar) with antibiotic selection (ampicillin at 100 µg/ml or kanamycin at 
50 µg/ml) using a sterile spreader and placed at either 30 ⁰C or 37 ⁰C until visible bacterial 
colonies formed (16 – 30 h).  
For large plasmids requiring higher transformation efficiency, XL10‐Gold Ultracompetent Cells 
(Stratagene/Agilent) were used. A similar method was used as for DH5α transformation, 
above, with the following exceptions. Firstly, after thawing cells on ice, 4 μL β‐
mercaptoethanol was added per 100 μL aliquot of cells and samples were incubated on ice 
for 10 min with gentle swirling every 2 min. Next, after incubation with β‐mercaptoethanol 
the DNA was added (1 ng purified DNA or <2 μL ligation reaction per aliquot) and samples 
were incubated for 30 min on ice. After incubating on ice, the tubes were heat shocked in a 
42 ⁰C water bath for 30 sec. Heat shocked cells were placed on ice for 2 min and recovery in 




2.1.1.2 Electro-competent cells 
For cloning purposes requiring maximum transformation efficiency with reduced 
recombination, Endura™ electro‐competent cells (Lucigen) were used. These cells were 
thawed on ice and a 25 μL aliquot was placed into a pre‐chilled microcentrifuge tube. Next, 1 
μL of ligation reaction was added and gently mixed. This mixture was then directly transferred 
to a chilled 1.0 mm gap cuvette (Bio‐Rad) and flicked downwards to ensure that all of the 
liquid was inside the cuvette gap without air bubbles forming. Next the cuvette was 
electroporated using a Bio‐Rad Gene Pulser II with the optimal setting (10 µF, 600 Ohms, 1800 
Volts). Room temperature Lucigen recovery media (975 μL) was then added to the cuvette 
and all the liquid was transferred into a new 10 mL yellow cap polystyrene tube for recovery 
at 37⁰C for 1 h (unless otherwise stated). Recovery and plating were done as previously 
mentioned.  
  
2.1.2 DNA purification methods 
2.1.2.1 Small-scale plasmid DNA extraction (mini-preparation) 
To perform small scale plasmid preparations, individual transformed colonies were picked 
and inoculated into separate 10 mL yellow cap polystyrene tubes containing 5 – 10mL of LB 
broth containing the appropriate antibiotic selection (ampicillin at 100 µg/ml or kanamycin at 
50 µg/ml). Bacteria were cultured at 37⁰C overnight unless otherwise stated. After sufficient 
bacterial growth was observed (up to 24 h for low copy number plasmids), these cultures 
were centrifuged at 4000 ×g for 7 min and the supernatant was discarded. To extract and 
purify the plasmid DNA, the NucleoSpin® Plasmid EasyPure kit (Macherey‐Nagel) was used as 
per manufacturer’s instructions. Briefly, the bacterial pellet was resuspended in 250 µL of 
resuspension buffer (with RNAse added) and transferred to a fresh microcentrifuge tube. 
Following resuspension, 250 µL of lysis buffer was added and mixed by inversion. Cells were 
lysed for 5 min at room temperature prior to adding 300 µL of neutralization buffer and mixing 
by inversion. The lysate was pelleted at 11,000 ×g for 5 min prior to transferring supernatant 
to a spin column. This was then centrifuged at 11,000 ×g for 30 sec to bind DNA and flow 
through was discarded. Two wash steps were performed (11,000 ×g, 30 sec) with 700 µL of 
wash buffer. Next the column was transferred to a fresh collection tube and pre‐heated 70⁰C 
elution buffer was incubated on the membrane for 2 min. Low copy number plasmids were 
eluted in 30 µL volumes and high copy number plasmids were eluted in 50 µL volumes. 
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Purified DNA samples were analysed for DNA concentration and sample purity (A260/A280 
ratio) using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific) and stored at ‐
20°C until used in downstream applications. 
 
2.1.2.2 Large-scale plasmid DNA extraction (maxi-preparation) 
To perform large scale plasmid preparations, a single transformed colony was picked and 
inoculated into 500 – 1000 mL of LB broth with the appropriate antibiotic selection. Bacteria 
were cultured at 37⁰C overnight unless otherwise stated. After sufficient bacterial growth was 
observed (up to 24 h for low copy plasmids), these cultures were centrifuged at 6000 ×g for 
15 min and the supernatant was discarded. These bacterial pellets were then stored frozen 
at ‐20⁰C or used immediately for plasmid preparation using the NucleoBond Xtra Maxi kit 
(Macherey‐Nagel) as per manufacturer’s instructions. Briefly, for each sample the bacterial 
pellet was resuspended in 12 mL resuspension buffer with RNAse added. Following 
resuspension, 12 mL of lysis buffer was added and sample was mixed by inversion and cells 
were lysed for 5 min prior to adding 12 mL of neutralization buffer and mixing by inversion. 
The lysate was then transferred to 50 mL tubes and pelleted at 4000 ×g for 5 min prior to 
transferring the supernatant to the column filter that was pre‐equilibrated with 25 mL of 
equilibration buffer. DNA within the supernatant was bound to the column by gravity flow‐
through. Next, two wash steps were performed; first with 15 mL of equilibration buffer and 
then with 25 mL of wash buffer. Following washes, the DNA was eluted from the column in 
15 mL pre‐heated (70⁰C) elution buffer into a 30 mL centrifuge tube. 10.5 mL of room 
temperature isopropanol was added and samples were vortexed prior to centrifugation at 
20,000 ×g for 1 h at 4⁰C to pellet the DNA precipitate. After precipitation most of the 
supernatant was removed, and the pellet was resuspended in the remaining 1 mL of 
supernatant and transferred to a microcentrifuge tube. The DNA pellet was re‐formed by 
centrifuging at 10,000 ×g for 5 min. Next, two washes were performed using 1mL of 70 % 
ethanol and centrifugation at 10,000 ×g for 3 min each. After washing the ethanol was 
removed and DNA pellets were air dried and resuspended to a concentration of 
approximately 1 µg/µL in nuclease‐free (NF) water (Invitrogen). Purified DNA samples were 
analysed for DNA concentration and sample purity (A260/A280 ratio) using a NanoDrop 2000 




2.1.2.3 Gel extraction  
A UV light box was used to visualize DNA that was separated on a 1% agarose gel containing 
1× RedSafe Nucleic Acid Staining Solution (iNtRON Biotechnology). The desired band was cut 
out using a clean scalpel blade and transferred to a pre‐weighed microcentrifuge tube. Gel 
extractions were performed with the Isolate II PCR / Gel clean‐up kit (Bioline) as per the 
manufacturer’s instructions. Briefly, 200 μL of binding buffer was added per 100 μg of agarose 
gel and this was heated at 60 ⁰C for 10 min with regular mixing by vortex. For dissolving 
agarose gel to extract large DNA fragments (>10 kbp), samples were placed in binding buffer 
and heated to 60 ⁰C and mixed by gentle inversion to prevent shearing of the DNA. This 
mixture was transferred directly to the column and centrifuged at 11,000 ×g for 30 sec to bind 
DNA to the column and the flow through was discarded. Next, the column was washed twice 
with 700 μL of wash buffer via centrifugation at 11,000 ×g for 30 sec and the flow through 
was discarded. Following washes, the column was dried by centrifuging at 11,000 ×g for 2 min 
and then transferred to a new collection tube. For elution, the elution buffer was pre‐heated 
to 70 ⁰C and 15 ‐30 μL was incubated on the membrane for 2 min prior to centrifugation at 
11,000 ×g for 1 min. For maximal recovery, the eluate was re‐incubated on the membrane for 
a further 2 min prior to centrifugation at 11,000 ×g for 1 min to collect the final extracted 
DNA. Purified DNA samples were analysed for DNA concentration and sample purity 
(A260/A280 ratio) using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific) and 
stored at ‐20°C until used in downstream applications. 
 
2.1.2.4 Column purification reaction clean-up 
The Bioline Isolate II PCR / Gel clean‐up kit as per the manufacturer’s instructions. Briefly, 200 
μL of binding buffer was added per 100 μL of reaction volume. This mixture was transferred 
directly to the column and spun at 11,000 ×g for 30 sec to bind DNA to the column and the 
flow through discarded. Next, the column was washed twice with 700 μL of wash buffer each 
spun at 11,000 ×g for 30 sec and the flow through was discarded. Following washes, the 
column was dried by centrifuging at 11,000 ×g for 2 min and then transferred to a new 
collection tube.  For elution, the elution buffer was pre‐heated to 70 ⁰C and 15 ‐30 μL was 
incubated on the membrane for 2 min prior to centrifugation at 11,000 ×g for 1 min. Purified 
DNA samples were analysed for DNA concentration and sample purity (A260/A280 ratio) 
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using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific) and stored at ‐20°C 
until used in downstream applications. 
  
2.1.2.5 Ethanol DNA precipitation reaction clean-up 
To precipitate the DNA first a 1/10th volume of 3 M sodium acetate (pH 5.5) was added to the 
reaction mixture (i.e. 2 μL per 20 μL reaction). Next, 2.5 volumes of 94% ethanol were added 
and mixed by pipetting. This mixture was incubated at ‐20 ⁰C for 20 minutes prior to 
centrifugation at 15,000 ×g  for 30 min at 4 ⁰C. Supernatant was removed and the pellet rinsed 
carefully with 500 μL 75% ethanol. After completely removing the ethanol, the DNA was air 
dried and re‐suspended to the required concentration with deionised water. Purified DNA 
samples were analysed for DNA concentration and sample purity (A260/A280 ratio) using a 
NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific) and stored at ‐20°C until used 
in downstream applications. 
 
2.1.3 Recombinant DNA cloning methods 
2.1.3.1 Restriction enzyme digestion 
To perform restriction digests 250 ng – 5 µg of purified plasmid DNA was added per 20 µL 
reaction containing 0.5 – 2 units of restriction enzyme (NEB), 2 µL 10x buffer and the 
remaining volume of water. These were incubated at the recommended temperature for 3 – 
16 h using a Bio‐Rad thermal cycler depending on required completeness of cutting. All 
reactions were carried out using the BioRad S1000 Thermal Cycler or equivalent.  
 
2.1.3.2 Primer design  
Primers for recombinant DNA cloning were designed using NCBI GenBank sequences that 
were visualized using SnapGene software to derive complementary annealing sequences and 
overlap extensions. These sequences were then assessed using the OligoAnalyzer online tool 
(IDT) to predict internal secondary structures, self and hetero‐dimerisation based on free 
energy changes (ΔG). The primer annealing temperature was determined using the NEB Tm 
calculator. Primers pairs had a maximum difference of annealing temperature of 2 ⁰C. For 
custom qRT‐PCR primers, these were designed using the NCBI primer database, specifying 
product size between 80‐120 bp, annealing temperatures between 59‐61 degrees with no 
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more than 2 degrees difference between primer pairs. All primers were made by Sigma 
Aldrich and diluted to 20 μM in NF water. Primers were stored at ‐20°C. 
 
2.1.3.3 Q5 High-fidelity Polymerase Chain Reaction (PCR) 
Unless otherwise stated all PCR reactions were performed using the Q5 High‐Fidelity 2 X 
Master Mix (NEB). PCR was performed as per the manufacturer’s instructions with the 
appropriate annealing temperature for individual primers determined by the NEB Q5 Tm 
calculator. Briefly, each reaction contained 12.5 μL of 2 X Master Mix, 1.25 μL of forward and 
reverse primer (10 μM), DNA template (1 ng purified DNA or 1 μL cDNA) and water to 25 μL 
total volume. Annealing time per cycle was 30 sec, extension time per cycle was 30 sec/kb 
and a minimum of 35 cycles were run. All reactions were carried out using the Bio‐Rad S1000 
Thermal Cycler or equivalent.  
 
2.1.3.4 Agarose gel electrophoresis 
All agarose gels were made with molecular grade 1% w/v Agarose (Bioline) in 1 x TAE buffer, 
with 5 μL RedSafe™ Nucleic Acid Staining Solution (iNtRON Biotechnology) added per 100 mL 
of molten Agarose solution. These gels were immersed in 1 x TAE running buffer in a Bio‐Rad 
gel tank. DNA or RNA was pre‐mixed with 6 x loading dye (NEB) and loaded into the wells, 
with a 1 kb ladder to determine product size (NEB). Gels were run at 100 – 120 V for 
approximately 30 min to 1 h to achieve appropriate separation. For separation of in vitro 
transcribed RNA fresh agarose solution was made with autoclaved dH2O and the gel‐tank was 
washed first with ethanol and then with autoclaved dH2O. Also, separate loading dye was 
used that had only NF pipette tips used. Gel images were taken using the ChemiDoc XRS+ 
(Bio‐Rad) and accompanying image analysis software using the Gel Red nucleic acid setting.  
 
2.1.3.5 DNA ligation 
T4 DNA ligase (NEB) was used for DNA ligations as per the manufacturer’s instructions. Briefly, 
each reaction contained 2 μL T4 DNA Ligase Buffer (10X), 50 ng of vector DNA, insert DNA, 1 
μL T4 DNA ligase and water to 20 μL, assembled at room temperature. Overnight incubations 
at 16 ⁰C were routinely used. For ligations used for electrocompetent E.coli transformation, 
NEB ElectroLigase® was used as per the manufacturer’s instructions. Briefly, each reaction 
contained 50 ng of vector DNA, insert DNA, 5 μl ElectroLigase Reaction Buffer, 1 μL 
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ElectroLigase and water to 10 μL assembled on ice. Reaction incubation was for 1 h at room 
temperature prior to heat inactivation at 65 ⁰C for 15 min. Insert‐to‐vector ratios of 3:1 or 5:1 
were routinely used for ligations. All reactions were carried out using the Bio‐Rad S1000 
Thermal Cycler or equivalent.  
 
2.1.3.6 Gibson assembly  
Gibson Assembly Master Mix (NEB) was used as per the manufacturer’s instructions. Each 
reaction contained 10 μL Gibson Assembly Master Mix (2X), 50 ng vector DNA, insert DNA and 
water to 20 μL. Insert‐to‐vector ratios of 3:1 or 5:1 were used and each reaction was 
performed at 50 ⁰C for 1 h. All reactions were carried out using the Bio‐Rad S1000 Thermal 
Cycler or equivalent.  
 
2.1.3.7 Plasmid DNA Sanger sequencing 
Approximately 1 μg of the purified plasmid DNA was added to two separate microcentrifuge 
tubes. Alternatively, if the concentration of DNA was too low for 1 μg per reaction the 
maximum volume (12 μL) per tube was added. To each tube 1 μL of 10 µM primer was added 
either in the forward or reverse orientation. Volumes were adjusted to 13 μL with dH2O water 
and dispatched to AGRF for sequencing. FASTA format files were aligned to the expected 
sequence using SnapGene.  
 
2.1.4 Total RNA extraction 
2.1.4.1 TRIsure (Bioline) 
The supernatants from cell monolayers were removed and the cells were then washed once 
with 1x PBS. Next, cells were lysed in 500 μL of TRIsure per 12 well or scaled accordingly. To 
ensure complete lysis a pipette was used to rinse the lysate over the well several times prior 
to transferring to a labelled nuclease‐free microcentrifuge tube. This lysate was either stored 
frozen (‐80 ⁰C) or used directly to extract RNA. To extract total RNA, lysates were defrosted 
and brought to room temperature for 5 min prior to adding 200 μL chloroform per 1 mL 
TRIsure. Samples were mixed by vigorous shaking for 15 sec and then left to rest for 5 min at 
room temperature. Once settled, tubes were centrifuged at 4 ⁰C, 20,000 ×g for 15 min. Next 
the clear aqueous layer (approximately 400 μL per 1 mL TRIsure) was transferred to a fresh 
labelled NF microcentrifuge tube. Then 500 μL of ice‐cold isopropanol was added per tube, 
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these were mixed by inversion and incubated to precipitate RNA, either for 10 min at room 
temperature or for 30 min on ice. To pellet the precipitate, tubes were centrifuged at 4 ⁰C, 
20,000 ×g for 15 ‐ 30 min. Once pelleted, the supernatant was carefully removed and replaced 
with 75 % ethanol, then tubes were re‐centrifuged briefly for 3 min at 4 ⁰C, 10,000 ×g and this 
process was repeated. After washing, the ethanol was removed and the pellet was air dried 
and resuspended in NF water to the appropriate concentration. Purified RNA samples were 
analysed for RNA concentration and sample purity (A260/A280 ratio) using a NanoDrop 2000 
Spectrophotometer (Thermo Fisher Scientific) and stored at ‐80°C until used in downstream 
applications. 
 
2.1.4.2 NucleoZOL (Macherey Nagel) 
The supernatants were removed from cell monolayers, then cells were washed once with 1x 
PBS and lysed in 250 μL of NucleoZOL per 24 well or scaled accordingly. To ensure complete 
lysis a pipette was used to rinse the lysate over the well several times prior to transferring to 
a labelled nuclease‐free microcentrifuge tube. This was either stored frozen (‐80 ⁰C) or used 
directly to extract total RNA. Where required, NucleoZOL lysates were defrosted and brought 
to room temperature for 5 min prior to adding 100 μL of chloroform per 250 μL NucleoZOL. 
This was mixed by vigorous shaking for 15 sec and then left to rest for 5 min at room 
temperature. Once settled, samples were centrifuged at room temperature, at 16,000 ×g  for 
15 min. After pelleting cell debris, the clear supernatant (approx. 250 μL) was transferred to 
a fresh labelled NF microcentrifuge tube. Next, an equal volume of room temperature 
isopropanol was added per tube and these were mixed by inversion. This mixture was then 
incubated to precipitate RNA for 10 min at room temperature. To pellet the precipitate, these 
samples were centrifuged at room temperature at 16,000 ×g  for 10 min. Once pelleted, the 
supernatant was carefully removed and replaced with 75 % ethanol, then tubes were re‐
centrifuged briefly for 3 min at RT, 10,000 ×g and this process was repeated. After washing, 
the ethanol was removed and the pellet was air dried and resuspended in NF water to the 
appropriate concentration, measured using a using a NanoDrop 2000 Spectrophotometer 
(Thermo Fisher Scientific), as detailed above. Samples were stored at ‐80°C until used in 





2.1.4.3 RNeasy Mini Kit (Qiagen) with or without DNase treatment 
For cell monolayers (RNA preparation for NextSeq 550 Illumina sequencing) 
First, fresh RLT lysis buffer was prepared by adding β‐mercaptoethanol (10μL per 1mL). Then, 
the supernatants were removed from cell monolayers, cells were then washed once with 1x 
PBS and 350 μL of lysis buffer was added per well of a 6 well try. To ensure complete lysis, a 
pipette was used to rinse the lysate over the well several times prior to transferring to a 
labelled nuclease‐free microcentrifuge tube. This was either stored frozen (‐80 ⁰C) or used 
directly. The lysate was then homogenized by passing through a 20‐gauge (0.9 mm) needle 
attached to a sterile plastic syringe at least 5–10 times. Next, 1 volume of 70% ethanol was 
added to the homogenized lysate and mixed well by pipetting. From here, 700 μL of lysate 
mixture was transferred to a pre‐labelled RNeasy Mini column and centrifuged for 15 sec at 
10,000 ×g , afterwards discarding the flow‐through. Subsequent wash steps were performed 
as per the RNeasy Mini Kit instructions. Briefly, 700 µl Buffer RW1 was added to the RNeasy 
spin column and centrifuged for 30 sec at 10,000 ×g and the flow through discarded into a 
waste container for appropriate disposal. At this stage if DNase treatment was required, 80 
µl of pre‐diluted RNase‐Free DNase solution (Qiagen) was applied to the column and 
incubated at RT for 15 min. Again, 700 µl Buffer RW1 was added to the RNeasy spin column 
and centrifuged for 30 sec at 10,000 ×g  and the flow through discarded into a waste container 
for appropriate disposal. Next, the column was washed twice with 500 µl RPE buffer solution 
by centrifuging for 30 sec at 10,000 ×g and the flow through was discarded. To elute the RNA, 
40 μL of NF water was applied to the column, incubated for 2 min and centrifuged for 1 min 
at 10,000 ×g. This eluate was then re‐applied to the column and the process repeated.  
For extraction of RNA from solid tissues 
Frozen tissues stored in nuclease‐free microcentrifuge tubes (at ‐80⁰C) were transferred to 
fresh tubes to dry. To each tube, 500 μL of TRIsure was added and frozen tissues were then 
immediately homogenized using an RNase‐free tissue grinder (Kimble‐Chase). Once 
sufficiently homogenized these lysates were transferred to wet ice. An additional 500 μL of 
TRIsure was added and this was briefly vortexed, centrifuged and left to rest at room 
temperature for 5 min. Next, 200 μL chloroform was added per 1 mL of TRIsure. This was 
mixed by vigorous shaking for 15 sec and then left to rest for 5 min at room temperature. 
Once settled, this was centrifuged at 4 ⁰C, 20,000 ×g for 15 min. Next, the upper clear aqueous 
layer (approximately 400 μL per 1 mL TRIsure) was transferred to a fresh labelled NF 
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microcentrifuge tube. To this, 500 μL of 100% ethanol was added per 1 mL TRIsure. Each 
sample was then mixed by pipetting and immediately transferred to a pre‐labelled RNeasy 
Mini column. The RNA was bound to the column by centrifuging for 15 s at 10,000 ×g, 
afterwards discarding the flow‐through. This process was repeated with any remaining 
aqueous phase liquid. Washing and elution was done as described above and RNA 
quantification and storage was similarly performed as described above.  
 
2.1.5 Nucleic acid quantification 
DNA or RNA samples were routinely quantified using the NanoDrop spectrophotometer 
(Thermo Scientific) based on the 260/280 absorbance ratio. For low concentrations of nucleic 
acids requiring high‐sensitivity (HS) detection ether the Qubit dsDNA or RNA HS Assay Kits 
(Thermo Scientific) were used. Briefly, 1 μL of 200 x concentrate detection reagent was 
diluted in 200 μL of buffer per sample at room temperature (including extra for standards). 
Next, volumes between 2 – 10 μL of sample were diluted in the 1 X detection reagent to a 
final volume of 200 μL aliquoted in a Qubit® assay tube. Following dilution of standards and 
samples, these were loaded onto the Qubit® Fluorometer for determination of concentration 
based on fluorescence readings.  
 
2.1.6 cDNA synthesis 
2.1.6.1 M-MLV reverse transcriptase cDNA preparation (Promega) 
For standard applications, cDNA synthesis was performed using M‐MLV reverse transcriptase 
(Promega). Reactions contained either 500 ng or 1000 ng of RNA (dependent on the lowest 
RNA yield in a sample cohort for consistency). 500 ng of random hexamer (IDT) was added to 
the RNA and then this mixture was diluted to 14 μL with NF water and incubated at 70 ⁰C for 
5 min. Next, a master mix was made containing the 5 μL of 5x reaction buffer, 1.25 μL of 10 
nM dNTP mix, 0.5 μL of RNasin inhibitor, 1 μL of RT enzyme and 3.25 μL of NF water. 11 μL of 
master mix was added to each tube, samples were mixed and this was incubated at 42 ⁰C for 
1 h. These cDNA mixtures were then stored at ‐20 ⁰C or diluted 1 in 4 with NF water for use. 






2.1.6.2 SuperScript™ III first-strand synthesis (Invitrogen) 
For high quality cDNA preparations (viral cloning or sequencing purposes) the SuperScript™ 
III First‐Strand Synthesis kit was used. First, a total of 1 – 5 μg of total RNA was incubated with 
1 μL primer*, 1 μL 10mM dNTP and NF water to 10 μL at 65 ⁰C for 5 min.  
*For full‐length DENV first strand synthesis 1 μL of 20 μM specific reverse primer binding to 
the end of the 3’ UTR was used. 
*For all other first strand synthesis reactions 1 μL of 50 ng/μL of random hexamer was used. 
Next, a master mix containing 2 μL of 10X RT buffer, 4 μL of 25mM MgCl2, 2 μL of 0.1 M DTT, 
1 μL of 40 U/μL RNaseOUT and 1 μL of SuperScript III RT (200 U/μL) was added per tube. For 
specific primed reactions, the reaction was carried out at 50 ⁰C for 50 min. For random primed 
reactions, first the reaction was placed at 25 ⁰C for 10 min then the temperature was 
increased to 50 ⁰C and samples were incubated for 50 min. Reactions were stopped by heating 
at 85 ⁰C for 5 min and chilled on ice prior to adding 1 μL RNase H and returning the tubes to 
37⁰C for 20 min. All reactions were carried out using the Bio‐Rad S1000 Thermal Cycler or 
equivalent. 
 
2.1.7 Real-Time Quantitative PCR (qRT-PCR) 
2.1.7.1 FastStart Universal SYBR Green Master (Rox) (Roche) 
For cDNA samples the FastStart Universal SYBR Green Master (Rox) qRT‐PCR system was used. 
First, a master mix was made for each primer set containing 5μL of SYBR Green Master mix, 
0.15 μL of each gene specific forward and reverse primer (at 20 μM) and 2.2 μL of NF H20 per 
reaction. 7.5 μL of master mix of this was added per tube in 8 tube‐strips, 96‐well plates or 
384‐well plates (Applied Biosystems). Next, 2.5 μL of diluted cDNA was added per reaction. 
Cycling conditions were as follows:  
pre‐cycling: 50 ⁰C for 2 min then 95 ⁰C for 10 min,  
cycling (40 cycles): 95 ⁰C for 15 sec then 60 ⁰C for 1 min.  
At the end of 40 cycles a melt curve was run for each product with images taken every 0.5 
sec. Reactions were carried out using the QuantStudio™ 7 Flex Real‐Time PCR amplifier 






2.1.7.2 Luna® Universal One-Step qRT-PCR (NEB) 
For RNA samples the Luna® Universal One‐Step qRT‐PCR kit was used. First a master mix was 
made for each primer set containing 5 μL of Luna Universal One‐Step Reaction Mix (2X), 0.2 
μL of each gene specific forward and reverse primer (at 20 μM), 0.5 μL of Luna RT Enzyme Mix 
(20X) and 1.6 μL of NF H20 per reaction. 7.5 μL of master mix of this was added per tube in 8 
tube‐strips, 96‐ or 384‐well plates (Applied Biosystems). Next, 2.5 μL of diluted cDNA was 
added per reaction. Cycling conditions were as follows: 
pre‐cycling: 55 ⁰C for 10 min then 95 ⁰C for 1 min,  
cycling (40 cycles): 95 ⁰C for 10 sec then 60 ⁰C for 1 min.  
At the end of 40 cycles a melt curve was run for each product with images taken every 0.5 
sec. Reactions were carried out using the QuantStudio™ 7 Flex Real‐Time PCR amplifier, as 
above.  
 
2.1.8 SDS-PAGE western blot assay 
To perform Western blot assays, cell monolayers were washed in 1 X PBS prior to adding 200 
μL of lysis buffer (RIPA) containing 2 μL of protease inhibitor cocktail (Sigma‐Aldrich) per well 
of a 6‐well try, or scaled accordingly. Complete lysis was done on ice for 20 min. Next the wells 
were scraped with a pipette and lysates were transferred to individual labelled 
microcentrifuge tubes. Lysates were homogenized by pipetting using a 1000 µL pipette tip 
and then by passing through a 25 G needle 10 times. For each sample, cell debris was pelleted 
by centrifugation at 16,000 ×g at 4 ⁰C for 10 min and the supernatant was transferred to a 
fresh labelled microcentrifuge tube. Next, 1 part of 4 x SDS‐PAGE reducing loading buffer was 
added to 3 parts of cleared protein lysate in a fresh microcentrifuge tube and this mixture 
was boiled at 95 ⁰C for 5 m using a heat block. These samples were then cooled on ice prior 
to loading into a Mini‐PROTEAN® TGX™ Precast Gel (Bio‐Rad) suspended in 1 X SDS‐PAGE 
running buffer. To separate proteins the gel was run for 90 min at 100 V. Next, protein was 
transferred to a nitrocellulose membrane using the Trans‐Blot Turbo Transfer system and 
transfer buffer (Bio‐Rad) using the mixed molecular weight setting for one gel (7 min transfer). 
After transfer, the membrane was blocked for 1 h in 5% w/v skim milk diluted in TBS‐T (see 
appendix). Following blocking, primary antibody to the protein of interest was diluted to an 
appropriate concentration (see Appendix III) in 1% w/v skim milk diluted in TBS‐T. This was 
incubated overnight with agitation at 4 ⁰C. The following day membranes were washed in 
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TBS‐T for 10 minutes 3 times prior to incubating for 1 h at room temperature in HRP‐
conjugated secondary antibody that was reactive against the primary antibody species diluted 
in 1% w/v skim milk. Next, the membranes were washed 5 times in TBS‐T for 10 minutes per 
wash. After washing the membranes were developed using Clarity Western ECL Substrate 
(Bio‐Rad) mix for 5 min at room temperature. Images were taken using the ChemiDoc XRS+ 
(Bio‐Rad) and accompanying image analysis software using the Chemi or Colorimetric settings 
for blots. To strip and re‐probe membranes, developed nitrocellulose membranes were 
washed 3 x for 5 min per wash in TBS‐T then were incubated in Western blot stripping buffer 
at 60⁰C for 30 min with gentle shaking. Stripped membranes were again washed 3 x for 10 
min in TBS‐T prior to returning to 5% w/v skim milk to block, as above.   
 
2.1.9 Dual luciferase assay (Promega) 
For dual luciferase assays, HeLa cells were seeded at 8 X 104 cells/well in 12‐well trays or 
scaled accordingly and cultured overnight. The following day, cells were co‐transfected with 
500 ng of the ISRE firefly luciferase reporter construct (ISRE‐luc), 500ng of the according 
plasmid of interest, and 10 ng of the constitutive Renilla luciferase reporter plasmid (pRL‐TK) 
per 12 well using Lipofectamine 2000 (Life Technologies). Each transfection condition was 
carried out in triplicate. 24 hours following stimulation with IFN (or control media), cells were 
lysed in 1 x Passive Lysis Buffer (Promega; diluted from 5x in dH2O) and stored at ‐20°C in 
plates. To detect luciferase activity in samples, 20 μL of each sample was aliquoted into a 
white‐well Optiplate 96 (Perkin Elmer). To these wells, 50 μL of each 1 X luciferase assay 
reagent II (LARII) and 1 X Stop and Glow reagent (Promega) were added sequentially using 
the GloMax luminometer and luciferase activity was recorded, as per manufacturer’s 
instructions. ISRE promoter activity was determined by normalising Firefly luciferase values 
to Renilla luciferase values and expressed as relative light units (RLU) (Firefly/Renilla = RLU) 
or these values were converted to a percentage of control by normalising to control sample 
RLU (RLU experimental / RLU control average x 100). Data were analyzed using GraphPad 
Prism 8 software. 
 
2.1.10 Immunofluorescence staining 
To perform immunofluorescent staining, cultured cells were fixed with a 1:1 ratio of ice cold 
acetone:methanol solution for 10 minutes on ice. After washing twice with 1X PBS, samples 
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were blocked in 5% w/v BSA diluted in 1X PBS for 30 min at room temperature. After blocking, 
the BSA solution was removed and replaced with primary antibody (for specific usage see 
Appendix III) diluted in 1% w/v BSA in PBS for 1 h at room temperature. After washing twice 
with 1X PBS, cells were incubated with Alexa Fluor‐conjugated secondary antibody diluted 
1:200 in 1% w/v BSA for 1 h at 4 °C in the dark. Samples were then washed three times with 
1X PBS and incubated with DAPI (Sigma‐Aldrich, diluted in PBS to 1 μg/ml) for 5 min at room 
temperature in the dark. Samples were then washed three times with 1X PBS. Images were 
acquired using a Nikon TiE inverted fluorescent microscope. Contrast was applied using the 
‘Autoscale’ function of the NIS Elements program (Nikon). 
 
2.2 Tissue culture methods 
2.2.1 Tissue culture medium, cell culture reagents and recombinant interferons 
Cultures of HeLa, Huh‐7, Huh‐7.5, Ishikawa, 293T and Vero cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) containing 4.5 g/L D‐Glucose, 25 mM HEPES and 
2 mM L‐glutamine (Gibco, Invitrogen) supplemented with 10% (v/v) foetal calf serum (FCS; 
Corning Life Sciences), Penicillin (Invitrogen; 100 U/ml) and Streptomycin (Invitrogen; 100 
μg/ml). Culture of HTR8 cells was maintained in RPMI‐1640 Medium (Gibco BRL, Invitrogen) 
supplemented antibiotics and with 10% (w/v) foetal calf serum (FCS; Corning Life Sciences), 
Cultures of Ect1 and VK2 cells were maintained Keratinocyte‐Serum Free medium (Gibco, 
Invitrogen) with 0.1 ng/ml human recombinant EGF (Gibco, Invitrogen), 0.05 mg/ml bovine 
pituitary extract (Gibco, Invitrogen), and additional calcium chloride to 44.1 mg/L (final 
concentration 0.4 mM).  
Lyophilized human recombinant IFNα‐2A was purchased from Peprotech (lot #090CY28) and 
was diluted in sterile NF water to a concentration of 20,000 U/μL. Frozen 2 μL aliquots were 
stored at ‐20⁰C until use. Progesterone was purchased from Sigma Aldrich as a powder and 
was diluted in ethanol to a concentration of 1 mg/mL stock solution. This was filtered using a 
sterile 0.2 μm cellulose acetate Minisart syringe filter (Sartorius) and stored at ‐80 °C until 
use. Cell culture treatments of progesterone were prepared by performing serial dilutions of 
the stock solution (or ethanol vehicle control) in appropriate cell culture media to a final 
concentration of 10 µM prior to use. Human recombinant IFNε was made by our collaborators 
at the Hudson Institute of Medical Research refolded from bacteria as described previously 
[110]. Frozen 10 μL aliquots were stored at ‐80⁰C until use. Recombinant human IL‐28B (IFNλ‐
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III) protein was purchased from R & D systems (cat# 5259‐IL‐025) diluted to 100 ng/μL. Frozen 
10 μL aliquots were stored at ‐80⁰C until use. Human recombinant IFNβ (Rebif) was provided 
by our collaborators purchased from Merck as a stock at 24, 000 U/μL. Liquid solution was 
stored at 4⁰C as per the manufacturers instructions. Murine recombinant IFNε was made by 
our collaborators at the Hudson Institute of Medical Research refolded from bacteria as 
described previously [105]. Frozen 30 μL aliquots were stored at ‐80⁰C until use.  
 
2.2.2 Cell maintenance  
Cell lines were maintained in vent capped tissue culture flasks (25 cm2, 75 cm2, or 175 cm2) 
(Corning). When cells reached 80‐90% confluence they were sub‐cultured into new flasks. 
First the culture medium was removed and the cell monolayer was washed once with 1X PBS. 
Next, Trypsin‐EDTA was used to cover the cell monolayer in a volume of 1 mL per 75 cm2 flask 
or scaled accordingly (see Appendix II). Cells were incubated for 5‐15 minutes (dependent on 
cell line) at 37⁰C until they started to detach from the flask. To completely detach the cells, 
flasks were agitated by tapping on the sides. Next, trypsinization was halted by the addition 
of fresh culture media containing FCS and cells were resuspended by pipetting. For cells 
cultured in FCS free media (Ect1 and VK2 cells) the cell suspension was centrifuged at 150 
×gfor 5 min at RT, the supernatant was removed, and the cells were resuspended in 
appropriate culture media. A portion of the cell suspension (1/3rd upto 1/10th) was transferred 
to a new flask and topped‐up with fresh culture media to cover the bottom of the flask (12 
mL total volume for 75 cm2 flasks or scaled accordingly). After transferring the cells to a new 
flask they were returned to a 37 °C incubator with 5% CO2. Cells were passaged every 2‐3 days 
or as required. 
 
2.2.3 Enumeration of cells - trypan blue exclusion  
To determine the concentration of cells in suspension an aliquot of inactivated trypsinised 
cells (10 μL) was transferred to a microcentrifuge tube. Next, an equal volume of Trypan Blue 
Stain solution was added to the cells and mixed by pipetting. 10μL of this solution was loaded 
into one chamber of a Neubauer Hemocytometer and the number of live cells (not dark blue) 
in one triple lined grid section were counted using a clicker counter. To calculate the 
concentration of cells per mL the following calculation was used: cell count per 5 x 5 grid x ½ 




2.2.4 Cryopreservation of cells 
For cryopreservation, cells that were at maximal growth rate (~80% confluent) were 
harvested by trypsinization, as described in 2.2.2 ‘Cell Maintenance’. Cell suspensions were 
centrifuged at ~200 ×g  for 5 min to pellet cells. The supernatant was removed and cells were 
resuspended in an appropriate volume of complete cell culture medium. Next, an equal 
volume of filter‐sterilised 2 x freeze mixture containing 50% DMEM or RPMI media (as 
appropriate), 30 % FCS and 20 % DMSO was added to the cells. 1 mL of resuspended cells 
were aliquoted into each sterile labelled cryopreservation tube (CryoTube vials, NUNC). These 
cryotubes were transferred immediately to a freezing chamber (Nalgene) containing fresh 
isopropanol and placed in a ‐80⁰C freezer overnight. After overnight freezing, cells were 
transferred to liquid nitrogen for long‐term storage.  
 
2.2.5 Resuscitating cells from cryopreservation  
Cryopreserved vials of cells were defrosted in a 37⁰C water bath. Once defrosted these cells 
were immediately transferred to a new vent‐capped flask (75cm2) pre‐filled with warmed 
culture media. Cells were returned to culture in a humidified 37⁰C/5% CO2 incubator to enable 
adherence to the flask. Following adherence, the media was removed and replaced with fresh 
culture media and cells were returned to culture.  
 
2.2.6 Transient transfection of plasmid DNA or poly I:C (Lipofectamine 2000, Invitrogen) 
To transfect cells with either plasmid DNA or polyI:C reagent (Sigma‐Aldrich) Lipofectamine 
2000 (Invitrogen) transfection reagent was used, as per manufacturer’s instructions. First, 
cells were seeded one day prior to reach 90% confluence on the day of transfection. Then, 1 
X 50 μL aliquot of Opti‐MEM reduced serum media (Gibco, Invitrogen) was added to a 
microcentrifuge tube for each well of a 12‐well tray to be transfected. To this aliquot 2 μL of 
Lipofectamine 2000 was added, the tube (tube A) was mixed by flicking and briefly centrifuged 
and incubated at room temperature for 5 min. In a separate tube (tube B) another 50 μL 
aliquot of Opti‐MEM was added for each well of a 12‐well tray to be transfected. Up to 1 μg 
of total plasmid DNA or polyI:C was added to tube B and mixed. Following the 5 min 
incubation the contents of tube A was combined with that of tube B, and again this was mixed 
by flicking the tube and briefly centrifuging to collect the liquid. This mixture was incubated 
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at room temperature for 15 min and then added dropwise to the cells in 12‐well culture plates 
(100 μL per well of a 12‐well tray). For smaller sized wells, the protocol was scaled down 
accordingly.  
 
2.2.7 Transient siRNA transfection (RNAiMAX, Invitrogen) 
For siRNA transfection RNAiMAX transfection reagent (Invitrogen) was used. One day prior to 
transfection, cells were seeded to be 90% confluent on the day of transfection. The following 
day the transfection was performed as follows. First, 1 X 100 μL aliquot of Opti‐MEM reduced 
serum media (Gibco, Invitrogen) was added to a microcentrifuge tube for each well of a 12‐
well tray to be transfected. To this aliquot, 3 μL of RNAiMAX (Invitrogen) was added, the tube 
(tube A) was mixed by flicking and briefly centrifuged and incubated at room temperature for 
5 min. In a separate tube (tube B) another 100 μL aliquot of Opti‐MEM was added for each 
well to be transfected. To this tube, 1 μL of gene specific siRNA or non‐targeting control siRNA 
(Dharmacon; 20 µM in siRNA resuspension buffer) was added and mixed to combine. 
Following the 5 min incubation, the contents of tube A were combined with that of tube B, 
and again this was mixed by flicking the tube and briefly centrifuging to collect the liquid. This 
mixture was incubated at room temperature for 5 min prior to adding dropwise to the cells 
in 12 well culture plates (200 μL per 12 well). For smaller wells, the protocol was scaled down 
accordingly.  
 
2.2.8 Concentration of protein in cell-culture supernatant  
To assess the antiviral properties of Ect1 cell culture supernatant it was first necessary to 
concentrate proteins in the size range of interest. Secreted IFNε has a molecular weight of 
approximately 20 kDa. Ect1 cells were cultured in a 75 cm2 flask until 90% confluent on the 
day of the experiment. The overlaying media (12 mL) or an equivalent volume of fresh 
Keratinocyte Serum Free Media (KSFM) were filtered using a sterile 0.2 μm cellulose acetate 
Minisart syringe filter (Sartorius) to remove cell debris. The filtered culture media or KFSM 
were then placed in the top of a 10,000 molecular weight cut‐off Vivaspin TURBO 15 
concentrator (Sartorius) that had been pre‐rinsed twice with 15 mL sterile dH2O water at 4000 
×g. The concentrator containing either filtered culture media or KFSM were centrifuged at 
4000 ×g for 10 min at room temperature. After centrifugation ~1.5 mL remained in the top of 
the concentrator, and the flow through was discarded. 500 μL per well of concentrated 
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filtered culture media or KFSM were applied in triplicate to Huh‐7 cells seeded one day prior 
at 5 x 104 cells/well in 24 well plates.  
 
2.2.9 Amplification of viral seed stocks 
Following generation of DENV or ZIKV infectious clone viral seed stocks from in vitro 
transcribed RNA or plasmid DNA transfections, these virus stocks were amplified to generate 
larger volume stocks. Vero cells were seeded at 6 x 106 cells in a 175cm2 flask. The following 
day the cells were inoculated at a MOI of 0.1 in a 10 mL volume and returned to culture. After 
2 h the inoculum was removed and replaced with 15 mL of fresh culture media. Flasks were 
returned to culture at 37°C for 4‐5 days. After 4‐5 days the supernatant was collected, 
centrifuged at 4000 ×g for 5 min to clear cellular debris and aliquoted in 1 mL aliquots for 
storage at ‐80 ⁰C. The viral stock was titrated for infectious virus by focus forming assay (DENV 
and ZIKV) and by plaque assay (ZIKV only).  
 
2.2.10 Plaque assay 
To assess the level of ZIKV in samples a plaque assay was used. First, Vero cells were seeded 
at a density of 2 X 105 cells/well in a 12 well plate or scaled accordingly. After overnight 
culture, neat viral stocks or cell culture supernatants were defrosted and serially diluted (1 in 
10 dilutions) using fresh culture media to a total volume of 1mL. Next, the overlaying media 
was removed from the Vero cell monolayers and replaced with the 500μL of the diluted 
sample containing virus. Plates were returned to the 37°C incubator for 1 h to allow viral 
adherence and entry. Following 1 h inoculation, the overlay was replaced with fresh DMEM 
containing a final concentration of 2% FCS v/v and 1.5 % w/v carboxymethylcellulose sodium 
salt high viscosity (Sigma Aldrich). Plates were returned to culture at 37°C for 5 days. After 5 
days, plates were fixed with 10 % v/v buffered formalin completely filling the wells. These 
were mixed by gentle swirling and then left in a fume hood at room temperature for 3 h. After 
fixation, plates were extensively washed with gentle flowing RO water until all residue had 
been removed (approximately 4 – 5 washes). Next, cell monolayers were stained using ~0.1% 
(w/v) crystal violet (CV) in a 10% (v/v) ethanol solution diluted in water for 20 minutes. Again, 
plates were extensively washed with gentle flowing RO water until all CV solution was 




2.2.11 Focus forming assay 
To titer the level of infectious DENV or ZIKV in supernatant samples, a focus forming assay 
was used. Huh7.5 cells were seeded at 2 X 104 cell/well in a total volume of 150 μL/well in 96 
well plates. The following day culture media was removed and the cells were inoculated with 
40 μL of 10‐fold serially diluted viral supernatants for 3 h at 37 °C with manual agitation of 
the plate every 20 minutes. After 3h, the inoculum was removed, monolayers were washed 
with PBS, and replaced with 100 μL fresh culture medium and then returned to culture at  37 
°C. After culturing, cells were fixed with a 1:1 ratio of ice cold acetone:methanol for 10 min 
on ice. For ZIKV, cells were fixed at 48 hpi, whereas for DENV cells were fixed at 72 hpi. 
Following fixation, ZIKV/DENV infection was detected via indirect immunofluorescence 
staining using the 4G2‐pan‐Flavivirus anti‐E primary antibody. Foci were enumerated by 
observation under a fluorescent microscope and were defined as more than 3 infected cells 
in a distinct cluster. Virus infectivity in each sample was calculated based on biological 
triplicates (with technical duplicates for each diluted virus sample) and then expressed as 
Focus Forming Units (FFU) per mL.   
 
2.3 Specific protocols for mutagenesis and mutant screening (Chapters 3 and 4) 
2.3.1 Generation of viral seed stocks from DNA transfection of ZIKV infectious clones 
To generate a viral seed stock from the pZIKV‐ICD infectious clone Vero cells were seeded in 
6 well plates at 2 x 105 cells/well. The following day the cells were transfected with the pZIKV‐
ICD plasmid using lipofectamine 2000 as described in section 2.2.6 with the following 
alterations: 200 μL Opti‐MEM, 8 μL Lipofectamine 2000 reagent, and 2 μg pZIKV‐ICD per well 
of a 6‐well tray. At 96 h post‐transfection the supernatants were collected, centrifuged at 
4000 ×g for 5 min to clear cellular debris and aliquoted for storage at ‐80 ⁰C. The seed stock 
was titrated for infectious virus by focus forming assay. To generate larger volume stocks, the 
‘amplifying viral stock protocol’ (section 2.2.9) was used.  
 
2.3.2 Half maximal inhibitory concentration (IC50) assay for IFNα treatment 
To perform an IC50 assay either Huh‐7 or Huh‐7.5 cells were seeded at 1 X 105 cells/well in a 
12 well plate (or scaled accordingly). The following day, cells were treated in triplicate with 
increasing concentrations of IFNα (0, 0.01, 0.1, 1, 10, 25, 50, 100, 250, 500, 1000 U/mL) diluted 
in fresh culture media. After 6 h the IFNα treatment was removed and cells were inoculated 
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with either ZIKV or DENV at MOI = 0.2. The following morning, the inoculum was removed, 
and the media was replaced with the appropriate concentrations of IFNα diluted in fresh 
media. Cells were returned to culture for 48 h in a 37 ⁰C incubator. 48 h post‐infection, 
supernatants containing infectious virus were collected and stored frozen at ‐80 ⁰C. These 
supernatants containing infectious virus were then titrated using a Focus Forming Assay in 
technical duplicates and used to calculate FFU/mL. Raw FFU/mL titers were normalized to the 
average raw titers at the minimum (0 U/mL) and maximum (1000 U/mL) inhibition 
concentrations of IFNα using the GraphPad Prism v8 “data normalization” function. Next the 
normalized data was used to fit a dose‐response curve using the [inhibitor] vs normalized 
response non‐linear regression analysis model. The IC50 was interpolated from the curve and 
is defined as the concentration of IFNα where the antiviral response was reduced by half. All 
normalization and statistical analysis were performed using GraphPad Prism v8 software.  
 
2.3.3 Cloning the ZIKV MuA transposon insertion mutant library (Mutation Generation 
System Kit, Thermo Scientific) 
To generate the ZIKV transposon insertion mutant library the Mutation Generation System 
Kit (Thermo Scientific) was used as per the manufacturer’s instructions and is described here 
in brief [348]. Each MuA transposase reaction contained 0.6 μg of target DNA (pZIKV‐ICD) to 
control the transposition rate to one insertion event per clone. To this, 4 μL of 5X Reaction 
Buffer, 1 μL of Entranceposon (M1‐KanR), 1 μL MuA Transposase enzyme mix and water to a 
total volume of 20 μL were added to a PCR tube. This was briefly mixed and incubated at 30 
⁰C for 1 h and afterwards the reaction was stopped at 75 ⁰C for 10 min, prior to chilling on ice. 
Next, the reaction was purified (see section 2.1.2.5 Ethanol DNA precipitation) and 
resuspended in 15 μL NF water. The purified DNA was aliquoted into separate 5 μL volumes 
before storing frozen at ‐20 ⁰C prior to use. Next, the purified DNA was transformed by 
electroporation into Endura (Lucigen) electro‐competent cells (see section 2.1.1.2) using 1 μL 
of reaction mixture per 25 μL of cells. 5 transformations were performed concurrently to 
prevent freeze‐thawing of the reaction mixture. Transformed cells were serially diluted and 
plated onto 15 cm2 LB Agar plates (3‐5 plates per transformation) containing a final 
concentration of 20 μg/mL Kanamycin (Kan) and 100 μg/mL Ampicillin (Amp), or plates 
containing only Amp for determination of reaction efficiency. Transformation plates were 
placed in a 30 ⁰C incubator for a minimum of 24 h to allow for bacterial growth. The following 
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day the number of bacterial colonies formed on the Kan/Amp compared to the Amp only 
plates were enumerated by manual counting of the dilution plates. Then bacterial colonies 
on the Kan/Amp plates were pooled in LB broth by scraping plates with a sterile cell spreader 
and the liquid was transferred to 250 mL centrifuge bottles, centrifuged at 6000 ×g for 15 
min, the supernatant removed and the pellet stored frozen at ‐20 ⁰C prior to use. This process 
was repeated for the remaining 2 x 5 μL aliquots of transposon reaction mixture. Following 
transformation and harvesting of bacteria harboring the transposon, the three frozen 
bacterial pellets were pooled and used to isolate plasmid DNA by maxi‐preparation (see 
section 2.1.2.2). Next the purified target DNA containing the transposon insertion was 
subjected to restriction digest by NotI‐HF enzyme to remove the 1kb transposon body (see 
section 2.1.3.1). Two separate restriction digests were performed each containing 5 μg of 
purified DNA and 2 μL of NotI‐HF per digest. Both digests were run on a 1% agarose gel and 
the high‐molecular weight band containing the mutagenized target DNA was gel‐extracted 
(see section 2.1.2.3) in 15 μL of elution buffer. Next, 375 ng of digested purified DNA was 
ligated using Electro‐Ligase (see section 2.1.3.5) in a total reaction volume of 10 μL at 25 ⁰C 
for 1 h, then inactivated at 65 ⁰C for 15 min prior to chilling on ice. Two identical ligation 
reactions were performed and pooled. 1.5 μL of reaction mixture was transformed directly 
into each 25 μL aliquot of Endura electro‐competent cells in 15 separate transformation 
reactions. Transformed cells were serially diluted and plated onto 15 cm2 LB Agar plates (3‐5 
plates per transformation) containing a final concentration of 100 μg/mL Ampicillin. 
Transformation plates were placed in a 30 ⁰C incubator for a minimum of 24 h to allow for 
bacterial growth. The following day the number of bacterial colonies formed on the Amp 
plates were enumerated by manual counting of the dilution plates. Then bacterial colonies 
on the Amp plates were pooled in LB broth by scraping with a sterile cell spreader and the 
liquid was transferred to 250 mL centrifuge bottles, centrifuged at 6000 ×g for 15 min, the 
supernatant removed and the pellet stored frozen at ‐20 ⁰C prior to use. Following 
transformation and harvesting of bacteria harbouring the transposon the frozen bacterial 







2.3.4 DENV mutant screening 
2.3.4.1 Recovery of library from frozen stock 
To recover the initial mutant library from frozen stock (Passage 0) Huh‐7.5 cells were seeded 
into six 75cm2 flask at 2x106 cells per flask in a 12 mL volume. The following day three flasks 
(n=3) were treated with IFNα at 1 U/mL diluted in fresh media and three flasks were left 
untreated for 6h. After 6 h of pre‐treatment, all flasks were inoculated with the defrosted 
DENV mutant virus stock diluted 1:1 with fresh media in a total volume of 12 mL per flask. In 
parallel, an aliquot of the frozen virus stock was used in a Focus Forming Assay (section 2.2.11) 
to retrospectively determine the MOI for this passage. After overnight incubation of the 
flasks, the inoculum was removed and replaced with IFNα at 1 U/mL diluted in fresh media. 
Once the titer had been determined by Focus Forming Assay (72 h post‐infection), the 
supernatant containing infectious virus was collected and cleared of cellular debris by 
centrifugation (4000 ×g, 5 min). Supernatant from each triplicate was divided in half and 
separately aliquoted into two 14 mL tubes (Corning). Additionally, smaller 1 mL volumes of 
each replicate were aliquoted into microcentrifuge tubes to titer the virus by Focus Forming 
Assay prior to use in the next passage. After removing infectious supernatant, the cell 
monolayer was washed with 1 X PBS and total RNA was harvested in 4 mL TRIsure reagent 
(Bioline) per 75cm2 flask. Both supernatants and RNA samples were stored frozen at ‐80 ⁰C 
until further use.  
 
2.3.4.2 Passaging of the recovered mutant library  
To perform subsequent passages (Passage 1 and Passage 2), Huh‐7.5 cells were again seeded 
into six 75cm2 flask at 2x106 cells per flask in a 12 mL volume. Additionally, 100 μL of diluted 
cells were seeded in 6 wells of a 96 well tray. The cells in 96 well trays were treated 
equivalently to the experimental replicates throughout the screen. This allowed monitoring 
of the rate of infection by indirect immunofluorescence using the 4G2 anti‐E primary 
antibody. On the morning after seeding, cells were again treated with IFNα at 1 U/mL diluted 
in fresh media and three flasks were left untreated for 6h. Then all flasks were inoculated with 
a MOI = 0.2 of the mutant DENV from the previous passage. Replicates were not pooled 
between passages. 48 h post‐infection, the supernatant containing infectious virus was 
collected and cleared of cellular debris by centrifugation (4000 ×g, 5 min). Supernatants from 
each replicate were divided in half and separately aliquoted into two 14 mL tubes (Corning). 
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Additionally, smaller 1 mL volumes of each replicate were aliquoted into microcentrifuge 
tubes to titer the virus by Focus Forming Assay prior to use in the next passage. After removing 
infectious supernatant, the cell monolayer was washed with 1 X PBS and total RNA was 
harvested in 4 mL of TRIsure reagent (Bioline) per 75cm2 flask. Both supernatants and RNA 
samples were stored frozen at ‐80 ⁰C until further use. Additionally, on the morning of the 
second day post‐infection the parallel 96 well plates were fixed for anti‐E 
immunofluorescence. This process was then repeated for an additional round of selection.  
 
2.3.4.3 Genome sample preparation and NGS 
To prepare samples of the selected DENV mutant library for NGS the following procedure was 
used. Briefly, total RNA was extracted separately from each replicate in passage 1 and 2 by 
standard TRIsure methods (section 2.1.4.1). Then this was used in a Superscript reverse‐
transcriptase III high‐fidelity first strand synthesis (Life Technologies) reaction (section 
2.1.6.2) performed using a reverse primer that bound specifically to the extreme 3’ end of the 
DENV2 genome to amplify the full‐length genome (see Appendix I). Next, full‐length DENV 
cDNA from each replicate was used as a template to PCR amplify 6 overlapping fragments 
covering the entire length of the DENV genome using the high‐fidelity Q5 polymerase (section 
2.1.3.3; see Appendix I for primer sequences). Each PCR product was gel‐extracted and 
purified (section 2.1.3.2). The resultant concentration of PCR product from each sample was 
determined using the Qubit dsDNA HS (High Sensitivity) Assay Kit (section 2.1.5). 
Subsequently, the 6 overlapping PCR fragments covering the full‐length genome were pooled 
in equimolar ratios (0.1pmol of each fragment) as calculated by the molecular weight of each 
fragment using the Promega online Biomath calculator. This was performed separately for 
each independent replicate. These samples were then sent to collaborators at UNSW and the 
Ramaciotti Centre for Genomics, where NGS libraries for each pool were prepared using the 
Nextera XT (Illumina) and sequenced on the NextSeq500 platform.  
 
2.3.5 Preparation of DENV infectious clone plasmids and in vitro synthesis of viral RNA 
(mMESSAGE mMACHINE® SP6, Invitrogen) 
To generate in vitro transcribed RNA for DENV infectious clones the mMESSAGE mMACHINE® 
SP6 kit (Invitrogen) was used. Initially 2‐ 5 μg of the parent pFK‐DVs plasmid or equivalent 
mutant infectious clone was linearized by overnight XbaI restriction digestion, cleaving at the 
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extreme 3’ terminus of the DENV genome. Following overnight digestion, the linearized 
plasmid was column purified as described previously in section 2.1.2.4 (Bioline) and eluted in 
15 μL of NF water. Next, the SP6 reaction was set up in PCR tubes containing 10 μL of NTP/Cap 
2 X mixture, 2 μL of 10 X reaction buffer, 1.5 μL of GTP (20 mM), 4.5 μL of linearized purified 
plasmid template and 2 μL of SP6 enzyme mix. The reaction was briefly mixed by pipetting 
and incubated at 37⁰C for 3 h using the Bio‐Rad S1000 Thermal Cycler. Then 1 μL of Turbo 
DNase was added per tube and returned to incubate for a further 15 min at 37⁰C. To purify 
the RNA the entire 20 μL reaction was spiked into 1 mL of TRIsure (Bioline) and the RNA was 
extracted as described in section 2.1.4.1.  
 
2.3.6 Transfection of in vitro transcribed RNA for viral production kinetics assays and the 
propagation of DENV infectious virus stocks (DMRIE-C, Invitrogen)  
One day prior to transfection, Huh7.5 cells were seeded at 2 X 105 cells/well in a 6 well plate. 
The following day the transfection mixture containing 1 mL Opti‐MEM (Gibco, Invitrogen), 6 
μL DMRIE‐C (Invitrogen) and 5 μg in vitro transcribed and purified RNA was made up in a 
microcentrifuge tube. Next, culture media was removed from the cells, then they were 
washed once with 1 X PBS prior to adding the entire transfection mixture onto the cells 
directly. These plates were returned to culture for 3 h at 37⁰C. After incubation, the 
transfection mixture was removed and replaced with fresh culture media (3 mL). Each day 
post transfection 250 μL of culture supernatant was collected from each well and stored 
frozen at ‐80 ⁰C. After 3 days of culture the transfected Huh‐7.5 cells had reached confluence 
and were harvested by trypsinisation, prior to application of equal volumes of the cell 
suspension from each well into a 25 cm2 flask and a 6 well plate. The virus‐containing 
supernatant was diluted 1:1 with fresh media and divided equally between the T25 and the 6 
well dish. A small portion of the transfected cells (100 μL) were concurrently seeded into 96 
well plates and left to attach to the wells prior to fixing with acetone/methanol. These 96 well 
replicates were used the following day to estimate the rate of infection at 72 hpi by 
immunofluorescent labelling of E‐protein. After re‐seeding, 250 μL of culture supernatant was 
collected from each well of the 6 well tray, each day until 7 dpi and stored frozen at ‐80 ⁰C. 
After the 7‐day time point had elapsed, these frozen aliquots were used to determine the 




2.3.7 IFN sensitivity assay 
To perform an IFN sensitivity assay Huh‐7.5 cells were seeded at 1 X 105cells/well in a 12 well 
plate (or scaled accordingly). The following day cells were treated in triplicate with increasing 
concentrations of IFNα diluted in fresh culture media or left untreated. After 6 h the IFNα 
treatment was removed and cells were inoculated with either ZIKV or DENV at an MOI of 0.2. 
The following morning, the inoculum was removed, and the media was replaced with the 
appropriate concentrations of IFNα diluted in fresh media. Cells were returned to culture for 
48 h in a 37 ⁰C incubator. 48 h post‐infection, supernatants containing infectious virus were 
collected and stored frozen at ‐80 ⁰C. These supernatants containing infectious virus were 
then titrated using a Focus Forming Assay in technical duplicates and used to calculate 
FFU/mL. Raw FFU/mL titers were normalized to the average titer of infectious virus generated 
by the untreated cells. Statistical analyses were performed on the normalized data using one‐
way AVOVA compared to untreated using the GraphPad Prism v8 software.  
 
2.4 Cultured Cell lines 
2.4.1 Ect1  
The ectocervical Ect1/E6E7 cell line was established in 1996 from normal epithelial tissue 
taken from a premenopausal woman. Cells at passage 3 were immortalized by transduction 
with the retroviral vector LXSN‐16E6E7 [96]. These cells were generously provided by Sarah 
Robertson of the Robinson Research Institute, Adelaide, Australia. 
 
2.4.2 HeLa 
The HeLa cell line is derived from cervical cancer cells isolated from Henrietta Lacks a 31 year 
old African American woman [301]. 
 
2.4.3 Huh-7  
The Huh7 cell line is a hepatocellular carcinoma cell line of epithelial origin isolated from a 57 
year old Japanese male [242]. 
 
2.4.4 Huh-7.5  
The Huh‐7.5 cell line is derived from the Huh‐7 cells which used to harbour replication of an 
HCV subgenomic replicon but were cured after IFN‐α treatment [26] and are defective in RIG‐
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I signalling [336]. These cells were kindly provided by Charles Rice, Rockefeller University, New 
York, USA. 
 
2.4.5 HTR8  
The HTR‐8/SVneo cell line was derived by transfecting the cells that grew out of chorinic villi 
explants of human first‐trimester placenta with the gene encoding for simian virus 40 large T 
antigen [120]. These cells were generously provided by Claire Roberts, Flinders University, 
Adelaide, Australia.  
 
2.4.6 HEK 293T  
The HEK 293T cell line is derived from the human HEK 293 cell line of embryonic kidney 
epithelial origin with the addition of the SV40 large T antigen [85].   
 
2.4.7 Ishikawa  
The Ishikawa cell line is derived from endometrial adenocarcinoma in a 39 year old pre‐
menopausal woman [252]. These cells were generously provided by Sarah Robertson of the 
Robinson Research Institute, Adelaide, Australia. 
 
2.4.8 Vero 
The Vero cell line was isolated from the kidney of a normal adult African green monkey and 
were established in 1962 by Y. Yasumura and Y. Kawakita at the Chiba University in Chiba, 
Japan.  
 
2.4.9 VK2  
The VK2/E6E7 cell line was established in 1996 from the normal vaginal mucosal tissue taken 
from a premenopausal woman. Cells at passage 3 were immortalized by transduction with 
the retroviral vector LXSN‐16E6E7 in the presence of polybrene [96]. These cells were 









Construction of a ZIKV transposon mutant library 
 
3.1  Introduction  
The ability to evade the type‐I IFN response is crucial to ZIKV infection and associated disease 
in humans. This is demonstrated by the difference in host adaption between primates that 
are naturally susceptible to ZIKV and mice that are the main small animal model used for ZIKV 
research. Immune competent mice are not susceptible to ZIKV infection by intravenous 
inoculation but IFNAR receptor knockout mice, which are readily infected and can succumb 
to the associated disease [181, 209, 231]. This stark difference in species adaptation and 
susceptibility to infection is primarily dependent on ZIKV NS5 mediated degradation of human 
but not mouse STAT2, resulting in blockade of the human IFN pathway [121]. Importantly, 
transgenic mice expressing human STAT2 demonstrate increased susceptibility to infection, 
implying ZIKV blockade of IFN signalling is the main barrier to infection in mice [115]. Together 
this data highlights the importance of IFN in prevention of ZIKV infections and suggests this 
axis of host‐virus interaction can be exploited to improve patient outcomes. In addition to 
species adaption, the importance of the IFN response is illustrated by ZIKV having evolved 
multiple strategies to evade both IFN production and signalling downstream of the IFNAR 
receptor. Several studies (detailed in section 1.3) have elucidated roles of NS1, NS4A, NS2A 
and NS5 and others in preventing induction of IFN downstream of the RIG‐I/MAVS pathway 
[189, 200, 249, 374, 393]. Other studies have discovered evasion mechanisms downstream of 
IFNAR activation. Aside from NS5 mediated degradation of STAT2 these include NS2B/3 
mediated degradation of JAK1 [374] and ZIKV increasing levels of the negative regulator 
SOCS1 after binding with the proposed attachment factor AXL on the cell surface [47, 216]. 
Each of these studies shares a similar limitation in that they rely on over‐expression of isolated 
viral proteins. As a result, they do not accommodate for potential synergistic effects of other 
viral proteins or untranslated genetic elements that are part of the full ZIKV lifecycle. This is 
especially important since the functions of individually expressed Flavivirus proteins have a 
limited capacity to recapitulate natural functions within the full lifecycle [167]. Furthermore, 
most studies have resolved only to the whole protein level, or at best to the domain level and 
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have not pinpointed the exact encoded region responsible for these evasion mechanisms. 
Another poorly understood area is the contribution of the ZIKV UTRs to IFN evasion. Flavivirus 
UTRs produce functionally significant sub‐genomic Flavivirus RNAs (sfRNA) that can 
antagonise IFN [379]. The IFN evasion capacity of DENV sfRNAs has been well established and 
was shown to depend on preventing activation of RIG‐I in a TRIM25 dependent manner [35, 
202]. Recently, ZIKV sfRNA was also shown to inhibit RIG‐I and MDA5, however these 
experiments relied on transient transfection of 3’UTR elements [82]. Additionally, WNV sfRNA 
was shown to inhibit signalling downstream of activated IFNAR1/2 [307]. Knowledge of ZIKV 
IFN evasion by viral proteins and UTR elements could be improved by testing these 
mechanisms within a fully infectious system.  
For these reasons, the primary aim of this chapter was to discover novel sequence elements 
within the ZIKV genome (both in translated and in un‐translated regions) that contribute to 
evasion of the IFN response downstream of the IFNAR1/2 receptor. To address this topic, we 
aimed to generate a high‐throughput random transposon mutagenesis library of a full‐length 
infectious cDNA clone of ZIKV. The underlying rationale was that the randomly distributed 15 
bp inserts generated by the MuA transposon mutagenesis process would create loss‐of‐
function mutations when sequences that were essential under the IFN selection condition 
were interrupted. This would result in a reduced fitness of these viral mutants and 
consequently a reduced frequency under selection when compared to the control (no IFN) 
environment. This knowledge could be useful in understanding Flavivirus immune evasion 
and may enable generation of attenuated virus strains for use in targeted vaccine 
development. In support of this approach, a ZIKV reverse genetics system has recently been 
used to test an IFN hypersensitive mutant as a live attenuated vaccine in mice [18, 186]. 
 
3.2  Results 
3.2.1 Testing ZIKV reverse genetics systems 
Recently our laboratory was gifted two different ZIKV infectious cDNA clones. These are 
described in full by their respective creators in the publications by Tsestarkin et al. (2016) and 
Schwarz et al. (2016) and are represented diagrammatically in Figure 3.1 [309, 350]. Briefly, 
the first clone named pZIKV‐ICD [350] was generated by incorporating full‐length ZIKV cDNA 
into a low copy number vector pACNR1811 (Fig. 3.1a). The viral cDNA for this clone was 






 (strain: Paraiba_2015) [59]. Following transfection of the plasmid into eukaryotic cells, the  
initial transcription of full‐length positive sense ZIKV RNA is driven by the eukaryotic RNA 
polymerase II cytomegalavirus (CMV) promoter. Authentic 3’ ends are generated by the anti‐
genomic hepatitis delta virus ribozyme (agHDVR) sequence downstream of the viral 3’ UTR 
region that auto cleaves after it is transcribed. Additionally, to minimize toxicity of viral 
sequence and to enhance plasmid stability in Escherichia coli (E. coli) two chimeric introns 
were introduced at nucleotide positions 2711 (NS1) and 8882 (NS5). The second clone named 
pZIKV‐MR766‐WT was generated from cDNA of the historical African strain MR766 first 
discovered in Uganda in 1947. This cDNA was cloned into the high‐copy‐number vector 
pCDNA6.2 (Fig. 3.1b) [309]. Like pZIKV‐ICD this clone utilizes a eukaryotic CMV promoter to 
drive transcription of viral sequence and a genomic HDVR (gHDVR) for generation of authentic 
3’ ends. Interestingly, this clone only required a single insertion of a chimeric intron in NS1 at 
nucleotide position 3127 for plasmid stability. To validate these clones for generation of 
infectious virus each plasmid was transfected into Huh‐7 cells that are permissive to the 
related DENV [94]. Figure 3.2 shows following transfection of these clones they successfully 
initiated transcription and translation of the viral proteins as determined by 
immunofluorescent detection of ZIKV E‐protein in transfected cells (Fig. 3.2a). The ZIKV E‐
protein was first detected at 48 hours post transfection (hpt) and increased by 72 hpt. 
Importantly, transfection of these plasmids resulted in the production of infectious virions in 
the supernatant 48 hpt detected by plaque assay on Vero cells (Fig. 3.2b). The ability of these 
virus particles to infect Vero cells and spread independently of plasmid transfection indicated 
de novo virions were packaged and exported with a full‐length copy of the +ssRNA ZIKV 
genome. Collectively this data confirms the ability of these infectious clones to initiate the 
complete virus lifecycle after direct transfection into mammalian cell culture. Due to a  
concurrent publication by Fulton et al. (2017) utilizing the pZIKV‐MR766‐WT clone for 
transposon mutagenesis screening [104] and the enhanced relevance of the pZIKV‐ICD clone 











3.2.2 Optimization of screening conditions 
Following validation of the pZIKV‐ICD reverse genetics system for production of infectious 
virus the next step was to select the appropriate cell type for use in the screen. The ideal cell 
type for the screen was one of human origin to rule out species‐specific differences with the 
IFN pathway. Also, cells were required to have an intact IFN signalling pathway downstream 
of the type‐I IFN receptor. Additionally, it was desirable that these cells have a low level of 
endogenous IFN production to the limited unintended induction of viral associated immune 
pathways in the untreated group. Huh‐7 cells used in our laboratory to culture flaviviruses 
such as DENV represented an ideal choice. These cells are of human liver origin, are known to 
respond well to IFN, have defects in IFN production pathways and are permissive to ZIKV [163, 
354].  
Other considerations for the screen related to the generation of the initial seed stock from 
transfection of plasmid DNA into mammalian cells. This step of transfecting the library into 
mammalian cells was a potential bottleneck that could constrict the diversity of the mutant 
virus represented in the subsequent passages. Therefore, to maximise mutant virus diversity 
from the cDNA library we aimed to optimise transfection efficiency for the pZIKV‐ICD clone 
and quantify the impact on virus production. Furthermore, we wanted to determine the cell 
lines that are most permissive to ZIKV infection for use in subsequent passages. Virus 
production by 48 hpt and spread by 72 hpt was compared in the indicated cell lines following 
transfection of the pZIKV‐ICD clone. Virus production was monitored over time by detection 
of infected cells using the 4G2 anti‐ E protein and immunofluorescence microscopy. These 
cell lines (Huh‐7, Vero and 293T) were selected based on their use in either the Tsestarkin et 
al. publication or in the mutant screen by Fulton et al., respectively, to generate high virus 
titres. Figure 3.3a demonstrated that at 48 hpt, 293T cells clearly have greater numbers of 
infected cells producing virus E protein compared to both Huh‐7 and Vero cells at the same 
time point indicating their improved transfection efficiency. However, the spread of virus by 
72 h post transfection was limited in 293T cells and was greatly improved in Huh‐7 and Vero 
cells,  
indicating that these cell types are more permissive to ZIKV infection after virus production 
was established. To confirm this differing permissiveness independent of transfection 
efficiency, all three cell types were infected with a virus stock of the MR766 strain at an MOI 






permissive followed by Vero cells and then 293T cells based on the number of E‐protein 
positive cells. Next, to quantify the impact of transfection efficiency and permissiveness on 
virus production, Huh‐7, Vero, 293T and HeLa cells were transfected with pZIKV‐ICD. 
Supernatants were collected at 24 h intervals following transfection, and the level of 
infectious virus was quantified by focus forming assay on Huh7.5 cells. Corresponding with 
the immunofluorescence data, Huh‐7 cells (Fig 3.4a) had low quantities (5x102 FFU/mL) of 
virus produced at 48 h indicating poor transfection efficiency and by 72 h infectious virus 
levels of approximately 7.5 x 102 FFU/mL were produced. 293T cells produced 1.3 x 103 
FFU/mL at 48 hpt, presumably reflecting their improved transfection efficiency compared to 
Huh‐7 cells (Fig. 3.4c). The subsequent plateau in virus production of 1.1 x 103 FFU/mL at 72 
h and the maximum of 2.3 x 104 FFU/mL recorded at one‐week post transfection suggested 
that 293T cells do not support efficient virus replication and/or virus production. Vero cells 
started with the lowest recorded virus titer at 48 hpt (3.6 x 102 FFU/mL) but then rapidly 
generated higher levels of infectious virus (2.3 x 104 FFU/mL) at 72 hpt before a plateau at 
approximately 3.3 x 105 FFU/mL after one week (Fig. 3.4d). Comparatively, the titers 
generated following transfection of Vero cells with the same plasmid, transfection reagent 
and cell line were much lower than those reported in publication by Tsestarkin et al. 
(reportedly 1 x104 PFU/mL at 24 hpt and a maximum of 3x 106 PFU/mL at 72 hpt). 
Interestingly, HeLa cells had the highest initial titer at 48h of approximately 2.3 x 104 FFU/mL 
and the highest at 72 hpt (6.3 x 104 FFU/mL) compared to other cell lines (Fig. 3.4b).  From 
this data it was concluded out of the cell lines tested, HeLa cells had the preferred 
characteristics to generate a virus seed stock of the mutant library, as they generated the 
highest titer of virions following direct transfection and therefore would limit the bottleneck 
on mutant diversity following transfection. However, HeLa cells can mount a full IFN response 
to virus (see results Chapter 6). To reduce the impact of endogenous IFN production on the 
screen it was decided that virus library seed stock would be generated in HeLa cells for 48 h 
to generate an input pool of mutant virus (Pool 0). This seed stock would then be passaged 
onto Huh‐7 cells for the subsequent Pools 1 and 2 to apply selective pressure to the mutant 






The final consideration for the screening conditions was the concentration and timing of IFN 
treatments applied to the cells in following passages. Ideally this treatment would give 
adequate selection pressure to reduce the frequency of IFN sensitive mutants without 
dramatically reducing library diversity within the IFN treated pools. For this reason, the 
concentration of IFNα that inhibited ZIKV production by 50 % (IC50) was determined for Huh‐
7 cells (see Materials and Methods section 2.3.2 for details). Based on a similar screen by Qi 
et al. (2017) uncovering HCV IFN sensitive mutants, it was decided that a low multiplicity of 
infection (MOI = 0.2) would be used for passaging to prevent co‐infection with multiple 
mutant or wildtype viruses [274]. To determine the IC50 of IFNα for the screen, Huh‐7 cells 
were treated with increasing concentrations of IFNα for 6 or 18 h (overnight) prior to infection 
with ZIKV (MOI of 0.2). 48 h post infection (hpi) supernatants were collected, and infectious 
virus was enumerated by focus forming assay to calculate the FFU/mL. Raw FFU/mL values 
were then normalized to the average of the untreated control (maximum infection) and 
expressed as a percentage of the infectious virus titer of the untreated control. These 
normalized values were then used to determine the IC50 by non‐linear regression analysis. 
Figures 3.5a and 3.5b show that the IC50 for IFNα was inversely related to the length of pre‐
treatment. We hypothesized that this was likely a result of elevated ISG protein expression 
over the longer timeframe, improving antiviral protection against ZIKV infection. It was 
decided to continue the screen using the 6 h pre‐treatment IC50 as this was the most 
convenient timing for the screen and closely reflected the IFN concentration used in the afore‐
mentioned HCV screen (4 U/mL vs 1 U/mL) [274]. 
 
3.2.3 Generation of the ZIKV MuA transposon mutant library 
After selecting, validating, and optimising the experimental conditions related to the use of 
the pZIKV‐ICD infectious clone for the screen, construction of the transposon mutant library 
was initiated using the Thermo Fisher Mutation Generation System Kit (see Materials and 
Methods section 2.3.3 for details). The aim was to generate a library containing between 
250,000 to 1,000,000 individual mutant clones as had been reported for similar MuA 
transposon mutagenesis studies on flaviviruses [94, 104, 274] thereby providing good 
coverage of all possible transposon insertion events across the genome. The first step in the 
generation of the mutant library was the MuA transposase reaction to insert the 1.2 Kbp 





clone. Initial attempts to recover mutant clones (KanR, AmpR) after bacterial transformation  
by methods previously optimized for the DENV mutant library generation by Eyre et al. were 
unsuccessful (summarised in Table 3.1) [94]. The recovery of mutant colonies per 
transformation was too low (1000 clones per transformation) to adequately address the aim 
of comprehensively exploring all regions of the ZIKV genome that are involved with IFN 
evasion. Additionally, diagnostic restriction digests performed on individual plasmid clones 
revealed deletions of large fragments of DNA that was characteristic of bacterial 
recombination events (results not shown). The frequency of plasmid recombination in 
multiple randomly selected mutant clones was considered too high (43% of individual mutant 
clones) to be practical within a pooled mutant library. To improve these outcomes multiple 
systematic attempts to optimise the transformation conditions were made. Factors optimised 
for transformation efficiency included, (i) improved input plasmid purity, (ii) decreasing the 
concentration of Kanamycin antibiotic on Agar plates, (iii) introducing a purification step after 
the MuA transposase reaction prior to transformation and (iv) changing the competent cells 
to electro‐competent cells that were specialised for viral sequence stability (detailed in Table 
3.1). Further optimization to reduce the percentage of recombinant clones included reducing 
the temperature of bacterial recovery and out‐growth to 30 ⁰C for 24 h instead of 37 ⁰C for 
16 h. These combined variables resulted in significantly improved recovery of mutants as 
measured by the number of dual resistance mutants on Kanamycin / Ampicillin plates 
compared to Ampicillin only selection (see Fig. 3.6a & b). Furthermore, the frequency of 
recombination occurring in randomly selected individual clones was reduced more than 2.5‐
fold. After performing multiple transformations (15 in total) approximately 385,000 individual 
mutant clones were transformed. These bacterial clones were then pooled from all the dual 
selection plates and plasmid DNA was purified. To assess the pooled plasmid DNA preparation 
for signs of recombination and for successful insertion of the 1.2 kb insert, a NotI restriction 
digest was performed to release the transposon body from the pooled mutant pZIKV‐ICD DNA 
(see Fig 3.6c). The clearly defined upper band in lane 4 that was the same size as the full‐
length linear pZIKV‐ICD plasmid in lane 3 indicated that most mutants within the library 
retained full‐length ZIKV sequence (not recombined). The lower band in lane 4 present at the 
expected 1.2 kb size indicated successful incorporation of the transposon containing the 
Kanamycin resistance cassette. Together this process generated an intermediate pooled 






between 250,000 – 1,000,000 mutant clones to adequately cover the ZIKV genome.  This  
intermediate library was not substantially contaminated with recombinant clones and 
contained the expected transposon insert.  
The next step in library preparation was to remove the transposon body by NotI restriction 
digestion and then to re‐ligate the full‐length mutant pZIKV‐ICD sequence, leaving behind the 
final 15 bp mutant insertion. Initial attempts were hampered by low yield of DNA recovered 
after gel‐extraction of the mutant pZIKV‐ICD sequence and additionally after purification of 
the T4 ligation reaction prior to electroporation. To overcome this barrier, NEB ElectroLigase 
was used because it does not require an additional purification step prior to transformation 
into electro‐competent cells. Table 3.2 shows that after transformation with the optimised 
recovery and outgrowth at 30 ⁰C comparable numbers of mutant clones were recovered for 
each transformation (~20,000 – 30,000). After performing multiple transformations, a total 
of ~300,000 mutant colonies were recovered, indicating maintenance of the library diversity 
generated in the intermediate cloning step. To assess the outcome of the re‐ligation a panel 
of randomly selected individual plasmid clones were subjected to restriction digest with NotI. 
Unfortunately, restriction digest screening of individual clones revealed widespread 
recombination as indicated by bands of smaller than expected size. A staggering 90% of 
individual clones harboured recombinant plasmid DNA. The combined effect of this can be 
observed in the gel image of the pooled library digested with NotI (Fig. 3.7). Instead of 
appearing on the gel as a clearly defined band at the same size as the NotI digested 
intermediate transposon insertion library (lane 2) or the linearized pZIKV‐ICD parent DNA 
(lane 3) the mutant library appeared as a smear (lane 1). This indicated significant proportions 
of the mutant clones had lost segments of the plasmid DNA due to recombination following 
bacterial transformation. Multiple systematic attempts were made to reduce the 
recombination frequency such as by reducing recovery and out‐growth temperatures (25 ⁰C), 
and the use of different competent cells reported to be more stable for viral sequences 
(Stable 3, Invitrogen). Unfortunately, none of the optimization attempts were able to 












3.2.4 Testing the ZIKV MuA transposon mutant library for viability 
To determine if the final pZIKV‐ICD mutant library was able to initiate virus replication or 
infectious virus production even in the face of significant plasmid recombination the pooled 
library was transfected into HeLa cells in parallel with the parent pZIKV‐ICD plasmid. Figure 
3.8a shows markedly reduced ZIKV E‐protein detected by immunofluorescence at 24, 48 or 
72 hpt from cells transfected with the pooled mutant library compared to the parent plasmid. 
The distribution of E‐protein positive cells in wells transfected with the mutant library was 
limited to sparsely distributed individual cells at 24 hpt that expanded to sparsely distributed 
foci of infected cells by 72 hpt. This pattern implied initiation of virus replication was a result 
of rare non‐recombined plasmids within the library, and that the majority of the pooled 
plasmid stock was non‐functional. Comparatively, the parent plasmid pZIKV‐ICD transfection 
resulted in frequent detection of E‐protein positive cells that were evenly distributed 
throughout the culture at 24h and increased in frequency over time at 48 and 72h. Together, 
this indicated a severely diminished frequency of transfection events initiating viral 
replication and protein production by the pooled mutant library compared to the parent 
plasmid as a result of non‐functional recombined plasmid clones. To confirm and quantify this 
effect the level of infectious virus in cell culture supernatants were enumerated by focus 
forming assay on Huh7.5 cells for parallel cultures of transfected cells. Figure 3.8b shows that 
the parent pZIKV‐ICD transfection was able to initiate robust production of infectious virus 
that increased steadily over time to comparable titers previously observed in HeLa cells. On 
the other hand, the mutant library produced levels of infectious virus titers that were 3‐logs 
lower at all time points. Interestingly, the related study involving mutagenesis of the MR766 
clone by Fulton et al. [103] also found a 3‐log reduction compared to wildtype, validating our 
experimental procedure. However, in combination, the high frequency of recombination in 
the pooled mutant library reduced the estimated percentage of functional plasmids capable 
of generating de novo virus production by 90% of those recovered. This corresponded to 
~30,000 viable mutants in the pool. Consequently, when the mutant library was transfected 
into cells it produced approximately 3‐log lower levels of infectious virus. Some loss of 
function was expected in the screening process since not all mutants would be replication 
competent. However, it was of major concern that the theoretical coverage of the 11 kb 





targeting each residue in the genome and limited the screening power to a point not 
appropriate for continuation. Unfortunately, due to these significant experimental issues and 
time constraints the decision was made to discontinue work on ZIKV transposon mutagenesis. 
Instead, a related line of investigation to detect Flavivirus IFN evasion genetic elements was 
initiated as outlined in the following Chapter 4.  
 
3.3 Discussion 
The ability of ZIKV to evade the type‐I IFN response is key to it causing infection and disease 
in humans. Specific components encoded within the ZIKV genome are responsible for this IFN 
evasion. To date, studies examining ZIKV IFN evasion have focused on expression of individual 
viral proteins or UTR elements and lack the context of the full virus lifecycle. This limitation 
means there are likely undiscovered genetic regions that are important for ZIKV IFN evasion. 
To address this gap in knowledge we aimed to generate a transposon mutant library of an 
infectious full‐length ZIKV cDNA clone. This mutant library was then to be subjected to 
selection in mammalian cell culture under conditions with or without IFN prior to the analysis 
of the impact of each mutation on IFN sensitivity. Together, this high‐throughput mutagenesis 
and selection approach coupled with NGS sequencing intended to reveal novel genetic 
elements involved in ZIKV IFN evasion. 
In preparation for screening a reverse genetics system was validated for generation of de novo 
virus production. This system (pZIKV‐ICD) was chosen based on its utility in initiating 
generation of infectious virus, its relevance to the recent outbreak strain and its novelty 
compared to an infectious clone based on the prototypical MR766 Uganda strain. Initially, 
there were challenges regarding the amount of infectious virus generated from transfection 
into cells used by other groups for similar screens (Huh‐7, Vero or 293T) [94, 104, 350]. This 
was found to depend on balancing transfection efficiency and permissiveness of cell lines. Of 
the cell lines tested, HeLa cells provided the best compromise, generating the highest titers 
of virus from direct transfection. This was an important consideration for the desired use of 
the plasmid in a high‐throughput mutagenesis approach, as low transfection efficiency would 
create a genetic bottleneck in library diversity entering cells. A better approach, rather than 
directly transfecting a full‐length cDNA plasmid that relies on CMV driven RNA transcription, 
could be to generate in vitro transcribed RNA from a bacteriophage promoter similar to that 
used by Eyre et al. in a recent DENV mutagenesis screen [94]. This would likely improve 
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transfection efficiency since the +ssRNA can directly initiate viral replication in the cytoplasm 
rather than requiring plasmid DNA entry into the nucleus as for DNA based expression 
systems. Further steps in preparation for the screen included determining the optimal 
treatment condition for IFN. As done previously for a relevant HCV mutagenesis screen using 
IFN selection, the IC50 was determined [274]. The IC50 value was found to be dependent on 
the duration of IFN pre‐treatment, likely as a result of accumulation of antiviral proteins in 
response to IFN stimulation. A 6 h treatment at 4 U/mL of IFNα on Huh‐7 cells was selected 
based on practical considerations for the screen.  
After validating the screening conditions, mutant library preparation was attempted. Briefly 
this required two cloning steps. The first step involved random insertion of transposon 
cassettes into the ZIKV genome that were then selected for based on Kanamycin resistance. 
The second step was removal of the bulk transposon body, ligating together a 15 bp insert 
that would disrupt essential sequence elements in both coding and non‐coding regions. We 
aimed to generate a library with between 250,000 to 1,000,000 individual mutants in order 
to provide adequate coverage of the 11 kb genome as reported by other groups with similar 
high throughput screening methods [94, 104, 274]. Unfortunately, due to widespread 
recombination in the library, it was deemed unfit for purpose. This brought the theoretical 
number of successfully mutated clones down to approximately 30,000 which was well below 
the required number. When transfected into HeLa cells the library failed to initiate efficient 
virus production, suggesting that the virus produced was from rare transfection events that 
would restrict mutant diversity in the screen.  
When working with the ZIKV infectious clone recombination was a continuous barrier to ZIKV 
plasmid manipulation and propagation. This has been extensively documented with similar 
Flavivirus reverse genetics systems and is reviewed by Aubry et al. (2015) [17]. The 
fundamental problem that causes plasmid instability in bacteria is unanticipated expression 
of viral cDNA encoding products toxic to the bacterial host. This can occur from cryptic 
bacterial promoters within viral sequences or from mammalian promoters (CMV) and is less 
commonly seen with bacteriophage promoters (SP6 or T7) [17, 273]. Consequently, Flavivirus 
clones are often difficult to maintain in E. coli due to spontaneous recombination or acquiring 
stabilizing mutations [292]. Several strategies to limit this problem had already been 
employed with the pZIKV‐ICD clone [350]. These included placing the viral cDNA in a low copy 
vector and the insertion of chimeric introns. These are only spliced out following transcription 
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in eukaryotic cells and therefore can disrupt toxic sequences in bacteria [17]. Considering the 
difficulty of stably cultivating the pZIKV‐ICD clone in bacteria, other approaches could have 
been taken to limit recombination. This however, would have required a full restructure of 
the infectious clone and subsequent mutagenesis cloning strategy which was beyond the 
scope of this project aims and timeframe. One strategy could be to employ a bacteria free 
approach to generate a full‐length clone. This would require splitting the viral cDNA into 
multiple vector backbones, limiting toxicity in bacteria of each individual plasmid. Then these 
plasmids would be separately cultivated and mutagenized. To reform the full viral sequence 
a Circular Polymerase Extension Reaction (CPER) could be used to PCR amplify and join each 
segment of viral cDNA, including a mammalian promoter directly upstream of the 5’ UTR for 
transcription. This method has been applied successfully to ZIKV reverse genetics systems by 
Setoh et al. (2017) [311]. This protocol results in the generation of a circular DNA product that 
is then transfected into mammalian cells, initiating de novo virus production.  
 
3.4 Conclusions 
The aim of this chapter was to determine novel sequence elements in the ZIKV genome that 
confer IFN resistance. To address this aim it was intended that a high throughput random 
transposon mutagenesis approach would be applied to a ZIKV infectious clone reverse 
genetics system. The resultant mutant library was then to be subjected to selection in 
conditions with or without IFN and the impact of each mutation on IFN sensitivity was to be 
analysed by NGS. Unfortunately, due to the low number of functional mutant clones 
generated by the transposon mutagenesis approach the resultant mutant library did not 
adequately cover the full‐length ZIKV genome at a depth appropriate for the screen. This 
occurred largely as a result of plasmid instability in E.coli that caused approximately 90% of 
recovered plasmid clones to have lost large fragments of DNA, rendering them non‐
functional. Therefore, a decision was made to adopt a related line of inquiry looking for 










Screening a DENV transposon mutant library to identify mutations that 
confer IFN sensitivity 
 
4.1 Introduction 
The type‐I IFN response plays a crucial role in the host control and pathogenesis of DENV. Like 
ZIKV, DENV replication exposes dsRNA replication intermediates to detection by cytosolic RLR 
PRRs as detailed in the introduction (section 1.2.1) [214]. In addition to detection by RLR, 
DENV infection results in the release of mitochondrial DNA (mitoDNA) into the cytosol. This 
serves to activate the cyclic GMP–AMP synthase and stimulator of interferon genes 
(cGAS/STING) pathway [5]. Briefly, cytosolic DNA activates cGAS and leads to the generation 
of cyclic GMP–AMP that acts as a second messenger to activate STING. Both RLR and STING 
activation leads to downstream activation of TBK1 and IRF3 resulting in the production of IFN 
[232]. The involvement of multiple pathways in sensing DENV infection implies a critical 
importance of the IFN response in protecting against this viral pathogen. Like ZIKV, type‐I IFNs 
significantly inhibit DENV replication and spread when cells are treated prior to infection [75]. 
This effect is mediated through the actions of ISGs upregulated in response to IFN. For 
example, members of the IFITM family disrupt early stages of the virus lifecycle [157]  (virus 
entry and uncoating) or Viperin [141] and ISG20 [157] that inhibit later stage processes such 
as viral protein or RNA biosynthesis. To overcome this barrier to replication DENV has evolved 
strategies to circumvent IFN mediated antiviral immunity. As a pathogen of global concern, 
the ability of DENV to evade the IFN response has been extensively studied in the hope of 
discovering druggable targets to improve patient outcomes, as reviewed in [229] and [52]. 
However, most of these studies utilise overexpression of individual viral proteins and do not 
recapitulate the complex roles of these proteins within the virus lifecycle [167]. Strategies 
that DENV uses to evade the IFN response involve several NS proteins targeting multiple 
stages of the IFN production or signalling downstream of receptor binding and are discussed 
in depth in the Introduction. Briefly these strategies include, DENV NS2B mediated lysosomal 
degradation of cGAS [5], NS2A and NS4B mediated inhibition of TBK1 phosphorylation [65], 
DENV NS4B blockade of STAT1 phosphorylation downstream of IFNAR1/2 receptor activation 
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[235] and akin to ZIKV, DENV NS5 mediated STAT2 degradation [108]. Importantly, this NS5‐
mediated degradation only occurs in the context of the natural cleavage and processing of 
NS5 from the viral polyprotein. As a result, this activity cannot be recapitulated by NS5 
overexpression alone [16]. The requirement for NS5 polyprotein processing for STAT2 
degradation relies on recruitment of a pro‐viral host factor UBR4, that preferentially binds to 
processed NS5 and facilitates STAT2 degradation [230]. The reliance of NS5 mediated STAT2 
degradation on natural polyprotein cleavage is an important example demonstrating the 
benefit of a fully infectious system in discovery of viral evasion mechanisms. Utilizing a high‐
throughput mutational screening method applied to the entire full‐length DENV genome has 
the potential to reveal novel evasion mechanisms previously undetected in overexpression 
studies. Additionally, this technique may assist in pinpointing specific genetic regions 
responsible for already known evasion strategies as identified in previous targeted mutational 
studies.  
Previously, our laboratory developed a high‐throughput random mutagenesis library of a 
cloned DENV serotype 2 viral genome using the MuA transposon mutagenesis approach 
described in the previous chapter [94]. This was created with the aim of mapping regions in 
the DENV2 genome that are tolerant to insertions in a fully infectious system. Briefly, the pFK‐
DVs infectious clone containing the full‐length DENV2 genome under the control of 
bacteriophage SP6 promoter was subjected to MuA transposon mutagenesis resulting in a 
library of ~250,000 mutant clones [94]. From this library, full‐length in vitro transcribed RNA 
was generated and transfected into Huh‐7.5 cells to initiate de novo virus production. The 
infectious virus produced from the RNA transfection was subjected to two subsequent rounds 
of passaging on naive Huh‐7.5 cells. This enriched for mutants that were replication‐
competent and able to generate infectious virus. After selection, the relative fitness of the 
remaining mutants was determined with respect to the input virus pool. This was done by 
isolating intracellular RNA, subjecting the RNA to first‐strand cDNA synthesis using a DENV2 
specific reverse primer, PCR amplifying across the full‐length DENV genome and performing 
NGS sequencing to detect the location of the 15 bp transposon insertion scars within the 
DENV genome. Mapping the individual transposon insertions to their position within the 
DENV genome allowed an assessment of their frequency within the remaining virus 
population compared to the input library. This map of relative insertion frequencies in the 
DENV genome was used to identify regions highly tolerant to insertions (regions of genetic 
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flexibility) and led to the rational design of tagged viruses for rapid and simple detection of 
DENV infection levels for a variety of purposes. Supernatant from the final passage contained 
a pool of mutant viruses that were replication‐competent and able to generate infectious 
virus in the Huh‐7.5 cell line. The aim of this chapter was to repurpose this library of 
replication‐competent and infectious insertion mutant viruses, further selecting these based 
on their differing ability to support the full virus lifecycle either in the presence or absence of 
type‐I IFN. This was coupled with NGS to pinpoint regions of the DENV genome that are key 
for IFN evasion. Mutations discovered to impact on DENV mediated IFN evasion were 
individually assessed and their mechanism of action defined.  
 
4.2 Results  
4.2.1 Optimisation of screening conditions 
In a similar approach to chapter 3, the IC50 value for IFNα treatment against DENV infection 
at a low MOI was determined for use in the screen. Huh‐7.5 cells were treated with increasing 
concentrations of IFNα for 6h prior to infection with DENV2 at MOI 0.2. Approximately 24 h 
post IFN treatment, the virus inoculum in each well was removed and replaced with fresh 
media containing IFNα or left untreated as required. 48 hpi supernatants were collected to 
enumerate the level of infectious virus in the supernatant by focus forming assay. Raw 
FFU/mL values were then normalised to the average of the untreated control (maximum 
infection) and transformed to a percentage of maximum. These normalised values were then 
used to determine the IC50 by non‐linear regression analysis using the [inhibitor] vs normalised 
response model of GraphPad Prism v8. The data represented in Figure 4.1 are a result of two 
independent experiments. From the curve the IC50 for DENV2 was calculated to be 
approximately 1 U/mL of IFNα. This coincides with expected results based on the reported 
IC50 of IFNα against the related virus HCV (1 U/mL) that was also determined using the Huh‐
7.5 cell line [274]. In addition, the DENV IC50 closely resembled the IC50 for ZIKV (4 U/mL) 
determined in the previous chapter using the related Huh‐7 cells. Following determination of 
the IC50 of IFNα against DENV, NGS‐dependent screening of the impact of transposon 






4.2.2 Recovery of the DENV2 insertion library  
Figure 4.2 shows the passaging strategy used for the screen. First, to repurpose the insertion 
library it was necessary to recover the frozen supernatant from passage 2 of the previous 
screen that was generated by passaging on untreated Huh7.5 cells (see Figure 2a). The library 
had been stored in a single 40 mL aliquot of unknown titer and therefore resuscitation of the 
library relied on estimated infection rates for the initial passage (passage 0). This estimate 
was based on the passaging strategy employed by Eyre et al. where viral supernatants were 
diluted 1:1 with fresh media between passages [94]. As detailed in the Materials and Methods 
(section 2.3) the DENV mutant library was recovered from frozen stock (Passage 0). Briefly, 
this was done by pre‐treating Huh‐7.5 cells either with media containing IFNα at 1 U/mL or 
leaving them untreated for 6h prior to inoculation with the defrosted DENV mutant library 
diluted 1:1 with fresh media before returning to culture. On the same day, without additional 
freeze‐thaws, 10‐fold serial dilutions of the mutant virus stock were procured for 
determination (in triplicate) of infectious virus via focus forming assay, enabling the 
retrospective titration of the stock. Approximately 24 h post IFN treatment, virus inoculum 
on each flask was removed and replaced with fresh media containing IFNα at 1 U/mL or 
untreated media as appropriate. After 72 hpi a focus forming assay performed in parallel was 
used to retrospectively determine the titer of virus and resultant MOI for passage 0. 
Surprisingly, the virus titer was higher than anticipated at approximately ~3x 106 FFU/mL. This 
meant that the MOI calculated retrospectively for this passage was 30 times greater (MOI = 
6) than intended based on the IFNα IC50 assay optimized for an MOI of 0.2. As a result of this 
high rate of infection the viral supernatant from each replicate was harvested at this time to 
minimize the impact of unwanted cytopathic effects on the screen. Supernatant from each 
replicate was independently collected and a smaller volume aliquoted for quantification of 
infectious virus. For subsequent passages (passage 1 and 2, see Figure 4.2) this allowed the 
titer of each replicate to be determined by FFA prior to inoculation onto naïve cells. Once the 
titer of infectious virus in the supernatant was determined from each replicate they were 
diluted to the appropriate concentration for the next passage. Then, naive Huh‐7.5 cells were 
treated with or without IFNα for 6h and inoculated with DENV mutant virus at an MOI of 0.2. 
Each treatment group and replicate were maintained independently of one another without 
pooling supernatants. This process was then repeated for an additional round of selection. 






time supernatants were taken. The excess supernatant and the total RNA were aliquoted and 
stored at ‐80⁰C for later processing.  
Alongside passage 1 and 2, small scale replicates in 96 well plates were treated and infected 
in parallel to monitor the rate of infection by detection of infected cells expressing the DENV 
E‐protein prior to harvesting the supernatant at 48 hpi for the next passage. On the morning 
of the second day post infection, these parallel replicates were fixed and stained with 4G2 IgG 
anti‐Flavivirus E primary antibody and fluorescent secondary (red). Figures 4.3d shows 
representative images for each replicate highlighting the extent of DENV infection amongst 
the cells of each passage on the morning prior to harvesting the supernatants. As expected, 
IFNα pre‐treatment resulted in a lower rate of infection in both passages as indicated by less 
frequent detection of E‐protein positive cells (Figure 4.3d). Interestingly, despite inoculating 
with the same MOI for both passages the spread of infection appears greater in passage 2 
compared to passage 1 at the same time post infection. In passage 1, DENV infection resulted 
in clustered foci of infected cells. Conversely, passage 2 resulted in extensive and uniform 
spread of infection that was no longer clearly defined in distinct clusters. This likely 
demonstrates enhanced cell‐to‐cell spread of the selected virus between the passages. The 
reduced level of infection in the presence of IFNα pre‐treatment and the enhanced replication 
fitness comparing virus from passage 1 and indicated that the screening process was 
successful in applying selective pressure upon the genetic diversity of the DENV mutant virus 
populations and validated continuation of the screening process.  
In addition to monitoring infection rate by immunofluorescent detection of E protein positive 
cells, the level of infectious virus present in supernatant was quantified by focus forming assay 
between each passage. Figure 4.3a shows that for passage 0 there was no detectable 
difference in the amount of infectious virus determined by focus forming assay in the treated 
and untreated groups. This indicated the IFN concentration used (1 U/mL) did not provide 
adequate selective pressure to the virus library in this initial passage. It was inferred that this 
was a result of the high MOI (MOI = 30) used to infect cells of this passage therefore causing 
the IFN pathway to be overwhelmed by virus mediated evasion. In contrast, after equalizing 
the MOI to 0.2 in Passage 1 and treating with the same amount of IFN, the amount of 
infectious virus detected in the supernatant was reduced by approximately 50% at 48 hpi 
(Figure 4.3b). This coincided with the expected result based on the IC50 assay and validated 






virus population. Interestingly, after repeating this process for passage 2, Figure 4.3c shows 
that the mean level of infectious virus from each treatment group was reduced by only ~25% 
under IFNα treated conditions (mean untreated = 3.2 x 107 FFU/mL vs IFNα treated 2.4 x 107 
FFU/mL). The difference between the means were not statistically significant comparing the 
IFNα and untreated samples in this passage. This data indicated a shift in the population 
genetics of the selected mutant virus pool compared to the input mutant pool towards IFN 
resistance. This was likely due to IFN hypersensitive mutations being selected out of the pool 
because of passaging in the presence of IFN. This quantifiable data agrees with the estimated 
observed rate of infection by immunofluorescence comparing untreated cells to IFNα treated 
cells as seen in Figure 4.3d. In addition to the expected selection pressure applied by IFNα 
treatment, the titer of infectious virus recovered in supernatant after 48h was higher in 
passage 2 compared to passage 1 for both the treated and untreated conditions (see Figure 
4.3b compared to 4.3c). Again, this agreed with the observed rate of infection by 
immunofluorescence comparing untreated cells to IFNα treated cells as seen in Figure 4.3d. 
In combination this data indicated that the virus population was better adapted to replication 
in the Huh‐7.5 cell line after multiple passages on the same cell type. The impact on selective 
adaptation to the Huh‐7.5 cell‐line was not further investigated as it was assumed to have 
equal impact on IFNα treated and untreated conditions.  
To investigate whether passaging the pooled mutant library in the presence of IFNα had 
resulted in adaptation of the population to these conditions, an IFN sensitivity assay was 
performed. The pooled mutant virus generated after passage 2 from untreated or IFNα 
treated groups were used to inoculate Huh‐7.5 cells (MOI = 0.2) pre‐treated for 6h with 
increasing concentrations of IFNα. At 48 hpi, supernatants were collected and virus titer 
determined by FFA. Figure 4.3e shows that the IFNα treated virus pool was significantly more 
resistant to IFN at the concentration of IFN used in the screen (1 U/mL IFNα). Importantly this 
data confirmed the successful selection of the mutant virus population of virus after IFN 
passaging. Interestingly, this effect was not observed when higher concentrations of IFNα 
were applied. This may reflect the ability of IFN to activate expression of different virus‐
controlling genes at higher concentrations. These genes, termed “tuneable” ISGs, have a 
higher threshold for promoter activation and as a result only are activated by high 
concentrations of IFN [352]. This may mean that the mutant library was selected for based on 
a set of genes expressed at 1 U/mL but not for genes that require higher concentrations of 
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IFN for activation. This data indicated the mutant library had successfully undergone selection 
based on its sensitivity to IFNα at the concentration used in the screen. 
 
4.2.3 Sample preparation and NGS analysis 
Once the passaging and selection under IFNα conditions were complete, the diversity and 
frequency of remaining DENV mutant genomes after selection was determined. Briefly this 
was achieved by extracting the total RNA from the cell monolayers of each passage and 
performing DENV specific RT‐PCR to prepare each sample for NGS sequencing. Since Passage 
0 showed no sign of IFN selection pressure this was excluded from the NGS analysis.  
Figure 4.4a shows the processing pipeline. Briefly, total RNA was extracted separately from 
each replicate in passage 1 and 2. Then this was used in a first strand cDNA synthesis reaction 
using a reverse primer that was complementary to the extreme 3’ terminus of the DENV2 UTR 
in order to amplify the full‐length genome using a high‐fidelity RT‐DNA polymerase as 
described in methods section 2.1.6.2. Next, full‐length DENV cDNA from each replicate was 
used as a template to PCR amplify 6 overlapping fragments covering the entire length of the 
DENV genome. Each PCR product was gel‐extracted, purified, quantified, and pooled in 
equimolar ratios for each independent replicate. These samples were then shipped to 
collaborators (R. Bull, UNSW) for NGS library preparation (Nextera XT Illumina) and 
sequencing on the NextSeq500 platform. Each sample was analysed as an independent 
replicate and these had on average 27 million reads per sample (Figure 4.4b). Of these total 
reads, ~44 thousand mutant insertion events were detected on average for each sample 
(Figure 4.4c). These individual insertion events were assigned to their nucleotide position 
based on the surrounding sequence alignment to the DENV2 genome. The analysis method 
used to convert raw insert counts at each nucleotide position into a measure of IFN sensitivity 
is described here in brief. First, to enable relative frequencies of insertions to be calculated, 
even in instances where insertion events were not measurable in the virus pools, 1 insert 
count was added for each nucleotide position, increasing the baseline in an even manner. 
Then, to remove bias of a ‘global’ reduction in insert counts in the independent replicates the 
insert frequency at each nucleotide position was divided by the total number of insert counts 
at all nucleotide positions in that replicate. This essentially gave a percentage or raw 
frequency of insertion at each position in the genome. To generate the graph of IFN 






insertion in IFNα passages were divided by the average frequency of insertion in the 
untreated passages. These frequency ratios were then log10 transformed and data was 
represented as Log10[IFNα/untreated] for each passage 1 and passage 2 in Figure 4.4d and 
4.4e respectively. Essentially, this means that if an insert at any given genome position were 
selected against in IFN conditions this resulted in log10 values represented by bars below the 
line. Figures 4.4d and 4.4e show the overall pattern of insertions that are differentially 
selected in untreated compared to IFN treated conditions across the genome by nucleotide 
position. This revealed a spread of insertions with differing frequencies between the 
treatment groups throughout the genome in both translated and untranslated regions. Some 
of these regions clustered into peaks, implying similar functional effects of closely positioned 
insertion mutations at these locations. In addition to regions negatively selected in IFN 
conditions there were also regions in which insertion mutations were enriched under IFN 
treatment, suggesting a selective advantage over other mutants in the pool. This could reflect 
the relative fitness compared to other mutants and as such may not reflect a gain in fitness 
compared to wildtype DENV. Since this sequencing does not detect the presence of wildtype 
virus the contribution of wildtype virus to the pool cannot be determined using this analysis 
method. Importantly, there appears to be a narrowing of peaks, an overall trend for a greater 
proportion of the peaks to exist below log 0, and for peaks to reach stronger negative log 
powers in passage 2 compared to passage 1. In combination, this implied additional selection 
between the two passages, further validating the selection conditions. Figure 4.5 shows 
selected zoomed regions from passage 2 that contained the 10 insertions that were most 
strongly selected against in the presence of IFN. Sequence specific information for each of 
these insertion mutations is given in Table 1 Appendix V.  These regions were in the 5’ UTR, 
E, NS3, NS5 and the 3’ UTR. In addition, the NS1 region also contained a peak existing above 
the line that was of interest. Importantly, 3 peaks that were most strongly selected against in 
the presence of IFN were clustered at positions 8069, 8077 and 8086. These all fell within the 
DENV NS5 protein which is known to be an important effector in DENV mediated shutdown 
of the IFN signalling pathway [213].  
The overall pattern and specific location of inserts in passage 2 compared to passage 1 
demonstrated the selection process occurred as expected. This was further validated by 






clustering within NS5, a known IFN evasion mediator. This meant that further characterization 
of insertions was viable.  
 
4.2.4 Identification of mutants that are likely to enhance DENV IFN sensitivity 
To statistically analyse the difference in insert frequency between the IFN treated and 
untreated group, the % insertion frequencies for each independent replicate were graphed 
for the insertions that were most strongly selected against in IFN conditions. We also 
compared the frequency of insertions as a percentage between passages 1 and 2, to identify 
evidence of consistent and increasing selection between the passages. Figure 4.6a shows a 
single insertion at nucleotide position 8086 within NS5 that was statistically significantly 
different between the two treatments in passage 1. Interestingly, although position 8086 was 
the most strongly selected against in both passage 1 and 2, the difference between the two 
treatments was not statistically significant in passage 2. Figure 4.6b shows that two 
alternative insertion events within NS5 at nucleotide positions 8077, 8069 and one peak in 
the 3’ UTR at position 10,297 were statistically significantly different between the two 
treatment conditions in passage 2. The strongly enriched for insertion at position 2941 within 
NS1 was not statistically significant between treatment groups despite having the largest 
difference between means. This data indicated increasing negative selection between 
passage 1 and passage 2. Furthermore, this data highlights NS5 at positions between 8069 to 
8086 as a likely genomic region that contributes towards IFN evasion. Due to the large 
variance in between the triplicates, additional replicates or a repeat screen would have been 
ideal to confirm these findings.  
 
4.2.5 Cloning individual mutations into the full-length DENV genome 
After selecting a panel of potential hits from the screen, the next step was to confirm the IFNα 
sensitization phenotype of each mutation by individually cloning these mutations into a DENV 
infectious clone (pFK‐DVs) and then to test these individual mutations for IFN sensitivity.  To 
achieve this aim, synthetic dsDNA constructs containing the desired mutations within the 
DENV genome sequence were purchased (GeneWorks). These fragments contained the 15 bp 
insertion mutation at nucleotide positions 1610 and 1760 within E, 2941 within NS1, 4884 
within NS3, 8069, 8077 and 8086 within N‐terminus of NS5 and 9795, 10297 and 10388 within 





constructs were designed to exploit pre‐existing unique restriction (natural restriction) sites 
within the DENV2 genome. However, for the N‐terminal NS5 (NS5) mutations and the C‐
terminal NS5/3’UTR (UTR) mutations, the large distance between naturally occurring unique 
restriction sites necessitated the introduction of synthetic mutations to generate unique 
restriction sites. For this reason, a larger region between naturally occurring unique 
restriction sites was selected to be synthesized within a sequenced pUC57 intermediate 
cloning plasmid. Within each of these plasmids (pUC‐57‐BmtI‐AvrII‐NS5‐silents, and pUC‐57‐
AvrII‐XbaI‐UTR‐silents) two restriction sites flanking the 15 bp insertion region were 
generated using synthetic mutations that maintained the amino acid sequence within the 
translated region. It was necessary to include one synthetic mutation within the 3’UTR, in this 
case only a single nucleotide was altered to minimize the impact of alterations the sequence. 
In addition, data from the transposon insertion screen by Eyre et al. indicated this region as 
being highly tolerant to insertions, hence implying its genetic flexibility and further supporting 
that changes to sequence within this region of the 3’UTR can be accommodated in an 
infectious system [94]. Diagrammatic representations of the pFK‐DVs plasmid showing 
natural restriction sites, the intermediate cloning pUC57 plasmids and the structure of the 
synthetic dsDNA mutant fragments with specific restriction sites are given in Appendix V.  
To clone the individual mutants the first step was to insert each NS5 or UTR mutation into 
their respective pUC57 intermediate cloning vector, the methods used to achieve this goal 
are summarised in Table 4.1. Initially, attempts were made to complete this task by simple 
restriction enzyme cloning methods. Briefly, both the plasmid and the insert were digested 
with the indicated restriction enzymes. The inserts were column purified and the vector 
backbone was gel‐extracted and purified. Then, T4 DNA ligase was used in an overnight  
ligation prior to transformation. This process was successful for sub‐cloning insertion 
mutations at nucleotide positions 8069, 9795, 10297 and 10388. Alternatively, when 
restriction cloning was unsuccessful after the second attempt (8077 and 8086), Gibson 
Assembly was used with the primer sequences shown in Appendix I. Each clone was 
confirmed by diagnostic restriction digest (not shown) and by Sanger sequencing to ensure 
there were no sequence errors in the synthetic dsDNA fragment prior to performing large 
scale plasmid purification.  
The next step was to subclone the individual insertion mutations into the pFK‐DVs destination 





was successful for all synthetic dsDNA fragments directly cloned into pFK‐DVs. On the other 
hand, restriction enzyme subcloning between the pUC57 intermediate vector and pFK‐DVs 
was not successful and instead the Gibson Assembly method was used. This method 
successfully generated the remaining pFK‐DVs individual mutant clones, which were 
confirmed by diagnostic restriction digest (not shown) and Sanger sequencing prior to large 
scale DNA preparation. The resulting plasmid DNA was compared to the parent pFK‐DVs 
plasmid by diagnostic restriction digest (see Figure 4.7a‐g) to rule out any bacterial 
recombination following transformation and outgrowth that is regularly observed when 
transforming this infectious clone system.  
 
4.2.6 Testing the replication kinetics of the individual DENV mutants 
After successfully generating the plasmid clones of each individual mutant it was then 
necessary to produce a working stock of each virus mutant, test each mutant for viability and 
assess their replication fitness compared to the parent virus strain. To perform this task, in 
vitro transcribed RNA was generated from each plasmid of the mutant, corresponding 
wildtype (synthetic mutation) and the original pFK‐DVs parent plasmid. A portion of purified 
in vitro transcribed RNA generated from each plasmid was separated on a non‐denaturing 1 
% agarose gel and visualised to confirm the quality of the RNA. Appendix V shows that each 
mutant clone generated high quality in vitro transcribed RNA that was indistinguishable in 
appearance to that of the parent (pFK‐DVs) transcribed RNA indicating that full‐length 
product had been generated. In addition, this RNA appeared as a single defined band on the 
gel indicating that it was not degraded or fragmented by the purification process.  
Once the quality of the RNA was confirmed it was then transfected in biological duplicates 
into Huh‐7.5 cells (see Materials and Methods section 2.3.6). Each mutant cohort was 
transfected concurrently along with the DENV2 RNA generated from the parent pFK‐DVs 
plasmid, a mock transfection control and a wildtype (synthetic mutant) RNA when 
appropriate.  
Following RNA transfection, samples of culture supernatant were collected at 24 h intervals 
for a one‐week period and stored at ‐80⁰C. At 72 hpt confluent cells were split and re‐seeded 
diluted 1:1 with fresh media. Concurrently, a fraction of the transfected cells was seeded for 
immunofluorescence‐based analysis of the rate of transfection/infection at 72 hpt (96 well 





working stocks of de novo generated virus were used in subsequent experiments for IFN 
sensitivity. Culture supernatant samples were used to determine the level of infectious virus 
generated at each time point by focus forming assay. Results from these assays are presented 
in Figures 4.8, 4.9 and 4.10 below and are representative of two independent experiments.  
Figure 4.8 shows the immunofluorescent detection of infected cells at 72 hpi and the 
replication kinetics of infectious virus production for mutant viruses with insertions at 
nucleotide positions 1610, 1769, 2941 and 4884 compared to the parent strain. Figure 4.8a 
shows that each mutant virus construct was able to successfully initiate virus replication after 
transfection into Huh‐7.5 cells, as indicated by a large proportion of E‐protein positive cells. 
All of these mutant viruses were able to initiate the expected log phase growth kinetics at 
early time points (24 – 48 hpi) compared to the pFK‐DVs parent virus (Figure 4.8b). The NS3 
4884 virus displayed indistinguishable replication kinetics from the parent strain whereas the 
E 1610 and 1760 mutant viruses had slightly lower peak virus titers at 96 hpt compared to the 
parent strain. Interestingly, the NS1 2941 mutant virus produced appreciably higher titers of 
infectious virus compared to the parent strain in the Huh‐7.5 cell line as indicated by rapid 
virus replication between 48 – 72 hpt and by higher peak titers at 96 hpt. This data indicated 
that the introduction of these 15 bp insertions to the DENV genome was associated with 
unchanged (4884 mutant), reduced (1610 and 1760 mutants) or enhanced (2941 mutant) viral 
replicative fitness compared to the parent strain.  
Figure 4.9 shows the corresponding set of data for all mutant viruses generated using the 
synthetic mutation N‐terminal NS5 pUC57 intermediate cloning vector compared to the 
parent stain pFK‐DVs. Figure 4.9a shows that unlike the parent strain, wildtype (synthetic 
mutation) or the NS5 8086 RNA transfections, there were no cells with positive E staining 
detected for the NS5 8069 or 8077 mutants at 72 hpt. This result indicated a critical defect in 
the replication of these two mutant viruses compared to the parent strain that was 
independent of the synthetic mutation introduced in the cloning process. This finding was 
substantiated by the lack of infectious virus detected in the culture supernatant of cells 
transfected with the 8069 or 8077 RNA up to one‐week post transfection (Figure 4.9b). 
Conversely, both the 8086 mutant and the wildtype (synthetic mutant) clones were able to 
generate comparable levels of infectious virus to the parent strain over this time course. This 
result was unexpected since both the 8069 and 8077 insertion mutations were detected in 











cell line, including the initial passaging by Eyre et al. to enrich for replication competent and 
infectious virus [94]. However, as outlined in the introduction, the NS5 protein is essential for 
viral RNA capping and replication via a ‐ssRNA intermediate. The complete lack of virus 
replication from these clones strongly indicated the insertion mutations at nucleotide 
positions 8069 and 8077 interfered with at least one of these essential processes. Therefore, 
further experiments for this cohort of mutant viruses were focused on the NS5 8086 mutant 
for characterization.  
Finally, Figure 4.10 shows the replication kinetics data for the group of mutant viruses 
generated using the UTR synthetic mutation that was introduced for cloning of insertion 
sequences into the pFK‐DVs plasmid. All the mutant viruses in this group supported viral RNA 
replication (Figure 4.10a) as indicated by positive E staining in all but the mock transfected 
panel. However, for each of the mutant viruses and the wildtype (synthetic mutation) there 
was clearly a lower rate of virus replication in transfected cells at this time point compared to 
the parent pFK‐DVs transfected cells. This data is concordant with that of Figure 4.10b, 
showing that of all the mutant viruses had delayed replication kinetics leading to an 
approximately 1 log reduction in the levels of infectious virus in supernatants at 96 hpt. This 
data indicated that there was a significant reduction in viral fitness as a result of the synthetic 
mutation introduced to clone these mutants (pFK‐DVs compared to pFK‐DVs‐UTR‐WT‐SM). 
Despite the reduction in replication fitness, all of the mutant viruses displayed log phase 
growth kinetics and were able to reach equivalent titers compared to the pFK‐DVs parent 
strain by day 7 post transfection. Together this data demonstrated that these mutant viruses 
were replication‐competent and were able to progress to further testing for IFN sensitivity. 
However, the delayed growth kinetics conferred by the synthetic mutations that were 
introduced for cloning purposes would need to be accounted for in controlled experiments 










4.2.7 Testing the IFN sensitivity of the individual DENV mutants 
After confirming the replication fitness of each mutant virus, it was then possible to 
individually test these mutants for changes to IFN sensitivity predicted by the screening 
process. The first experiments designed to test IFN sensitivity, replicated the conditions of the 
screen to confirm these results. Huh‐7.5 cells were pre‐treated for 6 h with increasing 
concentrations of IFNα prior to inoculating with each mutant virus at an MOI of 0.2. After 
overnight inoculation, the media was replaced with media containing the appropriate 
concentration of IFNα. Then, 48 hpi supernatants were harvested to determine the level of 
infectious virus in each treatment group by focus forming assay. Levels of infectious virus in 
supernatant were normalized independently to the untreated control group of each virus 
strain and were represented as a percentage of the levels of infectious virus for the untreated 
controls. This normalisation was essential to account for differences in replication fitness of 
the individual mutant virus strains compared to the parent DENV 16682 strain. Each IFN 
sensitivity experiment was conducted in biological triplicate and each focus forming assay was 
conducted in technical duplicates. For each cohort of mutants (natural restriction site, NS5 
synthetic mutation and UTR synthetic mutation), these experiments were conducted 
alongside the parent strain of DENV and the appropriate wildtype (synthetic mutation) 
counterpart generated from de novo RNA transfection from the same controlled experiment. 
Each figure represents two independent experiments for each group of viruses. Figure 4.11 
shows the IFN sensitivity assays for all mutant viruses generated using natural restriction site 
cloning into the pFK‐DVs plasmid. Figure 4.12 shows the IFN sensitivity assays for all mutant 
viruses generated using the NS5 synthetic mutation cloning strategy while Figure 4.13 shows 
the IFN sensitivity assays for the group of mutant viruses generated using the UTR synthetic 
mutation cloning strategy. As expected, these experiments revealed dose‐dependent 
reductions in the levels of wildtype and mutant infectious viruses present in the supernatants 
of infected cells that were treated with IFNα. The reduction in the levels of infectious virus 
was equivalent to that of the parent DENV strain for all viruses generated using natural 
restriction site cloning and those generated using the NS5 synthetic mutation cloning 
strategy. Conversely, for viruses generated using the UTR synthetic mutation cloning strategy 
there was a statistically significant difference at all three doses of IFNα in the IFN dependent 
reduction of infectious virus compared to the parent strain. Interestingly, this difference in 










consistent across the mutants generated from this clone. This data implied that one or both 
silent single nucleotide substitutions used to generate this cohort of viruses contributed to 
IFN sensitization of these clones. Collectively, this data demonstrated there were no changes 
to IFN sensitivity of mutant viruses based on the presence of the transposon insertion 
mutations predicted to cause this outcome by the screening process.  
Given that none of the viruses encoding transposon insertion mutations displayed differences 
in IFN sensitivity in experiments that were designed to mirror the screening conditions it was 
possible that the insertion mutations that appeared to cause this effect in the screen were a 
result of experimental variability. This is consistent with the demonstration that most of these 
mutations were not statistically significantly different between the treated and untreated 
conditions of the screening replicates. Additionally, the two most likely candidates for 
modulating IFN sensitivity based on statistical significance in the screen (mutants 8069 and 
8077) could not be tested for IFN sensitivity since they produced no infectious virus. Because 
all of the hits from the screen were not associated with altered IFN sensitivity in dose‐
response validation experiments, it was no longer viable to pursue this line on inquiry to 
discover DENV mutants with enhanced IFN sensitivity.  
 
4.3 Discussion 
DENV is a significant human pathogen, infecting approximately 390 million people resulting 
in more than 21, 000 deaths annually [127]. In addition, DENV is responsible for generating a 
considerable economic burden due to the high rate of hospitalizations for serious DENV 
infections [125]. Currently there is a deficiency in safe and effective antiviral treatments and 
vaccines available to manage DENV infection globally. Importantly, the ability of DENV to 
evade the innate immune response is crucial to establishing infection and causing disease in 
humans. In particular, the type‐I IFN response effectively controls DENV infection when 
activated prior to infection. To overcome this barrier DENV has evolved multiple evasion 
strategies targeting the IFN pathway in humans. Understanding the specific mechanisms and 
genetic determinants of these viral evasion strategies underpins the development of efficient 
immune modulating treatments, antivirals, and live attenuated vaccines. As a result, this axis 
of DENV host‐virus interaction has been extensively studied. Specific NS proteins including 
the NS5 RdRp are known to contribute to IFN evasion through a range of molecular 
mechanisms detailed in the Introduction (section 1.3). However, the knowledge of 
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mechanisms used by DENV to evade the IFN response is likely incomplete. This is because 
much of the research conducted on DENV evasion of the IFN response investigates 
mechanisms of individually expressed viral proteins. As a result, there is a need to perform 
mutational studies on the complete DENV genome in the context of a fully infectious system 
to further elucidate novel evasion mechanisms. For this reason, the aim of this chapter was 
to find novel mechanisms of DENV IFN evasion based on a high‐throughput genome wide 
mutational screening approach. Briefly, this approach utilized a pre‐existing library of 
replication competent and infectious DENV insertion mutants generated using a fully 
infectious clone by Eyre et al. [94]. This library then underwent passaging in conditions with 
or without type‐I IFN to select for mutants based on their sensitivity to type‐I IFN. This process 
allowed the identification of potential mutations causing a deficit of virus fitness under IFN 
conditions. After identifying potential hits from the screen, these mutations were re‐
introduced into the full‐length infectious clone of DENV allowing testing of their IFN 
sensitivity.    
To achieve the aim of this Chapter it was first necessary to establish a screening platform that 
was able to apply adequate selective pressure by IFN treatment to the population of mutant 
DENV. To this end the IC50 for IFNα treatment against DENV infection at low MOI was 
determined on the Huh‐7.5 cell line as done previously for a related HCV mutagenesis screen 
that had successfully discovered novel evasion mechanisms [274]. This level of IFNα 
stimulation was decided upon to give appropriate activation of the innate antiviral response 
without completely overwhelming the entire virus population. The IC50 for IFNα treatment 
against DENV was found to be approximately 1 U/mL when IFNα treatment was applied for 6 
h prior to infection. This was consistent with the IC50 for IFNα treatment against HCV [274] 
and was close to the IC50 for ZIKV determined in the previous Chapter.  
Initially the library of replication competent and infectious DENV insertion mutants required 
resuscitation from frozen storage. Since the titer of the frozen mutant library was unknown 
this required estimating the rate of infection based on its use in the previous screen. The 
frozen library was diluted 1:1 with fresh media and passaged onto cells treated with or 
without the calculated IC50 of IFNα diluted in fresh media. Unfortunately, due to the 
unexpectedly high titer of the frozen stock the IFN treatment applied in this initial passage 
(passage 0) was inefficient at reducing DENV infection to the expected 50 % compared to 
levels of infectious virus in untreated controls. The most likely explanation for this effect was 
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that the IFN pathway was effectively shut‐off by the high titer infection of DENV. According 
to this model, the higher titer of virus would lead to a greater multiplicity of infection per cell, 
greater levels of DENV protein expression and resultantly a greater level of inhibition of IFN 
signalling than anticipated. Importantly, while the impact of IFN treatment at the bulk 
population level was not apparent it is possible that individual mutations that conferred high 
sensitivity to IFN were underrepresented in the total virus population after this passage.  
Following this initial recovery passage, each of the IFNα treated and the untreated 
populations of mutant virus were passaged under the same condition with replicates 
maintained independently of one another. To ensure the efficacy of the IFN pre‐treatment, 
the MOI was scaled back to the intended 0.2 units of infectious virus per cell. This resulted in 
the expected degree of selection pressure in passage 1 determined by an observed 50 % 
reduction in the levels of infectious virus in supernatant of the IFNα treated group compared 
to the untreated group. Interestingly, when this process was repeated for passage 2 using the 
same infection conditions and the same concentration of IFN this resulted in a smaller 
reduction of DENV infection between the two treatments. Instead of a 50% reduction in the 
level of infectious virus in the supernatant from this passage, the mean difference was 
approximately 25%. Importantly, this data implied a shift in the genetics of the library at the 
population level to be more resistant to IFN treatment. This likely resulted from IFN sensitive 
mutants being outcompeted by IFN resistant mutants in the population. This rapid 
desensitization of the DENV population to IFN treatment could be exploited in future screens 
of this nature. Improved selection may have been possible by progressively increasing the IFN 
concentration between the passages to again achieve an approximately 50 % reduction in 
virus infection levels in the treated group. A greater degree of selective pressure on the 
population of mutant viruses would increase the likelihood of IFN sensitive mutants being 
removed from the population. This would have made the comparison between the remaining 
virus populations in different treatment groups more clearly defined and therefore improved 
the likelihood of detecting IFN sensitive mutations following NGS analysis. In addition to the 
IFN mediated selective pressure there was also evidence that both the IFNα treated and 
untreated populations had adapted to replication in the Huh‐7.5 cell line after multiple rounds 
of passaging. This was demonstrated by the higher titers generated following passage 2 
compared to passage 1 despite infecting at the same MOI and collecting supernatants at the 
same time post infection. As this effect was balanced in both the treatment groups the 
140 
 
assumption was made that this would not impact on the analysis of the screen. However, this 
data highlights the importance of validating results of individual mutations in multiple cell 
lines to ensure this is not specific to the Huh‐7.5 cell line. Importantly, comparison between 
the levels of infectious virus produced after each passage in either the IFNα treated or 
untreated conditions indicated the progressive negative selection of mutants with reduced 
fitness in IFN conditions. 
Comparison of the relative frequency of mutations remaining following each passage 
revealed a spread of mutations across both translated and untranslated regions of the 
genome. The effect of IFN‐mediated selection was demonstrated by the progressive 
narrowing breadth of mutation frequencies represented in subsequent passages. 
Additionally, there was a general trend towards under‐representation of mutations that were 
passaged in IFNα treatment conditions compared to the untreated controls. 
Analysis of specific regions revealed nucleotide positions of interest that demonstrated a 
lower frequency of mutations in IFN treated compared to untreated conditions. The 
exception to this was the insertion at nucleotide position 2941 (NS1) that showed a greater 
frequency of mutations in IFN treated compared to untreated conditions. Broadly the 
insertions of interest were found in regions of the E protein, NS1, NS3, NS5 and the 3’ UTR. 
Each of these regions are known to contribute to the ability of flaviviruses to modulate innate 
antiviral responses, giving weight to the possibility of their involvement in IFN pathway 
evasion. For example, the E protein of WNV inhibits TLR mediated IFN production through 
inhibition of NF‐κB activation [15]. NS1 is known to have multiple roles in immune modulation 
depending on the virus. The secreted form of DENV NS1 is known to modulate immune 
responses through binding TLR4, activating cytokine production [225]. Conversely, ZIKV NS1 
dampens IFN production through TBK1 inhibition [176]. Additionally, the DENV NS2B/3 
protein complex inhibits production of type‐I IFN via interaction with Iκκ‐ε [10]. The 3’ UTR of 
each DENV and ZIKV are known to generate sfRNA’s that inhibit RIG‐I dependent signalling 
[82, 202]. Of special interest, 4 out of 10 top hits were found within the NS5 protein 
(nucleotide positions 8069, 8077, 8086 and 9795). This was significant because DENV NS5 
protein is known to directly inhibit signalling downstream of the type‐I IFN receptor via 
degradation of the STAT2 protein [213]. As a result, it was anticipated that NS5 mutations 
would be highly represented amongst viruses with altered IFN sensitivity. 
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In addition to assessing the validity of potential hits based on the supporting literature, the 
impact of the top 10 insertions of interest were evaluated statistically. This was done by 
directly comparing the insertion frequencies from the IFNα treated to the untreated pool of 
mutants, considering the standard deviation between the triplicates. Of the 10 insertion 
events assessed, 3 were significantly different between the groups after the second round of 
passaging. These 3 insertions occurred at nucleotide positions 8069, 8077 within NS5 and 
10297 within the 3’ UTR. To validate the apparent effect of these insertions on IFN sensitivity 
the top 10 nucleotide position insertions were individually cloned into the pFK‐DVs parent. 
This allowed testing of each mutation independently of the pooled population for their 
sensitivity to IFNα. 
After each mutation was independently cloned into the parent plasmid it was then necessary 
to confirm the replication fitness of each virus. Of the 10 individual mutations introduced into 
pFK‐DVs, 8 produced replication competent viruses. Notably, the insertion mutations at 
positions 8069 and 8077 resulted in deleterious effects on DENV replication fitness. This is 
likely due to the impact of these insertions on the MTase domain of the NS5 protein. The 
catalytic site (K61‐D146‐K180‐E216) of this domain is formed by interacting amino acids at 
the centre of a β‐sheet extending from nucleotide positions 7750 to 8220 [171]. Interestingly, 
the mutant containing a 15 bp insertion at position 8086 was not similarly impacted. This 
indicated that insertions within this β‐sheet region had differing effects on replication fitness 
based on their exact position. Importantly, the 8077 and 8086 had highly similar amino acid 
insertions (MRPQE vs MRPQL) likely ruling out the impact of specific chemical properties of 
the inserted amino acids causing this change (see Appendix V, Table 1 for sequence details). 
A more likely explanation was that the insertions at 8069 and 8077 caused a steric change 
due to the additional 5 amino acids added and this reduced β‐sheet integrity, leading to the 
disruption of the MTase active site formation and producing a replication deficient mutation. 
Since the full‐length NS5 DENV crystal structure is available [392], it would be interesting to 
add these insertions in silico to observe any changes in the overall structure or free‐energy of 
the MTase domain. 
In addition to specific 15 bp insertions causing changes to replication fitness there was also a 
decrease in replication fitness caused by the single nucleotide change introduced into the 3’ 
UTR for cloning purposes. The effect of these synthetic mutations was consistent between 
the wildtype and the corresponding insertion mutants cloned through this intermediate. One 
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of these mutations within the NS5 coding region was designed to introduce the AscI site 
between positions 9776 – 9783 while maintaining amino acid sequence (gcagagcc  
ggcgcgcc). The other mutation was a single nucleotide substitution within the 3’UTR region to 
create a BsiWI site between positions 10476 – 10481 (tgtacg  cgtacg). Since the mutation 
in the NS5 region was a silent mutation it is unlikely this resulted in the observed reduction in 
replication fitness. It is more likely that the single nucleotide change within the 3’ UTR was 
responsible for the observed effect. After assessing the sequence change in more depth it 
was discovered that this substitution (t  c) occurred within the conserved loop structure of 
the DB1 region of the 3’ UTR [68]. This region is directly involved with long range RNA:RNA 
interactions between DB1 and the C1 sequence (RNA structure within the capsid coding 
region) required for DENV genome cyclization, and is essential for RNA replication [67]. A 
single nucleotide substitution in this region likely caused weaker RNA interactions and 
therefore impeded the replication fitness of these mutant viruses. However, these viruses 
were able to generate equivalent titers of infectious virus in the supernatant of transfected 
cells to the parent pFK‐DVs despite delayed replication kinetics. Therefore, these mutants 
were considered sufficiently replication competent to test for effects of the insertions on IFN 
sensitivity.  
Following assessment of viral replication fitness, the remaining replication competent mutant 
viruses were tested for their sensitivity to IFNα treatment. The ability of each mutant to 
replicate in a range of IFNα concentrations was tested. The IFNα treatment was administered 
to Huh‐7.5 cells prior to infection to recapitulate the conditions of the screen for testing the 
individual virus mutants. The levels of infectious virus in the supernatant after 48 h was 
compared to the appropriate wildtype or parent strain. From this analysis no evidence was 
found that any of the 15 bp insertion mutations resulted in increased IFNα sensitivity as 
predicted by the screen. However, unexpectedly synthetic mutations introduced into the 3’ 
UTR of wildtype virus for cloning purposes enhanced IFN sensitivity. All the mutants 
generated from this cloning strategy displayed the same sensitization effect indicating that 
this was an effect of the common synthetic mutation and not of the 15 bp insert. It is plausible 
that the increased IFN sensitivity resulted from the single nucleotide substitution within the 
DB1 structure of the 3’ UTR as DB1 acts to inhibit host 5’ exonuclease activity leading to the 
production of sfRNAs that are involved in IFN evasion [51]. DENV sfRNAs are known to reduce 
the production of type‐I IFN downstream of PRR activation [202]. Additionally, a mutational 
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study showed that sfRNA deficient WNV virus was more sensitive to pre‐treatment with IFNα, 
akin to the effect we observed in our screen [307] [51]. Future experiments to determine the 
impact of this single nucleotide substitution on the stability of DB1, RNA:RNA interactions and 
sfRNA formation could provide new insights into DENV pathogenesis and IFN evasion. 
In light of these combined results, it was determined that none of the 15 bp insertion 
mutations tested increased IFN sensitivity in a fully infectious DENV model system. This 
suggests that a more refined screening approach may be required to definitively map 
mutations that influence IFN sensitivity. 
One hypothesis explaining these results is that unintended naturally occurring mutations 
were introduced into the mutant virus population after multiple rounds of passaging. In 
general RNA viruses have high mutation rates (between 10−6 to 10−4 substitutions per 
nucleotide per cell infection) as a result of their error prone RdRp activity [298]. This leads to 
accumulation of mutations in the genome that, in nature, are important for population 
diversity and viral evolution [180]. If these mutations were linked to a transposon insertion 
mutation, they would be co‐selected for during the screen. Therefore, it is plausible that these 
unintended mutations impacted the apparent relationship between the frequency of a given 
transposon mutation under IFN treated and untreated conditions.  
Logically, these mutations were likely introduced during passage 0 of the current screen or 
accumulated in the original screen performed by Eyre et al. [94]. This is because in these 
scenarios the MOI and hence the rate of coinfection was not controlled for. This assumption 
is supported by both genetic studies and mathematical modelling on the impact of coinfection 
on RNA virus population genetics. One study investigating the impact of coinfection on RNA 
virus population genetics found that high coinfection rates reduced the clearance of 
deleterious mutants in RNA virus populations [102]. Importantly this was caused by 
complementation of deleterious mutations with replication competent viruses infecting the 
same cell. In addition, mathematical modelling shows that high coinfection rates leading to 
complementation increase the frequency of mutations accumulating in RNA virus populations 
over time [109]. In combination, these two forces mediated by the effect of high coinfection 
rate increase the likelihood of complementation that in turn leads to greater accumulation 
and sustained diversity of mutations (deleterious or otherwise) within viral populations over 
time [109].  
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Therefore, it is plausible that deleterious transposon mutations (such as those occurring in 
NS5) were able to persist when the rate of coinfection (MOI) was high due to 
complementation. In turn, this increased the likelihood of these mutants accumulating 
compensatory mutations that rescued the deleterious phenotype conferred by the 
transposon mutation. Therefore, these transposon mutants could have survived when 
subjected to subsequent passages even at low MOI. These combined effects may account for 
the representation of deleterious insertion mutations in the analysis of the screen. 
Alternatively, the accumulation of naturally occurring mutations could have led to altered 
fitness under IFN selection irrespective of a linked transposon mutation. Therefore, 
transposon mutations could have ‘piggybacked’ on linked naturally occurring mutations that 
altered IFN sensitivity. These transposon mutations would have then appeared to alter fitness 
under IFN selection in the analysis despite not conferring this function, as was shown in our 
validation studies using a number of highly‐represented transposon mutations.  
Evidence supporting this theory is given by the results of an alanine‐scanning mutagenesis 
screen investigating the function of the DENV NS2A protein. This study by Wu et al. [373] 
subjected a the N‐terminal domain of NS2A within a full‐length infectious clone of the DENV2 
genome to alanine substitution mutation. These mutants were then individually screened for 
their ability to yield infectious virus and to cause cytopathic effect (CPE). NS2A alanine 
mutants that displayed a lethal phenotype were then subjected to passaging in cells trans‐
complemented with expressed wildtype NS2A. Interestingly, after only 3 – 5 passages on 
NS2A transfected cells, 45% of the tested alanine mutants had accumulated compensatory 
mutations that rescued their lethal phenotype. This demonstrates that the natural mutation 
rate of DENV2 is sufficient to introduce adaptive compensatory mutations within the time 
frame of our screen (including the initial screen by Eyre et al. [94]).  
One way to confirm this theory would be to perform trans‐complementation experiments on 
the deleterious NS5 transposon mutants 8069 and 8077 to experimentally observe the 
accumulation of compensatory mutations over time. This would require co‐expressing 
mutant NS5 RNA with wildtype NS5 protein, allowing the generation of infectious virus that 
could be used in multiple passages. However, this approach is complicated by the fact that 
NS5 is notoriously difficult to trans‐complement due to its essential enzymatic function within 
the Flavivirus lifecycle. To date, mutations within the RdRp domain but not those in the MTase 
domain (covering the 8069 and 8077 mutations) of the Flavivirus NS5 have been trans‐
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complemented by NS5 expression constructs [166]. However, NS5 mutations can be trans‐
complemented by stably expressed DENV replicon RNA containing the full‐complement of NS 
proteins able to initiate viral RNA replication without the production of infectious virus [83]. 
Therefore, these experiments would require first generating a stably expressing DENV 
replicon cell line and therefore are beyond the scope of this current project. However, if this 
strategy were applied and revealed compensatory mutations for the NS5 transposon 
mutants, these adapted viruses could be used to test whether the transposon mutations 
genuinely conferred IFN sensitivity.  
Another important consideration for this theory is the proximity of accumulated mutations 
to the transposon insertion site. Interestingly, in the study by Wu et al. on NS2A function, the 
accumulated compensatory mutations were all detected within the NS2A region [372]. 
However, a similar study involving passaging replication impaired HIV mutants showed that 
mutations accumulated at distal sites of the viral genome were also able to compensate 
function [187]. This shows that accumulation of both short‐ and long‐range mutations can act 
to compensate for deleterious mutations or those impacting viral fitness. Consequently, 
further investigation of accumulated mutations in our screen or future screens of a similar 
nature would benefit greatly from new long‐read sequencing technology. Such technology, 
like the Nanopore system, is now able to continuously sequence sections over 10 kbp in a 
single read without compromising on the number of reads [205]. This new technology would 
provide valuable insight into the rate of accumulating mutations and linkage of unintentional 
mutations with transposon insertions under IFN selection.  
In addition to using new sequencing technology, future screens of this nature would benefit 
from de novo generation of the mutant library from the plasmid stock rather than pre‐
selecting for replication fitness. This would limit the number of passages and therefore reduce 
the likelihood of accumulation of unanticipated mutations. Additionally, this data highlights 
the importance of performing mutational screens at low MOI (≤ 1) to limit the rate of 
coinfection and complementation leading to accelerated accumulation of mutations in the 
viral population.  
Moreover, increasing the strength of selection could be used to limit unwanted compensatory 
mutations accumulating in future high‐throughput mutant screens. Modelling shows that 
increased selection pressure weakens the impact of complementation on maintaining mutant 
diversity in viral populations [109]. This theory supports that sequentially increasing the 
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concentration of IFNα would have benefited this screen. Alternatively using an IC80  instead of 
an IC50 concentration of IFNα treatment, as was applied in one influenza mutant screen 
differentiating based on IFN sensitivity [84], could have been another way of limiting 
accumulated mutations.   
 
4.4 Conclusions 
The aim of this chapter was to find novel mechanisms of DENV IFN evasion based on a high‐
throughput genome wide mutational screening approach. To address this aim, a library of 
replication competent and infectious transposon insertion mutant DENV was re‐purposed 
from a previous screen performed in our laboratory [94]. This library was subjected to 
selection by passaging in conditions with or without type‐I IFNα and the impact of this 
selection was assessed by determining the frequency of remaining insertion events at each 
position in the genome by NGS. The frequency of mutations at each genome position was 
then compared between the treatment groups to assess their impact on IFN sensitivity. 
Mutations of interest were then re‐introduced into the full‐length infectious clone of DENV 
allowing testing of their IFN sensitivity independently. Unfortunately, none of the individually 
cloned 15 bp insertion mutants displayed increased IFN sensitivity as predicted by the screen. 
This may have been a result of introduction of compensatory mutations resulting in non‐
replication competent virus being detected by the screen and/or transposon insertion‐linked 
mutations that confounded interpretation of the impact of transposon insertion during the 
screen. The results of this screen highlight the complexity of high‐throughput mutational 
studies on RNA virus genomes and have provided constructive recommendations to improve 
similar work conducted in the future. These include reducing accumulated mutations by 
lowering the number of non‐essential passages, reducing co‐infection, and increasing 
selection pressure applied to the mutant population. Additionally, the added power given by 
new long‐read sequencing technology could greatly benefit future screens of this nature by 
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5.1 Abstract  
The immunological surveillance factors controlling vulnerability of the female reproductive 
tract (FRT) to sexually transmitted viral infections are not well understood.  Interferon‐epsilon 
(IFNɛ) is a distinct, immunoregulatory type I IFN that is constitutively expressed by FRT 
epithelium and is not regulated by pathogens like other antiviral IFNs α, β and λ. We show the 
necessity of IFNɛ for Zika Virus (ZIKV) protection by: susceptibility of IFNɛ‐/‐ mice; their 
“rescue” by intravaginal recombinant IFNɛ treatment and blockade of protective endogenous 
IFNɛ by neutralising antibody. Complementary studies in human FRT cell lines showed IFNɛ 
had potent anti‐ZIKV activity, induced similar genes to IFNλ but not some IFNα‐induced 
proinflammatory genes. IFNɛ activated, similar to IFNα and λ, the STAT1/2 pathways which 
were inhibited by ZIKV‐encoded non‐structural (NS) proteins. Importantly in contrast, 
constitutive IFNɛ expression was not inhibited by ZIKV NS proteins which did block the PRR‐
induction of IFNα, β or λ.  The constitutive nature and resistance to virus blockade of IFNɛ 
enables it to precede virus and maximise antiviral activity. These results show that the unique 
spatiotemporal properties of IFNε provides an innate immune surveillance network in the FRT 
to govern viral infection with important implications for prevention and therapy. 
 
5.2 Introduction  
Zika virus (ZIKV) is a mosquito‐borne Flavivirus that can also be transmitted sexually [296], 
and in utero [270] leading to foetal infection and congenital symptoms in neonates [279] 
including microcephaly, intrauterine growth restriction, as well as ocular and cognitive 
impairment [284, 294].  
The innate immune response to ZIKV is critical for controlling infection [156] particularly at 
the mucosa of the female reproductive tract (FRT) where transmission to offspring occurs. 
Type‐I and type‐III IFNs, are the body’s premier antiviral cytokines that protect against viral 
infection at mucosal surfaces [214]. Type‐I and III IFNs orchestrate the cellular antiviral 
response via binding cognate receptors, IFNAR1/2 or IFNLR1/IL10Rβ, respectively. Receptor 
binding activates JAK/STAT signalling (as reviewed in [182]) leading to activation of thousands 
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of Interferon Stimulated Genes (ISGs) [293]. These ISGs encode effector proteins including 
Viperin, IFITM family, ISG15 and IFI6 that directly inhibit ZIKV [89, 129, 300, 354], or those 
with immune regulatory function [156]. Importantly, ZIKV is exquisitely sensitive to the 
biological effect of type‐I and III IFNs evidenced by its enhanced replication in IFN receptor 
knockout mouse models [36, 181]. Normally, these IFNs are only produced after detection of 
viral infection by pattern recognition receptors (PRRs) such as by the cytosolic PRR retinoic 
acid‐inducible gene‐I RIG‐I [224, 302]. This delay between pathogen detection and 
establishment of the IFN‐mediated antiviral state is exploited by ZIKV that, after entering the 
cell, translates non‐structural (NS) proteins that can inhibit the pathway and promote 
infection [52].  
Unlike the typical type‐I and type III IFNs, that are for the most part only expressed following 
viral detection, the unique type‐I IFN, IFN‐epsilon (IFNε) expression is constitutive, not reliant 
on pathogen detection pathways and is regulated by female sex hormones [105]. IFNε is 
produced primarily by the mucosal epithelium of the FRT in both mice and humans [105, 133] 
and like other type‐I IFNs, signals via IFNAR1/2 to induce expression of ISGs [105, 335]. This 
constitutive expression is important for protective mucosal immune responses to bacterial 
(chlamydia) and viral (HSV2) infection of the FRT [105]. Additionally, IFN demonstrates in 
vitro activity that inhibits multiple steps of the HIV lifecycle [110]. Our current knowledge of 
the role of IFNs in protection from ZIKV infection of the FRT has been elegantly investigated 
largely by the use of IFNAR1 [381] and IFNLR1 [36] null mice, however the particular ligands 
that act to protect the ZIKV infected FRT through these receptors are not well characterised. 
In this study we demonstrate the importance of IFN as a major contributor to protecting the 
FRT from ZIKV infection.  
 
5.3 Results 
5.3.1 ZIKV replication is inhibited by endogenous IFNε in a mouse model of vaginal 
transmission 
To determine the contribution of endogenous IFN expression in the FRT, relative to other 
(conventional) type‐I IFNs to prevent ZIKV infection, we compared the outcomes of 
intravaginal (iVag) infection [105] of wildtype (WT), IFNε‐/‐ or IFNAR1‐/‐ mice with 5 X 105 FFU 
of ZIKV Brazilian stain PRVABC59 (Fig. 5.1a).  
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In the absence of IFNε, mice were more susceptible to ZIKV infection in tissues of the 
reproductive tract with higher viral titres in vaginal washes (VW) 3, 5 and 7 days post‐infection 
(dpi) (Fig. 5.1b). Interestingly, the levels of infectious virus in VW at 5 dpi of IFNε‐/‐ mice were 
similar to that of IFNAR1‐/‐ mice. Higher viral load in VW correlated with increased viral RNA 
(vRNA) detected by qRT‐PCR in both the uterus and ovary on 5 (Fig. 5.1d & e) and 7 dpi (Sup. 
5.1). Interestingly, no significant difference was detected in the vagina (Fig. 5.1c) of IFNε‐/‐ 
mice compared to WT mice that had much greater levels of infection in the vagina (5.06 
Log10) compared to both the uterus (3.19 Log10) and ovary (2.28 Log10). The vagina had 
apparently lower IFNε RNA levels than the uterus and ovary but this was not statistically 
significant (Sup. 5.2). Additionally, we performed in‐situ hybridisation on FRT tissues at 5 dpi 
(Sup. 5.3). ZIKV RNA was detected in the lower FRT (LFRT) of WT, IFNε‐/‐ and IFNAR1‐/‐ mice, 
however this was below the limit of detection in the upper FRT (UFRT) except for IFNAR1‐/‐ 
mice. Unexpectedly, the absence of IFNε also led to greater spread of virus to the draining 
illiac lymph node and spleen by 5 dpi (Fig. 5.1f & g & h) despite these tissues having no 
detectable or very low levels of IFNε mRNA (Sup. 5.2). Similar to previous reports [133, 145], 
we found detectable levels of IFNε mRNA in the brain of WT mice, and in the absence of IFNε, 
mice displayed greater levels of infection in the brain by 5 dpi. However, unlike the uterus 
and ovary that remained infected in the absence of IFNε, by 7 dpi the levels of ZIKV RNA 
detected in the lymph node, spleen and brain were equivalent to WT (Sup. 5.1). In contrast 
to WT and IFNε‐/‐ mice, the high level of infection seen in all tissues of IFNAR1‐/‐ mice at 5 and 
7 dpi illustrated the major contribution of all type‐I IFNs in protecting against the systemic 
spread of ZIKV infection. Collectively this data emphasises the importance of type‐I IFNs, and 
specifically of IFN in early protection of the FRT from ZIKV infection and in limiting spread to 
other tissues via this route.  
To further characterise the role of IFNε in control of viral infection of the FRT, IFNε‐/‐ mice 
were reconstituted with intravaginal treatments of recombinant mIFNε or buffer alone 6 h 
prior to infection with ZIKV. As expected, mice treated with mIFNε had lower levels of 
infectious ZIKV in VW (Fig. 5.1i) and this effect seemed to be limited to the lower reproductive 
tract observed by qRT‐PCR (results not shown).  To further characterise this response, we 
treated uninfected IFNε‐/‐ mice with recombinant mIFNε or mIFNλ‐2 (4μg) and assessed 
antiviral ISG expression in the lower FRT (LFRT) (Fig. 5.1J) and upper FRT (UFRT) (Sup. 5.4) 6 h 
post‐treatment. We observed ISG induction induced by both recombinant mIFNε and mIFNλ‐
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2 importantly in the vagina but not uterus or ovary that is consistent with the antiviral effect 
of recombinant IFNε noted above.  
To further investigate the compartmentalisation of these intravaginal treatments to the LFRT, 
WT mice were injected with an IFNε blocking antibody which led to increased viral titres in 
comparison to the isotype controls. This effect was evident in vaginal samples (Fig. 5.1k&l), 
but not in samples from the UFRT, nor distant organs (Sup. 5.5). In the UFRT mice controlled 
the infection in part due to competent IFN signalling in these tissues [165], also likely 
indicating the instilled IFN or antibody treatments did not reach the UFRT. 
Together, this data demonstrates endogenous IFNε expression in the FRT has a significant 
impact on local ZIKV infection and viral dissemination at early times post infection. This effect 
is added to by other type‐I IFNs controlling infection especially at in peripheral tissues at later 
timepoints. 
5.3.2 Antiviral effect of IFNε on cells of vaginal and cervical origin 
Having demonstrated that IFNε plays an important role in control of ZIKV infection in our 
mouse model it was important to determine the effect and mechanism of action in human, 
for which we tested vaginal and cervical epithelial cells ‐ the first infected by sexually 
transmitted pathogens [2].  
We initially determined these cell types were permissive to infection by inoculating primary 
transformed ectocervical (Ect1) or vaginal keratinocyte (VK2) cells with increasing MOI of ZIKV 
(PRVABC59) and detection of infected cells by E‐antigen immunofluorescence staining (Fig. 
5.2a), or titrating infected cell supernatants by plaque assay (Fig. 5.2b &c). We then evaluated 
the impact of recombinant IFNε on ZIKV infection in these cells, compared to other IFNs that 
are important modulators of antiviral activity at mucosal surfaces (IFNα and IFNλ) [182]. IFN 
treatment inhibited viral infection of both Ect1 and VK2 cells by ~90%, whether determined 
by plaque assay or viral RNA (Ect1 vRNA: 88% reduced) (Fig. 5.2b‐e).  Similar reduction in viral 
titres or vRNA were elicited by IFNα (Ect1 vRNA: 78%) and IFNλ (Ect1 vRNA: 83%) (Fig. 5.2b‐
g), indicating that IFNε can generate an antiviral state similar to that of IFNα or IFNλ in 
epithelial FRT cell lines.  
To further investigate their antiviral functions, we compared the responses to these IFNs in 
FRT cells using whole transcriptome profiling by RNAseq analysis (NextSeq550 V2.5). 
Interestingly, IFNε and IFNλ‐III had almost indistinguishable gene signatures at this time point 
(Fig. 5.3a, Sup. 5.6) which contrasts recent reports comparing type‐I, IFNβ, and type‐III IFNs 
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that found several differently regulated ISGs [36, 98]. As expected, all IFN treatments 
significantly upregulated a number of canonical ISGs in both cell types compared to untreated 
controls (Fig. 5.3b, c & d). Consistent with the reported specific activities of these IFNs [134, 
318, 335], IFNα induced the strongest response, upregulating greater numbers and 
magnitude changes of responsive genes (See Fig 5.3b).  
Next, we performed qRT‐PCR analysis to confirm expression of key antiviral (Fig. 5.3e & f) or 
proinflammatory (Fig. 5.4g & h) genes. Key ISGs that protect against ZIKV infection (Viperin 
[354], ISG15 [327], IFITM1[300], IFI6 [89]) were upregulated in all three treatments. We also 
noted that while both type‐I and type‐III IFNs were able to induce expression of the 
proinflammatory CXCR3 ligands, CXCL10 and CXCL11, but that their expression was 
significantly lower in IFNε and IFNλ treatments. Interestingly, a recent report has suggested 
that temporal ISG induction by type‐I and III IFNs provides a collaborative antiviral response, 
with type‐I IFNβ promoting inflammation via an IRF‐1 dependant inflammatory response [98]. 
Consistent with this observation we also noted an increase in IRF‐1 expression in Ect1 and 
VK2 cells stimulated with IFNα as compared to stimulation with IFNε and IFNλ‐III (Fig. 5.3a, 
h,i). This increase in IRF‐1 expression for IFNα suggests that IFNα, like IFNβ, drives a greater 
proinflammatory phenotype in comparison to IFNε and IFNλ‐III that is reflected by increased 
expression proinflammatory ISGs like CXCL10 and CXCL11.  
To further understand the spatiotemporal action of IFNε in the FRT we compared ISG 
induction in Ect1 cells responding to IFNε, IFNα‐2A, and IFNλ‐III treatments over time. IFNε 
induced an early but transient induction of ISGs (ISG15, Viperin, CXCL10) while IFNα induced 
early induction of ISGs that was maintained over the 24 h time course (Fig. 5.3i, j &k) and IFNλ 
a gradual induction of ISGs over 24 hrs as seen previously in liver and lung epithelial cell lines 
[28, 98, 158, 172, 206, 356]. Collectively this suggests that these IFNs have evolved to perform 
specialised functions to coordinate antiviral responses spatiotemporally to combat viral 
infection of the FRT. Of these functions the apparent ability of IFNε to induce lower levels of 
the transcription factor IRF1 and proinflammatory genes in the FRT, like IFNλ rather than 
IFNα, warrants further investigation.   
5.3.3 Treatment of cells with IFNε prior to infection precedes ZIKV evasion of type-I and 
type-III IFN signalling pathways  
To understand the impact of IFNε’s unique constitutive expression on ZIKV evasion of IFN 
responses in humans that are mediated by viral NS proteins [121, 176, 374], we treated the 
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placental trophoblast cell line HTR8, with IFNε or IFNα either pre‐ or post‐infection with ZIKV 
(Fig. 5.4a). When administered at later time points post‐infection (24 hpi), both IFNε and IFNα 
treatments were less efficient at controlling ZIKV infection compared to early treatments (3 
hpi), leading to greater levels of vRNA in cells or levels of infectious virus in supernatants (Fig. 
5.4 b&c). However, compared to pre‐treated conditions, early post‐infection treatment was 
significantly less effective at limiting ZIKV infection. This observation is consistent with similar 
studies for other flaviviruses, showing a rapid shut‐down of IFN signalling following viral entry 
and detectable NS protein expression as early as 3 hpi [16]. As expected, this effect was also 
observed for IFNλ‐III, since this relies on a similar signalling pathway to type‐I IFNs (Fig. 5.4d 
&e).  
To observe the molecular target of ZIKVs evasion downstream of IFNε we first investigated 
STAT1/2 nuclear translocation by immunofluorescence, and STAT1/2 phosphorylation 30 min 
post‐treatment by western blotting in HeLa cells infected with ZIKV. Cells infected with ZIKV 
had a reduced capacity for STAT1 nuclear translocation (Fig. 5.5a) in comparison to uninfected 
cells and this correlated with a reduction in STAT1‐Y701P phosphorylation (Fig. 5.5c) post 
stimulation with IFNε. Importantly, STAT2 nuclear translocation (Fig. 5.5b), phosphorylation 
(STAT2‐Y690P) and total protein levels (Fig. 5.5c) were more potently reduced by ZIKV 
infection compared to the observed effects on STAT1. This effect on STAT1 and STAT2 
phosphorylation following ZIKV infection was comparable after stimulation with IFNα (Fig. 
5.5d), indicating a similar mechanism of ZIKV‐mediated evasion was responsible for inhibiting 
the pathway downstream of both IFNs.  
Next, we determined if inhibition of STAT2 activation by IFNε was driven by the same ZIKV 
factors as previously described for IFNα [121]. HeLa cells transfected with plasmids expressing 
ZIKV NS5, or an empty vector were stimulated with IFNε or IFNα and 30 minutes post 
stimulation, STAT1/STAT2 activation was assessed as above. In the presence of NS5 protein 
and IFNε stimulation, total STAT2 protein was reduced that corresponded to a concomitant 
decrease in STAT2 phosphorylation with no impact on STAT1 phosphorylation (Fig. 5.6a). A 
similar picture was also seen for IFNα stimulation (Fig. 5.6b).  Interestingly, total STAT1 and 
phosphorylated STAT1 in the presence of ZIKV NS2B/3 and IFNs remained constant despite 
previous findings that ectopic expression of NS2B/3 protein inhibits STAT1 activation [374].  
To confirm the impact of reduced STAT2 phosphorylation on downstream signalling we 
performed a dual luciferase assay for ISRE activity and qRT‐PCR for ISGs. Accordingly, Figure 
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5.6c shows NS5 expression also inhibits downstream ISRE and concomitant ISG expression 
(representative gene ISG15 shown for simplicity) in HeLa cells in a dose dependent fashion 
(Fig. 5.6d).  
Taken together this data demonstrates the potent ability of ZIKV to shut‐down type‐I and III 
IFN responses after infection is established, primarily via ZIKV NS5 induced STAT2 
degradation. This highlights the importance of priming with IFN before infection is established 
to limit virus spread and therefore implies the likely significance of IFNε as the only 
constitutively expressed IFN detectable in the non‐pregnant FRT.  
5.3.4 IFNɛ constitutive expression is not inhibited by ZIKV infection or NS proteins  
The expression of IFNɛ in the FRT prior to viral infection is hypothesised by us and others [62] 
to circumvent pathogen‐mediated IFN evasion helping to protect the FRT from viral and 
bacterial infections. However, this assumes infection cannot inhibit IFNɛ expression, 
therefore we asked if ZIKV infection could inhibit the expression of IFNε.  
HeLa cells are known to express IFNε RNA at levels similar to FRT cell lines [105], therefore 
we used these to investigate expression of IFNε compared to other type‐I and III IFNs in 
response to ZIKV infection or poly I:C stimulation (viral mimic). At a basal level, we found that 
IFNε was highly expressed compared to other type‐I and III IFNs (Fig. 5.7a). Consistent with 
previous reports [105] we saw minimal induction of IFNε in HeLa cells in response to either 
ZIKV infection or poly I:C transfection. Conversely, PRR‐mediated induction of type‐I IFNβ and 
type‐III IFNλ was required to generate expression levels equivalent to basal IFNε in these cells. 
Interestingly, we did not see ZIKV mediated dampening of poly I:C induced IFNβ induction 
when cells were infected prior to poly I:C stimulation as reported previously by our group 
[354] and others [374]. However, these experiments were conducted in either Huh‐7 or A549 
cells, suggesting the PRR pathways that contribute to HeLa cell IFN expression may differ and 
are not as efficiently inhibited by ZIKV.  
To isolate on the main pathway responsible for inducing IFN expression in response to ZIKV 
infection (RIG‐I/MAVS) [302, 381] we co‐transfected HeLa cells with a plasmid expressing 
constitutively active RIG‐I (RIG‐I‐N [384]) and either vectors expressing ZIKV‐NS1/NS4A/NS2B‐
3/NS5‐FLAG or an empty vector control (see Sup. 5.7 for protein expression levels). These NS 
proteins are known to restrict the expression of other type‐I IFNs in response to viral infection 
[176, 189, 198, 200, 375]. Expression of RIG‐I‐N alone resulted in the upregulation of IFNβ and 
type‐III IFNλ and this was restricted by the presence of co‐expressed ZIKV‐NS1, NS4A, NS5 but 
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not NS2B/3 (Fig. 5.7b). Conversely the constitutive expression of IFNε RNA was unaffected by 
RIG‐I pathway stimulation or by the presence of NS proteins in these cells.  
Together this data demonstrates IFNε constitutive expression is not altered following ZIKV 
infection. This contrasts with other type‐I and III IFNs (IFNβ and IFNλ‐I) that rely on PRR 
activation for their expression and are therefore susceptible to inhibition by ZIKV NS‐proteins.  
 
5.4 Discussion 
ZIKV is the only Flavivirus known to transmit both sexually and in utero, making it a unique 
threat to the FRT immunological niche, both during pregnancy and under normal physiological 
conditions. Here we demonstrate the non‐redundant role of a novel type‐I IFN; IFNε, in 
protecting the FRT from ZIKV infections both in vitro and in a mouse model of vaginal 
transmission.  
To assess the contribution of endogenous IFNε in controlling ZIKV FRT infections we used a 
murine model of vaginal transmission. In this model DMPA treatment was used to synchronise 
mice to diestrus, rendering mice susceptible to ZIKV iVag infection as reported by other 
groups [36, 341, 381]. Since IFNε is hormonally regulated its expression is reduced during 
diestrus and pregnancy in mice [105]. This reduction in IFNε may contribute to the natural 
susceptibility of WT mice during diestrus [341, 381] and pregnancy [381] to iVag ZIKV infection 
compared to systemic inoculation methods. Importantly, this means our data must be viewed 
as “no” versus “low” IFNε in the FRT when comparing IFNε‐/‐ to WT mice. ZIKV infection via 
iVag inoculation was compared between WT, IFNε‐/‐ and IFNAR1‐/‐ mice.  
Although WT mice expressed suboptimal levels of IFNε, we found that its presence in the FRT 
was sufficient to offer significant protection against ZIKV iVag infection compared to mice 
lacking IFNε. This protection was most significant during the early stages of infection as 
indicated by the high levels of infectious virus recovered in the VW of IFNε‐/‐ mice that closely 
mirrored levels observed in the highly susceptible IFNAR1‐/‐ mice. Interestingly, the antiviral 
activity of endogenous IFNε primarily acted in the UFRT tissues and not the vagina, despite 
the vagina expressing high levels of IFNε mRNA compared to peripheral tissues such as the 
spleen. Notably, there was also a smaller difference in vRNA levels between WT and IFNAR1‐
/‐ mice in this tissue compared to upper FRT tissues. This demonstrates a lesser overall impact 
of type‐I IFN signalling in the vagina and agrees with recent reports showing a small impact of 
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IFNAR1‐/‐ in ZIKV infected lower FRT (LFRT) compared to the upper FRT (UFRT) in mice, 
reportedly due to lower relative PRR expression in LFRT [165]. Our data suggests the LFRT is 
highly susceptible to ZIKV infection independent of endogenous or induced IFN expression, 
potentially explaining ZIKVs aptitude for sexual transmission in humans. Comparatively we 
demonstrate that IFNε expressed in the UFRT, the site of in utero transmission, is essential 
for ZIKV infection control. 
In apparent contrast to our observations that indicate IFNε plays a significant role in 
protecting the FRT from ZIKV infection, multiple groups have observed type‐I and III IFN 
independent protection of the FRT during estrus in mice [36, 61]. This appears 
counterintuitive to IFNε playing a significant role since mice in estrus have the highest levels 
of IFNε expression in FRT tissues [105]. This mechanism of estrus dependent, IFN independent 
protection against ZIKV infection in mice is yet to be fully characterised. However, one 
plausible theory is that this effect is mediated by thickening of the epithelial layer during 
estrus in both upper and lower reproductive tract of mice, presenting an additional physical 
barrier to infection. Comparatively in humans, the epithelium of the lower reproductive tract 
remains constant over the menstrual cycle [370]. This additional barrier during estrus may 
mask the contribution of IFNε during this stage of the cycle in mice. Therefore, it is plausible 
the effect of IFNɛ may be more significant in human sexual transmission due to physiological 
differences in FRT biology. Additionally, ZIKV NS5 mediated evasion of human but not mouse 
IFN signalling via STAT2 degradation [121] likely enhances the antiviral efficacy of ZIKV‐
induced IFNs in WT compared to IFNAR/IFNLR‐/‐ mouse models. 
Interestingly, IFNε also significantly decreased the dissemination of ZIKV to the peripheral 
tissues in WT mice by 5 dpi. Since IFNε is primarily expressed in the FRT it was surmised this 
effect resulted from additional replication in the FRT driving increased circulation of the virus 
to the peripheral organs. However, unlike the spleen and lymph node that do not express 
IFNε, we detected relatively high levels of IFNε mRNA in the brain (see Sup. 5.1) consistent 
with reports by others [133, 262]. If IFNε protein is functionally expressed in the brain it may 
have a role in protecting against ZIKV as a neurotropic Flavivirus. Interestingly, one study in 
humans has linked a polymorphism of IFNε to cerebral haemorrhage, indicating it may be 
functionally expressed in this tissue [169]. Studies to determine the antiviral role of IFNε in 
the brain would be an area of interest to ZIKV and other neurotropic viruses.  
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Collectively this data has demonstrated that IFNɛ plays a significant and non‐redundant role 
at physiological levels during early infection of the FRT and in preventing systemic 
dissemination in non‐pregnant adult female mice.  
Understanding the capacity to modulate immune responses is the first step towards 
developing new immune therapies. Here we have shown modulation of IFNε levels in the 
lower FRT can alter the infectivity of mice by ZIKV intravaginal infection. Antibody mediated 
neutralisation of IFNε in WT mice significantly increased infection. On the other hand, iVag 
treatment with IFNε was able to restore antiviral activity in IFNε‐/‐ mice. Furthermore, we 
investigated the immune stimulatory properties of intravaginally administered recombinant 
IFNε. This produced increased ISG expression in the vagina without significantly inducing ISGs 
in the UFRT. This indicates short iVag IFN treatments mainly act to prevent establishment of 
infection in the LFRT likely protecting against ascending infection and female to male sexual 
transmission.  
To extend these observations to human cell culture we next investigated the antiviral 
properties of IFNε on FRT cell lines. Pre‐treatment with either IFNε, IFNα or IFNλ3 protected 
Ect1 and VK2 cells from ZIKV infection, indicating the importance of both type‐I and III IFNs in 
protection of the FRT in humans. We found that IFNε generated antiviral responses in FRT 
Ect1 and VK2 cell lines by inducing a typical IFN antiviral signature, including upregulation of 
several ISGs known to inhibit ZIKV infection. Interestingly, the gene signature of IFNε 
treatment was almost indistinguishable to IFNλ at this time point (6 h) despite signalling 
through different receptors. Both IFNε and IFNλ were found to induce lower levels of the 
transcription factor IRF1 and proinflammatory genes compared to conventional type‐I IFNα 
treatment at the same concentration. Confirmation by qRT‐PCR of key anti‐ZIKV ISGs or 
proinflammatory genes indicated fold induction consistent with the reported specific 
activities of these IFNs, with IFNα inducing a more potent response than either IFNε or IFNλ 
at the same ng/mL concentration. Together this data shows at early times post‐stimulation, 
IFNε induces a typical antiviral gene signature in FRT cell lines, and like type‐III IFNs may have 
a lower propensity to induce inflammation via CXCR3 ligand regulation compared to 
conventional type‐I IFNs. We propose the lower specific activity of IFNε provides an 
evolutionary advantage because of its constitutive presence in the FRT, striking a balance 
between limiting infection, inflammation, and normal reproductive function in these tissues.  
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Additionally, we found that the kinetics of gene induction in response to IFNε in FRT cell line 
was rapid, having highest levels of ISGs at early times and waning by 24 h. Comparatively, 
IFNλ displayed typical type‐III induction having gradually increasing gene expression with the 
greatest levels of gene induction at 24 h. This suggests that type‐I and type‐III IFNs likely have 
differing spatial‐temporal roles in controlling ZIKV infection and most likely other infections 
of the FRT. 
The importance of both type‐I and type‐III IFNs protecting against ZIKV infection is now well 
established in mice [36, 87, 231, 341, 381]. However, in humans and other primates, ZIKV has 
adapted to evade IFN responses via multiple host‐viral interactions that restrict the 
effectiveness of IFN mediated protection [121, 176, 216, 374]. Understanding and exploiting 
this axis of host‐virus interaction is therefore important to improve patient outcomes. Here 
we have shown ZIKV can evade both type‐I and III IFN mediated antiviral activities 
downstream of receptor binding within hours after infection is established. ZIKV was able to 
limit the induction of ISGs via blocking both STAT1 and STAT2 activation. The key molecular 
mechanism underlying this effect was found to be NS5 mediated degradation of STAT2 
protein as previously described for IFNα [121]. Importantly this effect was equally applicable 
to IFNα, IFNε, and IFNλ. Equivalent viral evasion highlights the similarities between the type‐
I and III IFN signalling pathways that contribute to anti‐ZIKV activity. Furthermore, ZIKVs 
efficient evasion of both type‐I and III IFN antiviral activity after infection is established, 
highlights the importance of a rapid induction of ISGs or priming cells with IFN to effectively 
prevent infection. This also suggests that at times when IFNε is reduced, such as early 
pregnancy [105, 250], the FRT is likely more vulnerable to ZIKV infection. Importantly, IFNε is 
the only IFN known to be produced constitutively by mucosal surfaces of the non‐pregnant 
FRT [253] suggesting it may have a significant impact on human FRT infections.  
Additionally, we characterised the constitutive nature of IFNε expression under viral infection 
and showed that in contrast to type‐I and III IFNs, endogenous expression of IFNε was not 
susceptible to ZIKV‐mediated evasion. This demonstrates for ZIKV infections, the FRT can be 
pre‐emptively tuned to an antiviral state and that it appears to be a unique property of IFNε, 
stemming from the different regulatory pathways that govern its expression. Further 
exploration into the stimuli and pathways that regulate IFNε expression in the human FRT will 




In summary we have shown that IFNε is an important mediator of antiviral activity in the FRT 
of both mice and humans. This activity is effective to reduce ZIKV iVag transmission in mice 
and infection in FRT cell lines. The constitutive presence of IFNε in the non‐pregnant FRT is 
likely significant in human infections as ZIKV can effectively evade post‐infection IFN 
responses but is strongly inhibited by prophylactic treatment.  
 
5.6 Methods and Materials  
5.6.1 Virus. Low passage ZIKV strain PRVABC59 was propagated in C6/36 mosquito larvae 
cells. Infectious virus stock titres were determined by Focus Forming Assay on Huh7.5 cells.  
5.6.2 Cell lines, reagents and recombinant IFNs. HeLa and Vero E6 cells were cultured in 
DMEM supplemented with 10% FCS and 1% Penicillin/Streptomycin. HTR8 cells were 
maintained in RMPI with 10% FCS and 1% Penicillin/Streptomycin. Ect1 and VK2 cells were 
cultured in Keratinocyte Serum Free Media supplemented with 0.1 ng/mL human 
recombinant EGF, 0.05 mg/mL bovine pituitary extract, additional calcium chloride 44.1 
mg/mL and 1% Penicillin/Streptomycin. All cell lines were cultured at 37 °C with 5% CO2. 
Mouse and human recombinant IFNε protein (mIFNε, hIFNε) were made in house as 
previously described [110, 335]. Commercial IFNs were hIFNα‐2A (PeproTech), hIL‐28B (R&D 
systems) and mIFNλ2 (PeproTech). Due to the limited supply of hIFNε, large scale in vitro 
experiments on HTR8 or HeLa cells used mIFNε (10 U/mL) and hIFNα‐2A (500 U/mL). These 
concentrations were titered by direct comparison of receptor activation levels and antiviral 
properties (see Supl. Fig. 5.8). For specific use of antibodies see supplementary methods.  
5.6.3 Mice. Sexually mature female mice aged between 6 – 12 weeks at the time of infection 
were used in these experiments. Mice from each genetic background were age matched 
between experiment groups to minimise the impact of differing susceptibility. C57BL/6  (WT) 
mice were purchased from Monash Animal Services and acclimatised for one week prior to 
infection. IFNε‐/‐ and IFNAR1‐/‐ mice on C57BL/6 background were maintained in house.  
5.6.4 Intravaginal infection and treatments of mice. All mice were treated with 2 mg Depo‐
ralovera DMPA (Kenral) subcutaneously 5 days prior to infection to synchronize the estrus 
cycle into diestrus phase on the day of infection as previously described [105]. On day 0 mice 
were anesthetised using isoflurane then inoculated intravaginally with 5 x 105 FFU ZIKV in 10 
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μL PBS, then kept under aesthetic for 2‐3 minutes to promote viral adherence. Mice were 
monitored daily to assess clinical signs of disease: 0, no apparent signs of disease; 1, genital 
redness or minor genital swelling; 2, genital redness and genital swelling, huddled and 
inactive; 3, severe lethargy and little response to handling. At day 5 or 7 mice were culled, 
and tissues were extracted. Tissues for RNA extraction were flash frozen in liquid nitrogen 
and tissues for IHC or ISH staining were fixed in 10% neutral buffered formalin for a minimum 
of 24 h prior to embedding in paraffin. Treatments with 4 μg mIFNε or 100 μg IFNε neutralising 
antibody (made in house) were administered intravaginally 6 h prior to infection (or tissue 
collection) and again on day 3 post infection. Control groups were treated with either buffer 
or an IgG isotype control antibody equivalently.   
5.6.5 Plaque Assay – detection of infectious virus and collection of vaginal wash samples. 
Vaginal washes were collected by pipetting 30 μL of PBS into the vaginal cavity. Washes were 
performed twice for each mouse and pooled. Samples were immediately transferred to dry 
ice and stored at ‐80°C until ready for use. Then Vero cells in 12‐well trays at approximately 
90% confluency were infected with 300 μL of serially‐diluted virus‐containing supernatants 
for 1 hour at 37 °C. Supernatants were then replaced with a 1mL overlay of complete media 
containing 1.5% (w/v) carboxymethylcellulose (CMC) (Sigma) and cells returned to culture for 
5 days. Cell monolayers were then fixed with 10% formalin and incubation for 1 h. The CMC 
overlay was then removed, and plaques were visualised via crystal violet stain. Plaques were 
enumerated, and virus infectivity expressed as plaque‐forming units (PFU) per mL. 
5.6.6 Tissue RNA extractions and cDNA preparation and qRT-PCR. 500 μL of TRISURE reagent 
was added to each frozen tissue and these were dissociated in an RNAse free microcentrifuge 
tube (Eppendorf) using a homogenisation pestle. A further 500μL of TRISURE was added prior 
to the addition of 200 μL chloroform and separation of the aqueous phase by cold 
centrifugation. The aqueous layer was reserved and 500 μL 100% ethanol was added. This 
was then transferred to an RNAeasy column (QIAGEN) for final RNA isolation as per 
manufacturer’s instructions. cDNA synthesis was performed using MMLV‐reverse 
transcriptase (Promega), reactions contained either 500 ng or 1000 ng RNA (dependent on 
the lowest RNA yield in a tissue cohort for consistency) and primed with 500ng random 
hexamer. cDNA were diluted 1 in 4 prior to use. qRT‐PCR was performed with Roche FastStart 




5.6.7 Quantification and analysis of viral RNA (vRNA) genome copies per μg RNA 
determination of lower LOD for uninfected tissues.  A plasmid containing the full‐length 
genome of a Brazilian ZIKV (Paraiba_2015) was used to generate a standard curve for qRT‐
PCR analysis [350]. First the plasmid was linearised using EcoRV and column purified. The 
number of genome copies per ng of plasmid was enumerated based on the molecular weight 
of the plasmid. Serial dilutions on a log2 scale were used to place the curve within a detectable 
range (between 13 – 36 cycles). A standard curve containing 8 dilutions (including blank) was 
run with each tissue cohort. Raw CT values were plotted against log2 transformed genome 
copies and CT values from each tissue cohort were interpolated using the standard curve. 
Log2 interpolated values were then transformed to a linear scale and normalised to μg RNA 
used in total cDNA preparation. To achieve normal distributions and equal standard 
deviations between genotypes, data was log10 transformed and represented as log10 
genome copies per μg RNA. Determination of the limit of detection for uninfected tissues was 
performed by qRT‐PCR analysis of treatment, genotype and tissue matched uninfected 
samples (5 per group) using the same ZIKV PCR primers. CT values from uninfected tissues 
were compared between genotypes and tissues to ensure consistency in primer background. 
The earliest detected CT value for all uninfected tissues was determined to be 36.4. This value 
was then applied to each tissues standard curve to give the minimum value for infected tissue 
detection. Mice were determined to be uninfected by assessment of melt curves in both 
technical duplicates and their CT value compared to uninfected controls. 
5.6.8 Viral RNA In Situ Hybridization. RNA ISH was performed on formalin fixed paraffin 
embedded sections (5 µM) using RNAscope 2.5 HD (Brown) (Advanced Cell Diagnostics) 
according to the manufacturer’s instructions and as previously described [115]. 
5.6.9 RNAseq sample preparation and analysis. Ect1 and VK2 cells seeded to 90% confluency 
in 6 well plates were treated with hIFNε, hIFNα‐2a or hIFNλ‐3 (100 ng/mL) diluted in fresh 
culture media or left untreated (n = 4) for 6 h prior to harvesting RNA in RLT buffer (Qiagen) 
with added β‐ME. Lysates were homogenized by passing through a 20‐gauge needle attached 
to a sterile plastic syringe. Total RNA were extracted from lysates using the Qiagen RNeasy 
kit, including removal of DNA contamination using the Qiagen RNase free DNase set as per 
the manufacturers instructions. Library preparation and RNASeq analysis (Illumina 
NextSeq550 V2.5) were performed using a novel in house RNA‐seq pipeline (ACRF, Medical 
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Genomics Facility, Monash). Differentially expressed genes were determined with a 1.2‐fold 
cut‐off and adjusted p‐value < 0.05.  
5.6.10 Focus forming assay – detection of infectious virus. Vero or Huh 7.5 cells were seeded 
in 96 well plates (90% confluence for infection) were inoculated with 40 μL of serially diluted 
viral supernatants for 3 hours at 37 °C with manual agitation every 20 minutes. Inoculum was 
removed and replaced with 100 μL fresh culture medium for 48 hours in a level incubator 
without shaking. Cells were fixed with acetone/methanol prior to indirect 
immunofluorescence detection of ZIKV protein using the 4G2‐pan Flavivirus E primary 
antibody and fluorescently labelled secondary antibody. Foci were enumerated by 
observation under a fluorescent microscope and were defined as more than 3 infected cells 
in a distinct cluster. Each sample was calculated based on biological triplicates with technical 
duplicates then expressed as Focus Forming Units (FFU) per mL.   
5.6.11 Plasmids and transfections. Non‐structural proteins were PCR amplified from an 
infectious clone of a Brazilian isolate of ZIKV (Paraiba_2015) [350] and cloned into the 
expression plasmid pCDNA6.2 by Gibson Assembly using primers containing 3’ FLAG 
extension. Empty vector was used as a control in all expression experiments or as a filler for 











F GGGACCGATCCAGCCTCCGGACTCTAGAATGgggggtggaacag  
R GTTTCAGTTAGCCTCCCCCGTTTAAACTTACTTGTCGTCATCGTCTTTGTAGTCcagcactccaggtg 
Plasmids containing constitutively active RIG‐I‐N or ISRE‐Luciferase have been described 
previously [354, 384]. Transfections were performed using with a 2:1 ratio of lipofectamine 
2000 reagent (Invitrogen) to DNA.  
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5.6.12 Dual luciferase assay. HeLa cells were co‐transfected with the ISRE‐luciferase reporter 
construct, the constitutive renilla luciferase reporter pRL‐TK (Promega) as a transfection 
control and the according pCDNA6.2‐NS expression construct or empty vector (total DNA 1μg 
per 12 well). Each transfection condition was carried out in triplicate. 24 hours following 
stimulation with IFN cells were harvested in 1 x passive lysis buffer (Promega) and stored at ‐
20°C. For luciferase assays, the samples were thawed and aliquoted in technical duplicates 
for detection of firefly and renilla luciferase activity using the Dual‐Luciferase Reporter Assay 
kit using the GloMax luminometer to the manufacturer’s specifications (Promega). Promoter 
activity was determined by normalising firefly luciferase values to renilla luciferase values and 
expressed as relative light units (RLU).  
5.6.13 Immunofluorescence microscopy. Briefly, cells were grown in culture plates and fixed 
with ice‐cold acetone:methanol (1:1) for 10 minutes at 4 °C. After washing twice with PBS, 
samples were blocked with 5% BSA in PBS for 30 min at room temperature and incubated 
with primary antibody (for specific usage see Sup.) diluted in PBS/1% BSA for 1 h at room 
temperature. After washing twice with PBS, cells were incubated with Alexa Fluor‐conjugated 
secondary antibody diluted 1:200 in PBS/1%BSA for 1 h at 4 °C in the dark. Samples were then 
washed with PBS and incubated with DAPI (Sigma‐Aldrich, 1 μg/ml) for 5 min at room 
temperature. Samples were then washed with PBS. Images were then acquired using a Nikon 
TiE inverted fluorescent microscope. Contrast was applied using the ‘Autoscale’ function of 
NIS.  
5.6.14 Western blot for STAT1/STAT2 phosphorylation. HeLa cells were seeded in 6 well 
trays to be approximately 80 % confluent for transfections. Transfections of NS protein 
expression constructs or empty vector control were performed as previously described using 
lipofectamine 2000. 24 h post transfection HeLa cells were stimulated with type‐I IFN at the 
indicated concentrations, 30 minutes later protein was harvested in lysis buffer and left in the 
well on ice for 10 minutes prior to transfer into a new tube. Lysates were then homogenised 
by 10 passages through a 25 G needle prior to clearing cellular debris by centrifugation 
(16,000 RCF for 10 minutes at 4°C). Cleared lysate was diluted with reducing loading dye (3:4) 
and heated at 95 °C for 5 minutes prior to loading into SDS acrylamide gel and run for 90 
minutes. Separate gels were run for each protein of roughly the same molecular weight on 
the same day to prevent freeze / thaw degradation. Membrane transfer was done for 1 h in 
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cold transfer buffer. Primary antibodies were applied at 1: 1000 (or to the recommended 
dilution) overnight in 1 % skim milk at 4°C with agitation. The following day secondary HRP 
conjugated antibodies were applied to the manufacturers specification for 1 h at room 
temperature with agitation. SuperSignal™ West Femto Maximum Sensitivity Substrate 
(ThermoFisher) was used to detect HRP signal using the BioRad gel dock imager.  
5.6.15 Statistical analyses. For in vivo analysis of vaginal washes the ordinary two‐way 
ANOVA was used on log10 transformed data comparing independent time points. For qRT‐
PCR analysis of vRNA the ordinary one‐way ANOVA was used on log10 transformed data 
compared to wildtype. All graphing and statistical analyses were performed using GraphPad 
Prism 8.0. For in vitro experiments the analysis method is described in the figure legend.  
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5.7 Figures  
 
Figure 5.1: ZIKV replication is inhibited by IFNε in a mouse model of vaginal transmission. A) 
Experimental time‐line of WT (black), mice lacking IFNε (IFNε‐/‐) (red) or mice lacking the 
type‐I IFN receptor (IFNAR1‐/‐) (grey) were infected with ZIKV at 5 x 105 FFU iVag 5 days post 
DMPA treatment and vaginal washes were taken at 2, 5, 7 dpi. Groups of 8 mice were culled 
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at 5 dpi and 8 were culled at 7 dpi. B) Infectious virus was measured from vaginal washes by 
plaque assay at 2, 5, 7 dpi. C, D, E, F, G & H) Tissues taken at 5 dpi were used to harvest RNA 
for analysis of viral RNA by qRT‐PCR in the vagina, uterus, ovary, illiac lymph node spleen and 
brain respectively. I) IFNε‐/‐ mice were treated for 6h with either mIFNε or buffer prior to iVag 
infection with ZIKV, Infectious virus was measured from vaginal washes by plaque assay at 2 
and 5 dpi. J) IFNε‐/‐ mice were treated iVag with either mIFNε, mIFNλ2 or buffer for 6h prior 
to harvesting FRT tissues to determine the level of ISGs by qRT‐PCR. K) WT mice mice were 
treated for 6h with either IFNε neutralising antibody (α‐IFNε) or an isotype control (IgG) prior 
to iVag infection with ZIKV, Infectious virus was measured from vaginal washes by plaque 
assay at 2 and 5 dpi. Additionally, L) tissues taken at 5 dpi were used to harvest RNA for 























Figure 5.2: Ectocervical and Vaginal cell lines are permissive to ZIKV infection and treatment 
with IFNε is antiviral. A) Ect1 or VK2 cells were infected with ZIKV PRVABC59 at the indicated 
MOI for 24h prior to staining, anti‐flavi E staining (red), DAPI (blue). Ect1 or VK2 cells were 
treated overnight with 100 U/mL rhIFNε, rhIFNα‐2A then infected with MOI 10 or 5 
respectively for a further 48h prior to collecting supernatant and RNA for plaque assay (B & 
C) detection of infectious virus or qRT‐PCR detection (D & E) of vRNA. F & G) Ect1 or VK2 cells 
were treated overnight with 100 ng/mL rhFNλ‐III then infected with MOI 10 or 5 respectively 
for a further 48h prior to harvesting RNA for detection of vRNA by qRT‐PCR. Statistical 
analyses are performed by one‐way ANOVA compared to the untreated control (b‐e) or by 
two tailed t‐test (f &g), (n.s non‐significant, * P < 0.05, ** P < 0.01). Data are presented as 




Figure 5.3: IFNε displays typical type‐I IFN kinetics but induces an antiviral gene signature like 
IFNλ‐3 at early time points in ectocervical and vaginal cells.  Ect1 and VK2 cells were treated 
with IFNε, IFNα‐2a or IFNλ‐3 (100 ng/mL) or left untreated (n = 4) for 6hr prior to RNASeq 
analysis (NextSeq550 V2.5). Differentially expressed genes were determined with a 1.2‐fold 
cut‐off and adjusted p‐value < 0.05. A) Heat map showing expression of key ISGs. B, C & D) 
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Volcano plots indicating up or downregulation of genes after IFNα‐2a, IFNε or IFNλ‐3 
treatment, respectively.  E & F) Confirmation of anti‐ZIKV ISGs (ISG15, IFI6, IFITM1, Viperin) 
expression by qRT‐PCR. G & H) Confirmation of pro‐inflammatory ISGs (IRF1, CXCL10, CXCL11) 
expression by qRT‐PCR. I, J & K) Ect1 cells were treated with IFNε, IFNα‐2a or IFNλ‐3 (100 
ng/mL) and RNA was harvested from untreated cells (t = 0) and at the indicated time points 





























Figure 5.4: ZIKV evades type‐I and III IFN antiviral activity post‐infection. A) Timeline for IFN 
treatment regimes in HTR8 cells. B & C) HTR8 cells were infected with ZIKV PRVABC59 at a 
MOI of 1, cells were either primed with the indicated IFN (mIFNε 10 U/mL or hIFNα‐2A 500 
U/mL) or treated post infection. 48 hpi supernatants and RNA were harvested for 
determination of infectious virus by Focus Forming Assay or quantification of viral RNA by 
qRT‐PCR. D & E) HTR8 cells were infected with ZIKV PRVABC59 at a MOI of 1, cells were either 
primed for 24h with hIFN λ‐III (100 ng/mL) or treated post 24h post infection. Viral RNA and 
supernatant were collected 48hpi for determination of infectious virus by Focus Forming 
Assay or quantification of viral RNA by qRT‐PCR. Statistical analyses are performed by or one‐
way ANOVA compared to the untreated control, (n.s non‐significant, * P < 0.05, ** P < 0.01). 





Figure 5.5: Antiviral protection mediated by IFNε and other type‐I IFNs is potently inhibited 
due to ZIKV inhibition of STAT1/2 signalling. A & B) HeLa cells were infected with ZIKV MOI of 
10, 24h post infection cells were stimulated with mIFNε (10 U/mL) for 30 min then fixed with 
acetone/methanol for detection of ZIKV E antigen (Red) and phosphorylated STAT1 or STAT2 
proteins (Green) by indirect immunofluorescence, DAPI (Blue). C & D) HeLa cells were infected 
at the indicated MOI of ZIKV 24h prior to stimulation with the either mIFNε (10 U/mL) or 
hIFNα‐2A (500 U/mL) for 30 min, lysates were harvested for immunoblot of STAT1/2 protein 









Figure 5.6: Evasion of IFNε antiviral activity is mediated by ZIKV NS5 degradation of STAT2. A 
& B) HeLa cells were transfected with pCDNA6.2‐ZIKV‐NS5‐FLAG, NS2B/3‐FLAG or empty 
vector control and 24 h later stimulated for 30min with the indicated IFN prior to assessing 
total and phosphorylated STAT1/2 by immunoblotting. C) ISRE promoter activity was assessed 
following 24 h IFNε stimulation in the presence or absence of ZIKV NS5A expression. D) HeLa 
cells were transfected with pCDNA‐NS5‐FLAG expression plasmid or an empty vector control 
(EV), 24h post transfection cells were stimulated with the indicated type‐I IFN for 6 h prior to 






Figure 5.7: IFNε RNA expression is not reduced by ZIKV infection or NS protein expression. A) 
HeLa cells infected for 16h MOI 1 ZIKV PRV prior to stimulation with Poly I:C 1 µg for 8 h prior 
to assessing IFN gene induction by qRT‐PCR. B) HeLa cells were co‐transfected with expression 
plasmids encoding ZIKV NS1/2B/3/4A/5 or empty vector (pCDNA6.2) and the RIG‐I‐N plasmid 
or were mock transfected (Lipofectamine only), 24 h later RNA was harvested prior to 
assessing induction of type‐I and type‐III IFNs by qRT‐PCR. Statistical analyses are performed 
by two‐way ANOVA (a) or one‐way ANOVA compared to the empty vector control (b), (n.s 

































Characterising the regulation and intrinsic properties of IFNε in vitro 
 
6.1 Introduction 
As explored in the previous chapter, IFNε is a constitutively expressed type‐I IFN in the FRT 
that contributes to the local antiviral state and protects against ZIKV infection in mice and 
humans. In vivo expression patterns of IFNε indicate that it is predominantly controlled by 
changing levels of female sex hormones, Estrogen (E2) and Progesterone (P4), over the estrus 
or menstrual cycle and during pregnancy [105]. Accordingly, the proximal promoter of the 
gene that encodes IFNε (IFNe1) contains a putative response element for the Progesterone 
Receptor (PR) that is conserved between mice and humans [133]. The presence of this 
response element in the proximal promoter region suggests that the PR acts to directly 
control IFNe1 expression at the transcriptional level. Despite similarities in the proximal 
promoter of the mouse and human IFNe1 gene the expression pattern of IFNε in the FRT is 
different between these species. In mice, the levels of IFNε are highest during estrus (high E2, 
low P4) and are lowest during diestrus (low E2, high P4) [105]. These changes occur uniformly 
across the upper and lower reproductive tract (UFRT and LFRT). However, in humans the 
levels of IFNε are increased during the luteal phase (mid E2, high P4) and are reduced in the 
follicular phase (increasing E2, low P4) of the menstrual cycle [253]. These changes in humans 
occur only in the UFRT, whereas the LFRT maintains high levels of IFNε protein regardless of 
cycle stage [253]. These unexplained differences between expression of IFNε in mice and 
humans highlights how little is known about the regulation of this important antiviral 
cytokine. In general, hormonal control of gene expression is notoriously complex. For 
example, E2 and P4 are steroid hormones that primarily act through their cognate steroid 
nuclear hormone receptors. For E2 these are estrogen receptor‐α (ERα) and ERβ, transcribed 
from two separate genes [91]. P4 also has two nuclear receptor isoforms called PRA and PRB, 
encoded as long and short transcripts from the same gene [160]. Receptor subtypes have 
distinct and overlapping expression patterns, display differential gene activation and many of 
their physiological roles are poorly understood [91]. Gene expression in response to P4 is 
further complicated by the direct transcriptional control of both PRA and PRB by the ERs and 
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the hormonal environment of the FRT [160]. In addition to the hormonal control of IFNε there 
are other factors including seminal plasma [316] and TNFα [210] detailed in the Introduction 
(section 1.2.2.2) that can alter expression of IFNε at the RNA level. Currently the molecular 
mechanisms, signalling pathways, transcription factors and interactions between competing 
stimuli that govern IFNε expressed are unknown. In addition to stimuli normally present in 
the FRT, the impact of ZIKV infection on the expression of IFNε is poorly defined. ZIKV has 
evolved multiple evasion strategies to effectively restrict the production of other type‐I and 
III IFNs in response to viral infection [176, 200]. Since IFNε protects against ZIKV when 
administered prophylactically (chapter 5), the question remains if ZIKV has evolved strategies 
to evade the constitutive expression of this key antiviral cytokine in the human FRT. Viral 
evasion of constitutively expressed IFN is not unprecedented, as human papillomavirus (HPV) 
can dampen IFNκ constitutively expressed by keratinocytes of the skin [282]. Understanding 
the pathways that regulate IFNε will underpin its clinical use and improve existing in vivo 
model systems. Currently there is a lack of in vitro model systems that recapitulate 
endogenous IFNε expression patterns. Establishing in vitro model systems would enhance our 
capacity to dissect the pathways that govern IFNε expression at the molecular level. As a 
result, this chapter aims to establish in vitro models of endogenous IFNε expression and 
regulation. 
Another poorly understood aspect of IFNε biology is its ability to signal constitutively in vivo. 
Chapter 5 demonstrated that FRT cell lines displayed transient gene induction kinetics in 
response to a single treatment of IFNε. In a similar pattern to other type‐I IFNs [98], these 
cells displayed high levels of ISG induction in response to IFNε at early time points that waned 
by 24 h post stimulation. This pattern of expression is indicative of negative regulation of the 
pathway. As detailed in the Introduction (section 1.2.2.1.2) there are several ways the type‐I 
IFN pathway can be switched off. Two main mechanisms involve the accumulation of the 
regulatory ISGs, SOCS1 and USP18. Whereas SOCS1 inhibition is short lived and is responsible 
for rapidly returning ISG expression to baseline [322], USP18 mediated desensitization can 
last days [100]. Importantly, the effect of USP18 mediated desensitization on IFNAR1/2 
dependent signalling is observed in cells responding to IFNα, but not to IFNβ in vitro [99]. This 
differential signalling property is driven by IFNβs higher affinity for the IFNAR1 receptor 
subunit compared to IFNα [369]. This higher affinity interaction facilitates the formation of 
the ternary receptor‐ligand complex despite the presence of USP18, that otherwise 
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destabilises the complex [369]. Notably, IFNε shares greater sequence homology with IFNβ 
than IFNα [133]. Furthermore, the ratio of affinity for IFNε binding to each individual receptor 
subunit closely resembles that of IFNβ (these interactions are summarised in the introduction 
Figure 1.11). Specifically, IFNε has a high affinity for IFNAR1 and a weaker binding affinity for 
IFNAR2 compared to IFNα [134]. Together this information suggests that IFNε may signal via 
the IFNAR1/2 receptor constitutively despite the presence of IFN induced USP18 expression. 
Understanding this aspect of IFNε biology is important as it may change our understanding of 
viral infections of the FRT. For example, if cells responding to IFNε in the FRT become 
desensitized over a long period they may remain vulnerable to infection even when IFNε 
levels are high. Alternatively, if cells can respond to IFNε via the IFNε‐IFNAR1/2 receptor 
complex in the presence of USP18 then they may be constitutively protected against 
infection. Collectively, this Chapter investigates models of endogenous IFNε regulation and 
demonstrates preliminary results indicating that IFNε can signal constitutively in vitro.  
 
6.2 Results 
6.2.1 Cell lines of FRT origin express high levels of IFNε RNA  
The first step in establishing an in vitro model of endogenous IFNε regulation was to find cell 
line that naturally express IFNε mRNA. To this end the basal level of IFNε mRNA was compared 
between cell lines of non‐FRT and FRT origin by qRT‐PCR. Figure 6.1a shows the expression 
level of IFNε mRNA in Huh7 (liver), Ishikawa (endometrial adenocarcinoma), HTR8 
(transformed primary placental trophoblast) and HeLa (cervical adenocarcinoma) cell lines. 
As expected Huh7 cells expressed the lowest amount of IFNε mRNA. This coincides with other 
reports finding little to no IFNε expression in the liver [133, 145]. Comparatively, cell lines 
from FRT origin had greater levels of IFNε mRNA. HeLa cells expressed the greatest levels of 
IFNε followed by HTR8 and then Ishikawa cells. Because these cell lines were derived from 
adenocarcinomas or the placenta and are not normally present in the FRT it was important to 
compare the expression of IFNε mRNA in more relevant FRT cell lines. To address this need, 
the basal level of IFNε mRNA was compared between HeLa cells and Ect1 (ectocervical), or 
VK2 (vaginal keratinocyte) primary transformed cells [96] by qRT‐PCR. Figure 6.1b shows that 
both Ect1 and VK2 cells expressed high levels of IFNε mRNA that were comparable to those 
observed in HeLa cells. Together this data confirmed the cell type specific expression of IFNε. 






are cell type specific. Additionally, this data demonstrates that HeLa, Ect1 and VK2 cells 
express high levels of IFNε mRNA relative to other cell lines of FRT and non‐FRT origin. These 
cell lines may prove to be useful to investigate endogenous regulation of IFNε.  
 
6.2.2 Primary transformed FRT cell lines express high basal levels of ISGs 
After determining cell lines that express high levels of IFNε mRNA it was important to 
determine if this mRNA was translated into functional protein, as there are post‐
transcriptional controls in place for IFNε protein expression. For example, one study found 
that protein expression of IFNε was limited by the molecular transporter Importin 9 [211]. In 
this study, Importin 9 was found to associate with the 5’ UTR of IFNε mRNA, preventing its 
translation into functional protein in HeLa cells at a basal state. Currently, there are no 
commercially available antibodies to detect endogenous IFNε protein. Therefore, measuring 
the downstream effect of IFNε on ISG expression was used as an indirect method of assessing 
protein function. In theory, if IFNε protein was produced by these cells, the basal levels of ISG 
expression would increase due to autocrine signalling. To test this hypothesis, we first 
compared the baseline levels of a commonly upregulated ISG (ISG15) between Huh7, HeLa, 
Ect1 and VK2 cells by qRT‐PCR. Interestingly, both Ect1 and VK2 cells but not HeLa cells had 
significantly higher basal levels of ISG15 compared to Huh7 cells (Figure 6.2a). This supports 
the possibility that IFNε is translated into functional protein in Ect1 and VK2 cells. To extend 
these observations, the levels of multiple ISGs were assessed in these cells both at baseline 
and in response to a 6h treatment with 1000 U/mL of IFNα. Figure 6.2 shows that both Ect1 
(Fig. 6.2c) and VK2 cells (Fig. 6.2d) displayed higher basal levels of the ISGs MX1 and ISG15 
compared to HeLa cells (6.2b). In addition, VK2 cells displayed higher basal levels of IFITM1. 
This correlates with previous studies demonstrating some cells of epithelial origin have 
increased basal expression of the IFITM family proteins [19]. Moreover, these cells increased 
ISG expression in response to IFNα treatment, confirming the ability of both Ect1 and VK2 
cells to respond to type‐I IFN. Together this data supports that Ect1 and VK2 cells may produce 
functional IFNε protein, that can act in autocrine by increasing the basal levels of ISGs. In 
correlation with the higher basal level of ISGs observed in these cells, Ect1 and VK2 cells were 
less permissive to infection compared to HeLa cells. Figure 6.3 shows the level of ZIKV 
infection by staining for cells expressing ZIKV E‐protein (red) at 24 hpi by 









infection followed by VK2 and HeLa cells, respectively. Together this suggests that Ect1 and 
VK2 are less permissive to ZIKV infection, potentially due to their higher baseline expression 
of ISGs compared to other cell lines. In turn, it is possible that the higher basal level of ISG 
expression observed in these cells is driven by endogenous expression of IFNε protein. 
However, this experimental model does not rule out intrinsic differences in gene expression 
that are independent from expression of IFNε protein. 
 
6.2.3 Huh7 cells upregulate expression of ISGs in response to Ect1 cell culture supernatant 
Next, to determine if any potential IFNε expressed by these cells could regulate ISG 
expression, in the absence of intrinsic cell line differences, it was logical to assess the antiviral 
properties of supernatant from these FRT cells. This is because any prospective IFNε protein 
produced by FRT cells may display paracrine activity on another cell line. However, it has been 
demonstrated that IFNε protein is inefficiently secreted from cells compared to other type‐I 
IFNs [145]. This study found that poor secretion was a result of inefficient cleavage of the IFNε 
protein signal peptide in fibroblast cell lines. Importantly, this indicates the paracrine antiviral 
activity of IFNε protein may be limited in cell culture. To investigate any potential paracrine 
activity from cell culture supernatant we utilised the Huh7 cells that have a low baseline levels 
of IFNε and ISG mRNA expression but can respond to type‐I IFN. Huh7 cells were treated for 
6h with concentrated Ect1 culture supernatant (Ect1 SN) as described in Materials and 
Methods (section 2.2.8), similarly concentrated Huh7 supernatant (H7 SN), or similarly 
concentrated Keratinocyte Serum Free Media (KSFM) as controls prior to harvesting total RNA 
to detect expression of ISGs by qRT‐PCR. Huh7 cells were also treated with 100 U/mL of IFNα 
as to confirm these cells were IFN responsive. Figure 6.4a shows that in response to Ect1 
supernatant, Huh7 cells significantly increased the expression of ISG15 compared to H7 SN, 
or KSFM treated controls. Although this was only a small increase (3‐fold compared to H7 SN 
treated Huh7 cells) it should be noted that treatment with 100 U/mL of IFNα only resulted in 
a modest induction at this time point. Additionally, while the difference in Viperin expression 
was non‐significant a similar trend was observed for the Ect1 supernatant treated cells (Figure 
6.4b). To confirm this observation a dual luciferase assay was used to determine ISRE 
promoter activity in response to an 8h treatment of Ect1 supernatant. Figure 6.5 showed a 
small but significant increase in the levels of ISRE promoter activity in response to Ect1 









Although this experimental model does not preclude other immune effector molecules that 
may be present in Ect1 cell supernatant, the data supports the possibility of functional IFNε 
protein that is secreted by Ect1 cells that can act in paracrine to upregulate ISG expression.  
 
6.2.4 Transfection of siRNA targeting IFNε does not alter the levels of endogenous IFNε RNA, 
ISG expression, or ZIKV infection in Ect1 cells 
To establish a direct link between Ect1 IFNε mRNA expression with protein function, attempts 
were made to knockdown IFNε expression by an siRNA‐mediated knockdown approach. A 
pooled siRNA that specifically targeted 4 different sites of the IFNε mRNA (Dharmacon) was 
introduced into cells by transfection using RNAiMAX (Invitrogen) as outlined in the Materials 
and Methods (section 2.2.7). To confirm the activity of the siRNA, a CMV promoter IFNε‐FLAG 
expression construct was used for simple detection of exogenous IFNε protein expression (see 
Appendix VII for sequence details). The IFNε‐FLAG expression construct was introduced into 
HeLa (Figure 6.6a) or Ect1 cells (Figure 6.6b) by transfection (Lipofectamine 2000) 6 h prior to 
siRNA transfection (RNAiMAX) with a non‐targeting control (NTC) or the pooled IFNε siRNA 
reagent. Following siRNA transfection, cells were fixed at 24 h or 48 h for detection of 
exogenous IFNε protein levels by immunofluorescence using an anti‐FLAG antibody. Figures 
6.6a & b show that exogenously expressed IFNε‐FLAG protein was reduced in both HeLa and 
Ect1 at 24 and 48 h post transfection compared to NTC. This confirmed the ability of the siRNA 
pool to knockdown IFNε protein expression. Next, the effect of IFNε siRNA knockdown on 
endogenous expression was assessed in Ect1 cells. Figure 6.7 shows the level of IFNε (Fig. 
6.7a) and downstream ISGs mRNAs (Fig. 6.7b & c) following transfection of IFNε siRNA for 24, 
48 and 72 h by qRT‐PCR. Unexpectedly, in contrast to the efficient knockdown observed for 
IFNε‐FLAG protein no difference was observed in the levels of endogenous IFNε mRNA or 
downstream ISGs (ISG15 and MX1) in IFNε siRNA compared to NTC transfected cells. This 
result was consistent between two independent experiments. Notably, siRNAs can act by 
reducing translation of protein without impacting of mRNA stability [42]. Therefore, it was 
possible that the siRNA reduced endogenous IFNε protein without an observed effect on 
mRNA levels. In an attempt to measure functional changes to IFNε expression in response to 
siRNA knockdown, the relative permissiveness of Ect1 cells to ZIKV infection was assessed. If 
IFNε protein was expressed and siRNA knockdown was able to reduce IFNε protein levels one 









showed there was no significant difference in ZIKV infection in IFNε siRNA compared to NTC 
transfected Ect1 cells. This result was consistent with the level of ZIKV RNA detected by qRT‐
PCR (Fig. 6.8a) and the frequency of infected cells detected by immunofluorescence (Fig. 
6.8b). Collectively these results did not confirm the expression of IFNε protein by Ect1 cells. 
This may indicate that IFNε protein is not expressed in these cells, and that the higher basal 
level of ISGs and antiviral activity previously observed resulted from unrelated factors. 
Alternatively, it is possible that the siRNA was able to efficiently knockdown exogenous 
protein expression but not the endogenous expression of IFNε mRNA or protein. 
Unfortunately, this limited the use of Ect1 cells as an in vitro model to observe changes in 
IFNε expression at the mRNA level.  
 
6.2.5 IFNε RNA is regulated by progesterone in vitro  
Despite not confirming the expression of endogenous IFNε protein in Ect1 cells, these and 
other cell lines may be used to assess transcriptional control of IFNε mRNA expression. This 
was significant, as currently there is limited understanding of endogenous IFNε expression 
control in relevant FRT cell lines (see section 1.2.2.2.2 for a review of the current literature). 
Therefore, the level of IFNε mRNA expression in response to progesterone (P4) was assessed 
in FRT cell lines. P4 was chosen because it purportedly acts as the main regulator of IFNε 
transcription in vivo. Each HeLa, HTR8, Ect1 and VK2 cells (Figures 6.9a, b, c & d respectively) 
were treated with 10 μM of P4 or vehicle control diluted in fresh media for 24 h and the level 
of IFNε mRNA was observed by qRT‐PCR. Interestingly, we saw differing effects of P4 
treatments on the level of IFNε mRNA that were cell line dependent. Both HeLa and HTR8 
cells significantly reduced expression of IFNε mRNA in response to P4, correlating with 
previous reports using an IFNε promoter reporter assay in ECC1 cells [253]. Unexpectedly, the 
opposite effect was observed in both Ect1 and VK2 cells that significantly increased the level 
of IFNε mRNA in response to P4 treatment. However, both Ect1 and VK2 cell lines are derived 
from the LFRT (ectocervix and vagina). As noted in the chapter 6 introduction, the in vivo 
expression pattern of IFNε differs between the upper and lower FRT. Therefore, this 
observation may be a genuine effect of P4 transcriptional control in isolated primary 
transformed cell lines that is representative of human LFRT expression patterns in vivo. One 
hypothesis explaining the observed difference in IFNε regulation between cell lines in 









receptor isoforms. To determine if the observed differences in IFNε mRNA regulation were 
due to differing expression of PR isoforms, primers specific to the long (PRB) and short (PRA) 
isoform of the PR were used in qRT‐PCR on these samples (see Appendix I for sequences). 
Unfortunately, neither primer set was able to amplify the PRA or PRB isoform and displayed 
poor melt curves indicating non‐specific amplification (data not shown). This data confirms 
that P4 influences endogenous IFNε expression at the mRNA level. However, the mechanism 
that drives this effect appears to be cell type specific and may rely on the expression of 
different PR isoforms. Future investigation into the impact of different PR isoforms on IFNε 
expression would be required to confirm this conjecture. 
 
6.2.6 The constitutive expression of IFNε RNA is not altered by ZIKV infection in FRT cell 
lines  
Aside from regulation by P4, ZIKV infection may alter the constitutive expression of IFNε. The 
majority of RNA viruses, including ZIKV, can induce IFN expression but also limit the 
production of other type‐I and III IFNs by inhibiting pathways downstream of PRR activation. 
Specifically, ZIKV NS4A is shown to inhibit RLR signalling by preventing MAVS activation [200]. 
Additionally, NS1 inhibits IRF3 phosphorylation by preventing TBK1 activation [176]. NS5 also 
inhibits TBK1 and IRF3 activation [189, 375]. In chapter 5 we demonstrated that ZIKV infection 
or individually expressed viral proteins did not alter IFNε mRNA levels in HeLa cells. To extend 
these observations to primary transformed cells, Ect1 and VK2 cells were infected with ZIKV 
at increasing MOI or mock infected for 24 h prior to harvesting RNA to detect the levels of 
IFNε, IFNβ or IFNλI genes by qRT‐PCR. Figure 6.10a & b showed that IFNε remained highly 
expressed irrespective of ZIKV infection. This contrasts with IFNβ and IFNλ‐I that displayed 
low basal levels of mRNA expression in uninfected cells compared to IFNε. This data agrees 
with the lower level of other type‐I and III IFN expression compared to IFNε observed in 
biopsies from the vagina, ectocervix and endometrial tissue of healthy women in previous 
studies [253]. In contrast to IFNε, the levels of IFNβ and IFNλ‐I expression were upregulated 
in response to ZIKV infection suggesting that ZIKV does not entirely block PRR‐mediated IFN 
production in these FRT cell lines. Comparatively, ZIKV infection does not reduce the 
constitutive expression of IFNε in FRT cell lines at the mRNA level. This highlights the unique 
position of IFNε being present prior to infection compared to other type‐I and III IFNs that are 






as in vitro model systems that allow monitoring of endogenous IFNε expression levels. Despite 
not detecting expression of endogenous protein, these cell lines have shown promise in 
observing changes to IFNε expression at the mRNA level. Further characterization of these 
models, including determining the PR isoforms present and their effect on IFNε expression in 
these cell lines, would improve these models for future use.  
 
6.2.7 Human recombinant IFNε is resistant to long-term receptor desensitization compared 
to IFNα in vitro 
Another unanswered question regarding IFNε biology is the mechanism underlying its 
constitutive activity in vivo. In the previous chapter, it was demonstrated that gene induction 
in response to a single treatment of IFNε is subject to short‐term negative regulation, 
returning ISG expression to baseline 24 h post‐stimulus. However, it is unknown if IFNε is 
regulated by long‐term receptor desensitization mediated by the ISG USP18 like the related 
IFNα. To begin investigations into this novel line of enquiry, an assay that measures receptor 
desensitization was developed based on the seminal work by Francois‐Newton et al. on 
USP18 mediated receptor desensitization of IFNα [99]. Because of the limited supply of 
human recombinant IFNε protein this assay was optimised using readily available sources of 
IFNα and IFNβ (see Materials and Methods section 2.2.1 for details). Figure 6.11a outlines the 
timeline for this experiment. HeLa cells were either left untreated (naïve) or treated with IFNα 
(primed) for 8 h to induce expression of the negative regulator USP18. Figure 6.11b confirms 
that after 8 h of priming with IFNα, USP18 expression was upregulated compared to naïve 
cells by qRT‐PCR. Following priming, the IFN stimulus was removed by washing and the cells 
were returned to culture overnight. During this resting phase, the level of receptor activation 
was allowed to return to baseline. Following overnight culture, naïve or primed cells were 
introduced to a booster treatment of either IFNα or IFNβ at 800 U/mL. 30 minutes afterwards 
cellular protein was harvested for western blot analysis to detect STAT1 and STAT2 protein 
phosphorylation status downstream of receptor activation. Figure 6.11c compares the levels 
of STAT1 and STAT2 phosphorylation between naïve and primed cells following a booster 
treatment with IFNα or IFNβ. Naïve cells responded robustly to both IFNα and IFNβ (lane 2 
and 3) by increased levels of STAT phosphorylation compared to untreated cells (lane 1). 
However, in response to IFNα the levels of STAT1 and STAT2 phosphorylation in primed cells 






response to IFNβ the levels of STAT1 and STAT2 phosphorylation were enhanced in primed 
cells (lane 6) compared to the response in naïve cells (lane 3). The increase in STAT 
phosphorylation observed in primed cells when treated with IFNβ was likely a combined result 
of increased STAT1 and STAT2 protein expression and insensitivity to USP18 mediated 
desensitization. Importantly, these results are consistent with previous findings that IFNα but 
not IFNβ signalling is impacted by the build‐up of long‐term negative regulators such as USP18 
leading to receptor desensitization over this time period [99]. After validating an assay that 
compared susceptibility of different IFN subtypes to long‐term receptor desensitization, this 
was applied to assess the properties of IFNε. Figure 6.12a shows the experimental timeline. 
The protocol for priming and resting cells was maintained but in this experiment two booster 
treatment concentrations (100 and 600 U/mL) of IFNα, IFNβ or human recombinant IFNε were 
tested to see if the observed effect was consistent at lower concentrations. The results are 
shown in Figure 6.12b. Naïve cells responded to both concentrations of IFNα, IFNβ and IFNε 
booster treatments (Lanes 2‐7) as indicated by robust STAT1 and STAT2 phosphorylation 
compared to untreated cells (Lane 1). As observed previously, the response to IFNα in primed 
cells was weaker than that of naïve cells (Lanes 2,3 compared to Lanes 9,10), implying 
desensitization. Both IFNβ treatments displayed increased levels of STAT phosphorylation 
after priming compared to naïve cells, indicating resistance to desensitization (Lanes 4,5 
compared to Lanes 11,12). Interestingly, both treatments of IFNε were resistant to this effect 
of desensitization (lanes 6,7 compared to lanes 13,14) as indicated by greater levels of 
STAT1/2 phosphorylation in primed cells compared to naïve cells, like the observed result for 
IFNβ. This data implies that the human IFNε protein is resistant to long‐term receptor 
desensitization like IFNβ. Importantly, this data provides preliminary evidence suggesting that 
IFNε can signal constitutively via the type‐I IFN receptor. This finding has implications for the 














As the most recently discovered member of the type‐I IFN family less is known about the 
endogenous regulation and signalling properties of IFNε compared to the canonical examples 
IFNα and IFNβ. IFNε is a unique type‐I IFN because it is constitutively expressed in the FRT and 
is regulated by female sex hormones rather than by viral recognition [105]. These unique 
aspects of IFNε’s biology raise questions surrounding the mechanisms that govern its 
expression and signalling properties despite negative regulation of the type‐I IFN pathway. 
This chapter aimed to address these unknowns, first by attempting to validate a cell culture 
model of endogenous IFNε expression and by investigating the effect of IFN‐induced receptor 
desensitization on IFNε signal transduction in vitro.  
Initially, to validate a cell culture model of IFNε expression, cell lines were identified that 
expressed high levels of IFNε mRNA. In accordance with previous in vivo studies of IFNε 
expression patterns, cell lines of FRT origin were found to express high levels of IFNε mRNA 
[133, 145]. The cell lines expressing the highest level of IFNε mRNA were HeLa (cervical 
adenocarcinoma), Ect1 (ectocervical primary transformed) and VK2 (vaginal keratinocyte 
primary transformed) cells. For isolated cells in culture to maintain IFNε expression patterns 
outside of the structural and hormonal environment of the FRT indicates there are cell 
intrinsic regulation mechanisms imposed on IFNε expression. This supports the concept that 
IFNε evolved to be specifically expressed by cells at mucosal surfaces, such as the FRT, that 
are at increased risk of encountering pathogens. This unique and deliberate expression 
pattern implies IFNε plays a non‐redundant role as a type‐I IFN in specific biological contexts 
and tissue locations. In apparent contrast, genetics studies on whole populations have found 
that the IFNe1 gene displays high rates of homozygous nonsense mutations, suggesting a level 
of functional redundancy and an evolutionary shift towards pseudogenization [203]. 
However, this study did not divide the cohort into population subsets, including not 
differentiating based on gender. Therefore, it is possible IFNε may be non‐redundant within 
subsets of the population, such as in women but not in men, suggesting an evolutionarily 
refined role. Further studies into the tissue specific expression of IFNε and the genetic 
constraints especially comparing between men and women would be an interesting line of 
enquiry shedding light on its evolutionary role.  
After identifying cells expressing high levels of IFNε mRNA attempts were made to 
characterize whether this was expressed as functional protein. Interestingly, Ect1 and VK2 
205 
 
cells displayed elevated levels of ISGs, both at baseline and in response to stimulation with 
IFNα compared to HeLa cells. This elevated level of ISG expression was inversely correlated 
with permissiveness to ZIKV infection. Additionally, Ect1 cell supernatant demonstrated an 
ability to stimulate low levels of ISG expression when applied in‐trans to non‐FRT cells. 
Collectively this data provided circumstantial evidence that primary transformed FRT cells 
may produce and secrete functional IFNε protein. This data is in line with IFNε protein acting 
to initiate a low level of “tonic” pathway activation that protects the mucosal epithelium and 
adjacent tissues against viral infection in vivo (chapter 5). Currently, the concept of tonic 
signalling by type‐I IFNs is limited to IFNβ. Studies have demonstrated the presence of 
constitutive IFNβ expression at levels below assay detection in healthy animals [117]. This 
constitutive expression is important for maintaining a basal level of IFN‐inducible signalling 
intermediaries such the STAT proteins [116]. Importantly, cells lacking constitutive IFNβ are 
more susceptible and have diminished innate responses to viral infections [268]. Currently, 
the importance of constitutively expressed IFNε and its potential role in tonic IFN signalling in 
the FRT has not been explored.  
To address this dearth of information an attempt was made to link the elevated levels of ISG 
expression in Ect1 cells to IFNε directly by siRNA mediated gene silencing. Unfortunately, 
despite observing efficient knockdown of overexpressed IFNε protein no reduction of 
endogenous IFNε expression was characterized at the mRNA level, or via an effect on 
downstream ISG expression and antiviral activity. Failure to detect the expected reduction in 
IFNε expression or activity was likely caused by one of two reasons. Firstly, that a mechanism 
unrelated to endogenous IFNε expression was responsible for the observed heightened ISG 
expression and antiviral effect in Ect1 cells. Another possibility is that siRNA knockdown was 
inefficient at reducing endogenous IFNε expression compared to overexpressed protein. One 
theory explaining the latter cause may be due to differences in the abundance of mRNA 
expressed from the endogenous promoter compared to the IFNε‐FLAG expression construct. 
This is because siRNA knockdown of gene expression is most effective on highly expressed 
transcripts [151]. Therefore, overexpressed IFNε‐FLAG RNA may have been more susceptible 
to siRNA knockdown compared to endogenous IFNε transcripts. Continuing this line of 
enquiry would be greatly assisted by the development of new tools and antibodies to study 
this novel type‐I IFN. In future, to directly compare the effect of endogenous IFNε expression 
on the basal levels of ISGs would require generating an IFNε knockout Ect1 cell line using 
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CRISPR gene editing technology. Alternatively, murine FRT cells could be isolated from WT 
and IFNε‐/‐ mice and used to a similar effect. Overall, these experiments have left an 
unanswered question regarding the importance of IFNε in tonic signalling in Ect1 cells.  
Despite an inability to detect changes in IFNε protein and downstream signalling, progress 
was made using these cell lines to characterize responses at the transcriptional level. Here it 
was shown that various cell lines (HTR8, HeLa, Ect1 and VK2) responded differently to 
stimulation by P4 in their regulation of IFNε expression levels. Interestingly, primary 
transformed cell lines derived from LFRT tissues increased expression of IFNε mRNA in 
response to P4. This result was counterintuitive based on data in mice showing low levels of 
IFNε in response to diestrus (high P4, low E2) [105], and previous promoter assays in ECC1 
cells [253]. However, one study in humans found differences in IFNε regulation between the 
upper and lower FRT. In particular, this study demonstrated a stronger correlation between 
IFNε expression with levels of the level of the PR rather than the P4 hormone [253]. As 
mentioned previously, the levels of PRA and PRB are also hormonally regulated. Currently it 
is unknown how the expression and regulation of different PR isoforms by the hormonal 
environment and other competing stimuli impacts upon IFNε expression levels. To address 
this unknown, primers specific to both isoforms of the PR were used to assess their levels in 
different cell lines in response to P4 treatment. Unfortunately, these primers were not able 
to efficiently amplify PR isoform transcripts by qRT‐PCR. In the future, characterization of 
expression of PR isoforms, how they are altered in response to different hormone 
environments and if this is correlated with IFNε expression in vitro and in vivo would be 
valuable in understanding the hormonal regulation of IFNε in more detail.    
After confirming that endogenous IFNε mRNA levels are regulated in response to 
environmental stimuli, the impact of ZIKV infection on IFNε constitutive expression was 
investigated in FRT cell lines. This data adds to the results from chapter 5 that showed ZIKV 
infection or NS protein expression did not alter IFNε expression in HeLa cells. Ect1 and VK2 
primary transformed cells are likely a better model of endogenous IFNε expression as they 
closely resemble normal FRT cell function [96] and are not cancer derived lines that often 
have different signalling capabilities [313]. Using these cell culture models it was confirmed 
that ZIKV infection did not alter (reduce or increase) the constitutive expression of IFNε at the 
mRNA level. The inability of ZIKV to evade IFNε production agrees with the observed antiviral 
effect of constitutively expressed IFNε in wildtype mice (chapter 5, Fig. 5.1) and extends these 
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observations to human cell lines. Furthermore, the lack of virus mediated induction of IFNε 
expression confirms the absence of response elements downstream of PRR signalling 
pathways in the IFNe1 gene promoter [133]. This unique characteristic of IFNε to be 
constitutively expressed in cells of the FRT during viral infection contrasts with other type‐I 
and III IFNs. The basal levels of IFNβ or IFNλI mRNA were consistently lower than IFNε in FRT 
cell lines. However, the expression of IFNβ and IFNλI was induced by ZIKV infection indicating 
that PRR‐mediated signalling is not fully blocked by ZIKV NS‐protein expression in these cells 
at this time point. This incomplete blockade of PRR‐mediated signalling by ZIKV infection likely 
reflects the inbuilt redundancy of multiple PRR pathways to sense infection and implies that 
viral NS‐protein mediated inhibition of IFN production (as seen in chapter 5, Fig. 5.7) has 
evolved to reduce or delay rather than completely block IFN production in humans. This 
contrasts with the stark inhibition downstream of IFNAR1/2 receptor activation mediated by 
ZIKV NS5 that almost completely ablates the effect of type‐I IFN treatment in vitro (chapter 5, 
Fig. 5.5 and Fig. 5.6). Collectively, this ability of ZIKV to delay PRR‐mediated IFN production 
and then to block IFN‐mediated signalling highlights the importance of priming cells with IFN 
prior to infection. Collectively, this suggests that prophylactic expression of IFNε may 
significantly contribute to anti‐ZIKV protection in the human FRT.  
The constitutive expression of IFNε makes it unique amongst other IFNs. To date, research 
surrounding this unique IFN has implicitly assumed that IFNε is able to signal via the IFNAR1/2 
receptor constitutively. This would offer comprehensive protection to cells in the FRT to viral 
infection. However, the constitutive activity of IFNε contrasts the classical model of type‐I IFN 
signalling, whereby the signal leads to accumulation of negative regulators that switch off the 
response and prevent overt immune activation [70]. In the previous chapter it was 
demonstrated that a single dose of IFNε led to transient induction of ISGs implying the 
pathway was susceptible to short‐term negative regulation. However, it remained to be seen 
if this effect translated to long‐term receptor desensitization, as previously observed for type‐
I IFNα [95, 99]. Alternatively, more recent modelling has demonstrated that type‐I IFNβ 
present at low levels is able to constitutively induce “tonic” levels of ISGs that are required to 
mount an effective immune response to viruses [217]. Correlating with this activity, IFNβ 
signal transduction is not dependent on USP18 receptor desensitization [99]. Furthermore, 
these differing susceptibilities to long‐term receptor desensitization have been linked to 
these IFNs differential receptor binding kinetics to the individual subunits of the IFNAR1/2 
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receptor [369]. For the first time, the ability of IFNε to signal constitutively via the IFNAR1/2 
receptor despite accumulation of long‐term negative regulators was demonstrated with 
experimental evidence. This preliminary data supports the potential of an evolved link 
between the unusual receptor binding kinetics of IFNε with its unique biological properties. It 
would be valuable in future to extend these observations to effects on long term downstream 
ISG expression. Additionally, this model could be improved by repeating these experiments 
in cell lines that express USP18 in an IFN‐independent manner, directly linking this effect to 
the long‐term negative regulator. Moreover, molecular modelling to compare receptor 
dimerization upon binding of IFNε, IFNβ or IFNα in the presence or absence of USP18 should 
be conducted. These experiments could be modelled on the fluorescence‐based co‐
locomotion assays used by Wilmes et. al to determine the frequency of IFNAR1/IFNAR2 




IFNε is unique amongst the type‐I IFNs, most prominently because of its constitutive 
hormonally regulated expression. As a result, there is limited information regarding the 
mechanisms that govern its expression. Additionally, as the most recently discovered member 
of the family questions remain about the fundamental biology of this IFN such as how it can 
signal constitutively. In response to these gaps in knowledge, the aim of this chapter was to 
find models of endogenous regulation of IFNε expression and to determine its constitutive 
signalling properties in vitro. Cell lines of FRT origin were identified that express high levels of 
IFNε RNA. Accordingly, primary transformed FRT cell lines were found to have heightened 
basal expression of ISGs and intrinsic antiviral activity. However, due to the inability to 
monitor changes in endogenous IFNε mRNA or protein expression following siRNA 
knockdown it remains unclear if these properties are directly linked to these cell lines 
expressing functional IFNε protein. Despite being unable to confirm IFNε protein expression 
in these cells, these in vitro models were used to assess the impact of P4 on IFNε RNA 
expression. This led to the novel finding of cell lines responding differently to this 
environmental stimulus, opening discussion on further research into the impact of PR 
isoforms on IFNε expression. These cells were also used to confirm that ZIKV is unable to 
evade the constitutive production of IFNε RNA in human cell lines. This was an important 
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finding for future infection modelling experiments. Together these results have made 
headway into uncovering useful in vitro model systems to easily assess the impact of 
competing stimuli on IFNε expression. Future advances in this line of enquiry would benefit 
greatly from the development of commercially available antibodies to detect endogenous 
IFNε protein expression in cell culture. Moreover, for the first‐time experimental evidence 
demonstrated that IFNε can signal independently of long‐term receptor desensitization. This 
is likely a result of the unique binding characteristics of IFNε for the individual subunits of the 
IFNAR1/2 receptor, leading to USP18 insensitivity. Future experiments to confirm a direct link 
between USP18 expression and IFNε’s signalling properties would provide valuable insights 
























Conclusions and Future Directions 
Dengue virus (DENV) and Zika virus (ZIKV) are two closely related flaviviruses that infect 
humans. Although most infections are asymptomatic, these viruses can cause severe life 
threatening or debilitating disease. DENV has the greatest disease burden of all flaviviruses, 
infecting more than 390 million people and causing approximately 21,000 deaths annually 
[127]. Comparatively, ZIKV causes far fewer deaths but infection during pregnancy can result 
in foetal infection, early pregnancy loss, or developmental and neurological impairment in 
newborns [53]. To date there are no specific antiviral treatments or approved vaccines for 
ZIKV [365], and the approved vaccine for DENV (Dengvaxia®) has continuing issues 
surrounding safety and applicability for high‐risk groups [364]. The lack of effective 
treatments and vaccines for these viruses places the burden of controlling infection directly 
on the individual host immune response. Type‐I IFNs are a crucial host front‐line immune 
defence that protect against a broad range of viral pathogens. The IFNs are normally produced 
in response to sensing viral infection within cells [175]. Once secreted from infected cells 
these antiviral cytokines bind their cognate receptor to induce expression of hundreds of ISGs, 
including some that directly inhibit ZIKV and DENV replication such as Viperin [141, 354], 
ISG15 [64, 327] and members of the IFITM family [157, 300]. Aside from their direct antiviral 
roles, several ISGs regulate the innate and adaptive immune responses, giving rise to an 
appropriately managed antiviral state [305]. To counter the potent antiviral activity mediated 
by the IFNs, most, if not all, viruses have evolved ways to overcome this response. 
Consequently, viral evasion of the IFN pathway directly underpins the ability of these viruses 
to cause infection and disease. Likewise, to counter viral evasion the host must utilize the IFN 
response with the right spatiotemporal controls to bring infection under control whilst 
limiting damage to host tissues. This balance between viral immune evasion and an effectively 
managed innate immune response often determines the outcome of disease for the host. 
This thesis aimed to enhance our understanding of the molecular mechanisms that govern 
the interactions between the host innate immune response and these flaviviruses from the 
perspective of both the virus and of the host. It is hoped that an improved understanding of 
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these interactions will aid in the design of new therapeutics or vaccines that can shift the 
balance in favour of the host immune response and help to prevent disease.  
As detailed in Chapter 1, flaviviruses such as ZIKV and DENV have evolved a complex web of 
molecular interactions to undermine both the production and downstream signalling of the 
IFNs. Some of these mechanisms have been characterized [52]. However, to date most studies 
investigating mechanisms of innate immune evasion by ZIKV and DENV have relied on 
overexpressed viral proteins or genetic elements. Importantly the functions of individually 
expressed viral proteins are often not representative of their role within the complete virus 
lifecycle [167]. As a result, we hypothesized that the ZIKV and DENV genomes contain 
undiscovered regions that encode type‐I IFN response evasion mechanism. To test this 
hypothesis, in chapter 3 and 4 of this thesis, we aimed to perform genome‐wide mutational 
studies in the context of the full virus lifecycle to uncover novel evasion mechanisms used by 
ZIKV and DENV to counter the type‐I IFN response. The methodology for this work was 
preceded by a genome‐wide mutagenesis screen performed by Qi et al. to detect novel HCV 
IFN evasion mechanisms [274]. This study utilized the MuA transposon mutagenesis method 
to create an HCV mutant library that was selected for in conditions with or without exogenous 
IFN treatment (IFNα IC50, 1 U/mL), revealing novel mutations that conferred IFN 
hypersensitivity and, by inference, viral determinants of IFN resistance. Accordingly, to 
address our aim the MuA transposon mutagenesis approach was applied initially to a ZIKV 
infectious clone (pZIKV‐ICD). The results of chapter 3 revealed major challenges associated 
with instability and recombination of the ZIKV clone within bacteria indicating that this 
infectious clone was unsuitable for high‐throughput mutagenesis approaches that require the 
use of bacteria for plasmid propagation. Unfortunately, approximately 90% of the mutant 
clones in the final transposon library displayed large deletions of viral sequences due to 
bacterial recombination, resulting in non‐functional clones and reducing the theoretical 
coverage of mutations across the genome to numbers below those that are practical or 
meaningful for this type of study [94, 104, 274]. Despite multiple attempts to correct this 
issue, this project was deemed unviable for the timeframe. Within the field, multiple studies 
have reported that cloned Flavivirus genomes are toxic in bacteria due to the presence of 
cryptic bacterial promoters and are unstable due to the presence of highly repetitive 
sequences [17]. Interestingly however, during the course of this thesis an identical 
mutagenesis approach was successfully applied to a ZIKV infectious clone harbouring the 
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historical African strain MR766 [104]. Importantly, there is approximately 10% sequence 
divergence at the nucleotide level between the MR766 strain compared to the Paraiba_2015 
strain used in this thesis to [389]. This level of sequence divergence is sufficient to account 
for phenotypic differences in viral replication observed by us (Figure 3.2) and others [9, 319] 
in various cell lines. The data from chapter 3 implies that this sequence divergence may also 
be responsible for the differing stability of these infectious clones in bacteria. Further 
evidence supporting this theory was given by the MR766 infectious clone being stable with 
only a single chimeric intron [309], as opposed to the two required to generate the original 
full‐length pZIKV‐ICD clone in bacteria [350]. This suggests that the Paraiba_2015 strain 
sequence incorporated in the pZIKV‐ICD clone may be inherently less stable compared to the 
MR766 strain in bacteria. At the time of writing, other infectious clones have become 
available for multiple different strains of ZIKV [49, 74, 241, 311]. It is possible that one of these 
clones may be better suited to the MuA transposon mutagenesis method. Aside from using a 
different infectious clone system, future attempts to apply this method to the ZIKV genome 
would benefit from bacteria‐free cloning methods. This approach would negate the impact of 
toxicity of viral sequences in bacteria and therefore reduce recombination of the final mutant 
library [17]. Individually mutagenized viral genome segments could then be used to generate 
full‐length sequence by methods such as circular polymerase extension reaction (CPER) [311] 
or in vitro ligation approaches [74] to generate full‐length ZIKV mutant libraries. Collectively, 
this data highlights the importance of selecting highly stable infectious clones for use in high‐
throughput mutagenesis approaches.  
To substitute for the ZIKV mutant library, a DENV MuA transposon mutant library was 
repurposed for the screen. This mutant library was pre‐selected based on replication 
competence and ability to produce infectious virus in a previous screen by Eyre et al. [94]. 
This library was then further selected and screened for relative sensitivity to type‐I IFN. The 
results of chapter 4 showed selection of the library was achieved using a pre‐treatment of 1 
U/mL of IFNα (Figure 4.3). NGS analysis of the selected mutant library generated a functional 
map of the DENV genome, highlighting regions likely to confer IFN evasion (Figure 4.4). Based 
on this functional map, several specific mutations were selected to test their ability to encode 
an IFN hypersensitive phenotype. These included two promising hits at nucleotide positions 
8069 and 8077 within the MTase domain of NS5. To our surprise, the results of chapter 4 
revealed that none of these mutations were able to confer IFN hypersensitivity when 
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introduced into the genome of the parent DENV2 strain (Figures 4.9, 4.10 & 4.11). We 
hypothesized that these unexpected results were due to naturally occurring mutations that 
accumulated after multiple passages and confounded the apparent impact of individual 
transposon insertions. These mutations, if present, most likely arose during high MOI 
passages that facilitated co‐infection and complementation of mutant viral genomes, leading 
to accumulated compensatory mutations [109]. Evidence supporting this hypothesis is 
provided by an alanine scanning DENV2 mutant screen. In this screen, trans‐complementation 
using heterologously expressed wildtype NS2 protein allowed compensatory mutations to 
accumulate after only three passages on the same cells [372]. These compensatory mutations 
were shown to rescue deleterious mutations introduced within the NS2 region. As detailed in 
Chapter 4, testing this theory for deleterious mutations occurring within the NS5 MTase 
domain would require the development of a stable DENV replicon cell line because the MTase 
domain of NS5 cannot be trans‐complemented by individual protein overexpression [83, 167]. 
Additionally, in future studies compensatory mutations could be detected using long‐read 
sequencing technology [205]. Other approaches to improve whole‐genome high‐throughput 
screening of RNA virus genomes relate to reducing the likelihood of accumulated mutations. 
This could be achieved by reducing the number of passages, limiting the rate of co‐infection 
by controlling MOI and increasing selection pressure on the virus population when 
performing screens [109]. One point of interest arising from this Chapter was the discovery 
of a synthetically introduced SNP at nucleotide position 10476 in the 3’UTR that conferred a 
weak IFN hypersensitive phenotype. Analysis determined this SNP occurred within a 
conserved loop of DB1 within the 3’UTR that was important for both vRNA replication [67] 
and inhibition of the IFN response via generation of sfRNAs [51]. Despite not aiming to detect 
this mutation as part of the transposon insertion screen it would be interesting in future to 
independently characterize the impact of this mutation on DENV IFN sensitivity. Currently, 
DENV sfRNA is known to inhibit IFN production downstream of RIG‐I by binding to the RIG‐I 
translocase protein TRIM25 [202]. However, our screen circumvented the RIG‐I pathway by 
applying exogenous IFN treatment directly to cells. Interestingly, mutations in the 3’ UTR of 
WNV are also known to confer an IFN hypersensitive phenotype downstream of the activated 
type‐I IFN receptor [307]. Currently the mechanism underlying WNV sfRNA‐mediated evasion 
of type‐I IFN signalling has not yet been elucidated. Importantly our data indicates the DENV 
3’ UTR not only inhibits signalling downstream of RIG‐I, but that like WNV, it also inhibits 
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downstream of IFNAR1/2 receptor activation, shifting our current understanding of DENV 
UTR‐mediated evasion. The mechanism of DENV sfRNA mediated evasion of IFNAR1/2 
signalling may be common amongst flaviviruses (such as WNV) or may have a different 
mechanism of action. Future experiments to validate and determine the mechanism whereby 
this SNP confers IFN hypersensitivity are required. These experiments could include 
generating individually expressed 3’UTR mutant constructs for DENV, WNV and ZIKV. These 
constructs could then be used to determine the impact that these mutations have on ISG 
expression and the phosphorylation status and/or stability of signalling intermediaries 
downstream of type‐I IFN receptor activation compared to WT sfRNA. This hypothesis could 
be further explored by generating an SNP mutant library targeting the 3’ UTR using error‐
prone PCR methods and screening in conditions with and without IFN to determine if other 
mutations in these RNA structures confer similar phenotypes. Indeed, this deep‐mutational 
scanning approach was successfully performed by Du et al. (2017) on the Influenza H1N1 
genome [84]. In this study a SNP mutant library was generated by error prone PCR on small 
240 segments of the influenza genome. The library of H1N1 mutants were then passaged in 
A549 cells with or without exogenous IFN treatment (IFNα at IC80). Deep sequencing (Illumina 
PE250) revealed specific mutations within NS1 that had reduced fitness under IFN treated 
conditions. More recently, another study utilized a cDNA mutant library containing 
synthetically engineered mutations representing all possible codon substitutions in the C‐
terminal of the ZIKV E‐protein [312]. This library was selected in mammalian or mosquito cells 
leading to the discovery of mutations conferring host‐specific adaptations. This study utilized 
barcoded sub‐amplicon sequencing coupled to the Illumina MiSeq v3.2 platform. Importantly, 
this method led to discovery of strains that were attenuated in mouse models of infection. 
Both studies exemplify the future of functional screening under selection conditions. New 
technology such as improved error prone PCR methods, lower costs of synthetic DNA 
generation and new sequencing technologies are shifting this field towards mutational 
studies that resolve to the individual nucleotide level. In combination, although the MuA 
transposon mutagenesis approach to screening was unsuccessful at discovering novel IFN 
evasion mechanisms for ZIKV or DENV, this information contributes to the body of knowledge 




On the other side of the evolutionary arms race, the host has evolved multiple families and 
subtypes of IFNs (see introduction section 1.1.2) to control viral infection in a range of 
biological contexts. Typically, the classical type‐I IFNs like IFNα and IFNβ are produced in 
response PRR detection [214]. The ubiquitous expression of the IFNAR1/2 receptor allows the 
type‐I IFNs to protect against both local and systemic viral infections [214]. Aside from the 
broad acting IFNα and IFNβ, other IFNs have evolved to contribute towards local protection 
in tissues with a higher risk of infection [203]. These include the type‐III IFNs that act almost 
exclusively on epithelial cells at mucosal surfaces due to the restricted expression of IFNLR1 
receptor subunit [143]. Type‐III IFNs are the first IFNs produced by infected epithelial cells 
[254] and provide localized antiviral protection without causing overt inflammation at 
mucosal surfaces in tissues such as the lung [66, 98, 182]. Therefore, it has been proposed by 
others that type‐III IFNs protect at the site of infection while having minimal impact on 
mucosal barrier integrity, preventing pathogens from entering more distant tissues [182]. 
However, as is the case for IFNα and IFNβ, expression of type‐III IFNs is reliant on pathogen 
detection [182]. Also, there is conflicting evidence regarding the impact of type‐III IFN on 
inflammation in different biological contexts. Type‐III IFNs appear to limit inflammation in the 
lung and in the gut [50, 66]. However, studies in both mice [113] and humans [190] link type‐
III IFNs to immune dysregulation in systemic lupus erythematosus via promoting 
inflammatory cytokine release from skin and kidney keratinocytes. Importantly, the impact 
that type‐III IFNs have on inflammatory pathways in the FRT are not yet understood.   
Another example of a specialized, locally acting IFN is IFNε. IFNε is a type‐I IFN produced 
primarily by the mucosal epithelium of the FRT in both mice and humans [105, 133]. Whereas 
other type‐I and type‐III IFNs are produced in response to viral infection, IFNε is unique 
because it is constitutively expressed in the FRT where it maintains a basal level of ISG 
expression and can protect against STIs [105]. For example, IFNε protects against HSV 
infection in the FRT of mice [105]. Furthermore, IFNε inhibits multiple steps of the HIV lifecycle 
in cell culture [110]. It is now known that ZIKV preferentially infects the FRT and it is capable 
of transmitting sexually even in asymptomatic cases [101]. Additionally, ZIKV evades both the 
production and downstream signalling of the classical type‐I and III IFNs due to the combined 
actions of multiple viral NS proteins (detailed in the introduction section 1.3 and reviewed in 
[52]). Coupled with the fact that the most severe foetal pathologies of ZIKV infection occur 
via infection of the FRT [288], we propose that the constitutive expression of IFNε may be 
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especially important for the host to control ZIKV infection in this biological niche. Therefore, 
we aimed to investigate the antiviral properties of IFNε and determine if it controls ZIKV 
infection in the FRT. The results of chapter 5 revealed that IFNε is unequivocally important to 
protect the FRT from viral infection. Endogenous IFNε expression significantly limited viral 
infection in WT mice compared to IFNε‐/‐ mice (Figure 5.1a ‐ h). Complementary experiments 
demonstrated the prophylactic potential of IFNε by iVag administration of exogenous rIFNε 
protein (Figure 5.1i ‐ J). In FRT cell lines we showed that IFNε induced a gene profile involving 
hundreds of ISGs that protected against ZIKV infection when administered prior to infection 
(Figure 5.2 & 5.3). Interestingly our RNAseq analysis and ISG induction kinetics assays showed 
that IFNε induced lower levels of pro‐inflammatory genes such as the transcription factor 
IRF1, and chemokines CXCL10 and CXCL11 compared to those induced by other type‐I and III 
IFNs at an early time point (6 h) and over an extended timeframe (4 ‐ 24 h). Interestingly, 
however, the antiviral response to IFNε treatment was dampened by ZIKV NS5‐mediated 
evasion to a similar degree to that of IFNα when administered post‐infection (Figure 5.5 & 
5.6). Conversely, the constitutive expression of IFNε was impervious to ZIKV NS4A‐, NS1‐ and 
NS5‐mediated inhibition, that delayed the production of other type‐I and III IFNs downstream 
of activated RIG‐I (Figure 5.7). Collectively, this data highlights the prophylactic potential of 
constitutively expressed IFNε in protecting the FRT from ZIKV sexual transmission, as it is the 
only type‐I or III IFN expressed prior to infection in the non‐pregnant human FRT [253]. This 
finding adds to our understanding of FRT immunobiology. The current model of immunity in 
the FRT implies that host‐mediated viral defences are organised into tiers that are activated 
in a distinct, sequential order. The first tier is comprised of the physical defences of the 
mucosal epithelium lining the upper and lower FRT. These defences include secreted mucus, 
commensal bacteria, low pH, the LFRT stratified epithelium and UFRT epithelial tight‐
junctions [317]. Collectively, the mucosal epithelium acts as a continuous physical barrier that 
non‐specifically impedes pathogen access to target cells and deeper tissues [321, 370]. If 
viruses overcome this first layer and colonize cells of the mucosal epithelium, they are 
recognized by PRRs, activating the second tier of innate immune defence [317]. PRRs that 
sense RNA viral pathogens (RLRs, TLRs) are expressed in cells of both the upper and lower FRT 
in humans [111, 135]. Viral recognition leads to the secretion of classical type‐I and III IFNs 
and other key cytokines or chemokines that have direct antiviral effects, cause inflammation 
and mediate immune cell activation and recruitment to the site of infection [317]. If viral 
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pathogens are not cleared by innate defences, the adaptive immune response is initiated and 
modulated by the innate immune response as the third tier of defence to control infection. 
Clearly, this archetypic model of immune protection is ineffective for viral infections like ZIKV 
that preferentially infect the mucosa of the FRT and efficiently evade IFN responses [41, 152]. 
Studies in mice [164] and humans [152] show that PRR‐mediated IFN production is delayed 
during ZIKV infection, including in the FRT. This delay likely facilitates the persistence of ZIKV 
in the FRT [63]. However, our data challenges this established view of FRT immunobiology, 
shifting it away from a reliance on reactionary responses (such as by other type‐I and type‐III 
IFNs) to one of pre‐emptive protection against viral infection. IFNε uniquely activates a pre‐
emptive immunological barrier to infection with both direct antiviral and immune modulatory 
functions. Our data implies that without endogenous IFNε in the human FRT, ZIKV sexual and 
in utero transmission may be even more prevalent. Studies investigating the expression of 
IFNε in the FRT of ZIKV infected patients could help to clarify the importance of IFNε.  
So far, our research has not addressed the antiviral potential of IFNε in the context of 
pregnancy. This will be an important avenue of research in the future because ZIKV infection 
can cross the placenta and cause birth defects [53]. Studies in humans [250] and mice [105] 
show that the levels of IFNε increase during the late stages of pregnancy. Furthermore, HSV 
infection during pregnancy in humans correlates to lower levels of IFNε compared to those of 
healthy women [250]. Collectively, this data implies that IFNε plays an important antiviral role 
in the context of pregnancy. Currently, there are conflicting views on the role of type‐I IFN 
during pregnancy. Type‐I IFNs are thought to play an essential role during the early stages of 
pregnancy following implantation. In both humans and mice type‐I IFNα is upregulated during 
early pregnancy [46]. Additionally, mice lacking the type‐I IFN receptor have abnormal 
pregnancy‐associated changes to the spiral arterioles, suggesting that this pathway is 
important for development of the early maternal decidua [237]. Moreover, functional type‐I 
IFN signalling can protect both the mother and foetus from viral infection during pregnancy. 
In vivo infection modelling has shown that pregnant IFNAR1‐/‐ mice have a greater 
susceptibility to Herpes Virus (MHV68) infection [276]. This led to greater levels of virus in 
maternal circulation, in the placenta and in the foetal compartment of these mice compared 
to WT counterparts. Similar results were seen for ZIKV infected pregnant mice [221]. In this 
study ZIKV infection in IFNAR1‐/‐ mothers led to greater levels of viral infection, more severe 
placental damage and increased frequencies of foetal demise compared to WT mice. 
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Moreover, IFNα treatment trialled in human pregnancies for women with essential 
thrombocythemia was well‐tolerated and did not alter the rate of miscarriage beyond the 
population average [22, 378]. Conversely, overactive type‐I IFN responses are known to have 
detrimental outcomes in pregnancy. For example, genetic deficiencies in the type‐I IFN 
negative regulator USP18 can lead to interferonopathy, foetal brain damage and pseudo‐
TORCH syndrome in humans [218]. Additionally, high levels of IFNβ induced by TLR4 in 
response to bacterial LPS can lead to foetal demise in mouse models [178]. Similarly, pregnant 
IFNAR1‐/‐ mice mated to immune competent IFNAR1+/+ males that were challenged with ZIKV 
displayed increased resorption in the presence of functional type‐I IFN signalling in the foetal 
compartment (IFNAR1+/‐) compared to IFNAR1‐/‐ littermates [383]. Collectively these studies 
imply there is a time, a place, and an extent of IFN signalling that is beneficial in protecting 
against infection and promoting healthy pregnancy. 
In light of the above data, other studies have proposed that type‐III IFNs would provide safer 
protection during pregnancy against ZIKV infections due to their reduced capacity to incite 
general inflammation in other tissues such as the lung [66, 98, 182].  Evidence supporting this 
theory was provided by investigations involving a non‐pregnant mouse model. In this study 
IFNLR1 KO mice were more susceptible to ZIKV infection in the LFRT [36]. However, this effect 
was mostly lost in UFRT tissues, the site where trans‐placental infection occurs. Additionally, 
studies have found that isolated primary human trophoblasts [21] and mid‐gestation 
organotypic placental explants [57] constitutively release type‐III IFNs that protect against 
ZIKV infection. However, this effect has not yet been confirmed in the hormonal and tissue 
micro‐environment of natural pregnancy. Moreover, our data (Figure 5.3k) indicated that 
type‐III IFN treatment induced greater expression of the inflammatory cytokine CXCL10 over 
a 24 h period in FRT epithelial cells compared to IFNε treatment that was applied at the same 
concentration of protein. Combined with ZIKV‐mediated evasion of type‐III IFN production, 
this suggests that further investigation into the importance of type‐III IFN protecting against 
ZIKV infection in pregnancy are required to support these assertions. Collectively, this data 
suggests that because IFNε is present during normal pregnancy and has a lower propensity to 
incite inflammation in FRT epithelial cells, it may be the most appropriate IFN to be explored 
as a therapeutic agent regarding safety and efficacy to prevent ZIKV infections in pregnancy. 
Testing this theory would require modelling iVag ZIKV infection during pregnancy and 
comparing infection outcomes between WT, IFNε‐/‐, IFNAR1‐/‐ and IFNLR‐/‐ mice. Further 
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experiments could use iVag treatment with recombinant IFNε or IFNλ during different stages 
of pregnancy in mice to compare their impact on tissue inflammation and normal pregnancy. 
In humans, the immune environment of the UFRT and LFRT are controlled hormonally, by 
damage signals and by recognition of foreign agents like viruses, sperm or the semi‐allogenic 
foetus [317]. These alterations to the immune environment are essential to support the 
normal biological functions of the FRT [382]. IFNε expression is also controlled by hormones, 
semen and other immune modulatory molecules like TNFα [105, 210, 316]. As a newly 
discovered IFN, less is known about the basic biology that allows IFNε to function 
constitutively without adverse effects in this biologically important tissue. The inter‐
relatedness of competing stimuli, the biological properties of IFNε, and their intersection with 
the normal reproductive process are not well characterised. This is in part due to a lack of in 
vitro models that recapitulate human IFNε expression patterns, and this concept was explored 
in chapter 6. Here we developed in vitro models that allowed observation of IFNε regulation 
at the RNA level in response to progesterone (Figure 6.9). This was a significant issue to 
address because previous studies that have investigated progesterone‐mediated IFNε 
regulation have only examined in vivo expression patterns or utilized promoter reporter assay 
systems [105, 253]. These studies were limited by the inability to control for multiple 
competing stimuli within a complex living system and by our current limited understanding of 
the IFNε gene promoter, respectively. Additionally, our in vitro models were used to 
demonstrate that ZIKV infection did not alter the expression of IFNε (Figure 6.11). With 
further optimization our in vitro model systems can serve as tools to complement in vivo and 
patient studies on IFNε expression. These models will improve our ability to dissect the 
pathways, transcription factors and promoter elements that control IFNε expression. 
Collectively this data highlights the importance of the unique properties of IFNε, shedding 
light on its evolved function to protect against viral infection in the FRT. In future, these 
models could be applied to investigate other stimuli that regulate IFNε expression at the RNA 
level. This could include investigation of the effects of combinations of hormones that better 
reflect the complex hormonal environments of the menstrual cycle or pregnancy. Likewise, 
investigation of the impact of hormonal contraceptives on expression of IFNε would be an 
important future avenue of research. If IFNε is regulated by hormonal contraceptives, this 
may help to explain observations that such contraceptives alter the permissiveness of the FRT 
to other viral infections like HIV [154]. Additionally, chromatin immunoprecipitation (ChIP) 
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assays combined with mass spectroscopy could be used to determine the transcription factors 
and promoter elements that are important for the regulation of IFNε expression in the context 
of different stimuli.  
Additionally, this thesis provided preliminary evidence that IFNε signals constitutively via the 
IFNAR1/2 receptor, giving insight into the unique biological properties that allow it to protect 
the FRT from viral infection. This was a significant finding because signalling induced by 
canonical type‐I IFNα is switched off by negative feedback loops involving the SOCS and USP18 
proteins. Unlike the short‐lived receptor desensitization that is mediated by SOCS proteins 
[322], USP18 desensitization is sustained over several days [99]. Importantly this has 
implications for the usage of IFNα as an antiviral therapy because USP18‐mediated receptor 
desensitization leads to unresponsiveness to prolonged IFNα treatment in mice [299]. 
Conversely, IFNβ can signal constitutively despite USP18‐mediated desensitization [99] and 
shares greater sequence homology to IFNε than to IFNα [133]. Here we demonstrated for the 
first time that unlike IFNα, recombinant IFNε activates the type‐I IFN receptor in cells that 
were primed with IFN over an extended period (Figure 6.13). This data highlights the 
importance of the evolutionary closeness of IFNε with IFNβ, that both signal constitutively via 
the IFNAR1/2 receptor. Interestingly, there is growing evidence that IFNβ is responsible for 
inducing basal levels of ISGs in healthy animal models, similar to the role of IFNε in the FRT of 
mice [105, 117]. Notably, these and other distinct functional properties of IFNβ have been 
linked to the higher binding affinity of IFNβ to the type‐I IFN receptor, and especially to the 
IFNAR1 subunit of the receptor complex [71, 369]. This higher affinity binding by IFNβ to the 
IFNAR1 subunit promotes the formation of ligand‐IFNAR1/2 complexes despite expression of 
USP18, that otherwise destabilises the signalling complex when weaker interactions are in 
effect [100, 369]. Although IFNε is roughly 1000‐fold less potent than IFNβ in both mice and 
humans [134, 335], IFNε has a similar affinity ratio for binding to the individual IFNAR1 and 
IFNAR2 subunits as compared to those of IFNβ [134, 179]. Therefore, our preliminary findings 
lead to the hypothesis that IFNε has evolved unique binding affinities to the IFNAR1/2 
receptor subunits thereby allowing its constitutive, low potency signalling in the FRT which 
leads to a basal antiviral state with limited induction of damaging inflammation. A graphical 
model of this working hypothesis, that ties together experimental observations from chapters 
5 and 6, is presented in Figure 7.1. Future studies to develop this hypothesis could involve 





independent of other upregulated ISGs. Additionally, molecular modelling to compare 
IFNAR1/2 receptor dimerization upon binding of IFNε, IFNβ or IFNα in the presence or 
absence of USP18 should be conducted to further explore the mechanism of receptor 
engagement and stability of receptor complexes for IFNε compared to IFNβ or IFNα [369]. 
Furthermore, the impact of sustained iVag treatment with IFNε, IFNβ, IFNα and IFNλ should 
be compared in mice to measure ISG profile, IFN induced desensitization and to compare the 
level of inflammatory pathway activation in the FRT. Collectively, this could clarify the relative 
impact of these IFNs on FRT antiviral immunity and tissue inflammation in the context of 
constitutive pathway activation.  
In summary, genome‐wide mutational analysis was used as a tool to study the molecular 
aspects of viral IFN evasion. Despite not finding novel ZIKV‐ or DENV‐mediated innate immune 
evasion mechanisms by this method, unintentionally a SNP within the DB1 region of the 3’ 
UTR of the DENV genome was found to confer a weak IFN hypersensitive phenotype. The 
findings of our screen and the recommendations arising from this thesis will contribute 
towards future studies using deep‐mutational screening of viral genomes under various 
innate immune selection conditions. Additionally, we have shown that constitutively 
expressed IFNε prophylactically protects the FRT from ZIKV infection. This finding has shifted 
the paradigm of antiviral protection of the FRT, demonstrating that constitutive protection, 
rather than reactionary IFN responses, can effectively protect against ZIKV sexual 
transmission. We have shown that the antiviral protection afforded by IFNε is able to 
circumvent ZIKV IFN evasion via its unique constitutive expression that is not dependent on 
viral recognition pathways unlike other type‐I and III IFNs. When combined with the ability of 
IFNε to signal constitutively via the IFNAR1/2 receptor this allows IFNε to support a basal 
antiviral state in the FRT that protects against ZIKV infection. Collectively, this project has 
made progress in characterizing the molecular interactions of the host innate immune 
response with two globally significant flaviviruses in relevant physiological contexts on both 











Appendix I: Primer sequences used in this thesis 
 
qRT-PCR primer sequences (F, forward, R, reverse) 
Gene/Target Sequence (5’ to 3’) 
36B4 or RPLP0 (mouse and human) F – AGA TGC AGC AGA TCC GCA T 
R – GGA TGG CCT TGC GCA  
Human IFNε F – TCA GCC TCT TCA GGG CAA ATA 
R – GAG GAA TTT CTC CGT GTG GTT T  
Human IFNβ  F – GCA GTC TGC ACC TGA AAA GAT ATT 
R – TGT ACT CCT TGG CCT TGA GGT A 
Human IFNλ1 F – GGA AGA GTC ACT CAA GCT GAA AAA C 
R – AGA AGC CTC AGG TCC CAA TTC 
Human IFNλ2‐3 F – CAG CTG CAG GTG AGG GA 
R – GCG GTG GCC TCC AGA ACC TT 
Human ISG15  F – TGG CGG GCA ACG AAT T 
R – GGG TGA TCT GCG CCT TCA 
Human IFIT1 F – AAC TTA ATG CAG GAA GAA CAT GAC AA 
R – CTG CCA GTC TGC CCA TGT G 
Human Viperin F – GTG AGC AAT GGA AGC CTG ATC 
R – GCT GTC ACA GGA GAT AGC GA 
Human CXCL10 (IP‐10) F – TCC ACG TGT TGA GAT CAT TGC 
R – TCT TGA TGG CCT TCG ATT CTG 
Human CXCL11 F – CCT TGG CTG TGA TAT TGT GTG C 
R – CCA CTT TCA CTG CTT TTA CCC C 
Human IRF1 F – CCA GCC CTG ATA CCT TCT CTG A 
R – AAG TCC TGC ATG TAG CCT GGA A 
Human IFI6  F – CTG AAG ATT GCT TCT CTT CTC 
R – CAC TTT TTC TTA CCT GCC TC 
Human PR isoform A (KiCqStart™ Primers, Sigma Aldrich) F – GCA TGA TCT TGT CAA ACA AC 
R – TCT GGA AAT TCA ACA CTC AG 
Human PR isoform B (KiCqStart™ Primers, Sigma Aldrich) F – ATT CAC TTT TTC ACC AGG TC 
R – AAC CTG GCA ATG ATT TAG AC 
Murine IFNε F – GAA ACG GAT TCC CTT CCA AT 
R – ACT GCT GGA CTG ACG AGC TT 
Murine IFNα F – CTG CCT GAA GGA CAG GAA GG 
R – GTC ATT GAG CTG CTG GTG GA 
Murine IFNβ F – AGA AAG GAC GAA CAT TCG GAA A 




Gibson assembly primers for subcloning mutations into the pUC57-BmtI-AvrII-NS5-s.m 









(used to digest 
vector) 
Gibson Assembly Primer Sequence (5’-3’) 
(complementary overhang in lower case) 
8077 pUC57‐NS5 PstI/ClaI F ‐ atgtcaacatatgggtggaatctAGTGCGTCTGCAGAG 
R‐ gctcgtaagtggctttcttgtatctcATTGTAAATCGATTGATCAACATCC 
8086 pUC57‐NS5 PstI/ClaI F ‐ atgtcaacatatgggtggaatctAGTGCGTCTGCAGAG 
R‐ gctcgtaagtggctttcttgtatctcATTGTAAATCGATTGATCAACATCC 
 
Gibson assembly primers for subcloning mutations into the pFK-DVs destination vector 
(F,forward, R, reverse) 
Mutation Insert 
position  
OR Wildtype silent 






(used to digest 
vector) 
Gibson Assembly Primer Sequence (5’-3’) 
(complementary overhang in lower case) 
UTR‐WT‐s.m pUC57‐UTR AvrII/XbaI F‐tgtggcttggagcacgcttcttagagtTTGAAGCCCTAGGATTCTTAAATGAAG 
R‐ aagaattgaattaaccctcactaaaggGACTAGTTCTAGAACCTGTTGATTCAAC 
9795 pUC57‐UTR AvrII/XbaI F‐tgtggcttggagcacgcttcttagagtTTGAAGCCCTAGGATTCTTAAATGAAG 
R‐ aagaattgaattaaccctcactaaaggGACTAGTTCTAGAACCTGTTGATTCAAC 
10297 pUC57‐UTR AvrII/XbaI F‐tgtggcttggagcacgcttcttagagtTTGAAGCCCTAGGATTCTTAAATGAAG 
R‐ aagaattgaattaaccctcactaaaggGACTAGTTCTAGAACCTGTTGATTCAAC 
10388 pUC57‐UTR AvrII/XbaI F‐tgtggcttggagcacgcttcttagagtTTGAAGCCCTAGGATTCTTAAATGAAG 
Murine IFNλ2 F – CCA CAT TGC TCA GTT CAA GTC TCT 
R – TCC TTC TCA AGC AGC CTC TTC T 
Murine ISG15 F – GGG GCC ACA GCA ACA TCT AT 
R – AGC CAG AAC TGG TCT TCG TG 
Murine IFIT1  F – TGG CGT AGA CAA AGC TCT TCA TC 
R – TAG CAG AGC CCT TTT TGA TAA TGT AA 
Murine Viperin F – TTG GGC AAG CTT GTG AGA TTC 
R – TGA ACC ATC TCT CCT GGA TAA GG 
Murine HPRT F – AAG CTT GCT GGT GAA AAG GA 
R – TTG CGC TCA TCT TAG GCT TT 
Murine CXCL10 F – ATG ACG GGC CAG TGA GAA TG 
R – ATG ATC TCA ACA CGT GGG CA 
ZIKV PRVABC59 – prM specific  F – GTG TGA TGC CAC CAT GAG CTA 




NS5‐WT‐s.m pUC57‐NS5 BmtI/AvrII F‐ atgaccctgggaatgtgctgcatAATCACGGCTAGCATCCTC 
R‐ ctctctggagaaccagtgatcttcattTAAGAATCCTAGGGCTTCAAACTC 
8069 pUC57‐NS5 BmtI/AvrII F‐ atgaccctgggaatgtgctgcatAATCACGGCTAGCATCCTC 
R‐ ctctctggagaaccagtgatcttcattTAAGAATCCTAGGGCTTCAAACTC 
8077 pUC57‐NS5 BmtI/AvrII F‐ atgaccctgggaatgtgctgcatAATCACGGCTAGCATCCTC 
R‐  ctctctggagaaccagtgatcttcattTAAGAATCCTAGGGCTTCAAACTC 
8086 pUC57‐NS5 BmtI/AvrII F‐ atgaccctgggaatgtgctgcatAATCACGGCTAGCATCCTC 
R‐ ctctctggagaaccagtgatcttcattTAAGAATCCTAGGGCTTCAAACTC 
 
Primers used to clone ZIKV NS-FLAG sequences from the pZIKV-ICD clone into the pcDNA6.2 
expression vector between the XbaI and PmeI restriction sites by Gibson Assembly (F, 
forward, R, reverse) 
NS protein Primers (3’ - 5’) 
NS1 F – ACCGATCCAGCCTCCGGACTCTAGAatggatgtggggtgctc 
R‐ TCAGTTAGCCTCCCCCGTTTAAACTTACTTGTCGTCATCGTCTTTGTAGTCtgcagtcaccactg 
NS2B3 F – ACCGATCCAGCCTCCGGACTCTAGAatgagctggcccccta 
R ‐ TCAGTTAGCCTCCCCCGTTTAAACTTACTTGTCGTCATCGTCTTTGTAGTCtcttttcccagcgg 
NS4A F – ACCGATCCAGCCTCCGGACTCTAGAatgggagcggcttttgg 
R ‐ TCAGTTAGCCTCCCCCGTTTAAACTTACTTGTCGTCATCGTCTTTGTAGTCtctttgcttttctggctca 
NS5 F – GGGACCGATCCAGCCTCCGGACTCTAGAATGgggggtggaacag 
R ‐ GTTTCAGTTAGCCTCCCCCGTTTAAACTTACTTGTCGTCATCGTCTTTGTAGTCcagcactccaggtg 
 
 
Primers used for amplifying full-length DENV2 sequence for NGS application 
Primer Name Primer Sequence (5’-3’) 
DV2NGS1F   agttgttagtctacgtggaccg 
DV2NGS1R   cgaatggaggttctgcttctatgt 
DV2NGS2F   gcagaaacacaacatggaacaatag 
DV2NGS2R   cctaaggctaacgcatcagtc 
DV2NGS3F   tgtcctttagagacctgggaag 
DV2NGS4F   cagcaagtatagcagctagagga 
DV2NGS4R   tttcccttctggtgtgaccatg 
DV2NGS5F   ctcaagtattgatgatgaggactacatg 
DV2NGS5R   acttgtgtccaatcattccatcc 
DV2NGS6F   ccgcaggatgggatacaaga 




Primers used to clone human IFNE-FLAG sequence into the pLenti6-V5-D-TOPO vector 
between the EcoRI and MluI restriction sites by restriction cloning (F, forward, R, reverse) 
cDNA target Primer Sequence (3’- 5’) 
Human IFNE1 gene F – tcgatcGAATTCaccatgattatcaagcac 








































Appendix II: General Solutions and Buffers 
 
The following solutions were obtained from the Central Services Unit (CSU) and Tissue 
Culture Services Unit (TSU), School of Biological Sciences, The University of Adelaide. 
  0.85% saline solution 
 10x Tris‐glycine‐SDS (TGS) buffer 
 10x Tris‐buffered‐saline (TBS) buffer 
 20x Tris‐acetate‐EDTA (TAE) buffer 
 1x Phosphate‐buffered‐saline (PBS) solution 
 20% Glucose solution 
 80% Glycerol solution 
 4M NaCl solution 
 3M Sodium Acetate (NaAc) pH 5.5 solution 
 Ampicillin 1 mg/ml 
 Ethylenediaminetetraacetic acid (EDTA) (different concentration and pH) 
 Dimethyl sulfoxide (DMSO) 
 Kanamycin 1 mg/ml 
 L‐Agar + ampicillin plates 
 Luria agar plates 
 Luria Broth 
 Sodium dodecyl sulfate (SDS) 
 Super Optimal broth with Catabolite repression (SOC) media 
 Tris solutions (different concentration and pH) 
 Penicillin/streptomycin 
 Trypan blue 
 Trypsin‐EDTA 
 Foetal calf serum (FCS) 
 
Prepared Solutions Components 
RIPA Cell lysis Buffer (40 ml)   150mM NaCl (1.5ml of 4M NaCl)  
 0.5% deoxycholate = 0.2g  
 0.1% SDS (0.4ml of 10% SDS)  
 1% NP‐40 (0.4 ml of NP‐40)  
 50mM Tris (2 ml of 1M Tris)  
 dH2O 35.7 ml 
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SDS‐PAGE 4 x Reducing Loading Buffer   500mM dithiothreitol (DTT) 
 0.5% bromophenol blue 
 50% glycerol  
 10% SDS  
 250mM Tris‐HCl (pH 6.8) 
 dH2O 
SDS‐PAGE Running Buffer   2.9% Tris Base  
 14.14% glycine  
 1% SDS  
 dH2O 
SDS‐PAGE Transfer Buffer   0.3% Tris Base  
 1.44% glycine  
 20% (v/v) methanol  
 dH2O 
Western Blot TBS‐T washing solution  
  
 1x TBS buffer in dH2O  
 0.1 % Tween® 20  
 dH2O 
Western Blot membrane stripping buffer  2% SDS 
 62.5mM Tris‐HCl (pH 6.7) 
 100mM 2‐mercaptoethanol 
Acetone:Methanol   50% acetone  
 50% methanol  
1% Agarose  1g Agarose  
 100ml 1xTAE buffer 
1% BSA  1 g of Bovine serum albumin (BSA) 
 100 ml of 1X PBS 
5% BSA  5 g of BSA  
 100 ml of 1X PBS 
2x Cell cryopreservation solution   50% complete DMEM 
 30% FCS 









Appendix III: Antibodies 




Dilution Incubation Supplier  










Mouse anti – 
FLAG 
Immunofluorescence  1⁰ 1:200 RT 1h Sigma 
Aldrich 

























Immunofluorescence 2⁰ 1:200 On ice 1h Invitrogen 
Rabbit anti – 
STAT2‐Y690P 
(#D3P2P) 















Mouse anti – 
FLAG 




Mouse anti – 
βactin 












Rabbit anti – 
STAT2 
(#D9JL) 




Rabbit anti – 
STAT1 
(#D1K9Y) 
























































Appendix V: DENV infectious clone and intermediate cloning vector plasmid maps, 
synthetic dsDNA for insertion mutation cloning and specific sequences changes for 


















































Figure 1: A) Diagrammatic representation of the pFK‐DVs infectious clone harbouring the full‐length genome of the DENV2 
16681 strain. The location of naturally occurring unique restriction sites used for cloning individual insertion mutants are shown 
for reference. B – E) Diagrammatic representations of the G‐Blocks used for cloning individual mutants at nucleotide positions 
1610, 1760 flanked by SphI and BamHI, 2941 flanked by MluI and KasI and 4884 flanked by NsiI and XhoI within the DENV 
genome. Each insert contains a 15 bp insertion mutation denoted by the NotI restriction site and the two flanking unique 





























































Figure 2: A) Diagrammatic representation of the intermediate cloning vector pUC‐57 containing the C‐terminus of NS5 of the 
DENV genome between the BmtI and AvrII restriction sites that are naturally occurring in the DENV2 16681 sequence. The 
location of synthetic mutations included to generate unique restriction sites used for cloning individual insertion mutants are 
shown for reference (PstI and ClaI). B – D) Diagrammatic representations of the synthetic dsDNA fragments used for cloning 
individual mutants at nucleotide positions 8069, 8077, and 8086 within the DENV genome. Each insert contains a 15 bp insertion 
























































Figure 3: A) Diagrammatic representation of the intermediate cloning vector pUC‐57 ordered from GeneWorks containing the 
N‐terminus of NS5 and the complete 3’ UTR of the DENV genome between the AvrII and XbaI restriction sites that are naturally 
occurring in the DENV2 16681 sequence. The location of synthetic mutations included to generate unique restriction sites used 
for cloning individual insertion mutants are shown for reference (AscI and BsiWI). B – D) Diagrammatic representations of the 
synthetic dsDNA fragments used for cloning individual mutants at nucleotide positions 9795, 10297, and 10388 within the 
DENV genome. Each insert contains a 15 bp insertion mutation denoted by the NotI restriction site and the two flanking unique 












































































































































































1. Abdulhaqq SA, Zorrilla C, Kang G, Yin X, Tamayo V, Seaton KE, Joseph J, Garced S, 
Tomaras GD, Linn KA, Foulkes AS, Azzoni L, VerMilyea M, Coutifaris C, Kossenkov AV, 
Showe L, Kraiselburd EN, Li Q, Montaner LJ (2016) HIV‐1‐negative female sex 
workers sustain high cervical IFNvarepsilon, low immune activation, and low 
expression of HIV‐1‐required host genes. Mucosal immunology 9:1027‐1038 
2. Africander D, Louw R, Verhoog N, Noeth D, Hapgood JP (2011) Differential regulation 
of endogenous pro‐inflammatory cytokine genes by medroxyprogesterone acetate 
and norethisterone acetate in cell lines of the female genital tract. Contraception 
84:423‐435 
3. Agrelli A, de Moura RR, Crovella S, Brandao LAC (2019) ZIKA virus entry mechanisms 
in human cells. Infection, genetics and evolution : journal of molecular epidemiology 
and evolutionary genetics in infectious diseases 69:22‐29 
4. Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, Maringer K, Bernal‐
Rubio D, Shabman RS, Simon V, Rodriguez‐Madoz JR, Mulder LC, Barber GN, 
Fernandez‐Sesma A (2012) DENV inhibits type I IFN production in infected cells by 
cleaving human STING. PLoS Pathog 8:e1002934 
5. Aguirre S, Luthra P, Sanchez‐Aparicio MT, Maestre AM, Patel J, Lamothe F, Fredericks 
AC, Tripathi S, Zhu T, Pintado‐Silva J, Webb LG, Bernal‐Rubio D, Solovyov A, 
Greenbaum B, Simon V, Basler CF, Mulder LC, Garcia‐Sastre A, Fernandez‐Sesma A 
(2017) Dengue virus NS2B protein targets cGAS for degradation and prevents 
mitochondrial DNA sensing during infection. Nature microbiology 2:17037 
6. Akey DL, Brown WC, Dutta S, Konwerski J, Jose J, Jurkiw TJ, DelProposto J, Ogata CM, 
Skiniotis G, Kuhn RJ, Smith JL (2014) Flavivirus NS1 structures reveal surfaces for 
associations with membranes and the immune system. Science (New York, NY) 
343:881‐885 
7. Aktepe TE, Mackenzie JM (2018) Shaping the flavivirus replication complex: It is 
curvaceous! Cellular microbiology 20:e12884 
8. Akter R, Naish S, Gatton M, Bambrick H, Hu W, Tong S (2019) Spatial and temporal 
analysis of dengue infections in Queensland, Australia: Recent trend and 
perspectives. PLoS One 14:e0220134 
9. Anfasa F, Siegers JY, van der Kroeg M, Mumtaz N, Stalin Raj V, de Vrij FMS, Widagdo 
W, Gabriel G, Salinas S, Simonin Y, Reusken C, Kushner SA, Koopmans MPG, 
Haagmans B, Martina BEE, van Riel D (2017) Phenotypic Differences between Asian 
and African Lineage Zika Viruses in Human Neural Progenitor Cells. mSphere 2 
10. Angleró‐Rodríguez YI, Pantoja P, Sariol CA (2014) Dengue virus subverts the 
interferon induction pathway via NS2B/3 protease‐IκB kinase epsilon interaction. 
Clin Vaccine Immunol 21:29‐38 
11. Ank N, Paludan SR (2009) Type III IFNs: new layers of complexity in innate antiviral 
immunity. BioFactors (Oxford, England) 35:82‐87 
12. Araya CL, Fowler DM (2011) Deep mutational scanning: assessing protein function on 
a massive scale. Trends in biotechnology 29:435‐442 
13. Arimoto KI, Lochte S, Stoner SA, Burkart C, Zhang Y, Miyauchi S, Wilmes S, Fan JB, 
Heinisch JJ, Li Z, Yan M, Pellegrini S, Colland F, Piehler J, Zhang DE (2017) STAT2 is an 
266 
 
essential adaptor in USP18‐mediated suppression of type I interferon signaling. 
Nature structural & molecular biology 24:279‐289 
14. Arimoto KI, Miyauchi S, Stoner SA, Fan JB, Zhang DE (2018) Negative regulation of 
type I IFN signaling. Journal of leukocyte biology 
15. Arjona A, Ledizet M, Anthony K, Bonafe N, Modis Y, Town T, Fikrig E (2007) West Nile 
virus envelope protein inhibits dsRNA‐induced innate immune responses. Journal of 
immunology (Baltimore, Md : 1950) 179:8403‐8409 
16. Ashour J, Laurent‐Rolle M, Shi PY, Garcia‐Sastre A (2009) NS5 of dengue virus 
mediates STAT2 binding and degradation. Journal of virology 83:5408‐5418 
17. Aubry F, Nougairède A, Gould EA, de Lamballerie X (2015) Flavivirus reverse genetic 
systems, construction techniques and applications: A historical perspective. Antiviral 
Research 114:67‐85 
18. Avila‐Perez G, Nogales A, Park JG, Vasquez DM, Dean DA, Barravecchia M, Perez DR, 
Almazan F, Martinez‐Sobrido L (2020) In vivo rescue of recombinant Zika virus from 
an infectious cDNA clone and its implications in vaccine development. Scientific 
reports 10:512 
19. Bailey CC, Zhong G, Huang IC, Farzan M (2014) IFITM‐Family Proteins: The Cell's First 
Line of Antiviral Defense. Annual review of virology 1:261‐283 
20. Barzon L, Percivalle E, Pacenti M, Rovida F, Zavattoni M, Del Bravo P, Cattelan AM, 
Palu G, Baldanti F (2018) Virus and Antibody Dynamics in Travelers With Acute Zika 
Virus Infection. Clinical infectious diseases : an official publication of the Infectious 
Diseases Society of America 66:1173‐1180 
21. Bayer A, Lennemann NJ, Ouyang Y, Bramley JC, Morosky S, Marques ET, Jr., Cherry S, 
Sadovsky Y, Coyne CB (2016) Type III Interferons Produced by Human Placental 
Trophoblasts Confer Protection against Zika Virus Infection. Cell host & microbe 
19:705‐712 
22. Beauverd Y, Radia D, Cargo C, Knapper S, Drummond M, Pillai A, Harrison C, 
Robinson S (2016) Pegylated interferon alpha‐2a for essential thrombocythemia 
during pregnancy: outcome and safety. A case series. Haematologica 101:e182‐e184 
23. Best SM (2016) Flaviviruses. Current biology : CB 26:R1258‐r1260 
24. Bhamarapravati N, Tuchinda P, Boonyapaknavik V (1967) Pathology of Thailand 
haemorrhagic fever: a study of 100 autopsy cases. Annals of tropical medicine and 
parasitology 61:500‐510 
25. Bhatnagar J, Rabeneck DB, Martines RB, Reagan‐Steiner S, Ermias Y, Estetter LB, 
Suzuki T, Ritter J, Keating MK, Hale G, Gary J, Muehlenbachs A, Lambert A, Lanciotti 
R, Oduyebo T, Meaney‐Delman D, Bolanos F, Saad EA, Shieh WJ, Zaki SR (2017) Zika 
Virus RNA Replication and Persistence in Brain and Placental Tissue. Emerging 
infectious diseases 23:405‐414 
26. Blight KJ, McKeating JA, Rice CM (2002) Highly permissive cell lines for subgenomic 
and genomic hepatitis C virus RNA replication. Journal of virology 76:13001‐13014 
27. Blumer T, Coto‐Llerena M, Duong FHT, Heim MH (2017) SOCS1 is an inducible 
negative regulator of interferon lambda (IFN‐lambda)‐induced gene expression in 
vivo. The Journal of biological chemistry 292:17928‐17938 
28. Bolen CR, Ding S, Robek MD, Kleinstein SH (2014) Dynamic expression profiling of 
type I and type III interferon‐stimulated hepatocytes reveals a stable hierarchy of 
gene expression. Hepatology (Baltimore, Md) 59:1262‐1272 
267 
 
29. Bollati M, Alvarez K, Assenberg R, Baronti C, Canard B, Cook S, Coutard B, Decroly E, 
de Lamballerie X, Gould EA, Grard G, Grimes JM, Hilgenfeld R, Jansson AM, Malet H, 
Mancini EJ, Mastrangelo E, Mattevi A, Milani M, Moureau G, Neyts J, Owens RJ, Ren 
J, Selisko B, Speroni S, Steuber H, Stuart DI, Unge T, Bolognesi M (2010) Structure 
and functionality in flavivirus NS‐proteins: perspectives for drug design. Antiviral Res 
87:125‐148 
30. Boyer J‐C, Haenni A‐L (1994) Infectious Transcripts and cDNA Clones of RNA Viruses. 
Virology 198:415‐426 
31. Brinton MA, Basu M (2015) Functions of the 3' and 5' genome RNA regions of 
members of the genus Flavivirus. Virus research 206:108‐119 
32. Broggi A, Granucci F, Zanoni I (2019) Type III interferons: Balancing tissue tolerance 
and resistance to pathogen invasion. The Journal of Experimental Medicine 217 
33. Brooks RB, Carlos MP, Myers RA, White MG, Bobo‐Lenoci T, Aplan D, Blythe D, 
Feldman KA (2016) Likely Sexual Transmission of Zika Virus from a Man with No 
Symptoms of Infection ‐ Maryland, 2016. MMWR Morbidity and mortality weekly 
report 65:915‐916 
34. Burkart C, Arimoto K‐i, Tang T, Cong X, Xiao N, Liu Y‐C, Kotenko SV, Ellies LG, Zhang 
D‐E (2013) Usp18 deficient mammary epithelial cells create an antitumour 
environment driven by hypersensitivity to IFN‐λ and elevated secretion of Cxcl10. 
EMBO molecular medicine 5:1035‐1050 
35. Bustos‐Arriaga J, Gromowski GD, Tsetsarkin KA, Firestone CY, Castro‐Jimenez T, 
Pletnev AG, Cedillo‐Barron L, Whitehead SS (2018) Decreased accumulation of 
subgenomic RNA in human cells infected with vaccine candidate DEN4Delta30 
increases viral susceptibility to type I interferon. Vaccine 36:3460‐3467 
36. Caine EA, Scheaffer SM, Arora N, Zaitsev K, Artyomov MN, Coyne CB, Moley KH, 
Diamond MS (2019) Interferon lambda protects the female reproductive tract 
against Zika virus infection. Nature communications 10:280 
37. Calvet G, Aguiar RS, Melo AS, Sampaio SA, de Filippis I, Fabri A, Araujo ES, de 
Sequeira PC, de Mendonca MC, de Oliveira L, Tschoeke DA, Schrago CG, Thompson 
FL, Brasil P, Dos Santos FB, Nogueira RM, Tanuri A, de Filippis AM (2016) Detection 
and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in 
Brazil: a case study. The Lancet Infectious diseases 16:653‐660 
38. Campos GS, Bandeira AC, Sardi SI (2015) Zika Virus Outbreak, Bahia, Brazil. Emerging 
infectious diseases 21:1885‐1886 
39. Cao‐Lormeau VM, Roche C, Teissier A, Robin E, Berry AL, Mallet HP, Sall AA, Musso D 
(2014) Zika virus, French polynesia, South pacific, 2013. Emerging infectious diseases 
20:1085‐1086 
40. Cao‐Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, Dub T, 
Baudouin L, Teissier A, Larre P, Vial AL, Decam C, Choumet V, Halstead SK, Willison 
HJ, Musset L, Manuguerra JC, Despres P, Fournier E, Mallet HP, Musso D, Fontanet A, 
Neil J, Ghawche F (2016) Guillain‐Barre Syndrome outbreak associated with Zika 
virus infection in French Polynesia: a case‐control study. Lancet (London, England) 
387:1531‐1539 
41. Carroll T, Lo M, Lanteri M, Dutra J, Zarbock K, Silveira P, Rourke T, Ma Z‐m, Fritts L, 
O’Connor S, Busch M, Miller CJ (2017) Zika virus preferentially replicates in the 




42. Carthew RW, Sontheimer EJ (2009) Origins and Mechanisms of miRNAs and siRNAs. 
Cell 136:642‐655 
43. Catteau A, Roué G, Yuste VJ, Susin SA, Desprès P (2003) Expression of dengue 
ApoptoM sequence results in disruption of mitochondrial potential and caspase 
activation. Biochimie 85:789‐793 
44. Chan YK, Gack MU (2016) A phosphomimetic‐based mechanism of dengue virus to 
antagonize innate immunity. Nature immunology 17:523‐530 
45. Chang HH, Huber RG, Bond PJ, Grad YH, Camerini D, Maurer‐Stroh S, Lipsitch M 
(2017) Systematic analysis of protein identity between Zika virus and other 
arthropod‐borne viruses. Bulletin of the World Health Organization 95:517‐525i 
46. Chen HW, Chen JJ, Tzeng CR, Li HN, Chang SJ, Cheng YF, Chang CW, Wang RS, Yang 
PC, Lee YT (2002) Global analysis of differentially expressed genes in early gestational 
decidua and chorionic villi using a 9600 human cDNA microarray. Molecular human 
reproduction 8:475‐484 
47. Chen J, Yang YF, Yang Y, Zou P, Chen J, He Y, Shui SL, Cui YR, Bai R, Liang YJ, Hu Y, 
Jiang B, Lu L, Zhang X, Liu J, Xu J (2018) AXL promotes Zika virus infection in 
astrocytes by antagonizing type I interferon signalling. Nature microbiology 
48. Chen LH, Hamer DH (2018) Zika virus and sexual transmission: updated 
preconception guidance. Journal of Travel Medicine 25 
49. Chen Y, Liu T, Zhang Z, Chen M, Rong L, Ma L, Yu B, Wu, Zhang P, Zhu X, Huang X, 
Zhang H, Li YP (2018) Novel genetically stable infectious clone for a Zika virus clinical 
isolate and identification of RNA elements essential for virus production. Virus 
research 
50. Chiriac MT, Buchen B, Wandersee A, Hundorfean G, Günther C, Bourjau Y, Doyle SE, 
Frey B, Ekici AB, Büttner C, Weigmann B, Atreya R, Wirtz S, Becker C, Siebler J, 
Neurath MF (2017) Activation of Epithelial Signal Transducer and Activator of 
Transcription 1 by Interleukin 28 Controls Mucosal Healing in Mice With Colitis and Is 
Increased in Mucosa of Patients With Inflammatory Bowel Disease. Gastroenterology 
153:123‐138.e128 
51. Clarke BD, Roby JA, Slonchak A, Khromykh AA (2015) Functional non‐coding RNAs 
derived from the flavivirus 3' untranslated region. Virus research 206:53‐61 
52. Coldbeck‐Shackley RC, Eyre NS, Beard MR (2020) The Molecular Interactions of ZIKV 
and DENV with the Type‐I IFN Response. Vaccines 8 
53. Contreras‐Capetillo SN, Valadez‐Gonzalez N, Manrique‐Saide P, Carcano‐Castillo RE, 
Pacheco‐Tugores F, Barrera‐Perez HAM, Pinto‐Escalante D, Lliteras‐Cardin M, Hoil‐
Parra JA, Caceres‐Solis JL, Pavia‐Ruz N (2018) Birth Defects Associated With 
Congenital Zika Virus Infection in Mexico. Clinical pediatrics 57:927‐936 
54. Control E‐ECfDPa (2015) Zika virus epidemic in the Americas: potential association 
with microcephaly and Guillain‐Barré syndrome.  
55. Control ECfDPa (2019) Sexual transmission of dengue in Spain.  
56. Coronel‐Ruiz C, Gutierrez‐Barbosa H, Medina‐Moreno S, Velandia‐Romero ML, Chua 
JV, Castellanos JE, Zapata JC (2020) Humanized Mice in Dengue Research: A 
Comparison with Other Mouse Models. Vaccines 8 
57. Corry J, Arora N, Good CA, Sadovsky Y, Coyne CB (2017) Organotypic models of type 
III interferon‐mediated protection from Zika virus infections at the maternal–fetal 
interface. Proceedings of the National Academy of Sciences 
269 
 
58. Cortese M, Goellner S, Acosta EG, Neufeldt CJ, Oleksiuk O, Lampe M, Haselmann U, 
Funaya C, Schieber N, Ronchi P, Schorb M, Pruunsild P, Schwab Y, Chatel‐Chaix L, 
Ruggieri A, Bartenschlager R (2017) Ultrastructural Characterization of Zika Virus 
Replication Factories. Cell reports 18:2113‐2123 
59. Crow YJ, Manel N (2015) Aicardi–Goutières syndrome and the type I 
interferonopathies. Nature Reviews Immunology 15:429 
60. Cugola FR, Fernandes IR, Russo FB, Freitas BC, Dias JL, Guimaraes KP, Benazzato C, 
Almeida N, Pignatari GC, Romero S, Polonio CM, Cunha I, Freitas CL, Brandao WN, 
Rossato C, Andrade DG, Faria Dde P, Garcez AT, Buchpigel CA, Braconi CT, Mendes E, 
Sall AA, Zanotto PM, Peron JP, Muotri AR, Beltrao‐Braga PC (2016) The Brazilian Zika 
virus strain causes birth defects in experimental models. Nature 534:267‐271 
61. Cumming HE, Bourke NM (2018) Type I IFNs in the female reproductive tract: The 
first line of defense in an ever‐changing battleground. Journal of leukocyte biology 
62. Cumming HE, Bourke NM (2018) Type I IFNs in the female reproductive tract: The 
first line of defense in an ever‐changing battleground. Journal of leukocyte biology 0 
63. da Cruz TE, Souza RP, Pelloso SM, Morelli F, Suehiro TT, Damke E, Bonfim‐Mendonca 
PS, da Silva VRS, Consolaro MEL (2019) Case Reports: Prolonged Detection of Zika 
Virus RNA in Vaginal and Endocervical Samples from a Brazilian Woman, 2018. The 
American journal of tropical medicine and hygiene 100:183‐186 
64. Dai J, Pan W, Wang P (2011) ISG15 facilitates cellular antiviral response to dengue 
and west nile virus infection in vitro. Virology journal 8:468‐468 
65. Dalrymple NA, Cimica V, Mackow ER (2015) Dengue Virus NS Proteins Inhibit RIG‐
I/MAVS Signaling by Blocking TBK1/IRF3 Phosphorylation: Dengue Virus Serotype 1 
NS4A Is a Unique Interferon‐Regulating Virulence Determinant. mBio 6:e00553‐
00515 
66. Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, Hartmann R, Wack A 
(2016) IFNlambda is a potent anti‐influenza therapeutic without the inflammatory 
side effects of IFNalpha treatment. EMBO molecular medicine 8:1099‐1112 
67. de Borba L, Villordo SM, Iglesias NG, Filomatori CV, Gebhard LG, Gamarnik AV (2015) 
Overlapping local and long‐range RNA‐RNA interactions modulate dengue virus 
genome cyclization and replication. Journal of virology 89:3430‐3437 
68. de Borba L, Villordo SM, Marsico FL, Carballeda JM, Filomatori CV, Gebhard LG, 
Pallarés HM, Lequime S, Lambrechts L, Sánchez Vargas I, Blair CD, Gamarnik AV 
(2019) RNA Structure Duplication in the Dengue Virus 3' UTR: Redundancy or Host 
Specificity? mBio 10:e02506‐02518 
69. de Paula Freitas B, de Oliveira Dias JR, Prazeres J, Sacramento GA, Ko AI, Maia M, 
Belfort R, Jr. (2016) Ocular Findings in Infants With Microcephaly Associated With 
Presumed Zika Virus Congenital Infection in Salvador, Brazil. JAMA ophthalmology 
134:529‐535 
70. de Weerd NA, Nguyen T (2012) The interferons and their receptors‐‐distribution and 
regulation. Immunology and cell biology 90:483‐491 
71. de Weerd NA, Vivian JP, Nguyen TK, Mangan NE, Gould JA, Braniff SJ, Zaker‐Tabrizi L, 
Fung KY, Forster SC, Beddoe T, Reid HH, Rossjohn J, Hertzog PJ (2013) Structural 
basis of a unique interferon‐beta signaling axis mediated via the receptor IFNAR1. 
Nature immunology 14:901‐907 
72. Delorme‐Axford E, Sadovsky Y, Coyne CB (2014) The Placenta as a Barrier to Viral 
Infections. Annual review of virology 1:133‐146 
270 
 
73. Demers A, Kang G, Ma F, Lu W, Yuan Z, Li Y, Lewis M, Kraiselburd EN, Montaner L, Li 
Q (2014) The mucosal expression pattern of interferon‐epsilon in rhesus macaques. 
Journal of leukocyte biology 96:1101‐1107 
74. Deng C‐L, Zhang Q‐Y, Chen D‐D, Liu S‐Q, Qin C‐F, Zhang B, Ye H‐Q (2017) Recovery of 
the Zika virus through an in vitro ligation approach. Journal of General Virology 
98:1739‐1743 
75. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, Harris E (2000) Modulation of 
Dengue Virus Infection in Human Cells by Alpha, Beta, and Gamma Interferons. 
Journal of virology 74:4957‐4966 
76. Diamond MS, Pierson TC (2015) Molecular Insight into Dengue Virus Pathogenesis 
and Its Implications for Disease Control. Cell 162:488‐492 
77. Diner BA, Lum KK, Toettcher JE, Cristea IM (2016) Viral DNA Sensors IFI16 and Cyclic 
GMP‐AMP Synthase Possess Distinct Functions in Regulating Viral Gene Expression, 
Immune Defenses, and Apoptotic Responses during Herpesvirus Infection. mBio 
7:e01553‐01516 
78. Ding Q, Gaska JM, Douam F, Wei L, Kim D, Balev M, Heller B, Ploss A (2018) Species‐
specific disruption of STING‐dependent antiviral cellular defenses by the Zika virus 
NS2B3 protease. Proceedings of the National Academy of Sciences of the United 
States of America 115:E6310‐e6318 
79. Dixit E, Boulant S, Zhang Y, Lee ASY, Odendall C, Shum B, Hacohen N, Chen ZJ, 
Whelan SP, Fransen M, Nibert ML, Superti‐Furga G, Kagan JC (2010) Peroxisomes are 
signaling platforms for antiviral innate immunity. Cell 141:668‐681 
80. do Rosario MS, de Jesus PA, Vasilakis N, Farias DS, Novaes MA, Rodrigues SG, 
Martins LC, Vasconcelos PF, Ko AI, Alcantara LC, de Siqueira IC (2016) Guillain‐Barre 
Syndrome After Zika Virus Infection in Brazil. The American journal of tropical 
medicine and hygiene 95:1157‐1160 
81. Domanski P, Fish E, Nadeau OW, Witte M, Platanias LC, Yan H, Krolewski J, Pitha P, 
Colamonici OR (1997) A region of the beta subunit of the interferon alpha receptor 
different from box 1 interacts with Jak1 and is sufficient to activate the Jak‐Stat 
pathway and induce an antiviral state. The Journal of biological chemistry 
272:26388‐26393 
82. Donald CL, Brennan B, Cumberworth SL, Rezelj VV, Clark JJ, Cordeiro MT, Freitas de 
Oliveira Franca R, Pena LJ, Wilkie GS, Da Silva Filipe A, Davis C, Hughes J, Varjak M, 
Selinger M, Zuvanov L, Owsianka AM, Patel AH, McLauchlan J, Lindenbach BD, Fall G, 
Sall AA, Biek R, Rehwinkel J, Schnettler E, Kohl A (2016) Full Genome Sequence and 
sfRNA Interferon Antagonist Activity of Zika Virus from Recife, Brazil. PLoS neglected 
tropical diseases 10:e0005048 
83. Dong H, Chang DC, Xie X, Toh YX, Chung KY, Zou G, Lescar J, Lim SP, Shi PY (2010) 
Biochemical and genetic characterization of dengue virus methyltransferase. 
Virology 405:568‐578 
84. Du Y, Xin L, Shi Y, Zhang TH, Wu NC, Dai L, Gong D, Brar G, Shu S, Luo J, Reiley W, 
Tseng YW, Bai H, Wu TT, Wang J, Shu Y, Sun R (2018) Genome‐wide identification of 
interferon‐sensitive mutations enables influenza vaccine design. Science (New York, 
NY) 359:290‐296 
85. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP (1987) Analysis of 
mutation in human cells by using an Epstein‐Barr virus shuttle system. Molecular and 
cellular biology 7:379‐387 
271 
 
86. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, Pretrick M, 
Marfel M, Holzbauer S, Dubray C, Guillaumot L, Griggs A, Bel M, Lambert AJ, Laven J, 
Kosoy O, Panella A, Biggerstaff BJ, Fischer M, Hayes EB (2009) Zika virus outbreak on 
Yap Island, Federated States of Micronesia. The New England journal of medicine 
360:2536‐2543 
87. Duggal NK, Ritter JM, Pestorius SE, Zaki SR, Davis BS, Chang G‐JJ, Bowen RA, Brault 
AC (2017) Frequent Zika Virus Sexual Transmission and Prolonged Viral RNA 
Shedding in an Immunodeficient Mouse Model. Cell reports 18:1751‐1760 
88. Duggal NK, McDonald EM, Ritter JM, Brault AC (2018) Sexual transmission of Zika 
virus enhances in utero transmission in a mouse model. Scientific reports 8:4510 
89. Dukhovny A, Lamkiewicz K, Chen Q, Fricke M, Jabrane‐Ferrat N, Marz M, Jung JU, 
Sklan EH (2019) A CRISPR activation screen identifies genes protecting from Zika 
virus infection. Journal of virology 
90. Duong V, Lambrechts L, Paul RE, Ly S, Lay RS, Long KC, Huy R, Tarantola A, Scott TW, 
Sakuntabhai A, Buchy P (2015) Asymptomatic humans transmit dengue virus to 
mosquitoes. Proceedings of the National Academy of Sciences of the United States 
of America 112:14688‐14693 
91. Edwards DP (2005) Regulation of signal transduction pathways by estrogen and 
progesterone. Annual review of physiology 67:335‐376 
92. El Costa H, Gouilly J, Mansuy J‐M, Chen Q, Levy C, Cartron G, Veas F, Al‐Daccak R, 
Izopet J, Jabrane‐Ferrat N (2016) ZIKA virus reveals broad tissue and cell tropism 
during the first trimester of pregnancy. Scientific reports 6:35296 
93. Esser‐Nobis K, Aarreberg LD, Roby JA, Fairgrieve MR, Green R, Gale M, Jr. (2019) 
Comparative analysis of African and Asian lineage‐derived Zika Virus strains reveals 
differences in activation of and sensitivity to antiviral innate immunity. Journal of 
virology 
94. Eyre NS, Johnson SM, Eltahla AA, Aloi M, Aloia AL, McDevitt CA, Bull RA, Beard MR 
(2017) Genome‐wide mutagenesis of dengue virus reveals plasticity of the NS1 
protein and enables generation of infectious tagged reporter viruses. Journal of 
virology 
95. Fan W, Xie S, Zhao X, Li N, Chang C, Li L, Yu G, Chi X, Pan Y, Niu J, Zhong J, Sun B 
(2016) IFN‐lambda4 desensitizes the response to IFN‐alpha treatment in chronic 
hepatitis C through long‐term induction of USP18. The Journal of general virology 
97:2210‐2220 
96. Fichorova RN, Rheinwald JG, Anderson DJ (1997) Generation of papillomavirus‐
immortalized cell lines from normal human ectocervical, endocervical, and vaginal 
epithelium that maintain expression of tissue‐specific differentiation proteins. Biol 
Reprod 57:847‐855 
97. Fontes‐Garfias CR, Shan C, Luo H, Muruato AE, Medeiros DBA, Mays E, Xie X, Zou J, 
Roundy CM, Wakamiya M, Rossi SL, Wang T, Weaver SC, Shi P‐Y (2017) Functional 
Analysis of Glycosylation of Zika Virus Envelope Protein. Cell reports 21:1180‐1190 
98. Forero A, Ozarkar S, Li H, Lee CH, Hemann EA, Nadjsombati MS, Hendricks MR, So L, 
Green R, Roy CN, Sarkar SN, von Moltke J, Anderson SK, Gale M, Jr., Savan R (2019) 
Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune 
Responses Elicited by Type I and Type III Interferons. Immunity 
99. Francois‐Newton V, Magno de Freitas Almeida G, Payelle‐Brogard B, Monneron D, 
Pichard‐Garcia L, Piehler J, Pellegrini S, Uze G (2011) USP18‐based negative feedback 
272 
 
control is induced by type I and type III interferons and specifically inactivates 
interferon alpha response. PLoS One 6:e22200 
100. Francois‐Newton V, Livingstone M, Payelle‐Brogard B, Uze G, Pellegrini S (2012) 
USP18 establishes the transcriptional and anti‐proliferative interferon alpha/beta 
differential. The Biochemical journal 446:509‐516 
101. Freour T, Mirallie S, Hubert B, Splingart C, Barriere P, Maquart M, Leparc‐Goffart I 
(2016) Sexual transmission of Zika virus in an entirely asymptomatic couple returning 
from a Zika epidemic area, France, April 2016. Euro surveillance : bulletin Europeen 
sur les maladies transmissibles = European communicable disease bulletin 21 
102. Froissart R, Wilke CO, Montville R, Remold SK, Chao L, Turner PE (2004) Co‐infection 
weakens selection against epistatic mutations in RNA viruses. Genetics 168:9‐19 
103. Fulton BO, Sachs D, Beaty SM, Won ST, Lee B, Palese P, Heaton NS (2015) Mutational 
Analysis of Measles Virus Suggests Constraints on Antigenic Variation of the 
Glycoproteins. Cell reports 11:1331‐1338 
104. Fulton BO, Sachs D, Schwarz MC, Palese P, Evans MJ (2017) Transposon mutagenesis 
of the Zika virus genome highlights regions essential for RNA replication and 
restricted for immune evasion. Journal of virology 
105. Fung KY, Mangan NE, Cumming H, Horvat JC, Mayall JR, Stifter SA, De Weerd N, 
Roisman LC, Rossjohn J, Robertson SA, Schjenken JE, Parker B, Gargett CE, Nguyen 
HP, Carr DJ, Hansbro PM, Hertzog PJ (2013) Interferon‐epsilon protects the female 
reproductive tract from viral and bacterial infection. Science (New York, NY) 
339:1088‐1092 
106. Funk A, Truong K, Nagasaki T, Torres S, Floden N, Balmori Melian E, Edmonds J, Dong 
H, Shi P‐Y, Khromykh AA (2010) RNA structures required for production of 
subgenomic flavivirus RNA. Journal of virology 84:11407‐11417 
107. Furusyo N, Hayashi J, Ohmiya M, Sawayama Y, Kawakami Y, Ariyama I, Kinukawa N, 
Kashiwagi S (1999) Differences between interferon‐alpha and ‐beta treatment for 
patients with chronic hepatitis C virus infection. Digestive diseases and sciences 
44:608‐617 
108. Gack MU, Diamond MS (2016) Innate immune escape by Dengue and West Nile 
viruses. Current opinion in virology 20:119‐128 
109. Gao H, Feldman MW (2009) Complementation and epistasis in viral coinfection 
dynamics. Genetics 182:251‐263 
110. Garcia‐Minambres A, Eid SG, Mangan NE, Pade C, Lim SS, Matthews AY, de Weerd 
NA, Hertzog PJ, Mak J (2017) Interferon epsilon promotes HIV restriction at multiple 
steps of viral replication. Immunology and cell biology 95:478‐483 
111. Ghosh M, Shen Z, Fahey JV, Crist SG, Patel M, Smith JM, Wira CR (2013) Pathogen 
recognition in the human female reproductive tract: expression of intracellular 
cytosolic sensors NOD1, NOD2, RIG‐1, and MDA5 and response to HIV‐1 and 
Neisseria gonorrhea. American journal of reproductive immunology (New York, NY : 
1989) 69:41‐51 
112. Giron S, Franke F, Decoppet A, Cadiou B, Travaglini T, Thirion L, Durand G, Jeannin C, 
L'Ambert G, Grard G, Noel H, Fournet N, Auzet‐Caillaud M, Zandotti C, Aboukais S, 
Chaud P, Guedj S, Hamouda L, Naudot X, Ovize A, Lazarus C, de Valk H, Paty MC, 
Leparc‐Goffart I (2019) Vector‐borne transmission of Zika virus in Europe, southern 
France, August 2019. Euro surveillance : bulletin Europeen sur les maladies 
transmissibles = European communicable disease bulletin 24 
273 
 
113. Goel RR, Wang X, O'Neil LJ, Nakabo S, Hasneen K, Gupta S, Wigerblad G, Blanco LP, 
Kopp JB, Morasso MI, Kotenko SV, Yu ZX, Carmona‐Rivera C, Kaplan MJ (2020) 
Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7‐
induced lupus. Proceedings of the National Academy of Sciences of the United States 
of America 117:5409‐5419 
114. Goertz GP, Abbo SR, Fros JJ, Pijlman GP (2018) Functional RNA during Zika virus 
infection. Virus research 254:41‐53 
115. Gorman MJ, Caine EA, Zaitsev K, Begley MC, Weger‐Lucarelli J, Uccellini MB, Tripathi 
S, Morrison J, Yount BL, Dinnon KH, 3rd, Ruckert C, Young MC, Zhu Z, Robertson SJ, 
McNally KL, Ye J, Cao B, Mysorekar IU, Ebel GD, Baric RS, Best SM, Artyomov MN, 
Garcia‐Sastre A, Diamond MS (2018) An Immunocompetent Mouse Model of Zika 
Virus Infection. Cell host & microbe 23:672‐685.e676 
116. Gough DJ, Messina NL, Hii L, Gould JA, Sabapathy K, Robertson AP, Trapani JA, Levy 
DE, Hertzog PJ, Clarke CJ, Johnstone RW (2010) Functional crosstalk between type I 
and II interferon through the regulated expression of STAT1. PLoS biology 
8:e1000361 
117. Gough DJ, Messina NL, Clarke CJP, Johnstone RW, Levy DE (2012) Constitutive type I 
interferon modulates homeostatic balance through tonic signaling. Immunity 
36:166‐174 
118. Gould EA, Solomon T (2008) Pathogenic flaviviruses. Lancet (London, England) 
371:500‐509 
119. Gould EA, Higgs S (2009) Impact of climate change and other factors on emerging 
arbovirus diseases. Transactions of the Royal Society of Tropical Medicine and 
Hygiene 103:109‐121 
120. Graham CH, Hawley TS, Hawley RG, MacDougall JR, Kerbel RS, Khoo N, Lala PK (1993) 
Establishment and characterization of first trimester human trophoblast cells with 
extended lifespan. Experimental cell research 206:204‐211 
121. Grant A, Ponia SS, Tripathi S, Balasubramaniam V, Miorin L, Sourisseau M, Schwarz 
MC, Sanchez‐Seco MP, Evans MJ, Best SM, Garcia‐Sastre A (2016) Zika Virus Targets 
Human STAT2 to Inhibit Type I Interferon Signaling. Cell host & microbe 19:882‐890 
122. Green AM, Beatty PR, Hadjilaou A, Harris E (2014) Innate immunity to dengue virus 
infection and subversion of antiviral responses. Journal of molecular biology 
426:1148‐1160 
123. Green B, Bouchier C, Fairhead C, Craig NL, Cormack BP (2012) Insertion site 
preference of Mu, Tn5, and Tn7 transposons. Mobile DNA 3:3 
124. Grischott F, Puhan M, Hatz C, Schlagenhauf P (2016) Non‐vector‐borne transmission 
of Zika virus: A systematic review. Travel medicine and infectious disease 14:313‐330 
125. Gubler DJ (2012) The economic burden of dengue. The American journal of tropical 
medicine and hygiene 86:743‐744 
126. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, 
Kroeger A, Margolis HS, Martinez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, 
Peeling RW (2010) Dengue: a continuing global threat. Nature reviews Microbiology 
8:S7‐16 
127. Guzman MG, Harris E (2015) Dengue. Lancet (London, England) 385:453‐465 
128. Halstead SB (2007) Dengue. Lancet (London, England) 370:1644‐1652 
129. Hamel R, Dejarnac O, Wichit S, Ekchariyawat P, Neyret A, Luplertlop N, Perera‐Lecoin 
M, Surasombatpattana P, Talignani L, Thomas F, Cao‐Lormeau VM, Choumet V, 
274 
 
Briant L, Despres P, Amara A, Yssel H, Misse D (2015) Biology of Zika Virus Infection 
in Human Skin Cells. Journal of virology 89:8880‐8896 
130. Hammond SN, Balmaseda A, Perez L, Tellez Y, Saborio SI, Mercado JC, Videa E, 
Rodriguez Y, Perez MA, Cuadra R, Solano S, Rocha J, Idiaquez W, Gonzalez A, Harris E 
(2005) Differences in dengue severity in infants, children, and adults in a 3‐year 
hospital‐based study in Nicaragua. The American journal of tropical medicine and 
hygiene 73:1063‐1070 
131. Han Y, Li R, Gao J, Miao S, Wang L (2012) Characterisation of human RING finger 
protein TRIM69, a novel testis E3 ubiquitin ligase and its subcellular localisation. 
Biochem Biophys Res Commun 429:6‐11 
132. Hanck T, Stricker R, Sedehizade F, Reiser G (2004) Identification of gene structure 
and subcellular localization of human centaurin alpha 2, and p42IP4, a family of two 
highly homologous, Ins 1,3,4,5‐P4‐/PtdIns 3,4,5‐P3‐binding, adapter proteins. Journal 
of neurochemistry 88:326‐336 
133. Hardy MP, Owczarek CM, Jermiin LS, Ejdeback M, Hertzog PJ (2004) Characterization 
of the type I interferon locus and identification of novel genes. Genomics 84:331‐345 
134. Harris BD, Schreiter J, Chevrier M, Jordan JL, Walter MR (2018) Human interferon‐ 
and interferon‐kappa exhibit low potency and low affinity for cell‐surface IFNAR and 
the poxvirus antagonist B18R. The Journal of biological chemistry 293:16057‐16068 
135. Hart KM, Murphy AJ, Barrett KT, Wira CR, Guyre PM, Pioli PA (2009) Functional 
expression of pattern recognition receptors in tissues of the human female 
reproductive tract. J Reprod Immunol 80:33‐40 
136. Hasan S, Jamdar SF, Alalowi M, Al Ageel Al Beaiji SM (2016) Dengue virus: A global 
human threat: Review of literature. Journal of International Society of Preventive & 
Community Dentistry 6:1‐6 
137. Hastings AK, Yockey LJ, Jagger BW, Hwang J, Uraki R, Gaitsch HF, Parnell LA, Cao B, 
Mysorekar IU, Rothlin CV, Fikrig E, Diamond MS, Iwasaki A (2017) TAM Receptors Are 
Not Required for Zika Virus Infection in Mice. Cell reports 19:558‐568 
138. Hayashida E, Ling ZL, Ashhurst TM, Viengkhou B, Jung SR, Songkhunawej P, West PK, 
King NJC, Hofer MJ (2019) Zika virus encephalitis in immunocompetent mice is 
dominated by innate immune cells and does not require T or B cells. J 
Neuroinflammation 16:177 
139. Heaton NS, Sachs D, Chen CJ, Hai R, Palese P (2013) Genome‐wide mutagenesis of 
influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. 
Proceedings of the National Academy of Sciences of the United States of America 
110:20248‐20253 
140. Helbig KJ, Eyre NS, Yip E, Narayana S, Li K, Fiches G, McCartney EM, Jangra RK, Lemon 
SM, Beard MR (2011) The antiviral protein viperin inhibits hepatitis C virus 
replication via interaction with nonstructural protein 5A. Hepatology (Baltimore, Md) 
54:1506‐1517 
141. Helbig KJ, Carr JM, Calvert JK, Wati S, Clarke JN, Eyre NS, Narayana SK, Fiches GN, 
McCartney EM, Beard MR (2013) Viperin is induced following dengue virus type‐2 
(DENV‐2) infection and has anti‐viral actions requiring the C‐terminal end of viperin. 
PLoS neglected tropical diseases 7:e2178‐e2178 




143. Hemann EA, Gale M, Jr., Savan R (2017) Interferon Lambda Genetics and Biology in 
Regulation of Viral Control. Frontiers in immunology 8:1707 
144. Hennessey M, Fischer M, Staples JE (2016) Zika Virus Spreads to New Areas ‐ Region 
of the Americas, May 2015‐January 2016. MMWR Morbidity and mortality weekly 
report 65:55‐58 
145. Hermant P, Francius C, Clotman F, Michiels T (2013) IFN‐epsilon is constitutively 
expressed by cells of the reproductive tract and is inefficiently secreted by 
fibroblasts and cell lines. PLoS One 8:e71320 
146. Hertzog J, Dias Junior AG, Rigby RE, Donald CL, Mayer A, Sezgin E, Song C, Jin B, 
Hublitz P, Eggeling C, Kohl A, Rehwinkel J (2018) Infection with a Brazilian isolate of 
Zika virus generates RIG‐I stimulatory RNA and the viral NS5 protein blocks type I IFN 
induction and signalling. European journal of immunology 
147. Hertzog PJ, Williams BRG (2013) Fine tuning type I interferon responses. Cytokine & 
Growth Factor Reviews 24:217‐225 
148. Hilgenfeld R (2016) Zika virus NS1, a pathogenicity factor with many faces. The 
EMBO journal 35:2631‐2633 
149. Hoenen A, Liu W, Kochs G, Khromykh AA, Mackenzie JM (2007) West Nile virus‐
induced cytoplasmic membrane structures provide partial protection against the 
interferon‐induced antiviral MxA protein. The Journal of general virology 88:3013‐
3017 
150. Holmes EC, Twiddy SS (2003) The origin, emergence and evolutionary genetics of 
dengue virus. Infection, genetics and evolution : journal of molecular epidemiology 
and evolutionary genetics in infectious diseases 3:19‐28 
151. Hong SW, Jiang Y, Kim S, Li CJ, Lee D‐k (2014) Target gene abundance contributes to 
the efficiency of siRNA‐mediated gene silencing. Nucleic Acid Ther 24:192‐198 
152. Hu Y, Dong X, He Z, Wu Y, Zhang S, Lin J, Yang Y, Chen J, An S, Yin Y, Shen Z, Zeng G, 
Tian H, Cai J, Yang Y, Guan H, Wu J, Li M, Zhu X (2019) Zika virus antagonizes 
interferon response in patients and disrupts RIG‐I‐MAVS interaction through its 
CARD‐TM domains. Cell & bioscience 9:46 
153. Huang WC, Abraham R, Shim BS, Choe H, Page DT (2016) Zika virus infection during 
the period of maximal brain growth causes microcephaly and corticospinal neuron 
apoptosis in wild type mice. Scientific reports 6:34793 
154. Huijbregts RP, Helton ES, Michel KG, Sabbaj S, Richter HE, Goepfert PA, Hel Z (2013) 
Hormonal contraception and HIV‐1 infection: medroxyprogesterone acetate 
suppresses innate and adaptive immune mechanisms. Endocrinology 154:1282‐1295 
155. Ivashkiv LB, Donlin LT (2014) Regulation of type I interferon responses. Nature 
reviews Immunology 14:36‐49 
156. Jain A, Pasare C (2017) Innate Control of Adaptive Immunity: Beyond the Three‐
Signal Paradigm. Journal of immunology (Baltimore, Md : 1950) 198:3791‐3800 
157. Jiang D, Weidner JM, Qing M, Pan X‐B, Guo H, Xu C, Zhang X, Birk A, Chang J, Shi P‐Y, 
Block TM, Guo J‐T (2010) Identification of five interferon‐induced cellular proteins 
that inhibit west nile virus and dengue virus infections. Journal of virology 84:8332‐
8341 
158. Jilg N, Lin W, Hong J, Schaefer EA, Wolski D, Meixong J, Goto K, Brisac C, Chusri P, 
Fusco DN, Chevaliez S, Luther J, Kumthip K, Urban TJ, Peng LF, Lauer GM, Chung RT 
(2014) Kinetic differences in the induction of interferon stimulated genes by 
276 
 
interferon‐α and interleukin 28B are altered by infection with hepatitis C virus. 
Hepatology (Baltimore, Md) 59:1250‐1261 
159. Johansson MA, Mier‐y‐Teran‐Romero L, Reefhuis J, Gilboa SM, Hills SL (2016) Zika 
and the Risk of Microcephaly. The New England journal of medicine 375:1‐4 
160. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) 
Two distinct estrogen‐regulated promoters generate transcripts encoding the two 
functionally different human progesterone receptor forms A and B. The EMBO 
journal 9:1603‐1614 
161. Kato H, Takeuchi O, Mikamo‐Satoh E, Hirai R, Kawai T, Matsushita K, Hiiragi A, 
Dermody TS, Fujita T, Akira S (2008) Length‐dependent recognition of double‐
stranded ribonucleic acids by retinoic acid‐inducible gene‐I and melanoma 
differentiation‐associated gene 5. J Exp Med 205:1601‐1610 
162. Kell AM, Gale M, Jr. (2015) RIG‐I in RNA virus recognition. Virology 479‐480:110‐121 
163. Keskinen P, Nyqvist M, Sareneva T, Pirhonen J, Melén K, Julkunen I (1999) Impaired 
Antiviral Response in Human Hepatoma Cells. Virology 263:364‐375 
164. Khan S, Woodruff EM, Trapecar M, Fontaine KA, Ezaki A, Borbet TC, Ott M, Sanjabi S 
(2016) Dampened antiviral immunity to intravaginal exposure to RNA viral pathogens 
allows enhanced viral replication. The Journal of Experimental Medicine 213:2913 
165. Khan S, Lew I, Wu F, Fritts L, Fontaine KA, Tomar S, Trapecar M, Shehata HM, Ott M, 
Miller CJ, Sanjabi S (2019) Low expression of RNA sensors impacts Zika virus infection 
in the lower female reproductive tract. Nature communications 10:4344 
166. Khromykh AA, Sedlak PL, Westaway EG (1999) trans‐Complementation analysis of 
the flavivirus Kunjin ns5 gene reveals an essential role for translation of its N‐
terminal half in RNA replication. Journal of virology 73:9247‐9255 
167. Khromykh AA, Sedlak PL, Westaway EG (2000) cis‐ and trans‐acting elements in 
flavivirus RNA replication. Journal of virology 74:3253‐3263 
168. Killen H, O'Sullivan MA (1993) Detection of dengue virus by in situ hybridization. 
Journal of virological methods 41:135‐146 
169. Kim SK, Park HJ, Kim JW, Chung J‐H, Yoo SD, Kim DH, Yun DH, Kim H‐S (2014) T Allele 
of nonsense polymorphism (rs2039381, Gln71Stop) of interferon‐ε is a risk factor for 
the development of intracerebral hemorrhage. Human Immunology 75:88‐90 
170. Kimura T, Katoh H, Kayama H, Saiga H, Okuyama M, Okamoto T, Umemoto E, 
Matsuura Y, Yamamoto M, Takeda K (2013) Ifit1 inhibits Japanese encephalitis virus 
replication through binding to 5' capped 2'‐O unmethylated RNA. Journal of virology 
87:9997‐10003 
171. Klema VJ, Ye M, Hindupur A, Teramoto T, Gottipati K, Padmanabhan R, Choi KH 
(2016) Dengue Virus Nonstructural Protein 5 (NS5) Assembles into a Dimer with a 
Unique Methyltransferase and Polymerase Interface. PLoS pathogens 12:e1005451‐
e1005451 
172. Klinkhammer J, Schnepf D, Ye L, Schwaderlapp M, Gad HH, Hartmann R, Garcin D, 
Mahlakoiv T, Staeheli P (2018) IFN‐lambda prevents influenza virus spread from the 
upper airways to the lungs and limits virus transmission. eLife 7 
173. Kodati S, Palmore TN, Spellman FA, Cunningham D, Weistrop B, Sen HN (2017) 
Bilateral posterior uveitis associated with Zika virus infection. Lancet (London, 
England) 389:125‐126 
174. Kotenko SV, Gallagher G, Baurin VV, Lewis‐Antes A, Shen M, Shah NK, Langer JA, 
Sheikh F, Dickensheets H, Donnelly RP (2003) IFN‐lambdas mediate antiviral 
277 
 
protection through a distinct class II cytokine receptor complex. Nature immunology 
4:69‐77 
175. Koyama S, Ishii KJ, Coban C, Akira S (2008) Innate immune response to viral infection. 
Cytokine 43:336‐341 
176. Kumar A, Hou S, Airo AM, Limonta D, Mancinelli V, Branton W, Power C, Hobman TC 
(2016) Zika virus inhibits type‐I interferon production and downstream signaling. 
EMBO reports 17:1766‐1775 
177. Kumar A, Jovel J, Lopez‐Orozco J, Limonta D, Airo AM, Hou S, Stryapunina I, Fibke C, 
Moore RB, Hobman TC (2018) Human Sertoli cells support high levels of Zika virus 
replication and persistence. Scientific reports 8:5477 
178. Kwon JY, Aldo P, You Y, Ding J, Racicot K, Dong X, Murphy J, Glukshtad G, Silasi M, 
Peng J, Wen L, Abrahams VM, Romero R, Mor G (2018) Relevance of placental type I 
interferon beta regulation for pregnancy success. Cellular & molecular immunology 
179. Lamken P, Lata S, Gavutis M, Piehler J (2004) Ligand‐induced assembling of the type I 
interferon receptor on supported lipid bilayers. J Mol Biol 341:303‐318 
180. Lauring AS, Andino R (2010) Quasispecies theory and the behavior of RNA viruses. 
PLoS Pathog 6:e1001005 
181. Lazear HM, Govero J, Smith AM, Platt DJ, Fernandez E, Miner JJ, Diamond MS (2016) 
A Mouse Model of Zika Virus Pathogenesis. Cell host & microbe 19:720‐730 
182. Lazear HM, Schoggins JW, Diamond MS (2019) Shared and Distinct Functions of Type 
I and Type III Interferons. Immunity 50:907‐923 
183. Ledur PF, Karmirian K, Pedrosa CdSG, Souza LRQ, Assis‐de‐Lemos G, Martins TM, 
Ferreira JdCCG, de Azevedo Reis GF, Silva ES, Silva D, Salerno JA, Ornelas IM, Devalle 
S, Madeiro da Costa RF, Goto‐Silva L, Higa LM, Melo A, Tanuri A, Chimelli L, Murata 
MM, Garcez PP, Filippi‐Chiela EC, Galina A, Borges HL, Rehen SK (2020) Zika virus 
infection leads to mitochondrial failure, oxidative stress and DNA damage in human 
iPSC‐derived astrocytes. Scientific reports 10:1218‐1218 
184. Lescar J, Soh S, Lee LT, Vasudevan SG, Kang C, Lim SP (2018) The Dengue Virus 
Replication Complex: From RNA Replication to Protein‐Protein Interactions to 
Evasion of Innate Immunity. Advances in experimental medicine and biology 
1062:115‐129 
185. Li D, Aaskov J, Lott WB (2011) Identification of a cryptic prokaryotic promoter within 
the cDNA encoding the 5' end of dengue virus RNA genome. PloS one 6:e18197‐
e18197 
186. Li G, Adam A, Luo H, Shan C, Cao Z, Fontes‐Garfias CR, Sarathy VV, Teleki C, 
Winkelmann ER, Liang Y, Sun J, Bourne N, Barrett ADT, Shi PY, Wang T (2019) An 
attenuated Zika virus NS4B protein mutant is a potent inducer of antiviral immune 
responses. NPJ vaccines 4:48 
187. Liang C, Rong L, Laughrea M, Kleiman L, Wainberg MA (1998) Compensatory point 
mutations in the human immunodeficiency virus type 1 Gag region that are distal 
from deletion mutations in the dimerization initiation site can restore viral 
replication. Journal of virology 72:6629‐6636 
188. Lin JP, Fan YK, Liu HM (2019) The 14‐3‐3η chaperone protein promotes antiviral 
innate immunity via facilitating MDA5 oligomerization and intracellular 
redistribution. PLoS Pathog 15:e1007582 
278 
 
189. Lin S, Yang S, He J, Guest JD, Ma Z, Yang L, Pierce BG, Tang Q, Zhang YJ (2019) Zika 
virus NS5 protein antagonizes type I interferon production via blocking TBK1 
activation. Virology 527:180‐187 
190. Lin SC, Kuo CC, Tsao JT, Lin LJ (2012) Profiling the expression of interleukin (IL)‐28 
and IL‐28 receptor α in systemic lupus erythematosus patients. European journal of 
clinical investigation 42:61‐69 
191. Lisova O, Belkadi L, Bedouelle H (2014) Direct and indirect interactions in the 
recognition between a cross‐neutralizing antibody and the four serotypes of dengue 
virus. Journal of molecular recognition : JMR 27:205‐214 
192. Liu HM, Loo YM, Horner SM, Zornetzer GA, Katze MG, Gale M, Jr. (2012) The 
mitochondrial targeting chaperone 14‐3‐3ε regulates a RIG‐I translocon that 
mediates membrane association and innate antiviral immunity. Cell host & microbe 
11:528‐537 
193. Liu L, Chen Z, Zhang X, Li S, Hui Y, Feng H, Du Y, Jin G, Zhou X, Zhang X (2019) 
Protection of ZIKV infection‐induced neuropathy by abrogation of acute antiviral 
response in human neural progenitors. Cell death and differentiation 
194. Liu WJ, Wang XJ, Mokhonov VV, Shi P‐Y, Randall R, Khromykh AA (2005) Inhibition of 
Interferon Signaling by the New York 99 Strain and Kunjin Subtype of West Nile Virus 
Involves Blockage of STAT1 and STAT2 Activation by Nonstructural Proteins. Journal 
of virology 79:1934‐1942 
195. Liu Y, Liu J, Du S, Shan C, Nie K, Zhang R, Li XF, Zhang R, Wang T, Qin CF, Wang P, Shi 
PY, Cheng G (2017) Evolutionary enhancement of Zika virus infectivity in Aedes 
aegypti mosquitoes. Nature 545:482‐486 
196. Lodeiro MF, Filomatori CV, Gamarnik AV (2009) Structural and functional studies of 
the promoter element for dengue virus RNA replication. Journal of virology 83:993‐
1008 
197. Lovera D, Martinez de Cuellar C, Araya S, Amarilla S, Gonzalez N, Aguiar C, Acuna J, 
Arbo A (2016) Clinical Characteristics and Risk Factors of Dengue Shock Syndrome in 
Children. The Pediatric infectious disease journal 35:1294‐1299 
198. Lundberg R, Melen K, Westenius V, Jiang M, Osterlund P, Khan H, Vapalahti O, 
Julkunen I, Kakkola L (2019) Zika Virus Non‐Structural Protein NS5 Inhibits the RIG‐I 
Pathway and Interferon Lambda 1 Promoter Activation by Targeting IKK Epsilon. 
Viruses 11 
199. Lwande OW, Obanda V, Lindstrom A, Ahlm C, Evander M, Naslund J, Bucht G (2020) 
Globe‐Trotting Aedes aegypti and Aedes albopictus: Risk Factors for Arbovirus 
Pandemics. Vector borne and zoonotic diseases (Larchmont, NY) 20:71‐81 
200. Ma J, Ketkar H, Geng T, Lo E, Wang L, Xi J, Sun Q, Zhu Z, Cui Y, Yang L, Wang P (2018) 
Zika Virus Non‐structural Protein 4A Blocks the RLR‐MAVS Signaling. Frontiers in 
microbiology 9:1350 
201. Maltepe E, Fisher SJ (2015) Placenta: the forgotten organ. Annual review of cell and 
developmental biology 31:523‐552 
202. Manokaran G, Finol E, Wang C, Gunaratne J, Bahl J, Ong EZ, Tan HC, Sessions OM, 
Ward AM, Gubler DJ, Harris E, Garcia‐Blanco MA, Ooi EE (2015) Dengue subgenomic 
RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. 
Science (New York, NY) 350:217‐221 
279 
 
203. Manry J, Laval G, Patin E, Fornarino S, Itan Y, Fumagalli M, Sironi M, Tichit M, 
Bouchier C, Casanova JL, Barreiro LB, Quintana‐Murci L (2011) Evolutionary genetic 
dissection of human interferons. J Exp Med 208:2747‐2759 
204. Mansuy JM, Suberbielle E, Chapuy‐Regaud S, Mengelle C, Bujan L, Marchou B, 
Delobel P, Gonzalez‐Dunia D, Malnou CE, Izopet J, Martin‐Blondel G (2016) Zika virus 
in semen and spermatozoa. The Lancet Infectious diseases 16:1106‐1107 
205. Mantere T, Kersten S, Hoischen A (2019) Long‐Read Sequencing Emerging in Medical 
Genetics. Frontiers in genetics 10:426 
206. Marcello T, Grakoui A, Barba‐Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice 
CM (2006) Interferons alpha and lambda inhibit hepatitis C virus replication with 
distinct signal transduction and gene regulation kinetics. Gastroenterology 131:1887‐
1898 
207. Marijanovic Z, Ragimbeau J, van der Heyden J, Uze G, Pellegrini S (2007) Comparable 
potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential 
down‐regulation of IFNAR2. The Biochemical journal 407:141‐151 
208. Martina BE, Koraka P, Osterhaus AD (2009) Dengue virus pathogenesis: an integrated 
view. Clinical microbiology reviews 22:564‐581 
209. Marzi A, Emanuel J, Callison J, McNally KL, Arndt N, Chadinha S, Martellaro C, 
Rosenke R, Scott DP, Safronetz D, Whitehead SS, Best SM, Feldmann H (2018) Lethal 
Zika Virus Disease Models in Young and Older Interferon α/β Receptor Knock Out 
Mice. Frontiers in Cellular and Infection Microbiology 8:117 
210. Matsumiya T, Prescott SM, Stafforini DM (2007) IFN‐epsilon mediates TNF‐alpha‐
induced STAT1 phosphorylation and induction of retinoic acid‐inducible gene‐I in 
human cervical cancer cells. Journal of immunology (Baltimore, Md : 1950) 
179:4542‐4549 
211. Matsumiya T, Xing F, Ebina M, Hayakari R, Imaizumi T, Yoshida H, Kikuchi H, Topham 
MK, Satoh K, Stafforini DM (2013) Novel role for molecular transporter importin 9 in 
posttranscriptional regulation of IFN‐epsilon expression. Journal of immunology 
(Baltimore, Md : 1950) 191:1907‐1915 
212. Mazeaud C, Freppel W, Chatel‐Chaix L (2018) The Multiples Fates of the Flavivirus 
RNA Genome During Pathogenesis. Frontiers in genetics 9:595 
213. Mazzon M, Jones M, Davidson A, Chain B, Jacobs M (2009) Dengue Virus NS5 Inhibits 
Interferon‐α Signaling by Blocking Signal Transducer and Activator of Transcription 2 
Phosphorylation. The Journal of Infectious Diseases 200:1261‐1270 
214. McNab F, Mayer‐Barber K, Sher A, Wack A, O'Garra A (2015) Type I interferons in 
infectious disease. Nature reviews Immunology 15:87‐103 
215. Meertens L, Carnec X, Lecoin Manuel P, Ramdasi R, Guivel‐Benhassine F, Lew E, 
Lemke G, Schwartz O, Amara A (2012) The TIM and TAM Families of 
Phosphatidylserine Receptors Mediate Dengue Virus Entry. Cell host & microbe 
12:544‐557 
216. Meertens L, Labeau A, Dejarnac O, Cipriani S, Sinigaglia L, Bonnet‐Madin L, Le 
Charpentier T, Hafirassou ML, Zamborlini A, Cao‐Lormeau VM, Coulpier M, Misse D, 
Jouvenet N, Tabibiazar R, Gressens P, Schwartz O, Amara A (2017) Axl Mediates ZIKA 




217. Messina NL, Clarke CJP, Johnstone RW (2016) Constitutive IFNα/β signaling 
maintains expression of signaling intermediaries for efficient cytokine responses. 
JAK‐STAT 5:e1173804 
218. Meuwissen MEC, Schot R, Buta S, Oudesluijs G, Tinschert S, Speer SD, Li Z, van Unen 
L, Heijsman D, Goldmann T, Lequin MH, Kros JM, Stam W, Hermann M, Willemsen R, 
Brouwer RWW, Van Ijcken WFJ, Martin‐Fernandez M, de Coo I, Dudink J, de Vries 
FAT, Bertoli Avella A, Prinz M, Crow YJ, Verheijen FW, Pellegrini S, Bogunovic D, 
Mancini GMS (2016) Human USP18 deficiency underlies type 1 interferonopathy 
leading to severe pseudo‐TORCH syndrome. The Journal of experimental medicine 
213:1163‐1174 
219. Miagostovich MP, Ramos RG, Nicol AF, Nogueira RM, Cuzzi‐Maya T, Oliveira AV, 
Marchevsky RS, Mesquita RP, Schatzmayr HG (1997) Retrospective study on dengue 
fatal cases. Clinical neuropathology 16:204‐208 
220. Miller S, Kastner S, Krijnse‐Locker J, Buhler S, Bartenschlager R (2007) The non‐
structural protein 4A of dengue virus is an integral membrane protein inducing 
membrane alterations in a 2K‐regulated manner. The Journal of biological chemistry 
282:8873‐8882 
221. Miner JJ, Cao B, Govero J, Smith AM, Fernandez E, Cabrera OH, Garber C, Noll M, 
Klein RS, Noguchi KK, Mysorekar IU, Diamond MS (2016) Zika Virus Infection during 
Pregnancy in Mice Causes Placental Damage and Fetal Demise. Cell 165:1081‐1091 
222. Miner Jonathan J, Sene A, Richner Justin M, Smith Amber M, Santeford A, Ban N, 
Weger‐Lucarelli J, Manzella F, Rückert C, Govero J, Noguchi Kevin K, Ebel Gregory D, 
Diamond Michael S, Apte Rajendra S (2016) Zika Virus Infection in Mice Causes 
Panuveitis with Shedding of Virus in Tears. Cell reports 16:3208‐3218 
223. Miner JJ, Diamond MS (2017) Zika Virus Pathogenesis and Tissue Tropism. Cell host & 
microbe 21 134‐142 
224. Miorin L, Maestre AM, Fernandez‐Sesma A, García‐Sastre A Antagonism of type I 
interferon by flaviviruses. Biochemical and Biophysical Research Communications 
225. Modhiran N, Watterson D, Blumenthal A, Baxter AG, Young PR, Stacey KJ (2017) 
Dengue virus NS1 protein activates immune cells via TLR4 but not TLR2 or TLR6. 
Immunology and cell biology 95:491‐495 
226. Mor G (2016) Placental Inflammatory Response to Zika Virus may Affect Fetal Brain 
Development. American journal of reproductive immunology (New York, NY : 1989) 
75:421‐422 
227. Mor G, Aldo P, Alvero AB (2017) The unique immunological and microbial aspects of 
pregnancy. Nature reviews Immunology 17:469‐482 
228. Moreira J, Peixoto TM, Siqueira AM, Lamas CC (2017) Sexually acquired Zika virus: a 
systematic review. Clinical microbiology and infection : the official publication of the 
European Society of Clinical Microbiology and Infectious Diseases 23:296‐305 
229. Morrison J, Aguirre S, Fernandez‐Sesma A (2012) Innate Immunity Evasion by 
Dengue Virus. Viruses 4:397‐413 
230. Morrison J, Laurent‐Rolle M, Maestre AM, Rajsbaum R, Pisanelli G, Simon V, Mulder 
LC, Fernandez‐Sesma A, Garcia‐Sastre A (2013) Dengue virus co‐opts UBR4 to 
degrade STAT2 and antagonize type I interferon signaling. PLoS Pathog 9:e1003265 
231. Morrison TE, Diamond MS (2017) Animal Models of Zika Virus Infection, 
Pathogenesis, and Immunity. Journal of virology 91 
281 
 
232. Motwani M, Pesiridis S, Fitzgerald KA (2019) DNA sensing by the cGAS‐STING 
pathway in health and disease. Nature reviews Genetics 20:657‐674 
233. Mousavi SA, Malerod L, Berg T, Kjeken R (2004) Clathrin‐dependent endocytosis. The 
Biochemical journal 377:1‐16 
234. Mukhopadhyay S, Kuhn RJ, Rossmann MG (2005) A structural perspective of the 
flavivirus life cycle. Nature reviews Microbiology 3:13‐22 
235. Munoz‐Jordan JL, Laurent‐Rolle M, Ashour J, Martinez‐Sobrido L, Ashok M, Lipkin WI, 
Garcia‐Sastre A (2005) Inhibition of alpha/beta interferon signaling by the NS4B 
protein of flaviviruses. Journal of virology 79:8004‐8013 
236. Muñoz‐Jordan JL, Sánchez‐Burgos GG, Laurent‐Rolle M, García‐Sastre A (2003) 
Inhibition of interferon signaling by dengue virus. Proceedings of the National 
Academy of Sciences of the United States of America 100:14333‐14338 
237. Murphy SP, Tayade C, Ashkar AA, Hatta K, Zhang J, Croy BA (2009) Interferon gamma 
in successful pregnancies. Biol Reprod 80:848‐859 
238. Murray CL, Jones CT, Rice CM (2008) Architects of assembly: roles of Flaviviridae 
non‐structural proteins in virion morphogenesis. Nature reviews Microbiology 6:699‐
708 
239. Murray NEA, Quam MB, Wilder‐Smith A (2013) Epidemiology of dengue: past, 
present and future prospects. Clin Epidemiol 5:299‐309 
240. Musso D, Ko AI, Baud D (2019) Zika Virus Infection ‐ After the Pandemic. The New 
England journal of medicine 381:1444‐1457 
241. Mutso M, Saul S, Rausalu K, Susova O, Zusinaite E, Mahalingam S, Merits A (2017) 
Reverse genetic system, genetically stable reporter viruses and packaged 
subgenomic replicon based on a Brazilian Zika virus isolate. The Journal of general 
virology 98:2712‐2724 
242. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J (1982) Growth of human 
hepatoma cells lines with differentiated functions in chemically defined medium. 
Cancer Res 42:3858‐3863 
243. Nasirudeen AM, Wong HH, Thien P, Xu S, Lam KP, Liu DX (2011) RIG‐I, MDA5 and 
TLR3 synergistically play an important role in restriction of dengue virus infection. 
PLoS neglected tropical diseases 5:e926 
244. Nasr N, Maddocks S, Turville SG, Harman AN, Woolger N, Helbig KJ, Wilkinson J, Bye 
CR, Wright TK, Rambukwelle D, Donaghy H, Beard MR, Cunningham AL (2012) HIV‐1 
infection of human macrophages directly induces viperin which inhibits viral 
production. Blood 120:778‐788 
245. Nazmi A, Dutta K, Hazra B, Basu A (2014) Role of pattern recognition receptors in 
flavivirus infections. Virus research 185:32‐40 
246. Ng DHL, Ho HJ, Chow A, Wong J, Kyaw WM, Tan A, Chia PY, Choy CY, Tan G, Yeo TW, 
Leo YS (2018) Correlation of clinical illness with viremia in Zika virus disease during 
an outbreak in Singapore. BMC infectious diseases 18:301 
247. Ng WC, Soto‐Acosta R, Bradrick SS, Garcia‐Blanco MA, Ooi EE (2017) The 5′ and 3′ 
Untranslated Regions of the Flaviviral Genome. Viruses 9:137 
248. Ngo AM, Shurtleff MJ, Popova KD, Kulsuptrakul J, Weissman JS, Puschnik AS (2019) 
The ER membrane protein complex is required to ensure correct topology and stable 
expression of flavivirus polyproteins. eLife 8 
249. Ngueyen TTN, Kim SJ, Lee JY, Myoung J (2019) Zika Virus Proteins NS2A and NS4A 
Are Major Antagonists that Reduce IFN‐beta Promoter Activity Induced by the 
282 
 
MDA5/RIG‐I Signaling Pathway. Journal of microbiology and biotechnology 29:1665‐
1674 
250. Nickodem C, Criscitiello MF, Bazer F, Abiodun‐Ojo O, Taylor BD (2018) Interferon 
epsilon in the reproductive tract of healthy and genital herpes simplex virus‐infected 
pregnant women: Results of a pilot study. American journal of reproductive 
immunology (New York, NY : 1989) 80:e12995 
251. Nielsen‐Saines K, Brasil P, Kerin T, Vasconcelos Z, Gabaglia CR, Damasceno L, Pone M, 
Abreu de Carvalho LM, Pone SM, Zin AA, Tsui I, Salles TRS, da Cunha DC, Costa RP, 
Malacarne J, Reis AB, Hasue RH, Aizawa CYP, Genovesi FF, Einspieler C, Marschik PB, 
Pereira JP, Gaw SL, Adachi K, Cherry JD, Xu Z, Cheng G, Moreira ME (2019) Delayed 
childhood neurodevelopment and neurosensory alterations in the second year of life 
in a prospective cohort of ZIKV‐exposed children. Nature Medicine 
252. Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi K (1985) [Establishment of a 
new human endometrial adenocarcinoma cell line, Ishikawa cells, containing 
estrogen and progesterone receptors]. Nihon Sanka Fujinka Gakkai zasshi 37:1103‐
1111 
253. Nollaig M. Bourke SLA, Stephanie U. Huang, Helen E. Cumming, Irene Papageorgio, 
Linden J. Gearing, Suruchi Thakore, Niamh E. Mangan, Sam Mesiano, Paul J. Hertzog 
(2018) Human IFNε: Spatiotemporal expression, hormone regulation and innate 
immunity in the female reproductive tract. bioRxiv 
254. Odendall C, Dixit E, Stavru F, Bierne H, Franz KM, Durbin AF, Boulant S, Gehrke L, 
Cossart P, Kagan JC (2014) Diverse intracellular pathogens activate type III interferon 
expression from peroxisomes. Nature immunology 15:717‐726 
255. Odendall C, Kagan JC (2015) The unique regulation and functions of type III 
interferons in antiviral immunity. Current opinion in virology 12:47‐52 
256. Oliveira ERA, Mohana‐Borges R, de Alencastro RB, Horta BAC (2017) The flavivirus 
capsid protein: Structure, function and perspectives towards drug design. Virus 
research 227:115‐123 
257. Pagani I, Ghezzi S, Ulisse A, Rubio A, Turrini F, Garavaglia E, Candiani M, Castilletti C, 
Ippolito G, Poli G, Broccoli V, Panina‐Bordignon P, Vicenzi E (2017) Human 
Endometrial Stromal Cells Are Highly Permissive To Productive Infection by Zika 
Virus. Scientific reports 7:44286 
258. Paixao ES, Leong WY, Rodrigues LC, Wilder‐Smith A (2018) Asymptomatic Prenatal 
Zika Virus Infection and Congenital Zika Syndrome. Open forum infectious diseases 
5:ofy073 
259. Panayiotou C, Lindqvist R, Kurhade C, Vonderstein K, Pasto J, Edlund K, Upadhyay AS, 
Overby AK (2018) Viperin restricts Zika virus and tick‐borne encephalitis virus 
replication by targeting NS3 for proteasomal degradation. Journal of virology 
260. Payne S (2017) Family Flaviviridae.  Viruses ‐ from understanding to investigation, pp 
129 ‐ 139 
261. Paz‐Bailey G, Rosenberg ES, Doyle K, Munoz‐Jordan J, Santiago GA, Klein L, Perez‐
Padilla J, Medina FA, Waterman SH, Gubern CG, Alvarado LI, Sharp TM (2018) 
Persistence of Zika Virus in Body Fluids ‐ Final Report. The New England journal of 
medicine 379:1234‐1243 
262. Peng FW, Duan ZJ, Zheng LS, Xie ZP, Gao HC, Zhang H, Li WP, Hou YD (2007) 
Purification of recombinant human interferon‐epsilon and oligonucleotide 
283 
 
microarray analysis of interferon‐epsilon‐regulated genes. Protein expression and 
purification 53:356‐362 
263. Peregrine J, Gurung S, Lindgren MC, Husain S, Zavy MT, Myers DA, Papin JF (2019) 
Zika Virus Infection, Reproductive Organ Targeting, and Semen Transmission in the 
Male Olive Baboon. Journal of virology 94 
264. Perera‐Lecoin M, Meertens L, Carnec X, Amara A (2014) Flavivirus Entry Receptors: 
An Update. Viruses 6:69‐88 
265. Perera R, Kuhn RJ (2008) Structural proteomics of dengue virus. Curr Opin Microbiol 
11:369‐377 
266. Perng Y‐C, Lenschow DJ (2018) ISG15 in antiviral immunity and beyond. Nature 
reviews Microbiology 16:423‐439 
267. Pettersson JH, Eldholm V, Seligman SJ, Lundkvist A, Falconar AK, Gaunt MW, Musso 
D, Nougairede A, Charrel R, Gould EA, de Lamballerie X (2016) How Did Zika Virus 
Emerge in the Pacific Islands and Latin America? mBio 7 
268. Phipps‐Yonas H, Seto J, Sealfon SC, Moran TM, Fernandez‐Sesma A (2008) 
Interferon‐beta pretreatment of conventional and plasmacytoid human dendritic 
cells enhances their activation by influenza virus. PLoS pathogens 4:e1000193‐
e1000193 
269. Piganis RA, De Weerd NA, Gould JA, Schindler CW, Mansell A, Nicholson SE, Hertzog 
PJ (2011) Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) 
signaling via the interferon alpha receptor (IFNAR1)‐associated tyrosine kinase Tyk2. 
The Journal of biological chemistry 286:33811‐33818 
270. Pomar L, Lambert V, Madec Y, Vouga M, Pomar C, Matheus S, Fontanet A, Panchaud 
A, Carles G, Baud D (2019) Placental infection by Zika virus in French Guiana. 
Ultrasound in obstetrics & gynecology : the official journal of the International 
Society of Ultrasound in Obstetrics and Gynecology 
271. Prisant N, Bujan L, Benichou H, Hayot PH, Pavili L, Lurel S, Herrmann C, Janky E, 
Joguet G (2016) Zika virus in the female genital tract. The Lancet Infectious diseases 
16:1000‐1001 
272. Prisant N, Joguet G, Herrmann‐Stock C, Moriniere C, Pavili L, Lurel S, Bujan L (2019) 
Upper and lower genital tract Zika virus screening in a large cohort of reproductive‐
age women during the Americas epidemic. Reproductive biomedicine online 
273. Pu S‐Y, Wu R‐H, Yang C‐C, Jao T‐M, Tsai M‐H, Wang J‐C, Lin H‐M, Chao Y‐S, Yueh A 
(2011) Successful propagation of flavivirus infectious cDNAs by a novel method to 
reduce the cryptic bacterial promoter activity of virus genomes. Journal of virology 
85:2927‐2941 
274. Qi H, Chu V, Wu NC, Chen Z, Truong S, Brar G, Su SY, Du Y, Arumugaswami V, Olson 
CA, Chen SH, Lin CY, Wu TT, Sun R (2017) Systematic identification of anti‐interferon 
function on hepatitis C virus genome reveals p7 as an immune evasion protein. 
Proceedings of the National Academy of Sciences of the United States of America 
114:2018‐2023 
275. Qi Y, Li Y, Zhang Y, Zhang L, Wang Z, Zhang X, Gui L, Huang J (2015) IFI6 Inhibits 
Apoptosis via Mitochondrial‐Dependent Pathway in Dengue Virus 2 Infected Vascular 
Endothelial Cells. PloS one 10:e0132743‐e0132743 
276. Racicot K, Aldo P, El‐Guindy A, Kwon JY, Romero R, Mor G (2017) Cutting Edge: 
Fetal/Placental Type I IFN Can Affect Maternal Survival and Fetal Viral Load during 
Viral Infection. Journal of immunology (Baltimore, Md : 1950) 198:3029‐3032 
284 
 
277. Radukic MT, Brandt D, Haak M, Müller KM, Kalinowski J (2019) Nanopore sequencing 
of native adeno‐associated virus single‐stranded DNA using a transposase‐based 
rapid protocol. bioRxiv:2019.2012.2027.885319 
278. Raftery N, Stevenson NJ (2017) Advances in anti‐viral immune defence: revealing the 
importance of the IFN JAK/STAT pathway. Cellular and Molecular Life Sciences 
74:2525‐2535 
279. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR (2016) Zika Virus and Birth 
Defects‐‐Reviewing the Evidence for Causality. The New England journal of medicine 
374:1981‐1987 
280. Rastogi M, Sharma N, Singh SK (2016) Flavivirus NS1: a multifaceted enigmatic viral 
protein. Virology journal 13:131 
281. Reder AT, Feng X (2014) How type I interferons work in multiple sclerosis and other 
diseases: some unexpected mechanisms. Journal of interferon & cytokine research : 
the official journal of the International Society for Interferon and Cytokine Research 
34:589‐599 
282. Reiser J, Hurst J, Voges M, Krauss P, Munch P, Iftner T, Stubenrauch F (2011) High‐
risk human papillomaviruses repress constitutive kappa interferon transcription via 
E6 to prevent pathogen recognition receptor and antiviral‐gene expression. Journal 
of virology 85:11372‐11380 
283. Remenyi R, Qi H, Su SY, Chen Z, Wu NC, Arumugaswami V, Truong S, Chu V, 
Stokelman T, Lo HH, Olson CA, Wu TT, Chen SH, Lin CY, Sun R (2014) A 
comprehensive functional map of the hepatitis C virus genome provides a resource 
for probing viral proteins. mBio 5:e01469‐01414 
284. Rice ME, Galang RR, Roth NM, Ellington SR, Moore CA, Valencia‐Prado M, Ellis EM, 
Tufa AJ, Taulung LA, Alfred JM, Perez‐Padilla J, Delgado‐Lopez CA, Zaki SR, Reagan‐
Steiner S, Bhatnagar J, Nahabedian JF, 3rd, Reynolds MR, Yeargin‐Allsopp M, Viens 
LJ, Olson SM, Jones AM, Baez‐Santiago MA, Oppong‐Twene P, VanMaldeghem K, 
Simon EL, Moore JT, Polen KD, Hillman B, Ropeti R, Nieves‐Ferrer L, Marcano‐Huertas 
M, Masao CA, Anzures EJ, Hansen RL, Jr., Perez‐Gonzalez SI, Espinet‐Crespo CP, 
Luciano‐Roman M, Shapiro‐Mendoza CK, Gilboa SM, Honein MA (2018) Vital Signs: 
Zika‐Associated Birth Defects and Neurodevelopmental Abnormalities Possibly 
Associated with Congenital Zika Virus Infection ‐ U.S. Territories and Freely 
Associated States, 2018. MMWR Morbidity and mortality weekly report 67:858‐867 
285. Richardson RB, Ohlson MB, Eitson JL, Kumar A, McDougal MB, Boys IN, Mar KB, De La 
Cruz‐Rivera PC, Douglas C, Konopka G, Xing C, Schoggins JW (2018) A CRISPR screen 
identifies IFI6 as an ER‐resident interferon effector that blocks flavivirus replication. 
Nature microbiology 3:1214‐1223 
286. Riedl W, Acharya D, Lee JH, Liu G, Serman T, Chiang C, Chan YK, Diamond MS, Gack 
MU (2019) Zika Virus NS3 Mimics a Cellular 14‐3‐3‐Binding Motif to Antagonize RIG‐I‐ 
and MDA5‐Mediated Innate Immunity. Cell host & microbe 26:493‐503.e496 
287. Rivera‐Correa J, de Siqueira IC, Mota S, do Rosario MS, Pereira de Jesus PA, Alcantara 
LCJ, Ernst JD, Rodriguez A (2019) Anti‐ganglioside antibodies in patients with Zika 
virus infection‐associated Guillain‐Barre Syndrome in Brazil. PLoS neglected tropical 
diseases 13:e0007695 
288. Robinson N, Mayorquin Galvan EE, Zavala Trujillo IG, Zavala‐Cerna MG (2018) 




289. Roby JA, Funk A, Khromykh AA (2012) Flavivirus replication and assembly.  Molecular 
Virology and Control of Flaviviruses. Caister Academic Press, Norfolk, UK 
290. Rossi SL, Tesh RB, Azar SR, Muruato AE, Hanley KA, Auguste AJ, Langsjoen RM, 
Paessler S, Vasilakis N, Weaver SC (2016) Characterization of a Novel Murine Model 
to Study Zika Virus. The American journal of tropical medicine and hygiene 94:1362‐
1369 
291. Rothman AL (2011) Immunity to dengue virus: a tale of original antigenic sin and 
tropical cytokine storms. Nature reviews Immunology 11:532‐543 
292. Ruggli N, Rice CM (1999) Functional cDNA clones of the Flaviviridae: strategies and 
applications. Advances in virus research 53:183‐207 
293. Rusinova IF, S.; Yu, S.; Kannan, A.; Masse, M.; Cumming, H.; Chapman, R.; Hertzog, 
P.J. (2013) INTERFEROME v2. 0: an updated database of annotated interferon‐
regulated genes. Nucleic acids research:D1040‐D1046. 
294. Russo FB, Jungmann P, Beltrao‐Braga PCB (2017) Zika infection and the development 
of neurological defects. Cellular microbiology 19 
295. Saeedi BJ, Geiss BJ (2013) Regulation of flavivirus RNA synthesis and capping. Wiley 
Interdiscip Rev RNA 4:723‐735 
296. Sakkas H, Bozidis P, Giannakopoulos X, Sofikitis N, Papadopoulou C (2018) An Update 
on Sexual Transmission of Zika Virus. Pathogens (Basel, Switzerland) 7 
297. Sam SS, Omar SF, Teoh BT, Abd‐Jamil J, AbuBakar S (2013) Review of Dengue 
hemorrhagic fever fatal cases seen among adults: a retrospective study. PLoS 
neglected tropical diseases 7:e2194 
298. Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R (2010) Viral mutation rates. 
Journal of virology 84:9733‐9748 
299. Sarasin‐Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ, Zhang DE, Heim 
MH (2009) Alpha interferon induces long‐lasting refractoriness of JAK‐STAT signaling 
in the mouse liver through induction of USP18/UBP43. Molecular and cellular biology 
29:4841‐4851 
300. Savidis G, Perreira JM, Portmann JM, Meraner P, Guo Z, Green S, Brass AL (2016) The 
IFITMs Inhibit Zika Virus Replication. Cell reports 15:2323‐2330 
301. Scherer WF, Syverton JT, Gey GO (1953) Studies on the propagation in vitro of 
poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant 
epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J 
Exp Med 97:695‐710 
302. Schilling M, Bridgeman A, Gray N, Hertzog J, Hublitz P, Kohl A, Rehwinkel J (2020) 
RIG‐I Plays a Dominant Role in the Induction of Transcriptional Changes in Zika Virus‐
Infected Cells, which Protect from Virus‐Induced Cell Death. Cells 9 
303. Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, Barchet W, Coch C, 
Janke M, Mihailovic A, Wardle G, Juranek S, Kato H, Kawai T, Poeck H, Fitzgerald KA, 
Takeuchi O, Akira S, Tuschl T, Latz E, Ludwig J, Hartmann G (2009) Recognition of 5' 
triphosphate by RIG‐I helicase requires short blunt double‐stranded RNA as 
contained in panhandle of negative‐strand virus. Immunity 31:25‐34 
304. Schneider WM, Chevillotte MD, Rice CM (2014) Interferon‐stimulated genes: a 
complex web of host defenses. Annual review of immunology 32:513‐545 
305. Schneider WM, Chevillotte MD, Rice CM (2014) Interferon‐stimulated genes: a 
complex web of host defenses. Annual review of immunology 32:513‐545 
286 
 
306. Schoenborn JR, Wilson CB (2007) Regulation of interferon‐gamma during innate and 
adaptive immune responses. Advances in immunology 96:41‐101 
307. Schuessler A, Funk A, Lazear HM, Cooper DA, Torres S, Daffis S, Jha BK, Kumagai Y, 
Takeuchi O, Hertzog P, Silverman R, Akira S, Barton DJ, Diamond MS, Khromykh AA 
(2012) West Nile virus noncoding subgenomic RNA contributes to viral evasion of the 
type I interferon‐mediated antiviral response. Journal of virology 86:5708‐5718 
308. Schuler‐Faccini L, Ribeiro EM, Feitosa IM, Horovitz DD, Cavalcanti DP, Pessoa A, 
Doriqui MJ, Neri JI, Neto JM, Wanderley HY, Cernach M, El‐Husny AS, Pone MV, 
Serao CL, Sanseverino MT (2016) Possible Association Between Zika Virus Infection 
and Microcephaly ‐ Brazil, 2015. MMWR Morbidity and mortality weekly report 
65:59‐62 
309. Schwarz MC, Sourisseau M, Espino MM, Gray ES, Chambers MT, Tortorella D, Evans 
MJ (2016) Rescue of the 1947 Zika Virus Prototype Strain with a Cytomegalovirus 
Promoter‐Driven cDNA Clone. mSphere 1 
310. Scutigliani EM, Kikkert M (2017) Interaction of the innate immune system with 
positive‐strand RNA virus replication organelles. Cytokine Growth Factor Rev 37:17‐
27 
311. Setoh YX, Prow NA, Peng N, Hugo LE, Devine G, Hazlewood JE, Suhrbier A, Khromykh 
AA (2017) De Novo Generation and Characterization of New Zika Virus Isolate Using 
Sequence Data from a Microcephaly Case. mSphere 2:e00190‐00117 
312. Setoh YX, Amarilla AA, Peng NYG, Griffiths RE, Carrera J, Freney ME, Nakayama E, 
Ogawa S, Watterson D, Modhiran N, Nanyonga FE, Torres FJ, Slonchak A, Periasamy 
P, Prow NA, Tang B, Harrison J, Hobson‐Peters J, Cuddihy T, Cooper‐White J, Hall RA, 
Young PR, Mackenzie JM, Wolvetang E, Bloom JD, Suhrbier A, Khromykh AA (2019) 
Determinants of Zika virus host tropism uncovered by deep mutational scanning. 
Nature microbiology 4:876‐887 
313. Sever R, Brugge JS (2015) Signal transduction in cancer. Cold Spring Harb Perspect 
Med 5:a006098 
314. Shah I, Deshpande GC, Tardeja PN (2004) Outbreak of dengue in Mumbai and 
predictive markers for dengue shock syndrome. Journal of tropical pediatrics 50:301‐
305 
315. Shan C, Xia H, Haller SL, Azar SR, Liu Y, Liu J, Muruato AE, Chen R, Rossi SL, Wakamiya 
M, Vasilakis N, Pei R, Fontes‐Garfias CR, Singh SK, Xie X, Weaver SC, Shi PY (2020) A 
Zika virus envelope mutation preceding the 2015 epidemic enhances virulence and 
fitness for transmission. Proceedings of the National Academy of Sciences of the 
United States of America 
316. Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA (2007) Seminal plasma 
differentially regulates inflammatory cytokine gene expression in human cervical and 
vaginal epithelial cells. Molecular human reproduction 13:491‐501 
317. Sheldon IM, Owens SE, Turner ML (2017) Innate immunity and the sensing of 
infection, damage and danger in the female genital tract. J Reprod Immunol 119:67‐
73 
318. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, 
Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, 
Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, 
McKnight G, Clegg C, Foster D, Klucher KM (2003) IL‐28, IL‐29 and their class II 
cytokine receptor IL‐28R. Nature immunology 4:63‐68 
287 
 
319. Sheridan MA, Balaraman V, Schust DJ, Ezashi T, Roberts RM, Franz AWE (2018) 
African and Asian strains of Zika virus differ in their ability to infect and lyse primitive 
human placental trophoblast. PLoS One 13:e0200086 
320. Shu Q, Lennemann NJ, Sarkar SN, Sadovsky Y, Coyne CB (2015) ADAP2 Is an 
Interferon Stimulated Gene That Restricts RNA Virus Entry. PLoS pathogens 
11:e1005150‐e1005150 
321. Shukair SA, Allen SA, Cianci GC, Stieh DJ, Anderson MR, Baig SM, Gioia CJ, Spongberg 
EJ, Kauffman SM, McRaven MD, Lakougna HY, Hammond C, Kiser PF, Hope TJ (2013) 
Human cervicovaginal mucus contains an activity that hinders HIV‐1 movement. 
Mucosal immunology 6:427‐434 
322. Siewert E, Muller‐Esterl W, Starr R, Heinrich PC, Schaper F (1999) Different protein 
turnover of interleukin‐6‐type cytokine signalling components. European journal of 
biochemistry 265:251‐257 
323. Simon O, Billot S, Guyon D, Daures M, Descloux E, Gourinat AC, Molko N, Dupont‐
Rouzeyrol M (2016) Early Guillain‐Barre Syndrome associated with acute dengue 
fever. Journal of clinical virology : the official publication of the Pan American Society 
for Clinical Virology 77:29‐31 
324. Simonin Y, Erkilic N, Damodar K, Cle M, Desmetz C, Bollore K, Taleb M, Torriano S, 
Barthelemy J, Dubois G, Lajoix AD, Foulongne V, Tuaillon E, Van de Perre P, Kalatzis 
V, Salinas S (2019) Zika virus induces strong inflammatory responses and impairs 
homeostasis and function of the human retinal pigment epithelium. EBioMedicine 
39:315‐331 
325. Singh PK, Guest J‐M, Kanwar M, Boss J, Gao N, Juzych MS, Abrams GW, Yu F‐S, Kumar 
A (2017) Zika virus infects cells lining the blood‐retinal barrier and causes 
chorioretinal atrophy in mouse eyes. JCI insight 2:e92340‐e92340 
326. Singh PK, Guest J‐M, Kanwar M, Boss J, Gao N, Juzych MS, Abrams GW, Yu F‐S, Kumar 
A (2017) Zika virus infects cells lining the blood‐retinal barrier and causes 
chorioretinal atrophy in mouse eyes. JCI insight 2:e92340 
327. Singh PK, Singh S, Farr D, Kumar A (2019) Interferon‐stimulated gene 15 (ISG15) 
restricts Zika virus replication in primary human corneal epithelial cells. The ocular 
surface 
328. Sirohi D, Chen Z, Sun L, Klose T, Pierson TC, Rossmann MG, Kuhn RJ (2016) The 3.8 Å 
resolution cryo‐EM structure of Zika virus. Science (New York, NY) 352:467 
329. Song BH, Yun SI, Woolley M, Lee YM (2017) Zika virus: History, epidemiology, 
transmission, and clinical presentation. Journal of neuroimmunology 
330. Soo KM, Khalid B, Ching SM, Chee HY (2016) Meta‐Analysis of Dengue Severity 
during Infection by Different Dengue Virus Serotypes in Primary and Secondary 
Infections. PLoS One 11:e0154760 
331. Spencer JL, Lahon A, Tran LL, Arya RP, Kneubehl AR, Vogt MB, Xavier D, Rowley DR, 
Kimata JT, Rico‐Hesse RR (2018) Replication of Zika Virus in Human Prostate Cells: A 
Potential Source of Sexually Transmitted Virus. J Infect Dis 217:538‐547 
332. Sprokholt J, Helgers LC, Geijtenbeek TB (2017) Innate immune receptors drive 
dengue virus immune activation and disease. Future virology 13:287‐305 
333. Stanifer ML, Pervolaraki K, Boulant S (2019) Differential Regulation of Type I and 
Type III Interferon Signaling. International journal of molecular sciences 20 
334. Stassen L, Armitage CW, van der Heide DJ, Beagley KW, Frentiu FD (2018) Zika Virus 
in the Male Reproductive Tract. Viruses 10:198 
288 
 
335. Stifter SA, Matthews AY, Mangan NE, Fung KY, Drew A, Tate MD, Soares da Costa TP, 
Hampsey D, Mayall J, Hansbro PM, Garcia Minambres A, Eid SG, Mak J, Scoble J, 
Lovrecz G, de Weerd NA, Hertzog PJ (2017) Defining the distinct, intrinsic properties 
of the novel type I interferon, epsilon. The Journal of biological chemistry 
336. Sumpter R, Jr., Loo YM, Foy E, Li K, Yoneyama M, Fujita T, Lemon SM, Gale M, Jr. 
(2005) Regulating intracellular antiviral defense and permissiveness to hepatitis C 
virus RNA replication through a cellular RNA helicase, RIG‐I. Journal of virology 
79:2689‐2699 
337. Suwanmanee S, Luplertlop N (2017) Dengue and Zika viruses: lessons learned from 
the similarities between these Aedes mosquito‐vectored arboviruses. Journal of 
microbiology (Seoul, Korea) 55:81‐89 
338. Suy A, Sulleiro E, Rodo C, Vazquez E, Bocanegra C, Molina I, Esperalba J, Sanchez‐
Seco MP, Boix H, Pumarola T, Carreras E (2016) Prolonged Zika Virus Viremia during 
Pregnancy. The New England journal of medicine 375:2611‐2613 
339. Swarbrick CMD, Basavannacharya C, Chan KWK, Chan S‐A, Singh D, Wei N, Phoo 
WW, Luo D, Lescar J, Vasudevan SG (2017) NS3 helicase from dengue virus 
specifically recognizes viral RNA sequence to ensure optimal replication. Nucleic 
acids research 45:12904‐12920 
340. Tabata T, Petitt M, Puerta‐Guardo H, Michlmayr D, Wang C, Fang‐Hoover J, Harris E, 
Pereira L (2016) Zika Virus Targets Different Primary Human Placental Cells 
Suggesting Two Routes for Vertical Transmission. Cell host & microbe 20:155‐166 
341. Tang WW, Young MP, Mamidi A, Regla‐Nava JA, Kim K, Shresta S (2016) A Mouse 
Model of Zika Virus Sexual Transmission and Vaginal Viral Replication. Cell reports 
17:3091‐3098 
342. Tang WW, Young MP, Mamidi A, Regla‐Nava JA, Kim K, Shresta S (2016) A Mouse 
Model of Zika Virus Sexual Transmission and Vaginal Viral Replication. Cell reports 
17:3091‐3098 
343. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N (2001) IRF family of transcription 
factors as regulators of host defense. Annual review of immunology 19:623‐655 
344. Tassaneetrithep B, Burgess TH, Granelli‐Piperno A, Trumpfheller C, Finke J, Sun W, 
Eller MA, Pattanapanyasat K, Sarasombath S, Birx DL, Steinman RM, Schlesinger S, 
Marovich MA (2003) DC‐SIGN (CD209) mediates dengue virus infection of human 
dendritic cells. J Exp Med 197:823‐829 
345. Tesla B, Demakovsky LR, Packiam HS, Mordecai EA, Rodriguez AD, Bonds MH, 
Brindley MA, Murdock CC (2018) Estimating the effects of variation in viremia on 
mosquito susceptibility, infectiousness, and R0 of Zika in Aedes aegypti. PLoS 
neglected tropical diseases 12:e0006733 
346. Teterina NL, Lauber C, Jensen KS, Levenson EA, Gorbalenya AE, Ehrenfeld E (2011) 
Identification of tolerated insertion sites in poliovirus non‐structural proteins. 
Virology 409:1‐11 
347. Thanachartwet V, Oer‐Areemitr N, Chamnanchanunt S, Sahassananda D, 
Jittmittraphap A, Suwannakudt P, Desakorn V, Wattanathum A (2015) Identification 
of clinical factors associated with severe dengue among Thai adults: a prospective 
study. BMC infectious diseases 15:420 
348. ThermoFisher (2012) Mutation Generation System Kit: Technical Manual.  
349. Tsai YT, Chang SY, Lee CN, Kao CL (2009) Human TLR3 recognizes dengue virus and 
modulates viral replication in vitro. Cellular microbiology 11:604‐615 
289 
 
350. Tsetsarkin KA, Kenney H, Chen R, Liu G, Manukyan H, Whitehead SS, Laassri M, 
Chumakov K, Pletnev AG (2016) A Full‐Length Infectious cDNA Clone of Zika Virus 
from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus‐Host 
Interactions and Vaccine Development. mBio 7 
351. Uchida L, Espada‐Murao LA, Takamatsu Y, Okamoto K, Hayasaka D, Yu F, Nabeshima 
T, Buerano CC, Morita K (2014) The dengue virus conceals double‐stranded RNA in 
the intracellular membrane to escape from an interferon response. Scientific reports 
4:7395 
352. Urin V, Levin D, Sharma N, Harari D, Schreiber G (2015) Fine Tuning of a Type 1 
Interferon Antagonist. PLoS One 10:e0130797 
353. van den Pol AN, Mao G, Yang Y, Ornaghi S, Davis JN (2017) Zika Virus Targeting in the 
Developing Brain. The Journal of Neuroscience 37:2161 
354. Van der Hoek KH, Eyre NS, Shue B, Khantisitthiporn O, Glab‐Ampi K, Carr JM, Gartner 
MJ, Jolly LA, Thomas PQ, Adikusuma F, Jankovic‐Karasoulos T, Roberts CT, Helbig KJ, 
Beard MR (2017) Viperin is an important host restriction factor in control of Zika 
virus infection. Scientific reports 7:4475 
355. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy 
TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A (2000) Dengue viremia titer, 
antibody response pattern, and virus serotype correlate with disease severity. J 
Infect Dis 181:2‐9 
356. Voigt EA, Yin J (2015) Kinetic Differences and Synergistic Antiviral Effects Between 
Type I and Type III Interferon Signaling Indicate Pathway Independence. Journal of 
interferon & cytokine research : the official journal of the International Society for 
Interferon and Cytokine Research 35:734‐747 
357. Waggoner JJ, Gresh L, Vargas MJ, Ballesteros G, Tellez Y, Soda KJ, Sahoo MK, Nunez 
A, Balmaseda A, Harris E, Pinsky BA (2016) Viremia and Clinical Presentation in 
Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and Dengue Virus. 
Clinical infectious diseases : an official publication of the Infectious Diseases Society 
of America 63:1584‐1590 
358. Wang K, Zou C, Wang X, Huang C, Feng T, Pan W, Wu Q, Wang P, Dai J (2018) 
Interferon‐stimulated TRIM69 interrupts dengue virus replication by ubiquitinating 
viral nonstructural protein 3. PLoS pathogens 14:e1007287‐e1007287 
359. Weisblum Y, Oiknine‐Djian E, Vorontsov OM, Haimov‐Kochman R, Zakay‐Rones Z, 
Meir K, Shveiky D, Elgavish S, Nevo Y, Roseman M, Bronstein M, Stockheim D, From I, 
Eisenberg I, Lewkowicz AA, Yagel S, Panet A, Wolf DG (2017) Zika Virus Infects Early‐ 
and Midgestation Human Maternal Decidual Tissues, Inducing Distinct Innate Tissue 
Responses in the Maternal‐Fetal Interface. Journal of virology 91 
360. Wells MF, Salick MR, Wiskow O, Ho DJ, Worringer KA, Ihry RJ, Kommineni S, Bilican B, 
Klim JR, Hill EJ, Kane LT, Ye C, Kaykas A, Eggan K (2016) Genetic Ablation of AXL Does 
Not Protect Human Neural Progenitor Cells and Cerebral Organoids from Zika Virus 
Infection. Cell stem cell 19:703‐708 
361. Westcott MM, Liu J, Rajani K, D'Agostino R, Jr., Lyles DS, Porosnicu M (2015) 
Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer 
Cells from Vesicular Stomatitis Virus‐Induced Oncolysis. Journal of virology 89:7944‐
7954 
362. WHO (2009) Dengue Guidelines for Diagnosis, Treatment, Prevention and Control. 
Neglected Tropical Diseases 
290 
 
363. WHO (2016) WHO Director‐General summarizes the outcome of the Emergency 
Committee regarding clusters of microcephaly and Guillain‐Barré syndrome.  
364. WHO (2018) Revised SAGE recommendation on use of dengue vaccine.  
365. WHO (2019) WHO Vaccine Pipeline Tracker.  
366. WHO (2019) WHO guidelines for the prevention of sexual transmission of Zika virus: 
executive summary.  
367. WHO (2019) Dengue and Severe Dengue.  
368. Wichit S, Hamel R, Yainoy S, Gumpangseth N, Panich S, Phuadraksa T, Saetear P, 
Monteil A, Morales Vargas R, Misse D (2019) Interferon‐inducible protein (IFI) 16 
regulates Chikungunya and Zika virus infection in human skin fibroblasts. EXCLI 
journal 18:467‐476 
369. Wilmes S, Beutel O, Li Z, Francois‐Newton V, Richter CP, Janning D, Kroll C, Hanhart 
P, Hotte K, You C, Uze G, Pellegrini S, Piehler J (2015) Receptor dimerization 
dynamics as a regulatory valve for plasticity of type I interferon signaling. The Journal 
of cell biology 209:579‐593 
370. Wira CR, Rodriguez‐Garcia M, Patel MV (2015) The role of sex hormones in immune 
protection of the female reproductive tract. Nature reviews Immunology 15:217‐230 
371. Wu NC, Young AP, Al‐Mawsawi LQ, Olson CA, Feng J, Qi H, Luan HH, Li X, Wu TT, Sun 
R (2014) High‐throughput identification of loss‐of‐function mutations for anti‐
interferon activity in the influenza A virus NS segment. Journal of virology 88:10157‐
10164 
372. Wu RH, Tsai MH, Chao DY, Yueh A (2015) Scanning mutagenesis studies reveal a 
potential intramolecular interaction within the C‐terminal half of dengue virus NS2A 
involved in viral RNA replication and virus assembly and secretion. Journal of virology 
89:4281‐4295 
373. Wu RH, Tsai MH, Tsai KN, Tian JN, Wu JS, Wu SY, Chern JH, Chen CH, Yueh A (2017) 
Mutagenesis of Dengue Virus Protein NS2A Revealed a Novel Domain Responsible 
for Virus‐Induced Cytopathic Effect and Interactions between NS2A and NS2B 
Transmembrane Segments. Journal of virology 91 
374. Wu Y, Liu Q, Zhou J, Xie W, Chen C, Wang Z, Yang H, Cui J (2017) Zika virus evades 
interferon‐mediated antiviral response through the co‐operation of multiple 
nonstructural proteins in vitro. Cell discovery 3:17006 
375. Xia H, Luo H, Shan C, Muruato AE, Nunes BTD, Medeiros DBA, Zou J, Xie X, Giraldo 
MI, Vasconcelos PFC, Weaver SC, Wang T, Rajsbaum R, Shi PY (2018) An evolutionary 
NS1 mutation enhances Zika virus evasion of host interferon induction. Nature 
communications 9:414 
376. Xu S, Ci Y, Wang L, Yang Y, Zhang L, Xu C, Qin C, Shi L (2019) Zika virus NS3 is a 
canonical RNA helicase stimulated by NS5 RNA polymerase. Nucleic acids research 
47:8693‐8707 
377. Yan H, Krishnan K, Lim JT, Contillo LG, Krolewski JJ (1996) Molecular characterization 
of an alpha interferon receptor 1 subunit (IFNaR1) domain required for TYK2 binding 
and signal transduction. Molecular and cellular biology 16:2074‐2082 
378. Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G (2012) A systematic review 
of the fetal safety of interferon alpha. Reproductive Toxicology 33:265‐268 




380. Ye Q, Liu ZY, Han JF, Jiang T, Li XF, Qin CF (2016) Genomic characterization and 
phylogenetic analysis of Zika virus circulating in the Americas. Infection, genetics and 
evolution : journal of molecular epidemiology and evolutionary genetics in infectious 
diseases 43:43‐49 
381. Yockey LJ, Varela L, Rakib T, Khoury‐Hanold W, Fink SL, Stutz B, Szigeti‐Buck K, Van 
den Pol A, Lindenbach BD, Horvath TL, Iwasaki A (2016) Vaginal Exposure to Zika 
Virus during Pregnancy Leads to Fetal Brain Infection. Cell 166:1247‐1256.e1244 
382. Yockey LJ, Iwasaki A (2018) Interferons and Proinflammatory Cytokines in Pregnancy 
and Fetal Development. Immunity 49:397‐412 
383. Yockey LJ, Jurado KA, Arora N, Millet A, Rakib T, Milano KM, Hastings AK, Fikrig E, 
Kong Y, Horvath TL, Weatherbee S, Kliman HJ, Coyne CB, Iwasaki A (2018) Type I 
interferons instigate fetal demise after Zika virus infection. Science immunology 3 
384. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, 
Akira S, Fujita T (2004) The RNA helicase RIG‐I has an essential function in double‐
stranded RNA‐induced innate antiviral responses. Nature immunology 5:730‐737 
385. Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T (2005) Negative regulation 
of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther 
7:100‐110 
386. Yu CY, Liang JJ, Li JK, Lee YL, Chang BL, Su CI, Huang WJ, Lai MM, Lin YL (2015) 
Dengue Virus Impairs Mitochondrial Fusion by Cleaving Mitofusins. PLoS Pathog 
11:e1005350 
387. Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman PR, Kuhn RJ, 
Rossmann MG, Chen J (2008) Structure of the immature dengue virus at low pH 
primes proteolytic maturation. Science (New York, NY) 319:1834‐1837 
388. Yun SI, Lee YM (2017) Zika virus: An emerging flavivirus. Journal of microbiology 
(Seoul, Korea) 55:204‐219 
389. Yun SI, Song BH, Frank JC, Julander JG, Olsen AL, Polejaeva IA, Davies CJ, White KL, 
Lee YM (2018) Functional Genomics and Immunologic Tools: The Impact of Viral and 
Host Genetic Variations on the Outcome of Zika Virus Infection. Viruses 10 
390. Zanluca C, Melo VC, Mosimann AL, Santos GI, Santos CN, Luz K (2015) First report of 
autochthonous transmission of Zika virus in Brazil. Memorias do Instituto Oswaldo 
Cruz 110:569‐572 
391. Zhao B, Yi G, Du F, Chuang YC, Vaughan RC, Sankaran B, Kao CC, Li P (2017) Structure 
and function of the Zika virus full‐length NS5 protein. Nature communications 
8:14762 
392. Zhao Y, Soh TS, Zheng J, Chan KWK, Phoo WW, Lee CC, Tay MYF, Swaminathan K, 
Cornvik TC, Lim SP, Shi P‐Y, Lescar J, Vasudevan SG, Luo D (2015) A crystal structure 
of the Dengue virus NS5 protein reveals a novel inter‐domain interface essential for 
protein flexibility and virus replication. PLoS pathogens 11:e1004682‐e1004682 
393. Zhao Z, Tao M, Han W, Fan Z, Imran M, Cao S, Ye J (2019) Nuclear localization of Zika 
virus NS5 contributes to suppression of type I interferon production and response. 
The Journal of general virology 
394. Zheng H, Qian J, Varghese B, Baker DP, Fuchs S (2011) Ligand‐stimulated 
downregulation of the alpha interferon receptor: role of protein kinase D2. 
Molecular and cellular biology 31:710‐720 
292 
 
395. Zheng Y, Liu Q, Wu Y, Ma L, Zhang Z, Liu T, Jin S, She Y, Li YP, Cui J (2018) Zika virus 
elicits inflammation to evade antiviral response by cleaving cGAS via NS1‐caspase‐1 
axis. The EMBO journal 37 
396. ZhongLi J, HongminLi (2017) Flavivirus NS2B/NS3 Protease: Structure, Function, and 
Inhibition.  Viral Proteases and Their Inhibitors, pp 163 ‐ 188 
397. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R (2007) Type III 
interferon (IFN) induces a type I IFN‐like response in a restricted subset of cells 
through signaling pathways involving both the Jak‐STAT pathway and the mitogen‐
activated protein kinases. Journal of virology 81:7749‐7758 
398. Zmurko J, Neyts J, Dallmeier K (2015) Flaviviral NS4b, chameleon and jack‐in‐the‐box 
roles in viral replication and pathogenesis, and a molecular target for antiviral 
intervention. Reviews in medical virology 25:205‐223 
399. Zust R, Cervantes‐Barragan L, Habjan M, Maier R, Neuman BW, Ziebuhr J, Szretter KJ, 
Baker SC, Barchet W, Diamond MS, Siddell SG, Ludewig B, Thiel V (2011) Ribose 2'‐O‐
methylation provides a molecular signature for the distinction of self and non‐self 
mRNA dependent on the RNA sensor Mda5. Nature immunology 12:137‐143 
400. WHO (2019) Countries and territories with current or previous Zika virus 
transmission, accessed: 01/11/2019, https://www.who.int/ith/Zika_map.pdf?ua=1 
401. CDC (2019) Dengue Around the World, accessed: 01/11/2019, 
https://www.cdc.gov/dengue/areaswithrisk/around‐the‐world.html  
